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Staphylococcus aureus and Enterococcus faecium are opportunistic pathogens that cause a wide 
range of infections, especially in patients with underlying medical conditions. Multidrug 
resistant versions of these bugs cause frequent outbreaks in the hospital and community. The 
emergence of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
enterococcal (VRE) strains severely limits the treatment options. Bacteria release extracellular 
vesicles, which has been defined in the minimal information for studies of extracellular vesicles 
guideline as “particles naturally released from the cell that are delimited by a lipid bilayer and 
cannot replicate”. While they are packaged with an armamentarium of virulence factors, 
resistant determinants, and nucleic acids, the characterization of EVs cargo still is limited in 
Gram-positive bacteria. sGiven the importance of EVs, this thesis aimed to examine proteome 
and RNA content of these nanoparticles upon exposure to a diverse range of growth conditions 
(Paper I-III).  
Isolation of EVs from clinical E. faecium strains (Paper I) and MRSA (Paper III) was done 
by series of filtration, concentration, and (ultra) centrifugation, followed by density gradient 
ultracentrifugation with OptiPrep™. Using a label-free proteomic approach, E. faecium EVs 
proteome was profiled for the first time (Paper I), and our data revealed that growth phase and 
growth conditions (e.g., media and exposure to the sub-MIC dosage of antibiotics) could 
influence the proteome content (Paper I). Aligned with other studies, the EV cargo in E. 
faecium was found to contain a wide range of different proteins including vaccine candidates, 
antimicrobial resistance determinants and virulence factors (Paper I). The sub-inhibitory 
dosage of vancomycin also influenced the proteome profile of MRSA and revealed relatively 
increased expression of EV- associated proteins that might be involved in bacterial colonization 
and antibiotic resistance (e.g., multiple antibiotic resistance regulators, amino acyltransferases, 
and penicillin binding proteins) (Paper III). Supplementation of purified EVs in a typical MIC 
assay using bacteriologic and tissue-mimicking media, RPMI, attenuated MRSA susceptibility 
to vancomycin (Paper III). This might suggest the act of EVs as decoy, in agreement with 
several other studies. The release of EVs was increased when the S. aureus MSSA476 was 
grown in iron-depleted BHI in presence of sub-inhibitory concentration of vancomycin (Paper 
II). Intriguingly, transcriptomic analysis of RNA isolated from MSSA476-derived EVs 
revealed presence of various RNA biotypes including mRNA, rRNA, tRNA, and small RNA 
(sRNA). Three enriched sRNAs (SsrA, RsaC, and RNAIII) were further validated by qPCR, 




The obtained transcriptome and proteome data from our research can provide basis for future 
detailed studies of the EV functions. Further characterization of EV cargos will provide grounds 







1.1.1. Nomenclature and taxonomy 
The term “entérocoque” was coined by Thierscelin during 1899, while he isolated the bacterium 
from the patients suffering from infective endocarditis1. In Greek, the word “entero” (“έντερο”) 
mean “intestine” and “coccus” (“κόκκος”) mean “spherical particle or granule,”- reflecting the 
origin of the organisms and its morphology. However, later they were classified as group D 
streptococci based on Lancefield's precipitin test2,3. In 1970, Kalina and colleagues proposed to 
reclassify enterococci based on detailed studies on biochemical, cultural and molecular 
techniques4. The Enterococcus genus belongs to Enterococcaceae family and to date 68 species 
and two subspecies have been reported. (https://www.bacterio.net/genus/enterococcus#r] 
1.1.2. Biology and general characteristics 
Enterococci are Gram-positive cocci that usually occur individually, in short chains, or in a 
group. They are catalase-negative (although a few strains are catalase-positive), non-spore 
forming, chemo-organotrophic facultative anaerobes and some of the species also produces 
pigment5. Most of the species of Enterococcus are non-motile except Enterococcus gallinarum 
and Enterococcus casseliflavus. The genome of Enterococci is highly malleable with low G+C 
content (36-40%), but this can vary among species. The average length 
of Enterococcus genomes is ~ 3.20 Mb6. They are mesophilic organisms, but can survive in a 
temperature ranges from 10°C-60°C for about 30 min7. They can thrive in a broad pH range 
(4.8-9.6), but optimal growth has been observed at pH 7.5. They have been isolated from high-
salt concentration (6.5% NaCl, 40% bile salt), which would otherwise inhibit other 
streptococci8. Remarkably, they are also able to tolerate high heavy metal concentrations and 
desiccation9. They are ubiquitous and found in plants, soil, water, fermented food and dairy 
products and the gastrointestinal tract (GIT) of various insects, reptiles, birds and 
mammals.10,11. 
Approximately 1% of the microbial community of the GIT are constituted of the genus 
Enterococcus12. Of note, Enterococcus faecium, Enterococcus faecalis, Enterococcus durans, 
and Enterococcus avium are the species most frequently colonizing the human GIT. These 




products of their sugar metabolism is lactic acid. Hence, they are also classified as lactic acid 
bacteria13.  
1.1.3. Pathogenicity of enterococci 
Pathogenicity refers to the “ability of an organism to cause disease (i.e., harm the host)”14. 
Enterococcal colonization of the GIT is considered to be an important risk factor for infection. 
E. faecalis and E. faecium are predominantly found in the GIT as commensal microorganisms. 
However, exposure to broad-spectrum antibiotics, results in skewing of the microbial 
community referred to as “dysbiosis”. Microbial dysbiosis, along with impairment of the host 
immune system facilitates flourishment of the opportunistic pathogens. They can cause diseases 
ranging from minor urinary tract infections and soft tissue infections to severe bacteremia, 
neonatal sepsis and endocarditis15. The severity of infection depends upon various factors 
including virulence factors (VFs) released by the bacteria, host immune status and site of 
infection16. Various epidemiological and observational cohort studies examined the risk factors 
associated with enterococcal infections17. Among them, age of patients, duration of the hospital 
stay and other co-morbidity such as diabetes, cancer, organ transplant (kidney, heart, and liver), 
surgery like heart-valve or hip replacement, long-term indwelling catheters, and prior antibiotic 
exposures are major risk factors for enterococcal infections18-20. Upon broad-spectrum 
antibiotic treatment, antibiotic-resistant bacteria outcompete commensal bacteria, which 
generally restrict enterococcal proliferation. Specifically, inhibition of Gram-negative 
organisms via antibiotics will facilitate a downregulation of REGIIIγ- a secreted C-type lectin 
that keeps the number of Gram-positive bacteria, including enterococci low21. 
1.1.4.  Enterococci cause hospital-acquired infections 
E. faecalis and E. faecium are mainly responsible for infections.  During 1980s’, E. faecalis was 
the most predominant species (80-90%) identified in the clinical samples. On the other hand, 
E. faecium only constituted less than 10% of enterococcal clinical specimens. Interestingly, 
there has been a gradual increased ratio of infections by E. faecium compared to E. faecalis 
recent years. Vancomycin resistant infection are more challenging, given vancomycin are used 
as last resort antibiotics to treat multi-drug-resistant (MDR) pathogens22,23 and the E. faecium 
are more often vancomycin resistant than E. faecalis24,25. 
Enterococci can also easily adapt to the hospitals settings due to their unique tolerance to 
commonly used antiseptics, disinfectants, UV radiation, desiccation and starvation26,27. 




classes such as penicillins, cephalosporins and aminoglycosides28,29. The vancomycin resistant 
enterococci (VRE)-contaminated inanimate objects such as doorknobs of hospitals, over-bed 
tables, alarm buttons, toilet seats, and medical surfaces (blood-pressure cuffs, catheter devices) 
are potential hidden reservoirs and high-contact points for the transmission26. It is challenging 
to eradicate major reservoirs of multidrug-resistant strains in hospital wards since E. faecium 
can easily tolerate low concentrations of chemicals such as alcohol and chlorine27,30,31, which 
are generally used as disinfectants in hospitals. Another important factor why it is difficult for 
healthcare workers to control infections caused by enterococci is because enterococci are 
capable of surviving on inanimate objects 3-5 times longer compared to other Gram-positive 
nosocomial pathogens. They can even survive in a dry environment without nutrition for more 
than five years in a hostile ecological niche such as hospital30. Moreover, hospital settings also 
facilitate the selection and/or exchange of antibiotic resistance among strains as well as 
continuous genomic organization through recombination and horizontal gene transfer (HGT). 
The latter drives the evolution and clonal expansion of hospital acquired lineages32.  
1.2. Enterococcus faecium and antibiotic resistance 
Within the last three decades, E. faecium, the harmless commensal quickly turned into a 
notorious pathogen and ranked among frequent causes of bloodstream infections33. The burden 
of diseases is amplified as E. faecium turned out to be intrinsically resistant to various classes 
of antibiotics such as cephalosporins, aminoglycosides, clindamycin and trimethoprim-
sulfamethoxazole34. In addition, resistance to glycopeptide antibiotics such as vancomycin is 
spreading rapidly, which is considered as an important hallmark in the evolution of enterococci 
towards MDR pathogen. E. faecium turned out to be resistant towards vancomycin due to 
acquisitions of van gene clusters35. Currently, there are eight different acquired van clusters, 
described as vanA, vanB, vanD, vanE, vanG, vanL, vanM, and vanN that mediate varying 
degrees of susceptibility (i.e., resistance) to the glycopeptides antibiotics such as vancomycin36. 
Of note, vanA and vanB gene clusters are most prevalent because they often are transferable via 
plasmids and other mobile genetic elements (MGE). Overexpression of the van genes results in 
an alteration in the synthesis of peptidoglycan precursors thereby decreasing the binding affinity 
of vancomycin37. Due to the acquisition of the vancomycin resistance clusters in MGE, the 
propensity of dissemination of these resistant genes to other isolates via HGT is also enhanced. 
Enterococci are not only able to exchange resistance gene within species but also show inter-
species gene transfer mostly with other Gram-positive organisms such as staphylococci and 




E. faecium is one of the high-risk pathogens belonging to the “ESKAPE” group. The acronym 
“ESKAPE” encompasses a collection of six most troublesome pathogens (Enterococcus. 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species), that are capable of escaping all available 
conventional antibiotics treatment, thus creating a global health threat. Worldwide, the 
morbidity and mortality rates caused by ESKAPE pathogens ranging from 30 to 70%39. Patients 
suffered from Vancomycin Resistant Enterococcus faecium (VREfm) along with other 
comorbidities (old age, diabetes, organ transplant) required hospitalization for treatment. 
VREfm infection in patients with underlying co-morbidity can also cause sepsis. To treat the 
patients, they need hospitalization and intensive care unit (ICU) facility that create a financial 
burden especially to the patients from third-world nations40. The treatment procedure are often 
lengthy and during this period the risk of transmission of the infection to other healthcare 
personnel working in close proximity with infected patients is also potentially higher, leading 
towards sporadic outbreak in hospital settings41.  
1.2.1.  Vancomycin-Resistant Enterococcus faecium (VREfm) 
Shortly after Leclercq and colleagues reported the isolation of vancomycin resistance E. 
faecium (VREfm) in 1986, it became public health threat42. First reported in England, a year 
after, it was reported in the United States43 and now is documented to be worldwide42,44. 
According to annual reports published by the European Antimicrobial Resistance Surveillance 
Network (EARS-Net), VREfm in EU countries increased from 10.2% in 2015 to 17.3% in 2018. 
The prevalence of VREfm in the United States is reported to be 66%, Australia 48.7-56.8% and 
Latin America 31%45-48. Another prospective study conducted in Brazil among 26 different 
hospitals reported that more than 60% of E. faecium isolates were VRE during 2007-201549. A 
five year data (2012-2017) analysis obtained from German Antimicrobial Resistance 
Surveillance reveal that VREfm were higher among population aged 40-59 years compared to 
young and adolescent groups50. 
Along with an increase in the prevalence of VREfm, the attributable death associated with VRE 
was also found to be doubled between 2007-201551. Due to the rising trend of VREfm across 
the globe, the World Health Organization and the U.S. Centers for Diseases Control and 
Prevention listed VREfm as a high priority pathogen. Appropriate epidemiological surveillance 




1.2.2.  Evolution of E. faecium genome 
Before genome sequencing became easily available, Multilocus sequence typing (MLST), an 
unambiguous procedure for characterizing isolates of bacterial species with a set of seven 
housekeeping genes (adk, atpA, ddl, gyd, gdh, purK, and pstS) was used to determine sequence 
type (ST) of an isolate. The hospital associated isolates were then clustered into clonal complex 
17 (CC17) using the eBURST algorithm. CC17 possess important characteristics such as 
resistance to antibiotics (ampicillin and quinolone), and harbor a pathogenicity island encoding 
gene for enterococcal surface protein (Esp) in the majority of isolates52. The most important 
sequence types in the CC17 lineage are ST17, ST18 and ST78 which cluster separately from 
the community isolates53. Recently, Turner and co-workers showed that the reliability of 
eBURST network to infer information about evolutionary relationship is not accurate for 
genomes with high recombination rate such as E. faecium leading to error prone phylogenetic 
analyses54 and inappropriately linkage of lineages ST17, ST18 and ST78 into a clonal complex.  
To understand the evolution of E. faecium from commensals to hospital-adapted strains, 
Lebreton et al.55 sequenced the genomes of 51 E. faecium strains, which showed that the 
genomes grouped into two main clades. Clade A consists of hospital associated and animal 
isolates, while clade B isolates especially are of human commensal origin. With the aid of 
comparative genomics, clade A was further sub-divided into clade A1 (hospital-associated), 
which includes the former CC17, and clade A2 (animal-associated) (Figure 1).  
The diversification of nosocomial clade A from commensal clade B started approximately 
started 3000 years ago - a time wherein human beings started domestication of animals and 
urbanization and hygiene practiced were introduced. Moreover, with the introduction of 
antibiotics 75 years ago in clinical medicine and agriculture, there has been another bifurcation 
between subclades A1 and A2. This phenomena might reflect that human intervention such as 
domestication and antibiotic use played a pivotal role in evolution of enterococci56. Notably, 
clade A1 has been circulating all over the globe and distinguished from other lineages as they 
have some specific features such as resistance to ampicillin and quinolone. The ability to sustain 
in harsh environment like the hospital environment is probably due to resistance to disinfectants 
and survival in draught environment. Indeed, hospital-adapted strains have bigger genome size 
due to acquisition of MGEs as well as antimicrobial resistance and virulence 
determinants55,57,58. The flexible genome complemented with the difference in restriction 
modification system, presence of an Insertion sequence element and a pathogenicity Island 




virulence, which enable them to adapt to hostile circumstances, colonizes and cause 
pathogenicity in their host59-61. 
 
Figure 1: Clade structure of E. faecium. The origins of the strains and the dates for the split 
between the clades are indicated (ya, years ago). Reprinted with permission, modified from 
mBio62. 
1.2.3.  Virulence factors of E. faecium 
Virulence is derived from Latin word “virulentus”, meaning “full of poison” or the capacity of 
a pathogen to cause disease/infection14,63. In other words, the quantitative measurement of 
pathogenicity is termed as virulence. Bacteria express a multitude of virulence factors (VFs) to 
enhance their pathogenicity32,64. VFs enable pathogens to colonize and proliferate better 
subsequently leading to tissue damage and infection65. In addition, they play a vital role in 
escaping from host defenses systems66,67. They are encoded by genes integrated in the genome 
both on the chromosome and on extrachromosomal elements, often on MGEs termed plasmids. 
They can also be encoded on pathogenic islands or bacteriophages. Conventional VFs include 
non-secreted or secreted proteins involved in adherence, tissue invasions, and escape from host 
immune surveillance or in forming pores in eukaryotic cell membranes (pore-forming toxins). 
Moreover, determinants involved in providing nutrients such as iron scavengers (e.g., 




comprehensive databases such as VirulentPred68 and Virulent-GO69, virulence factor database 
(VFDB)70, victors71 available to predict the virulence factors present in bacteria.  
E. faecium harbor a surplus of VFs which reinforce the pathogen to flourish as versatile 
opportunist mediating nosocomial infections. The characterization and knowledge on the VFs 
will provide insight on understanding the complex pathogenic process of opportunistic bacteria 





Table 1: Overview of E. faecium virulence factors. Virulence factors utilized by E. faecium include cell wall components, secreted virulence factors 
and membrane-bound factors. Table modified from32. 
Virulence factors Biological effects 
Lipoteichoic acid (LTA) Contributes biofilm formation and increased susceptibility to antimicrobial peptides. 
Wall teichoic acid (WTA) 
Involves in host cell attachment. Protects against complement-mediated killing mechanism of 
neutrophils. 
Enterococcal surface protein (Esp) Promotes biofilm formation, different variants in nosocomial isolates.   
Collagen-binding adhesin (Acm) Binds to collagen types IV, laminin and dentin, assist in biofilm formation. 
Second collagen -binding adhesion (Scm) Binds to collagen type V and fibrinogen. 
Fibronectin-binding protein (fnm) Binds to fibronectin and play key role in pathogenesis of endocarditis. 
Proline-rich protein (PrpA) Binds to immobilized fibrinogen and fibronectin. 
E. faecium collagen binding protein (EcbA) Binds to the collagen type V and fibrinogen. 
Pili (PilA and PilB) Contributes to adherence during biofilm formation. 
Gelatinase (gelE) 
Hydrolyzes gelatin, collagen, and other small peptides. Inhibits complement mediated immune 
responses and contributes biofilm formation.  
E. faecium secreted antigen(sagA)  
Binds to fibrinogen, collagen type I, collagen type IV, fibronectin, laminin and contributes biofilm 
formation. 
Catabolite control protein A (CcpA) Affects growth and biofilm formation capacity.  




Serine glutamate repeat A (SgrA) 
Binds to the extracellular matrix nidogen 1 and nidogen 2. Involved in pathogenesis of catheter 
related infections and biofilm formation.  
TIR-domain-containing proteins (TirEs) Promotes bacterial proliferation in human blood and may contribute to the pathogenesis. 
Cytolysin (Cyl) Facilitates infection via damaging host cell membrane.  
Capsule (CapD) 
Contributes in biofilm formation and evade from host immune system such as attack from 
neutrophil and phagocytosis. 
PTS permease 
Promotes biofilm formation in presence of human serum and pathogenesis of infective 
endocarditis  
Biofilm and endocarditis-associated 
permease A (BepA)  





1.3.1. Nomenclature and taxonomy 
Historically, Alexander Ogston described Staphylococcus in 1880s while he isolated the 
pathogen from wound infection72. The word Staphylococcus originate from Greek “Staphyle” 
(σταφυλαί) which means bunch of grapes and “coccus” (“κόκκος”) means spherical particles 
or granule. In 1884, Rosenbach differentiated S. aureus from S. albus based on colony 
characteristics on agar plate. S. aureus impart golden yellow color (from Latin aurum, gold) 
and S. albus white (Latin albus, white)73. Later, S. albus was renamed S. epidermidis because 
they are native flora of human skin. Interestingly, S. aureus is one of the first described pathogen 
and still knowledge on this bacterium is continuously expanding till date74. 
The genus Staphylococcus belongs to Staphylococcaceae family and till date 63 species and 30 
subspecies have been validated and deposited in Prokaryotic Nomenclature database 
(https://lpsn.dsmz.de/, report accessed on 11.09.2020).  
1.4.  Staphylococcus aureus 
Staphylococcus aureus are Gram-positive bacteria often clustering resembling “bunch of 
grapes” under microscopic observation75,76. Although they can remain as commensals, they are 
capable of causing infection in humans and animals. S. aureus are aerobic and/or facultative 
anaerobes, catalase positive, oxidase negative, coagulase positive, non-spore forming 
microorganism. Some of the strains are also capsule formers77. The bacterium has a diameter 
of 0.5-1.0 μm78. The thick cell-wall of the bacterium consist of peptidoglycan backbone 
together with wall teichoic acid (WTA), forming tough insoluble heterogenous matrix79,80. In 
addition, S. aureus are differentiated from other members of Staphylococci as it has yellow 
pigment production and ability to produce coagulase. The secondary metabolites 
staphyloxanthin secreted during stationary phase impart yellow pigmentation81. In addition, 
staphylococci can tolerate high concentration of salt and grow in presence of  10% NaCl82. S. 
aureus is furthermore capable of producing plethora of toxins (α, β, γ, δ, exfoliative, 
enterotoxin) having wide spectrum of  hemolytic and cytolytic activity83,84. 
1.4.1.  Colonization and pathogenesis 
S. aureus is an opportunistic pathogen and humans are frequently colonized for a short term or 
throughout the life. Approximately, 20-30 % of healthy adult population carry S. aureus in the 




of skin, throat, perineum and intestine85. To be defined as persistent nasal S. aureus carriers, at 
least two-culture positive isolated from a nasal swab in one-week duration is required86. 
Colonization is important risk factor for subsequent S. aureus infection. Multiple factors, 
including array of adherence as well as immune-modulating proteins expressed by the bacteria, 
in addition to host factors, and presence of local microbiota influence S. aureus colonization 
and infection. In a host-microbe interface, there is a battle between immune system of host and 
pathogenicity of the bacteria. Humans are protected against infection by both innate and 
adaptive immune system, in addition to physical barriers such as skin, epithelial and mucous 
membrane surfaces. S. aureus are inhibited in crossing the skin barrier due to secretion of 
antimicrobial peptides, such as defensins and cathelicidins87. An accidental breach of such 
barriers poses a risk to human infection. Moreover, immune status of host also affects the 
severity of the disease that ranges from minor skin infections to life-threatening diseases such 
as endocarditis,  meningitis, osteomyelitis, hemolytic pneumonia and toxic shock syndrome88. 
1.4.2.  S. aureus genome 
The first S. aureus genome was sequenced in 200189 and till date more than 150 S. aureus 
genomes have been sequenced and are  available in NCBI genome database. The staphylococcal 
genomes are about 2.8 Mbp with GC content of 32.7%. The genome is classified into core 
genome and accessory genome. Approximately 75% is defined as core genome, while the rest 
is accessory genome, which may contain MGE including plasmids, parts of bacteriophage 
genomes, pathogenicity islands, transposons and staphylococcal cassette chromosomes (SCC). 
The core genome is mostly conserved among the species and accessory genome play a pivotal 
role in clonal evolution, which provide the beneficial advantage to the strain to escape from 
available antibiotics, colonization new host and adapt to new ecological niches90. 
1.4.3.  Methicillin resistant Staphylococcus aureus (MRSA) 
Methicillin-resistant S. aureus  was first reported from clinical isolates from hospitalized 
patients in England in 1961, only two years after methicillin was introduced into clinical 
practice to treat infections caused by S. aureus91. However, treatment with methicillin in 
hospital settings was discontinued due to its toxicity and replaced by penicillins and their 
derivatives such as oxacillin, flucloxacillin and dicloxacillin. Nevertheless, the acronym MRSA 
continues to be used until date. The spread of MRSA probably occurs through disseminations 
of existing resistant clones or by acquisition of SCCmec by a methicillin-sensitive S. aureus 
(MSSA) strain. SCCmec is a mobile genetic element that encodes a variant methicillin-resistant 




mostly resistant to all β-lactam antibiotics such as penicillin. During the 1960s’, MRSA strains 
were only confined to the hospital environment, but the prevalence is increasing all over the 
globe. However, the  prevalence of MRSA is highly variable among different geographical 
regions, ranging from < 1% in some Northern European countries to > 50% in some American 
and Asian countries93. The incidence of MRSA exceeds 20% from the recent data reported from  
85 World Health Organization (WHO) member states countries94.  
Community acquired methicillin-resistant S. aureus (CA-MRSA) are frequent causes of 
infection and considered more virulent and pathogenic than hospital acquired MRSA strains 
(HA-MRSA). Generally, there is no sharp distinction between HA-MRSA and CA-MRSA. 
Nevertheless, CA-MRSA emerged during late 1990s and is capable of causing skin and soft 
tissue infections even in healthy and young people. CA-MRSA strains harbor SCCmec types 
IV or V, Panton Valentine Leukocidin (PVL) encoding genes LukS-PV and LukF-PV, as well 
as arginine catabolic mobile element (ACME) cluster95-97. SCCmec is a mobile genetic element  
that harbors resistance genes for beta-lactam antibiotics98. PVL is a prophage-encoded toxin 
involved in white blood cell lysis99 and ACME assists in enhanced transmission, survival and 
persistence of the pathogen100. Among CA-MRSA clone, USA300 belonging to CC8 lineages 
was successful in adaptation and spread rapidly across the globe (predominant in the United 
States, Canada and Europe). They are able to adapt and transmit infection and cause outbreaks 
in various settings such as prisons101, children day care centers102, youth sports center103, and 
military camps104. Of concern, MRSA isolates are only susceptible to few antibiotics such as 
vancomycin, linezolid, teicoplanin and clindamycin. However, MRSA isolates have recently 
been reported to have reduced susceptibility to vancomycin, known as vancomycin 
intermediate-resistant S. aureus (VISA) (MIC=4-8 µg/mL) and complete resistance to 
vancomycin (MIC≥16 µg/mL) termed vancomycin-resistant S. aureus (VRSA)105. VISA and 
VRSA raises prominent public health threat, given vancomycin was last resort antibiotic to treat 
MDR infections. Due to limited therapeutic options available to treat MRSA, understanding the 
pathogenesis of MRSA and molecular characterization using omic approaches (e.g., 
transcriptomic and proteomics) are essential106. 
1.4.4.  Virulence factors in S. aureus 
S. aureus contain diverse set of VF, including in average 24 different cell wall anchored 
proteins and over 40 secreted proteins and enzymes involved in steps from host colonization to 
pathogenesis107. The pathogenicity of S. aureus is driven by a battery of virulence factors 




include microbial surface proteins such as clumping factors, fibronectin binding proteins and 
Protein A. The secreted proteins involve extracellular enzymes such as protease, hyaluronidase, 
lipase, coagulase and proteases, as well as a wide range of toxins (pore-forming toxins, 
exfoliative toxins and super antigens). The combination of the VFs contributes to adhesion, host 
tissue penetration, immune evasion and proliferation of the bacteria causing the disease (Figure 
2). The VF are expressed depending on the requirement of pathogens to establish infection. For 
example, at the early colonization stage, adhesion proteins are expressed while for later onset 
of infection, toxins play major roles. In addition, VFs also facilitate long-term persistence inside 
host through e.g., its ability to evade host immunity. The regulation of VFs is tightly controlled 
and coordinated and varies according to growth factors/and or growth conditions109. The 
innovative proteomics and advanced bioinformatics tools have made it easier to explore VF 
expressed by organisms, including evaluating their sub-cellular localization and putative 
biological function. 
 
Figure 2: Schematic representation showing examples of S. aureus virulence factors including 
surface factors and secreted factors. Examples of secreted factors include toxins, enzymes and 
invasins. Surface bound factors include structures such as lipoteichoic acid (LTA), wall teichoic 
acid (WTA) as well as cell wall-anchored (CWA) proteins including clumping factor (Clf), 




1.5. Regulatory RNA and virulence 
RNA is no longer considered as only an intermediate link as mRNA between genome and 
proteome. Indeed, there are diverse functions encompassed by the RNA molecules.  They can 
also be involved in gene regulation at the transcriptional/and or translational level111,112. 
Approximately ~20 % of the bacterial genes code for RNAs that have regulatory functions. 
With few exceptions like RNAIII, most of the regulatory RNA are about 80-200 nucleotides in 
length 113. The regulatory RNAs are also described as small RNAs (sRNA).  
Generally, prokaryotic sRNAs are non-coding, mainly originate from intergenic regions and 
are involved in gene regulation114. Based on the locations of sRNA genes and their targets, 
sRNA can be divided into different categories, the main two being cis-encoded RNAs and 
trans-encoded RNAs. Cis-encoded RNAs base pair with target mRNAs with perfect 
complementarity and are located in the same DNA region as their target mRNA. Trans-encoded 
RNAs are located in another genomic location and only share partial complementarity to their 
target mRNA. The hybridization of sRNA with mRNA control gene expression by modulating 
translation and/or stability of their target mRNA111,115. Moreover, Riboswitches are cis-
regulatory elements involved in gene regulation at the levels of the transcription and translation. 
Riboswitches consist of two structural domains: a ligand binding aptamer, and an expression 
platform113,116. Upon binding of ligand with aptameric region, the riboswitch undergoes 
conformational changes and regulate gene expression of downstream protein coding sequence 
(CDS) region117,118. 
Bacterial sRNAs are involved in diverse biological processes such, carbohydrate metabolism, 
metabolite transport, synthesis and degradation. They can also contribute in), growth processes 
(e.g., toxicity, biofilm formation), adaptation to stress and varying culture conditions such as 
temperature, iron limitation or cell density. Moreover, recent evidence shows that regulatory 




1.6. Bacterial Extracellular vesicles  
1.6.1. Nomenclature 
Secretion of vesicles is considered as a universal phenomenon which occur in prokaryotes 
(Gram-positive and Gram-negative bacteria), eukaryotes and archaea. The vesicles are 
described and termed differently depending upon the cell-type from which they originate. In 
Gram-negative bacteria, the vesicles are termed outer membrane vesicles (OMVs), while in 
Gram-positive bacteria, they are commonly referred to as membrane vesicles (MVs), 
extracellular vesicles (EVs) or cytoplasmic membrane vesicles (CMVs) as they originate from 
the cytoplasmic membrane121. Hence, the International Society for extracellular Vesicles 
(ISEV), recommend “Extracellular Vesicle” as an appropriated generic term for “particles 
naturally released from the cell that contain lipid bilayer and cannot replicate”122. Hereafter, the 
abbreviation EVs will be used in the thesis for mentioning vesicles from both Gram-positive 
and Gram-negative bacteria.  
1.6.2. Structure and cargo of extracellular vesicles 
EVs have spherical shape and are heterogeneous in size ranging from 50-500 nm123,124. These 
nano-sized bubbles are either attached to bacteria or released from bacterial cell surfaces during 
their growth (Figure 3). The maximum yield of EVs released by bacteria occur at late 
exponential phase and stationary phase of bacterial growth125. The EV cargo is packaged with 
various bioactive molecules such as toxins, enzymes, virulence factors, quorum sensing 
molecules, metabolites, and nucleic acid (DNA, RNA) (reviewed in126,127). Integrated database 
such as EVpedia (http://evpedia.info), Vesiclepedia (http://microvesicles.org/), and EV track 
(https://evtrack.org/) provide information on proteins, lipids, and nucleotides (DNA, mRNAs, 
miRNAs) enclosed in prokaryotic, non-mammalian eukaryotic, and mammalian EVs. 
The vesicles may also fuse and form elongated cylindrical shaped nanotube like structures. 
Such nanotubes are co-purified together with EVs from various Gram-negative and a few 
Gram-positive bacteria including S. aureus128. The composition and cargo of bacterial EVs is 




Figure 3: A) Schematic representation of EVs and its cargo, containing bioactive 
macromolecules. B) Atomic Force Microscopy (AFM) image of EVs forming nanotubes (Black 
arrow). C) AFM image of S. aureus grown in Brain Heart Infusion (BHI) releasing EVs (Joshi, 
Hegstad, Johannessen, unpublished). 
1.6.3. Extracellular vesicles from Gram positive bacteria  
The fact that Gram-positive bacteria also release vesicle was proven in the 1990s for Bacillus 
cereus129. Researchers were skeptical regarding the possibility of EV release from Gram-
positive bacteria as they possess a thick-peptidoglycan layer (50-100 nm) and lack outer 
membrane. Hence, it took almost 30 years to fully realize the importance of EV release from 
thick-wall organisms130. Lee and coworkers performed characterization of EVs released by S. 
aureus in 2009131. Thereafter, multiple researches are ongoing on proteomics characterization 
of EVs cargo and their function from Gram-positive bacteria (Table 2). The total number of 
EVs associated proteins varies according to growth phase at which EVs have been harvested, 
use of bacteriological media used for EVs isolation and also producer strains. It has been 
reported, the number of EVs associated proteins varies from 28 (Filifactor alocis) to 617 (S. 
aureus). Most of virulence factors including toxins and cell wall remodeling proteins (autolysin, 
penicillin binding proteins) have been found to be overrepresented in EVs cargo132. There are 




enrichment of short-chain saturated fatty acids were reported from B. anthracis and S. 




Table 2: EVs released by Gram-positive bacteria: their size, growth conditions from which they were isolated, number of proteins identified 
including virulence factors, and some remarks 
Species Size (nm) 
Growth phase 
or OD600 
Medium Virulence factors No. of protein   Remarks  Year^Reference 
S. aureus 
(ATCC14458) 
200 - 100 OD600 ~ 1.0 NB 
Penicillin-binding protein 
(PBP1, PBP2, PBP3), β-
lactamases, super antigen 
(SEQ1, SSAa1, SSAa2) 
90 
Isolated vesicular protein might play a 
role in bacterial pathogenesis, antibiotic 
resistance as well as eliminating 
competing microbes.  
2009131 
Bacillus 
anthracis 34F2  




Lethal factor (LF), oedema 
factor (EF; also known as 
Cya) and protective antigen 
(PA), anthrolysin (ALO)  
36 
Toxins were found to be associated with 
bacterial EVs, protected from 
degradation and allows to deliver into 
host cells in a highly concentrated form.  
2010134 




S. aureus EVs delivered their 
components to host cells through the 




20 - 100  OD600 = 2.0 BHI 
Internalin B (InlB) and 
listeriolysin O (LLO) 
130 
Transcription factor σB hold key role in 
vesiculation. EV associated virulence 
factors contribute towards pathogenesis 




20 - 400  OD600 ~1.0 
 (TPG) 
broth 
toxin-Beta2   431 
EVs contained many ribosomal proteins, 
DNA polymerases and several metabolic 
enzymes, suggesting role of vesicles 





20 - 80  
Late-exponential 
phase (OD600 = 
0.5) 
THB 
toxin Ply, hyaluronidase 
(hyl) 
208 
Pneumococcus- derived EVs enriched in 
lipoproteins confer protection against 
infections in animal model. 
2014133 




SspA, SsnA, Ide, Plr, 
HtpsC, and Mrp 
46 
 EVs produced from S. suis can degrade 
NETs and thereby escape from the host 
defense response and also activate NF-
κB pathway 
2015138 
S. pyogens 50 - 100 OD600 = 0.4 TSB 
Penicillin binding 
protein1b, Streptolysin O 
111 
Vesicles associated with lipoprotein were 













Streptolysin O, Penicillin 
binding protein 
195 
GAS EVs contain RNAs, lipids, proteins, 
and virulence factors. Genetic disruption 
of two-component regulator CovRS led 
to hypervesiculation. 
2016140 











In both vegetative growth phase and 
sporulation, EVs were detected. 
Variation in EV protein cargo was 









GBS associated EVs induced apoptosis 
of HeLa cells. The collagenase properties 





 50 - 350   ND LB   Listeriolysin O (LLO) ND 
EV- associated toxin (LLO) inhibits 






50 – 150 ND MRS  ND ND 
EVs were released by both planktonic 
and biofilm phenotypes and eDNA was 
found to be associated with both 




31 – 200 
Late exponential 
phase  
MRS ND 158 
EVs produced from L. plantarum 
WCFS1 enhance host immune responses 
via upregulation of the two host genes, 








BHI ND 262 
C. difficile-derived EVs stimulated the 
expression of pro-inflammatory cytokine, 
including interleukin (IL)-1β, IL-6, IL-8, 
and monocyte chemoattractant protein-1 







every 6 hour 
BHI ND ND 
Sporulation master regulator spo0A gene 
















EV surface proteins can act as antigens 
that induce adaptive immune responses 
in the host 
2017147 
S. aureus 
25 nm in LB, 







131 in LB and 
617 in BHI 
Immunization of mice with S. aureus 
derived EVs confer robust humoral 
immune response thereby enhanced 
protection against S. aureus infection.  
2018124 
Filifactor alocis 50-270 OD600 = 1.0 
 Columbia 
broth 
lipoproteins, autolysins, 28 
EVs induced the expression of various 
cytokines (IL‐1β, I IL‐6, IL‐8 etc) and 
chemokines (CXCL1, CXCL10) in THP‐
1 cells.  
2020148 















Core proteomes were found to be 
conserved among phylogenetically 
different species which strengthen the 
speculation regarding selective sorting of 








m at pH 7.5 
and 
105.5 ± 11.6 n






Cell surface antigen SpaP, 
Glucan-binding protein, 
Dextranase 
495 proteins at 
pH 7.5 and 351 
proteins at pH 
5.5. 
Significant change in ABC 
transporters proteins were observed in 
EVs released from S. mutans from acidic 




                                                 
1 ATCC- American Type Culture Collection    BHI- Brain Heart Infusion  
GAS- Group A Streptococci     GBS- Group B Streptococci     
LB- Luria Bertany      MRS- De Man, Rogosa and Sharpe agar   
PAMP- Pathogen Associated Molecular Pattern   NB- Nutrient Broth       
ND- Not Determined      NETs-Neutrophil Extracellular Traps     
THB- Todd Hewitt Broth     TLR- Toll Like Receptors      





1.6.4. Factors influencing EV release 
The composition of EVs cargo are influenced by growth conditions, strain and the whether the 
bacteria are exposed to stress. Comparatively, Gram-negative bacteria produced more EVs than 
Gram-positive bacteria. Moreover, pathogenic bacteria produce more EVs compared to non-
pathogenic bacteria151,152. The vesiculogenesis (formation of vesicles) is mostly studied in 
Gram-negative bacteria and route of vesicle formation occurs through budding of the outer 
membrane and hence termed OMVs. Likewise outer-inner-membrane vesicles (OIMVs)153, 
explosive outer-membrane vesicles154 and tube-shaped membranous structures were also 
observed from various bacteria, depending upon the inducer used for vesicle formation155. The 
biogenesis of EVs from Gram-positive bacteria despite having thick peptidoglycan layer and 
lack of outer membrane changed the view on vesicle biogenesis126. Toyofuku and colleagues 
reported that phage encoded endolysin create hole in thick peptidoglycan layer and trigger 
bubbling cell death, thus assisting release of vesicles from cytoplasmic membrane (Figure 4).  
 
 
Figure 4: Various mechanisms of EVs formation, depending on bacterial exposure to stress. 





Various stress factors trigger bacteria to hypervesiculate. Among them, nutrient stress (iron 
depletion156, cysteine depletion157), temperature stress (heat shock158 and cold shock159), 
chemical induced stress (ethylene-diamine-tetra acetic acid158, sodium chloride158, hydrogen 
peroxide160, 1-octanol158), to name a few.  Furthermore, changes in growth medium also affects 
vesiculation. The growth medium affects gene expression pattern in bacteria which 
subsequently alter the amount and/or content of vesicle release 161. Bager and colleagues  found 
significant changes in Gallibacterium anatis EV production and protein composition upon 
altering medium, e.g., by adding 1 mM EDTA to BHI medium, or by growing the bacteria in 
RPMI 1640 HEPES medium162. Similarly, Pseudomonas putida KT2440 EV production was 
three-fold higher in LB media than in two other minimal media containing succinate and 
benzoate163.  
Antibiotics are also considered strong stimulators for hypervesiculation. Mitomycin C, for 
example, induces genotoxic stress to the bacteria involving the RecA pathway, which then 
stimulate vesicle release. In addition, stress transcription factor sigB (σB) is responsible for an 
increment in EV yield in the food-borne pathogen Listeria monocytogenes. Lee and colleagues 
reported nine-fold increase in EV yield in a wild-type strain compared to its isogenic ∆sigB 
mutant of L. monocytogenes136. The shapes of the vesicles produced from the wild type were 
intact. Biogenesis of vesicles might be related to stress encountered by the pathogen. There has 
been observed a three-fold increase in EVs production in E. faecium when bacteria are stressed 
with vancomycin. In addition, under iron restriction, Rafael Prados-Rosales and colleagues 
observed more vesiculation from Mycobacterium tuberculosis156. EVs released by S. aureus 
contain cytolytic phenol-soluble modulins (PSMs) facilitating budding of vesicles from the 
cytoplasmic membrane. Autolysin activity promote EV biogenesis by disrupting the 
cytoplasmic membrane and altering bacterial cell wall permeability164. Collectively, EV 
biogenesis and release in Gram-positive bacteria seem to be dependent on phages, endolysins 
or stress that weaken the thick peptidoglycan layer. 
1.6.5 Biological Functions of bacterial extracellular vesicles 
Bacterial extracellular vesicle is type of secretion system that contain biomolecules required for 
the broad range of biological activities. The biological functions depend upon the content of the 
cargo. For example, the EV cargo from pathogenic bacteria is loaded with virulence factors 
including toxins that can damage host, while the cargo of commensal gut microbiota exchange 
nutrients via EVs and supports in the maintenance of gut health. In summary, EVs have both 




pathophysiological trait induced in the host cells. In a microbial world, competition and co-
operation are two important microbial traits required for microbial fitness and survival. The 
survival of Mycobacterium in a nutrient limiting environment (e.g., iron limitation) is made 
possible by enriching iron binding proteins (mycobactin) with in EVs. The mycobatin not only 
help in uptake of iron from the environment but also support proliferation of iron deficient 
bacteria165. Furthermore, microbial competition is mediated by autolysin that are capable of 
lysing targeted bacteria. EVs released by Gram-positive bacteria play role in biofilm formation, 
exchange of nucleic acid mediating resistance, competition with intruders via release of 
antimicrobial compounds (autolysin lyse bacterial cell wall), supply of nutrients to support and 
enrich their own microbial community, delivery of toxin, and modulation of host-immune 
responses including host cell death. During the last decade, remarkable progress has been made 
in the field of EV from elucidating EV biogenesis to evaluating their functional role166,167. The 
functions are illustrated in Figure 5.  
 
 
Figure 5: Biological function of bacterial EVs. Figure modified from167. 
1.6.5.1 Biological function of EVs associated toxins 
Bacterial toxins have been found to be associated with EVs. Bacterial toxins are classified into 
exotoxin and endotoxins. Exotoxins are soluble proteins secreted by both Gram-positive and 
Gram-negative bacteria, while endotoxins are the lipopolysaccharides (LPS) of the Gram-
negative outer membrane. Exotoxins are further classified based upon their structure and 
function as a) A-B toxins, b) membrane perforating/pore forming toxins (PFTs) and c) super 
antigens. Among them, PFTs are the most common water-soluble toxins that binds to target 




are found to be associated with EVs of Bacillus, Staphylococcus and Streptococcus134,142,168. 
They support pathogen growth and dissemination and alter plasma membrane permeability of 
their target cells, leading to target cell death.  The pore size formed by toxins are quite variable 
among Gram-positive bacteria ranging from 2-100 nm. Toxins released by L. monocytogenes 
and Streptococcus pyogenes form 30-50 nm heterogeneous pores while alpha-toxin from S. 
aureus creates pores of only ~ 2 nm in diameter169. The packaging of toxins inside vesicles 
might be an evolutionary defense mechanism allowing bacteria to deliver toxins on distance. 
The wrapping of toxins inside EVs has multiple advantages such as i) a concentrated punch of 
toxins can be directed to a small surface area, increasing stability and half-life of the toxin and 
ii) toxins delivery can be redirected to discharge the EV content to particular host cell, thereby 
avoiding degradation from extracellular proteases and maximizing the potency of the toxins130. 
Noteworthy, one of the important toxins, (α-hemolysin; Hla) released by S. aureus EVs is 
delivered to human cells via fusion with the plasma membrane with the assistance of a 
cholesterol moiety. Group B Streptococcus (GBS), an opportunistic pathogen causing 20%  
neonatal death worldwide 170, is highly virulent due to extracellular matrix degrading proteases 
concentrated inside vesicles. It has been reported that the intra-amniotic injections of GBS EVs 
in mouse in vivo result in damage of chorio-amnionitis membrane, heightened immune response 
and released inflammatory molecules leading to subsequent mice death142.  
Bacterial toxins also influence autophagy; which is a mammalian intracellular way of removing 
invading pathogens/toxins. The pathogen/toxin are engulfed inside double membrane 
autophagosomes and delivered to a lysosome for degradation. Purified toxins such Hla and 
Listerolysin (LLO) released by S. aureus and L. monocytogenes, respectively, are inducing 
autophagy. Interestingly, Svitlana Vdovikova and colleagues reported that LLO-induced 
autophagy was abrogated by pre-treatment with EVs143. Similar, host cell death caused by pure 
LLOs was inhibited by pre-treatment with EVs released by same species. EVs not only protect 
against autophagy, but also against host cell necrosis initiated by pore forming toxins143. 
1.6.6 Membrane vesicles and health benefits 
Besides pathogenic bacteria, non-pathogenic Gram-positive bacteria such as lactic acid bacteria 
(LAB) and species of Bifidobacterium also produces EVs. They are considered as good 
samaritans as they cross feed the commensal bacteria via vesicles to support fitness of gut 
microbial flora. The probiotic bacteria also outcompete the pathogenic bacteria, maintain the 




Lactobacillus casei contain effector proteins such as p40 and p75 that has probiotic effects and 
also protect the intestinal epithelium layer against inflammation172. Lactobacillus rhamnosus 
derived EVs induced apoptosis of cancer cells. Moreover, Bifidobacterium longum derived EVs 
induced apoptosis of mast cells and abrogated food allergy171. EVs from probiotic bacteria 
Lactobacillus plantarum was found to induced Caenorhabditis elegans defense genes clec-60 
and cpr-1 which resulted in clearance of VRE145. Interestingly, EVs released by vaginal 
microbiota (Lactobacillus crispatus BC3, Lactobacillus gasseri BC12) were capable of 
suppressing HIV-1 replication in cell line study173. 
1.6.7 EVs as therapeutic tools 
The bacterial cell machineries that produces EVs have gained a huge attention because of 
versatile cargo that can be utilized for multiple therapeutics purpose using biotechnological 
tools. One of the most fascinating and promising areas is to use EVs for vaccine development 
Besides vaccine research, EVs can be successfully utilized as drug delivery tools, bioreactors 
for enzyme production and transport, phage therapy and potential as source of 
disease biomarkers and diagnostics174.  
1.6.7.1 Vaccination 
Vaccination has been a remarkable achievement in reducing morbidity and mortality as well as 
combating infectious diseases. Most vaccines developed are based on the principle developed 
by Louis Pasteur “isolate, inactivate, and inject’’ the disease-causing microorganism. Though 
these vaccines are safe and efficacious, their potential side effects cannot be ignored 
completely. To provide improved safety and efficacy, EV-based vaccines are gaining 
momentum175-177. The obvious advantage of using EV-based vaccines is their non-replicative 
and non–infectious nature and enhanced capacity to modulate innate and adaptive immune 
response. In addition, EVs contain some especial characteristics (small size, broad distribution 
of concentrated antigens, stable in human circulation, tolerate room temperature, and easily 
uptake from immune cells and provide long term memory response) qualifying them as  
excellent vaccine candidates178. The antigenic nature of EV cargo also impart intrinsic adjuvant 
properties.  
MenB-4C (Bexsero) is an EV-based vaccine active against meningococcal disease, a bacterial 
form of meningitis caused by Neisseria meningitides has received license and are available for 
human use179-181. Protective effects of EV-based vaccines in mouse models have also been 




Recent report suggested that EVs from S. aureus showed promising cell-mediated and humoral 
immune responses in mouse model suggesting EV-associated proteins confer protecting 
activity against lethal doses of S. aureus without the use of other adjuvants124,183. The presence 
of surface proteins and enrichment of virulence factors and toxins stimulate the immune 
response and protect against infection thus making EVs as ideal vaccine candidates. Although, 
there is a potential for EVs based vaccine, their randomized clinical trials in human are still in 
infancy and need rigorous research to be licensed for human use, ascertaining human safety. 
1.6.7.2 Nanosystem for drug delivery 
EVs can be utilized as carriers for drugs184. They are able to carry not only therapeutics drugs, 
but also enzymes and nucleic acids, such as mRNA, miRNAs, and small interfering RNAs 
(siRNAs)185,186. Hence, they can also be used as RNA based therapeutics. Similar to liposomes, 
EVs are efficiently taken up by the host plasma membrane making them efficient candidates 
for cargo internalization and loading. Furthermore, better physiological properties such as 
stability and specificity in conjunction with slower release of drugs offer advantageous 
characteristics compared to liposome mediated drug delivery187. 
One of the limitations of chemotherapeutic drugs is severe toxicity. This problem can be 
mitigated by loading those anticancer drugs into suitable nano-carries such as liposomes and/or 
EVs. Liposomes face difficulty in packaging various drugs and disadvantages such as drug 
leakage and easy degradation upon circulation. EV based nano-carriers are efficient in drug 
packaging and solve the obstacle associated with drug leakage and degradation encountered by 
liposome mediated drug delivery188. 
1.6.7.3 Biomarker and Diagnostics 
The pathogen-derived EVs contain proteins, mRNAs, and sRNAs that could serve as 
biomarkers for the diagnosis and prognosis of many infectious diseases189. The cargo of EVs 
reflect the ongoing infection process and provide potential biomarkers that can be used as 
indicators for the disease progression190. The use of biomarkers for disease diagnosis is 
promising for bacteria in the viable but not cultivable state191, and for slow growers such as 
Mycobacterium tuberculosis. It has also been reported that M. tuberculosis associated peptides 
and sRNAs are in exosomes released by M. tuberculosis infected macrophages192. These are 
excellent candidates for biomarkers as they are stable in the host and remain in circulation due 




1.6.8 Extracellular vesicles double edge swords: offence as well as defense 
In a hostile ecological niche, microorganisms cope with multiple stress, and deploy multiple 
strategies including both offence and defense to survive. Offensive strategies include release of 
adhesion factors such clumping factor B and fibronectin binding protein. Similarly, vesicles as 
a defensive strategy, release antagonistic agents such as peptidoglycan-degrading enzymes, 
autolysins and antibiotic like compounds such actinorhodin and prodigiosins (found in 
Streptomyces coelicolor EVs), to kill the intruder present in their vicinity124,193. In addition, 
under nutrient limiting condition, S. aureus EVs are enriched with iron-binding factors for 
survival. Proteomics analysis of EVs released by S. aureus also highlight the presence of beta-
lactamase, an enzyme that degrade beta-lactam antibiotics including ampicillin. The packaging 
of beta-lactamase inside vesicles might enable ampicillin-susceptible Gram-positive and Gram-
negative bacteria to survive in the presence of ampicillin and contribute towards increment of 
an antibiotic resistant bacterial subpopulation194. 
1.6.9 Extracellular vesicles and horizontal gene transfer (HGT) 
Bacteria are constantly exchanging their nucleic acids (DNA, RNA) to other species 
(interspecies and/or intraspecies) via different routes such as conjugation, transformation and 
transduction. The presence of nucleic acids inside the vesicles open an avenue for their role in 
HGT. Recently, ‘Vesiduction’ has been postulated as a fourth mode of intercellular DNA 
transfer mediated though vesicles195. EV-mediated transfer of bacterial chromosomal DNA was  
found in Ruminococcus species196. Short fragments (1-4 kb) of DNA encoding proteins 
involved in virulence, stress response and antibiotic resistance are also found as EV cargo197. 
Moreover, EV- associated DNA have differences in the restriction/modification pattern196. 
Klieve and coauthors have found that chromosomal DNA from the “parent cell” are easily 
digested with EcoRI, however, particle-associated DNA from the same species are resistant to 
digestion with same restriction enzyme-suggesting processing of DNA might occurs while they 
are destined to EVs. In addition, the presence of phages associated with vesicle strengthen the 
speculation of a role of  EVs in HGT198.  
1.6.10 RNA secreted by microbial extracellular vesicles 
In general, microorganisms release RNA and secreted RNAs  quickly decay in the surrounding 
environment during apoptosis or by active secretion systems199. However, RNAs in the 
extracellular environment are prone to degradation by abundant ribonucleases (RNases) present 




the advancement in the technologies like RNA-seq, EV associated RNA from the marine 
cyanobacterium Prochlorococcus was reported in 2014200. Thereafter, intensive researches 
have been conducted to characterize EV associated RNAs and their functions (Table 3).  
From high-throughput sequencing of EV associated RNA isolated from various Gram-positive 
and Gram-negative bacteria, it is now well known that bacteria package a large diversity of 
RNA biotypes including mRNA, sRNA, tRNA, and CRISPR RNAs (reviewed in201,202). 
Interestingly, plasmid encoded transcripts are mostly enriched in EVs of Borrelia species203. In 
addition, sRNA secreted by microorganism are of special importance given their role in 
microbe-microbe and host-microbe interaction204. The cargo of EVs including sRNA and 
mRNA are loaded into recipient cell via fusion of the EVs with host-cell membrane using 
various routes of endocytosis such as clathrin or caveolin-mediated endocytosis / and or lipid 
raft dependent endocytosis205. The functional delivery of RNA associated with EVs is widely 
studied in eukaryotes206,207. Very few functional studies of EV associated RNA from 




Table 3: RNA associated with bacterial EVs and their function. Table modified from201,210. 
Microbial species Description of RNA  Method used Functional effect  Year^Reference 






94% rRNA; 89% of genome represented RNA-seq ND 2014200 
Porphyromonas 
gingivalis 33277 
16S rRNA, mRNAs (mfa1, sod, and 
fimA) 
RT-qPCR ND 2015212 
Escherichia coli 
MG1655  
All RNA classes detected, > 90% tRNA, 






mRNA and sRNA derived from intergenic 
regions. 
RNA-seq ND 2015214 
Streptococcus pyogenes  
rRNA and mRNA derived from coding 
regions  
RNA-seq ND 2016140 
Pseudomonas aeruginosa 
PA14 
15 - 45 nt sRNA which are stable due to 
formation of secondary structures, most 




Reduction in IL-8 secretion upon 





msRNA (<30 nt)  
RNA-seq, RT-
qPCR 
Reduced secretion of cytokines 
(IL-5, IL-13 and IL-15) after 
transfection of sRNA in Jurkat cell 




Majority of RNAs are rRNAs, sRNAs, 




Borrelia burgdorferi B31 
(ATCC 3521) 







sRNAs (S.S-439, S.S- 1964) of size less 
than 30 nt  
RNA-seq, RT-
qPCR 






RNA < 200 nt, mainly rRNA RNA-seq 
IFN-β expression upon 
transfection of EV-associated RNA 
(rli32) in BMDM cell line. 
2019208 
Vibrio cholerae 
Enrichment of noncoding and functional 
RNA such as VrrA, GcvB, tmRNA, 
RNase P, CsrB2, and CsrB3 
RNA-seq ND 2019218 
Helicobacter pylori sncRNAs (sR-2509025 and sR-989262)  
RNA-Seq, qRT-
PCR  
Reduce OMV-induced IL-8 
secretion in human gastric 






                                                 
2 BMDM- Bone-Marrow Derived Macrophages    IFN-β- Interferon -β    
HBE- Human Bronchial Epithelial Cells    mgeRNA- Mobile Genetic Element  
RmsRNA- MicroRNA-size RNA    ncRNA- Noncoding RNA    
ND- Not Determined      RNA-seq- RNA Sequencing 
RT-qPCR- Reverse Transcription Quantitative Real-Time PCR.  sncRNAs - Small Noncoding RNAs 
rRNAs- Ribosomal RNA     sRNAs- Small RNA 





2. Methodological considerations 
2.1 Extracellular vesicle isolation 
EVs are heterogeneous in size and secreted in the extracellular milieu during different stages of 
the growth phases. Crude vesicles are obtained by sequential ultracentrifugation and 
ultrafiltration procedure220. The workflow for the preparation of vesicles is shown in Figure 6. 
To prepare the crude vesicles, bacteria were pelleted by centrifugation at 6000×g for 30 min at 
4°C. Any residual bacterial cells were removed by successive filtration, first with 0.45 μm filter 
and then with 0.22 μm filter. To concentrate the filtrate, the supernatant was loaded on 100kDa 
Vivaflow 200 cassettes (Sartorius AG) and centrifuged at 30,000×rpm for 3 h at 4°C. In this 
study, concentration steps were added for vesicle isolation in E. faecium species (Paper I), 
while for S. aureus, the bacterial free supernatant was directly ultracentrifuged using 45Ti Rotor 
at 30,000 ×rpm for 3 h. The obtained vesicle pellets were either resuspended in ice-cold PBS 
(e.g., proteomics analysis) or RNAlater to protect RNA (e.g., RNA-seq analysis) depending 
upon the experimental goal (Paper I and II). In either case, isolated EVs were confirmed to be 
free of bacterial cells by plating aliquots of EVs on the blood agar plate, followed by incubation 
at 37°C for overnight incubation. EVs are generally stable at room temperature for short-term 
(e.g., overnight) storage; however, preservation at -80°C has been suggested for a long-term 
storage (e.g., a year) 221.  
 
 
Figure 6: Workflow for EV isolation and purification. Figure modified from222. Images adapted 




One of the major challenges in vesicle isolation from bacteria (e.g., Gram-positive)  is that the 
ultracentrifugation protocol result in  a crude pellet that not only contains EVs but also other 
contaminants such as membrane-bound proteins and nanoscale contaminants 220.  Several 
washing steps with PBS can help to eliminate a part of this contamination, and density gradient 
centrifugation can be used for further purification of EVs. Besides, optimization of speed and 
time during the ultracentrifugation step are of utmost importance in the isolation process. For 
instance, the excessive ultracentrifugation speed can lead to a high shearing force that might 
damage EVs.  
2.2 Extracellular vesicles purification by density gradient 
Density gradient ultracentrifugation is widely used for the separation and purification of EVs, 
which separates particles based on their density. The gradient can be generated  by using 
sucrose211 or Optiprep - an iodixanol-based solution223. OptiPrep stock solutions (60%) has a 
density of ~1.3 g/ml and PBS buffer can be used as diluent to prepare various gradients of 
Optiprep (final % Optiprep, v: v). For better purification, the optimal series of gradients are 
prepared in the ultracentrifugation tubes. EVs are either loaded on the top or bottom of the 
gradient depending on the bacterial species. As an example, for E. faecium and S. aureus124 a 
bottom- and top-loading approach were chosen, respectively. One of the biggest advantages of 
OptiPrep is that it to some extend allow depletion of bacteriophages, which are co-pelleted with 
EVs during the isolation processes. However, it doesn’t completely remove all nano-scale 
contaminants (e.g., phage filament, intact phage particles or capsid. In our study, presence of 
vancomycin probably enabled activation of prophages. Electron microscopy analysis revealed 
presence of several of mentioned nano-scale contaminants including phages in specific 
fractions after density gradient centrifugation (data not shown). Our results are in line several 
other studies that  reported co-purification of filamentous phages with EVs 
from  Stenotrophomonas maltophilia upon exposure to ciprofloxacin stress153, possibly due to 
induction of prophages residing in the S. maltophilia 44/98 genome153. Biller and colleagues 
also reported co-purification of the filamentous phage particles along with vesicles even post-
density gradient ultracentrifugation200. 
However, when high yield or enriched EVs is required and Optiprep is not the best option, 
ultrafiltration step can be used. The ultrafiltration column partly remove lipoprotein aggregates 
and thereby help in obtaining enriched EV224. This approach was utilized to minimize eventual 
RNA contamination originated from bacterial cell lysis that could have occurred during EV 




addition of RNase treatment of EVs can further ascertain removal of extracellular RNA we 
cannot rule out the possibility that our EV-associated RNA might contain nanoscale 
contaminants.  
2.3 Physical characterization of bacterial extracellular vesicles 
With the advancement of electron microscopy, which utilizes electrons as a source of 
illumination, one can view the structure of EVs, which are in the range of nanometer scale. The 
morphology of EVs can be visualized using transmission electron microscopy (TEM) and 
atomic force microscopy (AFM).We used the latter approach to evaluate the purity and 
intactness of EVs compared to crude pellet after Optiprep 216. Both methods have strengths and 
weaknesses, which are listed in Table 4. 
Table 4: Advantages and disadvantages with TEM and AFM224. 
Transmission electron Microscopy Atomic force microscopy 
Advantages 
Sample preparation is easier to prepare on 
TEM grids.  
Possible to image the particle size range from 
10–1000 nm and provides information on 
morphology. 
Less background and better signal to noise 
ratio.  
Possible to image vesicles in contact 
independent mode (tapping mode). 
Disadvantages 
Series of fixation and dehydration steps, 
direct contact of vesicles with grids during 
sample preparation, and imaging under 
vacuum and electron beam radiation might 
alter the true morphology of vesicles.  
The EVs are adsorbed onto support surfaces, 
such as mica, resulted in substantial 
background and might modify the structure 
of the vesicles. 
 
The sizes of EVs are measured by dynamic light scattering or Nanoparticle tracking analysis 
(NTA). NTA analysis (Paper II) can provide the possibility to analyze size distribution and 
particle number simultaneously 225. One of the challenges in NTA analysis is to find the 
“appropriate” dilution factor so that the NTA camera can quantify EV particles. Sometimes, in 
a heterogeneous population of EVs, the larger vesicles mask the smaller ones, affecting 
particles' overall concentration. Electron microscopy analysis was used previously for 
quantification of the particle number. However, the method was time consuming as it requires 




In our studies (Paper I and II), we have also used fluorescent dyes, DiD and PKH2, to visualize 
the EVs, as they efficiently bind to the lipid membrane of EVs226,227. One of the disadvantages 
of vesicle characterization using fluorophore conjugate lipophilic dyes is their non-specific 
binding to other co-pelleted contaminants that may be in a crude EV pellet, which subsequently 
might result false positive signals. Similarly, to validate the association of RNA with the EVs 
cargo, the commercially available RNA staining dyes (e.g., acridine orange, Syto84 or Syto-
RNASelect)228 can be used (Paper II), although  the specificity and efficiency of such dyes has 
not been validated so far228. 
In addition to particle number,  quantification of the EVs yield can be  performed based on 
protein estimation, e.g., Bradford reagent, bicinchoninic-acid assay (BCA), or lipids (FM4–
64)229. The choice of method might result in different EV yield. Hence, combination of various 
quantitative techniques (protein estimation, lipid estimation, and particle counts) are useful to 
assess the comparison of EV production under different growth conditions.  
2.4 Identification of proteins associated with vesicles by mass spectrometry 
Mass spectrometry (MS)-based approach is increasingly used for proteome identification. It is 
a powerful analytical technique due to its high-throughput nature, excellent sensitivity and 
selectivity. The label free proteomics approach was employed to study the EV associated 
proteome including, virulence factors, vaccine candidates, and antimicrobial resistance 
determinants, (Paper I and Paper III). After gradient centrifugation, aliquots of the fractions 
were loaded on the SDS-PAGE gel. Fractions with similar protein profiles were pooled 
together, and the EV- associated proteins were precipitated in TCA/Acetone, before being 
delivered to the Core-facility for the downstream analysis (Paper I and III). Next, the 
precipitated proteins went through urea re-solubilization and proteolytic digestion. Trypsin is 
generally used to cleave complex proteins into peptides due to its unique cleavage pattern at the 
C-terminal side of lysine and arginine residues230. Once the peptides are formed, they are 
separated on a nano-Liquid chromatography system based on differences in hydrophobicity and 
polarity of the peptides. Each peptide elutes at a specific retention time and is analyzed by 
MS/MS. The obtained spectra are matched to in silico-generated spectra using a database of 
known proteins and bioinformatics software such as Proteome discoverer with an inbuilt 
SEQUEST algorithm. To identify the accurate number of proteins, the database must be 
updated with correct protein sequence information. One of the disadvantages associated with  




such as reduction, alkylation, dehydration, and rehydration during protein extraction and 
digestions231. 
One of the challenges associated with EVs' proteomic analyses is low protein yield in pure EV 
fractions obtained after OptiPrep. The proteomics can also be performed on crude EV pellets. 
However, the membrane debris and lipoprotein aggregate co-pelleted during ultracentrifugation 
will affect the purity, thus questioning the validity of proteome profiling232. The choice of 
purification level of EVs for proteomic characterization depends upon the research question. 
For instance, if the purpose of the study is to identify vaccine candidates or to discover 
biomarkers, vesicles of high purity are needed.  
2.5 RNA sequencing 
RNA-sequencing (RNA-seq) produces millions of short (15-150 nt) sequences reads that 
constitute fragments of RNA. The RNA may be protein-coding or non-coding and incudes small 
RNA, which have regulatory functions. With these powerful techniques, it is possible to study 
gene expression and characterize novel transcripts at single-nucleotide resolution. To obtain 
proper sequencing results, the purity and yield of RNA is of utmost importance. The process 
typically consists of isolation of RNA, enrichment of non-ribosomal RNA, conversion of RNA 
to cDNA and assembly of cDNA library before sequencing on a high-through platform such as 
Illumina. 
 
Figure 7: Schematic representation of RNA-seq workflow for isolated EVs. 
The extraction of RNA from Gram-positive-derived EVs is challenging due to their release of 
little amount of EVs, which is consequently resulted in a low yield of RNA. To obtain a 
sufficient amount of EVs-derived RNA for downstream sequencing analysis, we pooled EVs 
isolated from several rounds of purification (500 mL cultures of S. aureus grown under stress 
condition) (Paper II). Next, sRNA was isolated using miRNA extraction kit and went through 




depletion strategies (Table 5), Ribo-zero rRNA depletion were employed due to efficient 
elimination of 16S and 23S rRNA from most of the bacterial species and its compatibility with 
fragmented RNA. 
2.5.1 Bioinformatics analysis of RNA-seq data 
The output of EVs-derived RNA-sequencing from Illumina consists of FASTQ files. FASTQ 
files contain information about the total number of sequences, sequence length distribution and 
percentage of GC content, which are important measurements for quality control. Based on % 
GC content, it is possible to predict the sequence reads carries any contamination originated 
from other species. The quality of sequence reads is based on the Phred scores. Generally, in 
the context of sequencing, Phred-scaled quality scores of 20 or above is acceptable.  
FASTQ files can be aligned to a reference genome by various alignment tool such as TOPHAT, 
BowTie or others. In our study (Paper II), BowTie 2 aligner was used since it is ultrafast, 
memory-efficient alignment program widely used to align sequence reads to large genomes233. 
Upon alignment, the software generates a Sequence Alignment Map (SAM), a text-based 
format suitable for storing aligned biological sequences. As SAM file requires huge space for 
storage, thus they converted to binary version, also called BAM files (.bam), which are memory 
efficient, faster to process, and importantly can be indexed. Several visualization/analysis tools 
can be used for  downstream analysis, including Tablet234, EagleView 235, Artemis236, and 
Integrative Genomics Viewer (IGV)237. An important feature of Artemis compared to other 
tools, is the possibility of annotating novel RNA. Similarly, IGV is useful for creating Sashimi 
plots, which provide information about transcript isoforms and splice junction variation 
commonly seen in eukaryotes. We also used Artemis (Paper II) due to its user-friendly web- 
based graphical interface that provides a comprehensive set of reading alignment views as well 
as an insight on coverage. Moreover, the sRNA information available from database such as 
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3. Objective of the study 
The overall aim of this PhD study was to characterize the EV cargo of two Gram-positive 
nosocomial pathogens, S. aureus and E. faecium. The study specifically aimed to explore 
whether stress and growth conditions influence the EV cargo.  
Specific objectives of paper I 
1) To evaluate whether clinical E. faecium strains release EVs 
2) To explore whether the enterococcal proteinaceous cargo is influenced by growth 
conditions 
3) To identify virulence factors and vaccine candidates associated with EVs  
Specific objectives of paper II 
1) To evaluate whether small RNAs are associated with S. aureus derived EVs  
2) To characterize the sRNAs associated with the EVs 
Specific objectives of paper III  
1) To evaluate the proteome profile of MRSA (USA300)-derived EVs grown in the 
absence or presence of sub-therapeutic concentrations of vancomycin.   
2) To explore the interactions between exogenously administered MRSA-derived EVs 




4.  Summary of results  
Paper I: Enterococcus faecium produces membrane vesicles containing virulence factors 
and antimicrobial resistance related proteins. 
E. faecium release membrane vesicles, which are spherical in shape and heterogenous in size. 
The size of vesicles ranges from 37 ± 23 nm in E155 strain to 83 ± 29 nm in the K59-68 strain. 
The vesicles were negatively charged and contained lipids and fragments of peptidoglycan. The 
EV-associated proteins varied among the strains and growth conditions. AtlA and SagA, 
involved in biofilm formation, were associated with EVs of all strains and both examined 
growth conditions (stationary and exponential growth phase). In addition, several immunogenic 
proteins such as penicillin-binding protein (PBP5), peptidoglycan-binding protein (LysM), D, 
D-carboxypeptidase (DdcP, and peptidyl-prolyl-cis-trans-isomerase (PpiC) were found in the 
EVs isolated from the four strains. In addition, 11 antimicrobial resistance-related proteins, e.g. 
the vanA cluster contributing to vancomycin resistance, was associated with EVs from E. 
faecium. 
Paper II: Transcriptome profiling of Staphylococcus aureus associated extracellular 
vesicles reveals presence of small RNA-cargo. 
Iron-depletion and sub-inhibitory concentration of vancomycin resulted in five folds increase 
in EVs obtained from S. aureus MSSA476. The presence of RNA associated with EVs was 
confirmed by confocal microscopy using RNA and lipid specific dyes.  In RNase treated EVs, 
~ 73% co-localization of RNA and lipid stained particles was found.  RNA-seq data showed 
presence of sRNA, tRNA, mRNA and various riboswitches including T-boxes. The most 
enriched sRNAs (SsrA, RsaC and RNAIII) identified by RNA-seq were further validated by 
qPCR, conventional PCR and Sanger sequencing.  
Paper III: Bacterial membrane-derived vesicles attenuate vancomycin activity against 
Methicillin-Resistant Staphylococcus aureus. 
We found that exogenous administration of EVs resulted in increment of the minimum 
inhibitory concentration (MIC) of vancomycin (VAN), a cell wall targeting antibiotics, up to 
two to four fold against MRSA  (USA300 strain) grown in convenient laboratory media (CA-
MHB) and physiological media (RPMI+5%BHI), respectively. The exogenous addition of EVs 
did not increase the MICs of nafcillin (NAF), cefazolin (CFZ) or daptomycin (DAP) in either 
media. In addition, increased survival of MRSA was found in presence of whole blood and 




Proteomic analyses revealed upregulation of multiple antibiotic resistance regulators, amino 
acyltransferases, and proteins known to facilitate resistance to β-lactams and quinolones upon 





5. General discussion 
Every species on the planet, from prokaryotes to eukaryotes, release extracellular vesicles. The 
EVs are involved in the maintenance of bacterial physiology and ecology, including nutrients 
transfer and release of antimicrobial compounds for survival and competitions. EVs also play 
a role in host-microbe interactions, e.g., during infection. Therefore, characterization of EVs 
released by these bacteria is worthwhile to research endeavor. 
The thesis aimed to get insight on extracellular vesicles cargoes shed by S. aureus and E. 
faecium. In the Paper I, we explored the proteome of the E. faecium-derived EVs and identified 
various EV-associated proteins that might be involved in promoting virulence, antimicrobial 
resistance and pathogenicity. In the Paper II, we identified the sRNAs associated with EVs 
(both embedded in the membrane and inside lumen) released by S. aureus strain MSSA476. 
Three sRNAs (SsrA, RNAIII, RsaC), were among the most enriched. These have molecular 
targets associated with metabolism, virulence and transport. In the Paper III, we found that 
exogenous addition of EVs derived from parental strain (MRSA USA300) increased the MIC 
up to 4-fold in physiological media, and thereby seemed to protect MRSA against killing by 
vancomycin, which is probably due to the decoy action of EVs.  
4.1 Size and morphology of EVs from S. aureus and E. faecium 
Three nosocomial E. faecium blood-stream isolates (DO, K59-68, and K60-39) and one fecal 
isolate (E155) and two S. aureus strains (MSSA476 and MRSA USA300) were selected for the 
studies. Although the morphology of EVs was found to be spherical in all selected species, their 
size, yield, and proteinaceous cargo were influenced by the species and growth conditions (e.g. 
media) (Paper I-III).  
The sizes of E. faecium-derived EVs varied between 37 nm (E155 strain) to 83 nm (K59-68 
strain) (Paper I). This is in concordance with another study where EVs were isolated from a 
vancomycin-resistant fecal isolate (E. faecium ATCC 700221) and reported spherical EVs with 
a size of ≤50 nm239. Similarly, we found spherical EVs with a heterogenous size (100-150 nm) 
in S. aureus MSSA476, which is consistent with others studies124,164,239 showing the mean size 
of EVs produced by various S. aureus strains (MW2, N305, RF122, O11, and O46) of diverse 
origins (human, bovine and ovine) was reported be less than ≤ 200 nm128. Notably, we should 
not rule out that the techniques used for size measurement, including tunable resistive pulse 
sensing (TRPS), NTA, AFM, and EM240 can influence at low extent on the outcome of 




considering using EVs as drug delivery tools132. The small size of EVs provides flexibility to 
cross the major biological membrane, even blood-brain barriers241, and EV loaded drugs can 
have the potential to treat neurological disorders.  
4.2 Extracellular vesicles associated proteins involved in vesicle biogenesis 
The ability to form EVs from thick-wall Gram-positive bacteria was neglected for a long period. 
Although our understanding of bacterial EVs begun soon after their discovery around 1960, 
research on the characterization of EV cargo from S. aureus was only started in 2009131. 
Afterward, multiple studies have been performed to characterize EVs cargo from other Gram-
positive bacteria using different high-throughput omics technology, e.g. proteomics, 
transcriptomic, and lipidomics. Moreover, functional assessment of EV- associated virulence 
factors and nucleic acid (RNA) upon interaction with host cell has also been 
studied124,135,164,208,242. It is still debatable how vesicles are formed from Gram-positive 
organisms with complex and thick cell walls. There were three hypotheses postulated for the 
biogenesis of EVs i) turgor pressure mediated vesicles release; ii) cell wall remodeling enzyme 
creating holes in peptidoglycan, thereby facilitating EVs release; iii) EVs release via protein 
channels126.Schlatterer and colleagues demonstrated that EV biogenesis depends upon the 
turgor pressure and presence of PSM peptides, which enhances the membrane fluidity243. Taken 
together and considering the thick peptidoglycan cell wall, it is conceivable to support the 
notion that enzymes interfering with peptidoglycan crosslinking (e.g., penicillin-binding 
protein (PBP), autolysin) and enzymes that enhances membrane fluidity (e.g., PSM) are key 
factors in vesiculogenesis. Using proteomics approach, we found that PBP and autolysin were 
associated with the EVs generated by nosocomial clade of E. faecium and S. aureus (Paper I 
and Paper III). We also detected PSM in the EVs cargo of S. aureus. The involvement of PBP, 
PSM and endolysin in release of EVs from S. aureus with higher yield has been previously 
reported183,244. Interestingly, PBPs and autolysins were also detected in EVs released from other 
Gram-positive bacteria such as Listeria monocytogenes136, Propionibacterium acnes245, 
Bacillus anthracis134, and Filifactor alocis148.  
Antibiotics such as vancomycin, a cell wall targeting antibiotics, and other stress factors such 
as temperature and nutrient limitation are known to be triggers for vesiculation127. Considering 
the vancomycin mechanism of action, this might be mediated by weakening the cell wall via 
inhibiting cross linking of peptidoglycan. We found a fivefold increase in the EV particle count 




presence of sub-MIC of vancomycin (Paper II). In addition, we observed that exposure to the 
stress was also induced the release of bacteriophages (Paper II). Interestingly, EV release 
triggered by phage endolysin is well demonstrated in B. subtilis and S. aureus198,244. 
4.3 EV associated proteins involved in virulence 
Using a proteomics approach, we found that several virulence factors were associated with the 
S. aureus or E. faecium -derived EVs (Paper I and III). This is also well-documented in several 
other studies performed on S. aureus124,128,131,135. Various adhesins (CapD and PrpA), collagen-
binding proteins (Acm and Scm), and fibronectin-binding protein (Fnm) are involved in host 
cell invasion leading to the pathogenesis of E. faecium32. In the Paper I, we found several of 
these virulence factors associated with EVs. We could hypothesize that the EVs containing 
these virulence factors might influence E. faecium pathogenesis; however, this remains to be 
investigated. Askarian and colleagues reported that exogenous addition of bacterial EVs at a 
concentration of 20µg can augment bacterial survival in presence of human blood, however the 
bacterial survival is abolished by exposure to sonicated/and or proteinase K treated EVs124. In 
addition, in all four isolates belonging to the nosocomial clade of E. faecium, the virulence 
factors AtlA and SagA were found to be EV-associated. AtlA and SagA are both involved in 
biofilm formation246, and might do similar as part of EVs.  
Biofilm is usually formed by aggregation of single or multispecies bacterial population 
surrounded by self-produced extracellular matrix. In addition, other microbial components such 
as pili, flagella, phage and EVs have been reported within microbial biofilms121. EVs not only 
support microbial community within biofilm by sharing nutrients to the colonizing 
microorganisms, but also send signaling compounds such as 2-heptyl-3-hydroxy-4-
quinolone (PQS) for co-aggregation of bacterial populations. PQS is essential for microbial 
communication (quorum sensing), biofilm formation247 and EV formation for Pseudomonas 
aeruginosa248.  
Both S. aureus and E. faecium are biofilm producers and can form biofilm on human body parts 
such as in the urinary tract and deep-seated wounds and on indwelling medical devices like 
catheter. Organisms within biofilms are resilient towards antibiotics and may survive within an 
encapsulated sheath of exopolysaccharides and proteins as persister cells249. Persisters are 
mostly resistant towards antibiotics, even after the disruption of biofilm by antimicrobials, 
viable persister cells are capable of repopulating and reforming biofilms thus ultimately 




biofilm, persister cells and EV formation could be novel strategies for hard to treat chronic 
infections 250.  
4.4 EV-associated nucleic acid 
EV-associated RNA released by S. aureus is challenging to work with, as Gram-positive 
bacteria shed very little amounts of EVs. We made a first attempt to validate RNA as part of 
the EV cargo of S. aureus (Paper II). The bacteria were grown under stress (iron-depleted BHI 
in presence of sub-inhibitory concentration of vancomycin) as this enhance vesicles yield. 
Various literature underscores the importance of stress for hypervesiculation and modulation 
of regulatory RNA in bacteria127,251. We found fragments of sRNA and tRNA enriched in EVs 
protected from exogenous RNase (Paper II). Interestingly, we have identified and validated a 
few sRNA fragments (e.g., SsrA, RNAIII, and RsaC) associated with S. aureus EVs. RNAIII 
is the longest sRNA (514 nt) known in S. aureus. It is also known as dual RNA because due to 
its  regulatory function and encoding a 26 amino acid long δ-endotoxin, which the latter seems 
to play a role in lysis of host cell membranes252. RNAIII also acts as an effector of the 
Agr quorum-sensing system in S. aureus cells and is involved in biofilm formation. Whether 
EV-associated RNA also contributes to biofilm formation, analogous to EV-associated eDNA 
that is upregulated during biofilm formation by Strepotocccus mutans, is yet to be proven253 . 
One might speculate that EVs act as a “postman” to deliver the cargo, including RNA 
molecules, to the target cells as a sole purpose for communication. In one of the studies, 
alignment of EV-associated sequence reads to the human genome using bioinformatics resulted 
in unique alignment to 14 different chromosomes, including X and Y chromosomes. The 
alignment of bacterial reads to human reads is not a very common phenomenon and more 
surprisingly, most of the aligned regions are on human long non-coding RNA involved in 
epigenetic modulation202,254. Similarly, some exciting results on human as well as plant- derived 
exosomal RNA prove that they can be involved in shaping the composition of gut 
microbiota255,256. E. faecium is part of commensal microbiota and might also modulate gene 
expression of other gut microflora residing in the same ecological niche or modulate gene 
expression of the host cells via the transfer of sRNA. The reciprocal regulation of gene 
expression between bacteria and host cells through exchange of sRNA via EVs and/or exosome 
open up a novel research area within host microbe interactions257. 
For future studies, it will be interesting to validate whether EVs can pack full-length transcript 




fragmented ones. So far, no studies have addressed whether S. aureus and E. faecium EVs are 
associated with DNA. Nevertheless, there are few reports showing EV mediated gene transfer 
in Gram-positive bacteria195,258. One study described  encapsulation of genetic material up to 
370 Kbp by EVs259. Since E. faecium are continuously evolving via the exchange of genetic 
material through horizontal gene transfer, other non-canonical pathways as “vesiduction” 
merits further investigations195. The transfer of genetic material via EVs have been reported 
from various bacterial species found from diverse ecologies like the deep sea and anaerobic 
environments such as the gut of ruminants (Ruminococcus species) and inner tooth cavities 
(Porphyromonas gingivalis)212,260.  
The interplay between host and microbe is a very dynamic process. During the infection 
process, pathogenic bacteria release EVs and deliver their cargo to host cells. To protect against 
infections, host cell also releases exosomes261. Indeed, EVs released by infected host cells 
contained pathogen-derived factors, e.g. lipoarabinomannan (LAM), CFP-10 (Rv3874), and 
circulating sRNA (ASdes) during Mycobacterium infection262,263. sRNA-associated with EVs  
is stable in human circulation for a considerable time and can resist over 100 ng/mL of RNase, 
which is present in tissue and body fluids195, implicating their potential as biomarkers.  
Generally, small RNA present in bacteria are not always constitutively expressed by the 
bacterial cells, as particular conditions including nutrient limitation, antibiotic exposure, change 
in pH, or oxidative stress for transcriptional induction264 are required. The stress condition 
(chelex treated BHI +antibiotics) that employed for vesicles isolation in Paper II mimic an 
infection condition in host. It would be interesting to explore other physiological relevant media 
such as RPMI1640 supplemented with bacteriologic media to support the bacterial growth for 
EV isolation and compare the yield and analyze the differentially enriched RNA in the presence 
of host components such as immune cells and/or mammalian exosomes.  
4.5 EVs and influence on spread of AMR and sensitivity to antimicrobials 
The detection of antimicrobial resistance determinants in EVs of E. faecium described in the 
Paper I (ribosome methylase ErmB, the aminoglycoside modifying enzymes Aac6′-Ie-Aph2′′-
Ia and Aph3′-III, and vanA cluster proteins involved in vancomycin resistance) might play an 
important role in drug resistance between commensal E. faecium and other gut microflora. It 
will be interesting to explore EV-mediating transfer of the above-mentioned antimicrobial 
resistance determinants to antibiotic sensitive commensal E. faecium strains.  In a microbial 




other species offers a survival advantage by sharing of the “public goods”265 and EVs play a 
key role in this phenomenon. For instance, it was shown that EV could mediate transfer of a 
carbapenem resistance (blaOXA-24) gene to a susceptible strain of Acinetobacter baumannii , 
thereby providing  protection against carbapenems266. The presence of resistant determinants 
and virulence factors in the bacterial EVs may serve as an efficient mean of dissemination of 
resistant genes, enzymes (β-lactamase, methyltransferase), and antimicrobial compounds. In a 
polymicrobial infection, exchange of resistance genes and protein through EV adds an extra 
layer of complexity to the understanding of host-microbe interactions and the development of 
therapeutic strategies.  
Vancomycin is considered as one of the last resort antibiotic for the treatment for MRSA and 
several other Gram-positive strains267. The glycopeptide antibiotic vancomycin inhibits 
peptidoglycan chain elongation by binding to the D-Ala-D-Ala residue of peptidoglycan 
precursors, which interferes with peptidoglycan crosslinking and eventually hinder cell wall 
biosynthesis and result in bacterial death. Vancomycin is still the drug of choice for over 50 
years to treat MDR infections in clinical settings. The treatment failure associated with organ 
toxicity (nephrotoxicity, ototoxicity) compounded by the emergence of resistant pathogens has 
questioned the therapeutic utility of this drug268.  
In Paper II and Paper III, we used vancomycin to stress the bacteria and characterize EV 
cargo. In Paper III, we found that the MIC of vancomycin was enhanced to 4 mg/L, when 
growing clinical MRSA strain in a more physiological medium (RPMI) in the presence of 
exogenously administered EVs. EUCAST has recommended the MIC breakpoint for S. aureus 
to be 2 mg/L against vancomycin when tested in Mueller Hinton Broth (MHB) 
(https://www.eucast.org/clinical_breakpoints/). Under these conditions, a MIC value above 2 
mg/L is determined as resistance towards vancomycin in MRSA. Hence, the observed MIC 
enhancement may contribute to therapeutic failure of vancomycin in clinical settings. While 
studying host-microbe interaction in vitro, it is beneficial to use physiological media such as 
RPMI instead of lab-based conventional media. For MIC testing, the Muller Hinton Broth 
(MHB) has been implemented in the diagnostic laboratory since 1941 and is still used in 
hospitals. Although MHB has made a substantial contribution to antibiotic susceptibility testing 
(AST) and drug discovery, it is high time to rethink and modify the chemical composition to 
resemble more host like conditions. The AST performed on conventional media like MHB were 




more host like condition and revealed specific antibiotics that caused bacterial clearance 
although standard MIC testing suggested these antibiotics were not effective. The MIC values 
obtained from host mimic media (RPMI, MHB+NaHCO3) may be more reliable/comparable to 
the infection condition269.  
One of the possible mechanisms of augmented MIC (≥ 2 mg/L) of vancomycin in presence of 
EVs could be the decoy action of EVs. We observed that stress can induce increased shedding 
of EV from S. aureus in vitro (Paper II). Induction of vesiculation has been reported in S. 
aureus upon exposure to several cell-wall targeting antibiotics such as vancomycin270, and 
daptomycin271 which supports the decoy action of EVs272,273. Moreover, the absorption or 
entrapment of antibiotics by EVs from E. coli274 and Shigella flexneri272 has been previously 
suggested. Thus, one might speculate that upon co-incubation of MRSA with EVs and 
vancomycin, the increased MIC might be due to either the role of EVs as decoy or due to 
entrapment of vancomycin by EVs thereby offering protection to bacteria. To follow up the 
study, it would be interesting to visualize vancomycin localization in bacteria and/or EVs in a 
co-culture condition using fluorescence dye such as vancomycin BODIPY275. This will help to 
ascertain if it is only the decoy action of EVs that protects MRSA killing against vancomycin 
or the decoy action can result in entrapment of the antibiotic. Additional experiments should be 
done to address the influence of other confounding factors such as strain to strain variation, 
laboratory set condition for MIC testing, slight changes in media composition and fluctuation 
in incubation temperatures276. 
Besides MIC and checkerboard assay, other ex vivo assays (such as whole blood killing assay, 
neutrophil killing assay and serum killing assay) were also studied in Paper III. Literature 
suggests bacteria can release EVs in vivo277. EVs were found to increase the survival of MRSA 
co-incubated with sub-MIC dosage of vancomycin. To understand the mechanism of survival, 
we have done proteomics assay to reveal differentially expressed proteins associated with EVs 
isolated under normal and vancomycin stress. Interestingly, we found substantial increase of 
catalase and Alkyl peroxide reductase under vancomycin stress conditions. One might speculate 
that ROS mediated killing mechanism of phagocytic cells such as neutrophils might be nullified 





4.6 Therapeutics use of EVs as vaccine candidate and antimicrobial agent 
Interestingly, the EV- associated virulence factors isolated from four different hospital-
associated enterococci showed an enrichment of peptidoglycan associated surface-anchored  
proteins, including PBP5 (Penicillin-binding protein), LysM (Peptidoglycan binding protein), 
DdcP (D,D-carboxypeptidase), and PpiC (Peptidyl-prolyl-cis-trans-isomerase) (Paper I). All 
of these could be utilized as vaccine candidates because they are surface exposed and suitable 
for easy recognition by immune cells for enhancing immune responses279. Saavedra and 
colleagues reported that rabbit antisera raised against all four recombinant proteins was efficient 
in killing not only E. faecium belonging to CC17 but also multiple E. faecalis280. The EV cargo 
released by E. faecium also contains peptidoglycan hydrolase SagA, which was very recently 
reported as a promising vaccine candidate in a glycoconjugate form consisting of SagA and 
capsular polysaccharide Diheteroglycan. Unlike polysaccharide antigen, which are considered 
a poor immunogen 281, the glycoconjugates with carrier proteins can elicit long lasting humoral 
immune responses via activation of T-cells282.  
For enterococcal vaccine design, attention should be paid to design a vaccine in such a way that 
it should be effective against the nosocomial strains but must safeguard asymptomatic carriers 
where enterococci are part of normal gut flora. Furthermore, vaccination against E. faecium is 
useful for patients having underlying diseases and belong to high-risk groups and/or are already 
infected with VRE. Commensal E. faecium SagA protected worms against Salmonella 
pathogenesis and boosted the efficiency of probiotic bacterial activity against Clostridium 
difficile pathogenesis in vivo283,284. In addition, the SagA also possessed anti-candida 
activity285. The secretion and packaging of SagA and other proteins inside EV cargo protect 
them against degradation by extracellular protease and assist in long-distance delivery. Further 






6. Conclusion and future perspectives 
The discovery of EV production by Gram-positive bacteria is relatively new. Both E. faecium 
and S. aureus have ambiguous positions in terms of causing infection. Scientific investigations 
on bacteria and their EVs are required to understand more regarding the mechanism of 
pathogenesis. Given the importance of characterizing the EV cargos, which are released by 
pathogenic bacteria, we isolated EVs from E. faecium and S. aureus and characterized their 
cargoes using transcriptomics and proteomics approaches. These descriptive studies of the 
proteome and transcriptome of EVs provide basis for future studies of their functions. Our data 
revealed that several virulence factors, immunogenic proteins, and small RNAs were associated 
with the EVs. The mechanism by which EV cargos are shuttled between same or different 
kingdoms and regulate gene expression in recipient cells is still in infancy. Considering the 
presence of virulence factors, targeting EVs can be a putative anti-virulence therapy approach 
to “disarm” the pathogen. The detection of immunogenic antigen (SagA) and small RNA (SsrA) 
associated with EVs holds promises for the development of vaccine and biomarkers for 
diagnostics and prognostic purposes.  
The recently explored arena of extracellular vesicles among Gram-positive bacteria has 
knowledge gaps and hopefully will be addressed in near future. Some of them includes 1) 
Which genes and/or proteins trigger extracellular vesicles formation? 2) Why do bacteria pack 
several bioactive molecules (proteins, nucleic acids and virulence factors) inside EVs? 3) Is the 
packaging of EVs cargos stochastic / random process or a conserved mechanism regulated by 
specific set of genes or proteins? 4) Are the EVs-associated sRNAs modulating the response of 
human-host? With the advancement in the largescale EV isolation and purification techniques, 
biophysical characterization using advanced imaging (super resolution microscopy), high-
throughput sequencing technology and advanced bioinformatics pipelines, it will be possible to 
decipher fundamental biology of EVs in the future. Improving our understanding within this 
field will provide an asset to utilize EVs for therapeutics purposes including as vaccines, novel 
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A B S T R A C T
Enterococcus faecium is a commensal but also a bacteremia causing pathogen, which is inherently resistant to
several antimicrobials and has a great ability to acquire new traits. Bacterial membrane vesicles (MVs) are
increasingly recognized as a mode of cell-free communication and a way to deliver virulence factors and/or
antimicrobial resistance determinants. These features make MVs interesting research targets in research on
critical hospital pathogens. This study describes for the first time that E. faecium strains produce MVs. It presents
a morphological as well as a proteomic analysis of MVs isolated from four different, clinically relevant E. faecium
strains grown under two different conditions and identifies MV-associated proteins in all of them. Interestingly,
11 virulence factors are found among the MV-associated proteins, including biofilm-promoting proteins and
extracellular matrix-binding proteins, which may aid in enterococcal colonization. Additionally, 11 anti-
microbial resistance-related proteins were MV-associated. Among those, all proteins encoded by the vanA-cluster
of a vancomycin resistant strain were found to be MV-associated. This implies that E. faecium MVs may be
utilized by the bacterium to release proteins promoting virulence, pathogenicity and antimicrobial resistance.
Significance: Enterococcal infections, especially bacteremia and endocarditis, are challenging to treat because E.
faecium have acquired resistance to multiple classes of antimicrobials, including ampicillin, aminoglycosides,
and glycopeptides. Thus, research on different modes of enterococcal pathogenicity is warranted. This study
utilized a proteomic approach to identify MV-associated proteins of different nosocomial E. faecium strains re-
presenting four clinically relevant sequence types (STs), namely ST17, ST18, ST78, and ST192. The presented
data suggest that E. faecium MVs are involved in virulence and antimicrobial resistance.
1. Introduction
Enterococci are Gram-positive, ubiquitous, facultative anaerobic
cocci. They are known to survive hostile conditions such as a saline
environment and wide temperature ranges and also for their ability to
persist long-term in the hospital environment [1]. Enterococcus faecalis
and Enterococcus faecium naturally colonize the human gut as com-
mensals. However, E. faecium in particular has undergone a pronounced
transition towards a multi-drug resistant pathogen. The most common
infection caused by E. faecium is urinary tract infection, but they may
also cause life-threatening infections such as endocarditis and bacter-
emia, especially in debilitated patients [2]. The genetic clade structure
of E. faecium is characterized by a distinct split of commensal lineage
(clade B) and hospital-associated lineage (clade A1) [3]. The nosoco-
mial A1 clade includes sequence types (STs) of the clonal complex 17
(CC17), a globally spread genetic complex characterized by ampicillin
resistance, possession of a pathogenicity island and association with
hospital outbreaks [4].
Extracellular vesicles are suggested as a mechanism for cell-free
intercellular communication across all domains of life. They are crucial
components of the bacterial secretome, as these 20–200 nm sized
spheres contain lipopolysaccharides, soluble membrane-associated
proteins, virulence factors and nucleic acids [5, 6].
Bacterial membrane vesicles were first described in the Gram-
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negative Escherichia coli in the 1960s [7, 8], and later in several other
Gram-negative species such as Shigella sp. [9], Salmonella sp. [10], and
Vibrio sp. [11]. In Gram-negative bacteria, the vesicles are called outer-
membrane vesicles (OMVs), as they derive from the outer membrane
(OM). The OMVs contain OM components as well as inner membrane
constituents and cytoplasmic elements. The role of OMVs in bacterial
physiology and pathogenesis, stress responses, biofilm formation as
well as secretion and delivery of biomolecules has been demonstrated
[12]. The mechanism of vesiculogenesis is poorly understood but seems
to involve phospholipid accumulation in the outer leaflet of the outer
membrane, whereupon vesicles pinch off from the outer membrane
among Gram-negative bacteria [13].
It used to be a long-standing assumption that the thick cell wall of
Gram-positive bacteria precluded the existence of vesicles, as they
could not escape such a barrier. Gram-positive MVs were discovered in
a study from the early 1990s in Bacillus cereus and Bacillus subtilis [14],
but not further characterized for the next 20 years. Finally, in 2009 MVs
were described in Staphylococcus aureus [15] and have since gained
increased attention, i.e. in Bacillus anthracis [16], Mycobacterium tu-
berculosis [17] and others, as reviewed by Brown et al. [6]. MVs are key
players in host-pathogen interactions, as they can cause disease without
the living bacterial cell [18] and may induce strong host responses [19].
MV production in enterococci has not been described previously.
The aim of this study was therefore to explore the potential of MVs
release from E. faecium. In addition, we investigated whether different
cultural conditions and strain backgrounds may account for variation in
proteinaceous cargo. Four strains representing different, clinically im-
portant sequence types (STs) within CC17, the major disease causing
clonal complex [20]: ST17, ST18, ST78, and ST192 respectively, were
therefore chosen for the study. To the best of our knowledge, this is the
first report describing MV release by clinical strains of enterococci and
their proteomics-based characterization using an in-solution approach.
2. Materials and methods
2.1. Strains and growth conditions
In the present study, the E. faecium strains DO (PRJNA71), E155
(PRJNA192879), K59-68 (in-house sequenced, under submission) and
K60-39 (PRJNA407052), representing ST 18, 17, 78 and 192, respec-
tively, were used. They are hospital isolates either from the US or
Norway. Their properties and additional information are presented in
Table 1.
E. faecium strains were routinely cultured on brain heart infusion
(BHI) or Luria Bertani (LB) agar or in liquid BHI or LB at 37 °C.
2.2. Isolation of membrane vesicles
Vesicles were isolated as described for S. aureus [16, 21] with a few
modifications.
First, to isolate vesicles from bacteria mainly in a viable state, cul-
tures in mid-exponential growth phase grown in nutrient-rich BHI were
used (Fig. S1A). Therefore, 1 L of BHI broth were inoculated with en-
terococci grown overnight in BHI broth (1100) and grown at 37 °C with
shaking (230 rpm) to mid-exponential phase (optical density at 600 nm
[OD600], approximately 1.5). The cultures were centrifuged at 6000×g
for 30min with a JLA 9.1000 rotor Beckman Instruments Inc., USA) and
the supernatant was transferred to a clean Erlenmeyer flask and filtered
through a 0.22 μm pore size filter (Merck Millipore, USA). The obtained
bacterial-free filtrate was concentrated using Amicon tubes (Merck
Millipore, USA, cut off 100 kDa) in a “Beckman” centrifuge at 4000×g
for 30min at 4 °C and the concentrate was ultracentrifuged using a SW
40-TI rotor (20,000 x g for 3 h at 4 °C) to pellet MVs. The MVs were
washed in phosphate-buffered saline (PBS) followed by another ultra-
centrifugation, before re-suspention in PBS. Purified MVs were stored at
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to confirm the sterility of isolated MVs.
Second, in order to isolate vesicles from bacteria under stress,
bacterial stationary phase cultures grown in growth-limiting LB were
used (Fig. S1B). For this, the above-described procedure was applied to
enterococcal overnight cultures grown in LB.
2.3. Density gradient centrifugation (DGC)
DGC was performed in order to fractionate and purify the MVs
further. Therefore, the MV sample was mixed with an equal volume of
ice-cold 60% OptiPrep (Sigma-Aldrich, Germany; 60% stock) to obtain
a 30% solution. The 30% solution was transferred into the bottom of an
ultracentrifugation tube (ultraClear™, 5 mL, 13×51mm, Beckman
Instruments Inc., USA) and 2mL of 25% (w/v), 1 mL of 5% (w/v)
OptiPrep solution and PBS were added. Centrifugation was carried out
at 100000×g for 3 h at 4 °C (rotor SW 50.1, Beckman Instruments Inc.,
USA) in slow acceleration and deceleration mode to prevent dis-
turbance in the various density layers and achieve MV ring formation
(see example in Fig. S2A). After centrifugation, the sample was divided
into 200 μL fractions, which were transferred into clean Eppendorf
tubes. Aliquots of the fractions were analyzed by SDS PAGE (see ex-
ample in Fig. S2B) and electron microscopy.
To remove the OptiPrep solution, the fractions containing MVs were
pooled and concentrated by ultrafiltration (10 kDa molecular weight
cut-off, Vivaspin 20, Sartorius, Germany) at 4000×g for 30min at 4 °C
and re-suspended in 200 μL PBS.
2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE)
Protein profiling of isolated MVs from all the four strains of en-
terococci was determined by SDS-PAGE using standard molecular stain.
Briefly, 15 μL of MV sample were mixed with 5.75 μL 4× NuPage LDS
sample buffer (NuPage Novex 4–12%; Invitrogen, Life Technologies,
USA) as well as 2.3 μL of dithiothreitol (DTT) and heated for 10min at
70 °C prior to electrophoresis. Samples were separated by 12% NuPage
Bis-Tris SDS-PAGE gel, and the gels were fixed in fixation solution
(methanol, acetic acid (50/50 v/v)) for 1 h at room temperature under
gentle agitation. The gels were then stained with Coomassie solution
(50% methanol, 10% acetic acid, 0.05% Coomassie brilliant blue R-250,
Thermo Fisher Scientific USA) for 1 h and excess dye was removed
through incubation in de-stain solution (H2O, methanol, acetic acid
(50/40/10v/v/v)) until bands were visible.
2.5. Transmission electron microscopy (TEM) analysis
Five μL of purified MVs were applied to Formvar coated 75 mesh
copper grids (Electron Microscopy Science, USA) and incubated for
5min. The sample was washed four times with double distilled water
and negatively stained with 9 parts of 2% methylcellulose and 1 part of
3% uranyl acetate for 2min on ice. The excess stain was removed and
samples were dried at room temperature. The samples were then vi-
sualized with a JEOL JEM 1010 transmission electron microscope
(JEOL, Japan) operated at 80 kV.
2.6. Atomic force microscopy (AFM) analysis
AFM analysis of E. faecium strains DO and E155 cultivated on LB
agar were performed as described previously [22]. A loop of bacterial
cells was suspended in ultrapure water and placed on a freshly cleaved
mica surface, incubated at room temperature and ultimately blotted dry
before being placed into a desiccator. Imaging was carried out using a
Nanoscope V Atomic Force Microscope (Bruker AXS, Germany).
2.7. Particle size distribution and measurement of zeta potential
The effective diameter and size distribution of the purified MVs
were determined by dynamic light scattering (DLS, also known as
photon correlation spectroscopy) (Nicomp Submicron Particle Sizer
370, PSS Nicomp Particle Sizing Systems, USA), at an angle of 90° with
a 632 nm laser as described in an earlier study [23]. Briefly, MVs were
diluted in PBS in a particle-free environment to a count rate of
250–350 kHz at room temperature. Analyses were run in a vesicle mode
data calculated as intensity weighted distribution from three measuring
cycles (10min cycle, 3 cycles) The zeta (ζ) potential of vesicles was
determined using Zetasizer Nano Z (Malvern Instruments, United
Kingdom). Three parallels were determined for each vesicle suspension.
2.8. Measurement of MV-derived protein per CFU
The protein content of isolated and purified MVs from bacterial
culture (2 L) was measured by Bradford assay (Bio Rad, USA). For each
strain, CFUs per mL were assessed by plating dilution series on blood
agar plates and counting CFUs. With these two values, MV-derived
protein in attogram (ag) per CFU was calculated from these two values.
2.9. Lipid staining of purified vesicles
The purified membrane vesicles were stained for 1 h with lipid-
specific dye (5 μM of DiD, Thermo Fisher Scientific, USA). The stained
vesicles were then ultra-centrifuged at a speed of 100,000× g for 1 h at
4 °C. The pellets were re-suspended in 20 μL PBS mounted on a glass
slide and examined using a confocal microscope (Leica Microsystems
CMS GmbH, Germany), with an excitation and emission spectra for DiD
at λ638nm and λ700nm, respectively.
2.10. Detection of peptidoglycan
ELISA was used to assess the presence of peptidoglycan, which was
exposed by incubating the membrane vesicles and bacteria with 25mM
HCl for 1 h at room temperature under shaking. Microtiter plates
(Maxisorb, Thermo Fischer Scientific, USA) were coated with mem-
brane vesicles or bacteria in coating buffer (100mM Sodium carbonate/
bicarbonate, pH 9.6) at 4 °C overnight. After 4 washes with PBS-T (PBS
with 0.01% Tween), plates were blocked with 0.05% BSA for 2 h at
37 °C and washed. To evaluate the presence of peptidoglycan in the
samples, mouse anti-bacterial peptidoglycan monoclonal antibody (IgG,
MAB995, Chemicon, Merck Millipore, USA; 1:1000) was added, and the
plate incubated for 2 h at 37 °C. Excess primary antibody was removed
by additional washing with PBS-T, before it was detected with perox-
idase-conjugated rabbit anti-mouse immunoglobulin (DAKO, Agilent,
USA; 1:500) for 20min at 37 °C. Thereafter, tetramethylbenzidine (3,
3′, 5, 5′-TMB, Sigma Aldrich, Germany) was added as peroxidase sub-
strate, and the reaction was stopped with sulfuric acid upon color
change. Absorption was measured at 450 nm.
2.11. MV-associated protein identification by mass spectrometry
The protein concentration within the MVs was quantified, and 20 μg
MV proteins were re-suspended in 8M urea. The sample was reduced by
adding 20mM DTT and alkylated with 40mM iodoacetamide.
Alkylation was quenched by 10mM DTT. Proteins were digested 4 h by
1:100 (w/w) lysyl endopeptidase (Wako Biochemicals, USA). The
sample was diluted to 1M urea and digested overnight by 1/20 (w/w)
trypsin (V511A, Promega, USA). OMIX C18 tips (Varian Inc., USA) were
used for sample cleanup and concentration. Peptide mixtures con-
taining 0.1% formic acid were loaded onto an EASY-nLC1000 system
(Thermo Fisher Scientific, USA) and EASY-Spray column (C18, 2 μm,
100 Å, 50 μm, 50 cm). Peptides were fractionated using a 2–100%
acetonitrile gradient in 0.1% formic acid over 50min at a flow rate of
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250 nL/min. The separated peptides were analyzed using a Q-Exactive
mass spectrometer (Thermo Fisher Scientific, USA). Data were collected
in data-dependent mode using a Top10 method. The raw data were
processed using the Proteome Discoverer 2.1 software. The fragmen-
tation spectra were searched against the predicted proteome from the
whole genome sequence (WGS) data of the strain itself using the
Sequest HT program. Peptide mass tolerances used in the search were
10 ppm, and fragment mass tolerance was 0.02 Da. Peptide ions were
filtered using a false discovery rate (FDR) set to 5% for protein iden-
tifications.
The MV-associated proteins were identified in 3 biological replicates
of MV derived from bacteria in the exponential growth phase in BHI,
and are represented as one in the results table without restrictions
(Supplementary table S1). For MV derived from bacteria in the sta-
tionary growth phase in LB one biological replicate is described in the
result table (Supplementary table S1).
2.12. Bioinformatic characterization of identified MV proteins
To evaluate MV-associated proteins, the entire proteomes were
classified into core and strain(s)-specific. The core proteome was as-
signed with the proteins shared by all four strains whereas the strain(s)-
specific proteome had proteins found only in one or few strains. All
proteins were clustered using CD-HIT with default settings [24].
Homologous clusters possessing at least one protein from each strain
were categorized into core proteins, if not as strain(s)-specific proteins.
Overlapping protein content among MVs isolated from four dif-
ferent strains was demonstrated using Venny 2.0 [25]. These results
were shown individually for proteomes of MVs isolated after growth in
LB to stationary phase and in BHI to mid-exponential phase.
Prediction of signal peptide cleavage sites was performed in SignalP
4.1 [26] and PrediSi [27] on all proteins identified in the MV pro-
teomes. The subcellular localization of identified proteins was predicted
using PSORTb version 3.0 [28]. Gene-term enrichment analysis was
performed with DAVID Functional Annotation Tool [29] on proteins
with an exponentially modified protein abundance index (empai) above
1.
Selected virulence factors and vaccine candidates were searched for
using BLAST [30].
Antimicrobial resistance genes were identified within the respective
genomes of the bacterial strains using ResFinder 3.0 [31] with an ID
threshold of 90% and a minimum length of 60%. Genes with<100%
ID threshold and 100% minimum length are indicated in Table 2.
Identified genes are aph(3′)-III, aac(6′)-aph(2″); vanR-A, vanS-A, vanH-
A, van-A, vanX-A, vanY-A, vanZ-A, vanR-B, vanS-B, vanY-B, vanW-B,
vanH-B, vanB, vanX-B; ermB, lnuB, msrC, tetM and dfrG. The corre-
sponding proteins were searched for in the MV proteome in order to
identify MV-associated antimicrobial resistance determinants.
3. Results
3.1. Clinical E. faecium strains produce MVs
This study explored whether four different clinical E. faecium
strains, belonging to distinct hospital adapted high-risk STs, were able
to release membrane vesicles in vitro. Notably, the growth rates of the
examined strains at the measured intervals showed only minor varia-
tion (Fig. S1).
MVs were isolated from E. faecium strains, which were grown in BHI
until mid-exponential phase (OD600 approximately 1.5). To ensure
purity of the vesicles from cellular debris and protein aggregates, MVs
were further purified and fractionated by gradient centrifugation (Fig.
S2A). The purified MVs were analyzed by TEM where the presence of
vesicle-like circular shape structures was confirmed (Fig. 1A). Similar
structures were detected for the other three examined strains (results
not shown). AFM was conducted as a complementary approach and
revealed release of MVs by the bacteria to the surrounding environment
(Fig. 1B). To measure the size distribution of larger populations of MVs
from the four E. faecium strains, dynamic light scattering (DLS) was
employed. While all strains generated MVs of various sizes, the average
size of enterococcal MVs ranged from 37 ± 23 nm in the E155 strain to
83 ± 29 nm in the K59–68 strain (Fig. 1C and Table 1). Furthermore,
the size measured by DLS corresponded to the results obtained from
TEM images (Fig. 1A–C, Table 1).
Based on protein content, the amount of MVs produced by the four
strains ranged from 1.2 ag/CFU in strain K59-68 to 14.6 ag/CFU in
strain E155 (Fig. 1D).
To gain insight into the interaction of the MVs in the colloidal
system and gain a better understanding of their physiochemical prop-
erties (aggregation, flocculation or dispersion), the membrane (ζ-) po-
tential, of the MVs was measured. The ζ-potential was calculated upon
measuring particles electrophoretic mobility. The E. faecium MV surface
charge in all examined strains was found to be negative in PBS and
reproducible (Table 1) demonstrating a high quality of the MV isola-
tion.
To further characterize the vesicle properties, the purified MVs of
strain E155 were stained with a lipophilic fluorescent dye (DiD) for
detection of lipids. The confocal microscopy analysis of the stained MVs
confirmed the presence of lipids in MVs (Fig. 2A). The presence of
peptidoglycan in the isolated MVs from all four strains was evaluated
using a competitive ELISA approach. Interestingly, peptidoglycan could
be detected in E. faecium-derived MVs from all examined strains. E.
faecium cells were included as a positive peptidoglycan control for this
particular assay (Fig. 2B).
3.2. Different cultural conditions and strain backgrounds account for
variation in enterococcal MV proteinaceous cargo
To investigate whether the MV protein cargo is strain dependent
and influenced by different conditions, the four strains were grown to
exponential phase in a nutritious media, BHI, and to stationary phase in
a growth-limiting media, LB. MVs were isolated and purified further by
gradient centrifugation, and proteomic analysis was performed using an
in-solution approach.
Proteomic analyses demonstrated variability in the number of
identified proteins among MV-associated proteins isolated from the four
selected strains grown in BHI and LB (Supplementary Tables 1–8).
Comparison of shared versus unique proteins revealed that, in ex-
ponential growth in BHI, a lower number (19.2%) of MV-associated
proteins was shared than in stationary growth in LB (36.9%), as illu-
strated in Fig. 3. MVs from K60-39 showed the highest number of total
MV-associated proteins and consequently also possess most unique MV-
associated proteins under both conditions. In contrast, MVs from K59-
68 showed a lower number of total vesicle associated proteins and
accordingly the lowest number of unique proteins.
Based on the sequence similarity of the entire proteome encoded by
all four genomes, homologous proteins present in all four were classi-
fied as core and the remaining as accessory. Accordingly, the MV-as-
sociated proteins were categorized based on their occurrence either in
core or accessory proteome. Notably, it was found that 88–91% of the
MV-associated proteins are from the core proteome (Table 1).
The predicted cellular localization of proteins encoded by the whole
genome based on WGS data and the origin of MV-associated proteins
was predicted by PSORTb. The predicted localization of proteins
showed a common pattern among strains and MV-associated proteins
originating from two different conditions (Fig. 4). As expected, most of
the MV-associated proteins were predicted as either cytoplasmic or part
of the cytoplasmic membrane proteins. A minor number of cell wall or
extracellular bound proteins were also predicted in the derived MVs.
SignalP and PrediSi were applied to predict the presence of signal
peptides. Although the number of identified proteins varied sub-
stantially between strains and conditions, the percentage of putative
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secreted proteins was comparable (Fig. 5). In all strains 4–5% of the
ORFs encode secreted proteins in the whole genome proteomes, while
10–22% secreted proteins were predicted in MVs derived from ex-
ponential growth phase in BHI, and 5–12% secreted proteins in MVs
derived from stationary growth phase in LB. The highest number of
secreted (22%) and extracellular (4%) proteins was associated with MV
proteinaceous cargo obtained from K59–68 grown in BHI to the mid-
exponential phase.
Gene functional enrichment analyses for strain DO identified 10
functional annotation clusters in MV-associated proteins from ex-
ponential growth conditions in BHI and 16 functional annotation
clusters in MV-associated proteins from stationary growth phase in LB.
The difference in cluster number is probably due to the lower protein
number in exponential growth phase (for empai> 1 nprotein= 138)
compared to stationary growth phase (for empai> 1 nprotein= 258).
The analysis showed that ribosomal, ATP synthesis, and membrane
proteins were enriched in both exponential and stationary growth
phase derived MVs in DO. The gene ontology enrichment analysis is
illustrated in Fig. 6.
3.3. Presence of virulence factors, vaccine candidates, and antimicrobial
resistance-related proteins among the E. faecium MV-associated proteins
Fifteen distinct E. faecium genes encoding virulence factors, asso-
ciated with biofilm formation and adherence, were identified within the
genomes of the 4 examined strains: atlA [32], acm [33, 34], bepA [35],
capD [36], ccpA [37, 38], ecbA [39], esp [40], fnm [41], pilA2 [42], pilB/
ebpfm [43], ptsD [44], prpA [45], sagA [46–48], scm [49] and sgrA [39].
gelE [50] was also searched for but was absent in the selected genomes.
Presence or absence of selected virulence factors associated with the
E. faecium-derived MVs is indicated in Table 2. Proteomic analysis de-
monstrated the absence of BepA, EcbA, PilB/Ebpfm and SgrA in the
purified MVs. Interestingly, the two biofilm determinants, namely AtlA
and SagA, were found to be associated with MVs of all tested strains
under both conditions. The adhesins Acm and CapD as well as the
catabolite protein CcpA were also associated with purified MVs of all
examined strains. Esp, an enterococcal surface protein enhancing bio-
film formation, Fnm, a fibronectin-binding protein, PilA2, a pilus pro-
tein, PrpA, an extracellular matrix binding protein, PtsD, a phospho-
transferase system protein, and the adhesin Scm, were associated with
MVs from some of the examined strains.
The search was expanded to further include the enterococcal bac-
teriocins EntA, EntP, EntB, EntL50 [51], EntQ [52], Bac32 [53] and
Table 2
Presence of virulence factors and antibiotic resistance related proteins associated with MVs.
Virulence factor and functional description WGS MV
Tag in genome stationary phase MV (LB) exponential phase MV (BHI)
DO E155 K60–-39 K59–-68 DO E155 K60–-39 K59–-68 DO E155 K60–-39 K59–-68
AtlA Major autolysin, biofilm formation Q3Y3J6 E155_00939 7_02408 6_02630 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Acm Collagen binding adhesion,
MSCRAMM
Q3XXN7 E155_00761 7_02160 6_02383 ✓ ✓ ✓ ✓ X X X ✓
CapD Capsular polysaccharide biosynthesis
protein, adhesion
Q3XXA5 E155_00870 7_00899 6_00915 ✓ ✓ ✓ X ✓ ✓ ✓ ✓
CcpA Catabolite control protein A, growth,
virulence
I3U3N8 E155_00210 7_01900 6_02068 ✓ ✓ ✓ X ✓ ✓ ✓ ✓
Esp Enterococcal surface protein, biofilm
formation
- - - 6_02803 - - - ✓ - - - -
Fnm Fibronectin binding protein, adhesion Q3XYE6 E155_00278 7_01343 6_01354 X ✓ ✓ X ✓ ✓ ✓ X
PilA2 Pilus subunit protein A Q3Y0Y4 - 7_02894 6_03276 X - ✓ X ✓ - X X
PrpA Prolinrich protein A, binding to
extracellular matrix proteins
Q3XZP6 - 7_01420 6_01433 ✓ - X X ✓ - X X
PtsD Enzyme IID subunit of
phosphotransferase stystem, intestinal
colonization determinant
Q3Y1Z0 E155_00486 7_00634 6_00710 X X X X ✓ ✓ X X
SagA Secreted antigen A, biofilm formation I3U595 E155_00236 7_02462 6_02688 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Scm Collagen adhesion, MSCRAMM I3U5K9 - 7_02636 6_02858 ✓ - X ✓ ✓ - X ✓
Vaccine candidate
PsaA Metal binding lipoprotein Q3Y2A0 E155_02566 7_00432 6_00512 ✓ ✓ ✓ ✓ ✓ ✓ ✓ X
PBP5 Penicillin binding protein Q3XZN6 E155_02659 7_01431 6_01444 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
LysM Peptidoglycan binding protein Q3Y2A3 E155_01532 7_00435 6_00515 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
DdcP D,D-carboxypeptidase I3U3E0 E155_02369 7_01824 6_01978 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
PpiC Peptidyl-prolyl-cis-trans-isomerase Q3Y2Y5 E155_01118 7_02348 6_02568 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓




Aminoglycoside resistance - E155_02844 - 6_03206 - X - ✓ - ✓ - X
Aph3′-III Aminoglycoside resistance Q3Y248 E155_02752 7_03002 6_03355 ✓ ✓ X ✓ ✓ ✓ X X
VanR-A Glycopeptide resistance - E155_02402 - - - ✓ - - - - - -
VanS-A Glycopeptide resistance - E155_02403 - - - ✓ - - - - - -
VanH-A Glycopeptide resistance - E155_02496 - - - ✓ - - - - - -
VanA Glycopeptide reistance - E155_02495 - - - ✓ - - - ✓ - -
VanX-A Glycopeptide resistance - E155_02494 - - - ✓ - - - - - -
VanY-A Glycopeptide resistance - E155_02850 - - - ✓ - - - ✓ - -
VanZ-A Glycopeptide resistance - E155_02851 - - - ✓ - - - ✓ - -
VanS-B Glycopeptide resistance - E155_02765 (ID:
96.49%)
- - - ✓ - - - - - -
ErmB Macrolide resistance Q3Y241 E155_02538 7_03003 6_03356 X ✓ ✓ X X X X X
MSCRAMM - Microbial Surface Component Recognizing Adhesive Matrix Molecules, ✓ presence, X absence, - not within genome.
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Bac43 [54]. Out of those, only the gene entA was present in all the four
genomes used in this study, but EntA was not found to be associated
with the E. faecium derived MVs.
As previous studies have identified putative enterococcal vaccine
targets, the following candidates were searched for in the vesicular
proteome: PsaA, AdcA [55], PBP5, LysM, DdcP, PpiC [56] and SagA
[48] (Table 2). PsaA and AdcA are both metal binding lipoproteins
[55], and PsaA was found associated with MVs from all four strains.
PBP5, LysM, DdcP, and PpiC are putative surface-exposed proteins,
which are associated with peptidoglycan [56], and all four were found
within all the examined MV samples. Additionally, SagA, which was
present in all MV samples, was not only described as a virulence factor
[46, 47], but also as the first promising vaccine candidate in E. faecium,
as it exhibited protective properties in a mouse model [48].
Furthermore, resistance genes were identified in the four genomes
using ResFinder [31], and subsequently, the corresponding proteins
were searched for in the MV proteomes (Table 2). The protein Aph3′-III,
a kanamycin kinase conveying resistance to aminoglycosides, was
found in MV samples in both conditions. Aac6′-Ie-Aph2″-Ia, a
bifunctional protein conferring broad-spectrum resistance to ami-
noglycosides such as gentamicin through N- and O-acetylation and
phosphorylation of hydroxyl groups [57], was associated with DO-,
E155- and K59-68-derived MVs, isolated from BHI and/or LB cultures.
ErmB, conferring macrolide, such as erythromycin, resistance, was as-
sociated with E155- and K60-39-derived MVs grown in LB to the sta-
tionary phase.
All proteins encoded by the vanA-cluster that contribute to glyco-
peptide resistance [58] were associated with E155-derived MVs grown
in LB to the stationary growth phase: VanR-A, VanS-A, VanH-A, VanA,
VanX-A, VanY-A, VanZ-A. A subset of those was also present in MVs
isolated from exponential growth phase. Additionally, VanS-B encoded
by the vanB-cluster was found associated with E155-derived MVs grown
to the stationary growth phase. However, the E155 genome also en-
codes the rest of the genes of the vanB-cluster: vanR-B, vanY-B, vanW-B,
vanH-B, vanB and vanX-B, but they were absent in the MVs (Table 2).
The macrolide resistance genes lnuB (K60-39) and msrC (all 4
strains) were present in the respective genomes but absent in the MVs.
This also accounts for tetM (DO and K59-68) and dfrG (E155).
Fig. 1. E. faecium releases spherical MVs in vitro. A)
TEM of MVs isolated from E. faecium E155 (the inset
in the upper left corner shows the vesicle indicated
by an arrow 2 times magnified). B) AFM of E. faecium
E155 surrounded by MVs (the inset in the upper left
corner shows the vesicle indicated by an arrow 2
times magnified). C) Abundance of the various sizes
of purified MV from DO, E155, K59-68 and K60-39
grown to exponential phase in BHI as determined by
DLS (mean in nm ± SD). D) MV-derived protein per
CFU in DO, E155, K59-68 and K60-39 in cultures
grown in BHI to OD600 approximately 1.5.
Fig. 2. E. faecium MVs contain lipids and pepti-
doglycan. A) Confocal microscopy of MVs stained
with lipid-tracer dye (DiD shown in red, the inset in
the upper left corner shows the vesicle indicated by
an arrow 2 times magnified). B) Fold changes in
absorbance using anti-peptidoglycan antibodies in
ELISA to detect peptidoglycan in bacteria and MVs
isolated for the four strains at mid-exponential
growth phase in BHI compared to the control (un-
coated well). (For interpretation of the references to
color in this figure legend, the reader is referred to
the web version of this article.)
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4. Discussion
All cells investigated so far have been found to release vesicles,
indicating a universal phenomenon. The release of bacterial membrane
vesicles and their functional importance, including both offense and
defense, has been widely studied in Gram-negative bacteria [59]. In
recent years, vesicle research has also increased in Gram-positive bac-
teria such as Listeria [60], Bacillus [16], Staphylococcus [61], Lactoba-
cillus [62], Streptococcus [63] and Clostridium [64]. Here we provide the
first report describing MVs released by E. faecium.
Rivera et al. [16] observed spherically shaped vesicles with the size
of 50–300 nm in B. anthracis. Similarly, MV isolated from Listeria, Sta-
phylococcus, Lactobacillus, Streptococcus, and Clostridium ranged from 20
to 400 nm [60, 61, 63, 65]. The morphology of MVs secreted by E.
faecium was found to be similar to the above-mentioned MVs from
Gram-positive bacteria, both in terms of size and appearance (Fig. 1,
Table 1). We also quantified the vesicles based on protein measurement
through Bradford reagent and found similar MV amounts produced by
the four E. faecium strains. However, a drawback of these types of
measurement approaches is the lack of a universal standard procedure
for MV quantification. Until now, vesicular proteins have been quan-
tified using protein-based (SDS-PAGE staining, Bradford reagent or bi-
cinchoninic-acid assay BCA) and lipid-based (lipid probes such as
FM4–64) approaches. However, all these methods have both strengths
and weaknesses [66]. Moreover, for the proteomic analysis assessment
of the purity of the MV sample is utmost important. Contaminating
artifacts may co-pellet in the ultracentrifugation step of MV isolation.
However, density gradient centrifugation was included in our study,
which improves the purity of the MV sample [66, 67].
As previously described in Gram-negative bacteria [68] and the
Gram-positive bacterium Clostridium perfringens [64], peptidoglycan
was confirmed to be associated with enterococcal vesicles, through use
of an antibody with specificity for the three-dimensional polymer
complex structure of peptidoglycan. In addition, the MVs from all four
strains exhibited negative surface charge, based on ζ-potential. The
surface charge of Pseudomonas aeruginosa and B. anthracis derived MVs
was also reported to be negative [16, 69] and in P. aeruginosa the ζ-
potential was more negative in stationary growth phase derived vesicles
compared to exponential growth phase [69]. Gram-positive and Gram-
negative bacterial cells are negatively charged, too. It has been sug-
gested that the charge is critical to understand the interaction between
MVs and the bacterial cells [69] and the selectivity of this interaction
since it was found that MVs are more likely to interact with bacterial
cells of the parent species than of other genera [70].
Besides the morphological characterization, a mass spectrometry
based approach was used to gain insight into the proteomic profile of
the isolated MVs. The overall proteomic pattern within MVs was similar
regarding the percentage of proteins that derived from the core
genome, their origin of localization, and whether they had a signal
peptide or not (Figs. 3–5). However, different numbers of MV-asso-
ciated proteins identified by proteomics were found among the four
examined strains and under varying conditions (Table 1, Fig. 3). Among
Gram-positive bacteria substantially varying numbers of MV-associated
proteins have been described previously, from 431 MV-associated
proteins in C. perfringens grown in Trypticase-peptone-glucose broth
[65] to 36 MV-associated proteins in B. anthracis 34F2 in BHI [16]. The
growth medium affects the gene expression in bacteria which subse-
quently alters the amount and/or content of vesicles released into the
Fig. 3. Four-set Venn diagram representing the number of shared and unique MV-associated proteins of MVs isolated from E. faecium cultures. A) Mid-exponential
phase growth in BHI, B) Stationary phase growth in LB. Numbers of shared or unique proteins are given in bold, percentage in brackets.
Fig. 4. Localization prediction of proteins in whole genome proteomes and in
proteomes of MVs derived from two different conditions. Subcellular localiza-
tion prediction was done in PsortB and is illustrated in proportional numbers.
Fig. 5. Proportion of proteins with a signal peptide in E. faecium whole genome
proteomes and MV associated proteomes from two different conditions. Signal
peptide prediction was done by SignalP.
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growth medium [71]. Similarly, Bager et al. found significant changes
in OMV production and protein composition upon altering medium
composition in Gallibacterium anatis [72]. Moreover, a recent study on
the proteome of Pseudomonas putida KT2440 by Choi et al. demon-
strated that OMV production in LB media was three-fold higher than in
two different minimal media containing succinate and benzoate [73].
Other previous studies identified a higher number of vesicular proteins
in P. aeruginosa in LB compared to a more nutrient rich media [74–76].
Likewise, in our study, we observed a higher number of different pro-
teins in MVs derived from E. faecium grown to stationary growth phase
in nutrient-limiting LB compared to exponential growth in nutrient rich
BHI. Under nutrient limitation and stationary growth, we expect the
bacteria suffer more stress, which might explain more different vesi-
cular proteins.
In the presented study we found a high abundance of cytoplasmic
proteins, especially ribosomal proteins, which is similar to the number
of cytoplasmic proteins encoded by the genome (Figs. 4, 6). This is in
agreement with previous studies of MVs derived from Gram-positive
bacteria [15, 19, 61]. This implicates, that the MV content represents
basically the composition of the parent cell, even though final conclu-
sions would require protein quantification rather than identification.
We furthermore found, that high numbers of MV-associated proteins
lack a secretion signal, which is in line with a previous study on S.
aureus [21] as well as Campylobacter jejuni [77] and suggests that MVs
may play an important role in the delivery of effector molecules, which
lack a secretion signal.
As previous studies have shown that MVs of Gram-positive bacteria
contain virulence factors [15, 16, 60, 78], serve as vaccine candidates
[79] and are contributing to antimicrobial resistance [80], in silico
methods were used to assess whether such factors are also associated
with E. faecium MVs. Indeed, we identified 11 known virulence factors
among the MV-associated proteins, including adhesins (CapD and
PrpA), collagen-binding proteins (Acm and Scm), and fibronectin-
binding protein (Fnm). These virulence factors are of particular im-
portance for enterococcal adhesion, colonization and tissue invasion
[34, 36, 41, 45, 49]. The association of collagen-binding proteins, as
well as the fibronectin-binding protein and adhesins with MVs may
suggest a role of the vesicles in enterococcal adhesion and colonization.
E. faecium utilizes biofilm formation as a survival strategy, which
enables protection and persistence [81, 82]. Previous studies demon-
strated that OMVs contribute to biofilm formation and stability [83,
84]. The virulence factors AtlA, Esp and SagA that contribute to en-
terococcal biofilm formation [32, 40, 46–48] were found to be MV-
associated. This may suggest that E. faecium MVs can contribute to
biofilm formation.
As highly stable, non-infectious, non-replicative particles vesicles
are interesting vaccine candidates. Furthermore, they contain major
immunogenic proteins of the MV producing bacterium that can act as
antigens and thus can elicit responses in both arms of the immune
system. Additionally, they display adjuvant activity (reviewed in [79,
85]). The first OMV-based vaccine to be licensed for human use was the
meningococcal serogroup B vaccine 4CMenB against the Gram-negative
Neisseria meningitidis [86]. Also in the Gram-positive Streptococcus
pneumoniae [87] and S. aureus [21, 88], the protective effect of im-
munization with MVs was recently shown. For enterococci, there are to
date no available vaccines, but there has been research towards iden-
tifying components for a vaccine to prevent E. faecium infection [48, 55,
56]. Here we found several previously described vaccine candidates to
be associated with MVs (Table 2). However, whether enterococcal MVs
can be used as vaccines remains to be investigated.
Special interest has been drawn to E. faecium due to their multidrug
resistance and high genomic plasticity, which allows them to steadily ac-
quire new resistance determinants. In the Gram-negative E. coli it was
shown that OMVs not only have a protective role against membrane-active
antimicrobials [80], but also that certain antimicrobials increase the pro-
duction of OMVs and OMV-associated Shiga toxin [89, 90]. Also resistance-
genes were found to be transferred via OMVs [91]. Furthermore, OMVs of
β-lactamase resistant Haemophilus influenzae and Moraxella catarrhalis were
shown to protect Streptococcus pyogenes against amoxicillin [92]. Interest-
ingly, our study demonstrates that both the ribosome methylase ErmB, the
aminoglycoside modifying enzymes Aac6′-Ie-Aph2″-Ia and Aph3′-III as well
as all proteins of the vanA vancomycin resistance cluster can be MV-asso-
ciated in E. faecium. All these proteins mainly function inside the en-
terococcal cell. Thus they could potentially be active in creating anti-
microbial resistance if they can be delivered to a recipient cell by the MVs.
However, low empai values of the vanA-cluster encoded proteins, ErmB,
Aac6′-Ie-Aph2″-Ia and Aph3′-III under the conditions studied here, suggest
that these MVs do not have a great potential to cause antimicrobial re-
sistance. Still, MV production and thus resistance-conferring proteins could
be more abundant upon induction through antimicrobial stress as seen in
MVs from Stenotrophomonas maltophilia [93] and E. coli [89] and then be
presented in high enough concentrations to a recipient cell to confer an
antimicrobial effect. This implicates that enterococcal MVs may play a role
in antimicrobial resistance, not only for E. faecium itself but also for the
bacterial community.
The mechanism of vesiculogenesis has not been conclusively clar-
ified in Gram-positive bacteria. Recently, prophage-triggered MV for-
mation was described and it has been postulated that phage endolysins
may confer MV escape by locally digesting the cell wall [94]. Inter-
estingly, by using PHASTER tool [95], we detected phage genes within
the genomes of DO, K59–68 and K60-39, but not in E155 (results not
shown). Thus, prophages may play a role in the release of MV from
certain strains. Apart from prophage-triggered MV formation, it has
been suggested, that the vesicles passage the peptidoglycan layer with
the aid of cell wall modifying enzymes such as peptidoglycan mur-
amidases/ hydrolases, which are part of the Gram-positive type 4 se-
cretion system (T4SS) [6, 15]. In the genomes of the four strains, we
found T4SS using T346Hunter [96] (data not shown), suggesting that
these strains might use components of this system for vesicle release.
However, the mechanism for MV release in enterococci remains elusive.
Fig. 6. Distribution of DO MV-associated proteins from two different conditions compared to the whole genome proteome of DO in gene ontology enrichment
analysis. Proteome of MVs derived in exponential growth in BHI is shown in A) and stationary growth in LB in B).
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5. Conclusion
A proteomic approach was used to describe the protein cargo of
membrane vesicles derived from four different, clinically relevant E.
faecium strains under varying conditions. It was found that the MV-
associated proteome is strain and condition dependent. The most in-
teresting MV-associated proteins were the virulence factors and anti-
microbial resistance related proteins. It is thus tempting to speculate
that enterococcal MVs play an important role in infection and anti-
microbial resistance. Our findings highlight the potential of bacterial
MVs for research on bacterial pathogenesis.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jprot.2018.05.017.
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Abstract  
Bacterial extracellular vesicles (EVs) have a vital role in bacterial pathogenesis. However, to 
date, the small RNA-cargo of extracellular vesicles released by the opportunistic pathogen 
Staphylococcus aureus has not been characterized. Here, we shed light on the association of 
small RNAs with EVs secreted by S. aureus MSSA476 cultured in iron-depleted bacteriologic 
media supplemented with a subinhibitory dosage of vancomycin to mimic infection condition. 
Confocal microscopy analysis on intact RNase treated EVs indicated that RNA is associated 
with EVs. Transcriptomic and in silico analysis of EV- associated RNA revealed the presence 
of potential gene regulatory small RNAs and high levels of tRNAs. Among the enriched small 
RNAs were SsrA, RsaC and RNAIII RNAs. Our finding invites new insights into the potential 
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Staphylococcus aureus, a Gram-positive bacterium, is a frequent colonizer of anterior nares of 
the healthy human population. These bacteria can cause various infections ranging from minor 
superficial skin infections to severe life-threatening infections such as osteomyelitis, 
pneumonia, endocarditis, bacteremia and sepsis (Wertheim et al., 2005; McCaig et al., 2006; 
Foster et al., 2014). The adaptation of diverse lifestyles and the ability to cause diseases is due 
to the fact that bacteria harbors arsenals of virulence factors involved in adhesion, invasion and 
dissemination (Novick, 2003).  
Small RNA (sRNA) are heterogeneous small-sized transcripts (50–500 nucleotides) 
expressed under stressful environmental conditions which play an important role in growth 
processes, metabolism, stress adaptation and virulence (Tomasini et al., 2014; Westermann, 
2018). Prokaryotic sRNAs are often non-coding and mainly originate from intergenic regions 
(Wagner and Vogel, 2003). They generally form secondary structures such as hairpins and 
stem-loops (Wagner and Romby, 2015). There are varieties of techniques (in silico, laboratory-
based) to identify and characterize sRNAs (Lagos-Quintana et al., 2001; Wang et al., 2009; Li 
et al., 2012). Mizuno and colleagues first reported sRNAs with regulatory functions in 
Escherichia coli in 1980’s, and a decade later Novick et al. reported regulatory sRNAs in S. 
aureus (Mizuno et al., 1984; Novick et al., 1989). Currently, there are about 250 sRNAs 
discovered in various strains of S. aureus grown under different experimental conditions, and 
the biological functions of most of them are yet to be determined (Guillet et al., 2013; 
Hermansen et al., 2018). Still, novel sRNA transcripts are reported from S. aureus strains, and 
the number is increasing with the advancement of high-throughput sequencing technology as 
well as robust in silico computational methods (Liu et al., 2018a; Westermann, 2018). 
Extracellular Vesicles (EVs) are nanosized-proteolipids, with a spherical shape that are 
heterogeneous in size ranging from 50-500 nm (Askarian et al., 2018). Sometimes fusion of 
vesicles have resulted in formation of filamentous structures, also known as nanopods or 
nanotubes (Dongre et al., 2011; Dubey and Ben-Yehuda, 2011; Gill et al., 2018). EVs may 
contain virulence factors (Devos et al., 2015; Askarian et al., 2018; Wagner et al., 2018; 
Nadeem et al., 2020), such as toxins (Rivera et al., 2010; Coelho et al., 2019) as well as other 
enzymes (Smalley and Birss, 1987; Elhenawy et al., 2014), quorum sensing molecules 
(Mashburn and Whiteley, 2005; Brameyer et al., 2018; Morinaga et al., 2018) and nucleic acids 
such as DNA (Hagemann et al., 2014; Bitto et al., 2017; Langlete et al., 2019) and RNA 
(Sjöström et al., 2015; Koeppen et al., 2016; Choi et al., 2017b). Their content may vary 
depending on species and growth conditions (Bager et al., 2013; Ghosal et al., 2015; Koeppen 
et al., 2016). EVs might act as a decoy against antimicrobial peptides and phages (Manning and 
Kuehn, 2011), and are also involved in co-operation and/or competition with other pathogens 
(Lynch and Alegado, 2017; Choi et al., 2020). EVs can also influence biofilm formation and 
modulate host-immune responses (Manning and Kuehn, 2013; Schwechheimer and Kuehn, 
2015; Liu et al., 2018b). 
EVs from Gram-negative bacteria harbor sRNA involved in intra-species (microbe-microbe) 
(Whitworth, 2018) and inter-kingdom (microbe-host) interactions (Koeppen et al., 2016; Frantz 
et al., 2019) as well as pathogenicity (Song and Wai, 2009). However, scant functional and 
analytical data exist to support these claims in Gram-positive bacteria (Ghosal et al., 2015; 
Sjöström et al., 2015; Koeppen et al., 2016; Choi et al., 2018; Malabirade et al., 2018).  
During infection, the availability of iron is strictly controlled by the host, and in order to 
survive pathogens must adapt their transcriptomic and metabolic pathways accordingly 
(Wilderman et al., 2004; Oglesby-Sherrouse and Murphy, 2013; Mäder et al., 2016). Nutrient 
limitation and antibiotics is furthermore known to increase vesiculation (Toyofuku et al., 2019). 




been shown to influence physiology, growth and toxin production by S. aureus (Hsu et.al, 2011; 
Cafiso et al., 2012; He et al., 2017), and has been found to increase EV production in another 
Gram-positive species, Enterococcus faecium (Kim et al., 2019). Hence, in this study, we used 
iron-chelated media supplemented with vancomycin to evaluate whether the EVs produced 
by S. aureus  MSSA476 are associated with sRNAs when grown in conditions that mimic an 
infection that is being treated with an antibiotic.  
 
MATERIALS AND METHODS  
Strain and growth conditions 
S. aureus subsp. aureus Rosenbach MSSA476 was purchased from LGC standard AB (ATCC- 
BAA-1721) (Sweden). The bacteria were grown at 37°C on BHI agar plate, BHI broth, or in 
trace metal-depleted BHI broth containing 0.5 µg/mL of vancomycin. The trace metals 
including divalent cations such as iron were lowered by treating the BHI broth with 2 g/L of 
chelex-100 resin (Bio-Rad, Californa, USA). The medium was subsequently filtered according 
to the manufacturer’s instructions.  
 
Isolation of bacterial extracellular vesicles 
The bacterial EVs were isolated by a procedure described earlier (Askarian et al., 2018; Wagner 
et al., 2018), with slight modifications. A fresh overnight culture of the methicillin-susceptible 
S. aureus MSSA476 (1:100 dilution) was inoculated into 500 mL BHI or Chelex-treated BHI 
broth containing 0.5 µg/mL of vancomycin at least two to five different days (Table S1). Since 
the RNA isolation was limited from each preparation, the experiment was done in triplicates. 
The cultures were grown with shaking at 37°C for 16 h. The cultures were then centrifuged at 
6000 × g for 30 min. Bacterial pellets were discarded, and the supernatants was filtered through 
0.2 μm filters (Millipore Express™ Plus, USA) and ultra-centrifuged at 100,000 × g for 3 h at 
4°C in a 45 Ti rotor (Beckman, USA). EV pellets from each isolation were re-suspended in 500 
µL RNAlater (Thermo Fisher Scientific, Massachusetts, USA) and kept at -80°C until further 
use. Prior to RNA isolation, EVs were thawed, pooled and concentrated using ultrafiltration 
(10 kDa Vivaspin 20, Sartorius, Germany). The vesicles were resuspended in Phosphate-
buffered saline (PBS) if EVs were to be used for microscopy or Nanoparticle Tracking 
Analysis.  
 
Transmission Electron Microscopy (TEM) 
TEM was performed as described previously (Cavanagh et al., 2018;Wagner et al., 2018). 
Briefly, 5 μL of purified EVs were applied to Formvar coated 75 mesh hexagonal copper grids 
(Electron Microscopy Science, Pennsylvania, USA) and incubated for 5 min. Grids were 
washed with MQ water, and negatively stained with 2% methylcellulose and 3 % uranyl acetate 
in a ratio of 9:1. The excess of stain was blotted away, and grids were then left to dry at room 
temperature. The samples were then visualized with a JEOL JEM 1010 transmission electron 
microscope (JEOL, Tokyo, Japan) operated at 80 kV. 
 
Atomic Force Microscopy (AFM) 
The EVs were imaged by AFM, as described previously (Lindmark et al., 2009;Ahmad et al., 
2019). Briefly, EVs were deposited onto a freshly cleaved mica surface (Goodfellow 
Cambridge Ltd., Cambridge, UK). Prior to imaging, EVs on mica were dried in a desiccator for 
about 2 h. Images were recorded on a Multimode 8 Nanoscope AFM equipment (Bruker AXS 




software using ScanAsyst in air with ScanAsyst cantilevers, at a scan rate of ~0.8–1.5 Hz. The 
final images were plane fitted in both axes and presented in a surface plot of the height mode. 
 
Nanoparticle Tracking Analysis (NTA) 
The size distribution of EVs were determined using NanoSight NS300 (Malvern Instruments 
Ltd., Worcestershire, UK) equipped with CMOS camera and a blue laser module (488 nm, 
LM12 version C) (Jamaly et al., 2018). Briefly, EV samples were thawed and diluted (500×) in 
PBS to obtain a concentration within the recommended measurement range (1-10 × 108 
particles/mL). Using a 1 mL syringe, the sample was injected into the instrument and videos 
were captured in triplicate for 30 s. The mean values for size and concentration were analyzed 
using the NanoSight (NTA software, version 3.0).  
 
Labeling of extracellular vesicles 
The EVs were stained using a previously described protocol with slight modifications (Nicola 
et al., 2009;Vdovikova et al., 2017).The vesicles were first treated with RNase (Roche 
diagnostics, Basel, Switzerland) to remove extracellular RNA then stained with lipid-specific 
dye, PKH2 or DiD (Sigma Aldrich) and subsequently with RNA specific dye SYTO RNASelect 
Green (Thermo Fisher Scientific, Massachusetts, USA). The stained vesicles were then ultra-
centrifuged at a speed of 100,000 × g for 1 h at 4°C. The stained EVs were resuspended in PBS. 
Samples were mounted on a glass slide and examined by Leica SP8 inverted confocal system 
(Leica Microsystems) equipped with a HC PL APO 63x/1.40 oil immersion lens. Images were 
captured and processed using LasX (Leica Microsystems). Fluorescence intensity profiles were 
generated using the plot profile command in ImageJ-FIJI distribution (Schindelin et al., 2012) 
For quantification, EVs from 8 randomly selected fields (180 μm2) were counted. Results were 
pooled from two independent experiments and data are expressed as percentage. 
 
Bacterial growth curve and viability assay  
A single colony of MSSA476 was inoculated into two 5 mL of BHI broth and grown overnight 
with shaking at 37°C. The 5 mL cultures were used to inoculate 500 mL BHI (normal) and 500 
mL iron depleted BHI containing antibiotics (stressed). The cultures were incubated with 
shaking at 37°C, and optical density was measured every 30 min for 16 h. For the viability 
assay, 500 µL of each culture of bacteria grown under normal and stressed conditions for 16 h, 
were harvested.  Viable plate count was carried out by plating 20 µL of 10-fold serial dilutions 
(from 10-5-10-10) on blood agar plates, which were incubated for 24 h at 37°C. Dilutions 
containing 10–100 colonies were counted, and the concentration was calculated as CFU/mL. 
 
Live and dead count 
Bacterial cultures grown for 16 h in BHI (normal) and iron depleted BHI containing antibiotics 
(stressed) were analyzed for live and dead cells using LIVE/DEAD BacLight bacterial Viability 
and Counting Kit (Thermo Fisher Scientific, Waltham, USA) and BD LSRFortessa flow 
cytometer. Each bacterial culture was diluted 1000-fold in 1 mL 0.85% filtered NaCl, which 
contain 0.5 µL SYTO 9, 2.5 µL Propidium iodide (PI), and 10 µL beads of size 6 µm. Beads 
had a concentration of 1x108/mL and were diluted 100-fold. Cells were stained for 10-15 min 
at room temperature. Stained bacteria were analyzed using BD LSRFortessa flow cytometer 
using a voltage of 600, 250, 400 and 800 for forward scatter (FSC), side scatter (SCC), AF488 
and PI, respectively. All scales were set to logarithmic amplification with gain voltages of 300, 
250 and 200 for FSC, SSC and AF488, respectively. Data were recorded for 1000 bead events. 
Total events were recorded and density of bacterial culture in terms of bacteria/mL was 
calculated as (numbers of events in bacterial region)×(dilution factor)/(numbers of events in the 




Extraction of RNAs  
The crude collection EVs was stored in RNAlater; which is a preservative compatible with 
RNA isolation and downstream applications such as RNA sequencing and Reverse 
transcription. The EVs were centrifuged using Vivaspin® ultrafiltration spin columns (cutoff 
10000MWCO) at 5000 RPM for 15 min. The concentrated EVs were treated with RNaseA 
(50µg/mL) for 30 min at room temperature to degrade all forms of extracellular RNA. 
Thereafter, to stop the RNase activity, EVs were treated with 5 µL of RNase inhibitor (Applied 
Biosystems, Massachusetts, USA) for 15 min at 37°C. Then the small RNA from S. aureus EVs 
were isolated by miRNeasy kit (Qiagen, Hilden, Germany), according to the manufacturer’s 
instruction. Trizol and Chloroform used during RNA isolation are sufficient to remove traces 
of RNAlater. The concentration of RNA was measured by Qubit HS kit, which quantify sample 
concentration ranging from 250 pg/µL to 100 ng/µL (Thermo Fisher Scientific, Waltham, 
USA), and the quality of RNA was assessed by Nanodrop (Thermo Fisher Scientific, Waltham, 
USA, USA). A 260/280 ratio of 1.8 or higher was considered optimal. In our RNA prep it was 
found to be 1.85. In order to evaluate whether the isolated RNA was extravesicular or associated 
with EVs, RNA concentration was measured on crude EVs, RNase treated EVs and finally in 
RNA isolated from the RNase-treated EVs.  
  
rRNA depletion, library preparation and sequencing 
The isolated EV associated RNA was treated with Ribo-zero rRNA removal kit (Illumina, 
Munich, Germany) according to the manufacturer’s instructions to reduce ribosomal RNA 
(rRNA). Thereafter, the concentration of RNA was measured using Experion RNA HighSense 
Chips (Bio-Rad Laboratories, Inc, USA). The depleted RNA was cleaned and concentrated 
using RNeasy MinElute Cleanup kit (Qiagen, Hilden, Germany) and RNA clean & 
concentrator-5 kit (Zymo Research, California, USA). The rRNA-depleted RNA was 
fragmented, and reverse transcribed into cDNA using high capacity cDNA reverse transcription 
kit (Applied Biosystems, California, USA), and sequenced on an Illumina NextSeq550 
platform. 
 
RNA preparation, cDNA synthesis and qPCR 
qPCR was used to confirm the presence of the three enriched sRNAs (SsrA, RSaC and RNAIII). 
The EV associated RNA was isolated as described above and treated with DNase (ArcticZymes, 
Tromsø, Norway) before RNA integrity and quantity were measured both by NanoDrop and 
Qubit. cDNA was prepared by reverse transcription kit (Applied Biosystems) using 100 ng 
RNA. qPCR reactions were performed in technical duplicates for pooled EV samples using 
SYBR Green master mix (Applied Biosystem) with the following primer pairs: SsrA-F/R: 
CACTCTGCATCGCCTAACAG/ GCGTCCAGAGGTCCTGATAC, RsaC-F/R: 
CAAAGGAAAGGGGCATACAA/ ACGCCATTCCCTACACACTC, RNAIII-F/R: 
AGTTTCCTTGGACTCAGTGCT/ GGGGCTCACGACCATACTTA. To perform qPCR, 
briefly, 2 μL of cDNA was used as a template for each 20 μL reaction, which was carried out 
with 100 nM of primers. Cycling conditions were as follows: initial denaturation 10 min at 
95°C, 40 cycles of 15 s at 95°C and 60°C for 1 min as annealing temperature. The data were 
treated and analyzed with the Applied Biosystems (7300 Real-Time PCR System) to determine 
the Ct.  
 
PCR and Sanger sequencing  
RT-PCR was carried out in a Thermal Cycler (Applied Biosystems, Foster City, CA) in order 
to verify the three PCR amplicons by agarose gel and DNA sequencing. The PCR was 
performed in a 20 µL reaction, containing gene-specific primers mentioned above and 




manufacturer's instruction. One μL of cDNA was used as the template. The cycling conditions 
were performed as follows: after an initial denaturation step of 2 min at 95 °C, 40 cycles were 
performed for 30s at 95 °C, 60 s at 60 °C, and 1 min at 72 °C. A final extension step for 10 min 
at 72 °C was used. PCR products were further separated on a 1% agarose gel, stained with 
GelRed and visualized using Syngen Gel Imaging (Bio-Rad Laboratories Inc, USA). The PCR 
product was cleaned using PCR Clean-Up Kit (Promega, Norway).  Sequencing reactions were 
performed in using a BigDye Terminator version 3.1 kit (Applied Biosystems) according to the 
manufacturer's instructions with the same primers as for the real-time PCR assay. Sequencing 
was performed on an Applied Biosystems 3130xl genetic analyzer. 
 
Bioinformatics analysis  
The fastQ files obtained after paired-end sequencing was checked for quality using the Galaxy 
webserver (https://galaxy-uit.bioinfo.no). Bcl2fastq program supplied by Illumina was used to 
convert bcl files to fastQ files, which automatically trims the adapters and generates clean reads. 
The clean reads were aligned with the reference genome (MSSA476; GenBank accession no. 
NC_002953.3) using Bowtie 2 (Langmead and Salzberg, 2012). Mapping of the EV reads to 
the reference genome resulted in a Sequence Alignment Map file that was converted to a Binary 
Alignment Map (BAM) file. The BAM and its associated annotation files of the reference 
genome were loaded into Artemis where manual searches for sRNAs were performed. 
Visualization and manual inspection of reading coverage were conducted using Artemis version 
1.0 (Rutherford et al., 2000). All the sRNAs are listed based on genomic coordinates provided 
from the bacterial small regulatory RNA repository BSRD 
(http://kwanlab.bio.cuhk.edu.hk/BSRD). The sRNAs identified from Artemis were run 
separately for Rfam search in Artemis to gather information about RNA families and RNA 
elements, including accession numbers. In addition, the Rockhopper tool (Tjaden, 2019) was 
used to identify transcripts and operons and to elucidate bacterial transcriptomes. Transcripts 
from Rockhopper were visualized (.wig files) in the Integrative Genomics Viewer (IGV) 
(Robinson et al., 2011). 
 
RESULTS  
RNA is associated with S. aureus derived EVs 
The MSSA476 bacterial growth in BHI (normal condition) or trace metal-depleted BHI 
supplemented with a subinhibitory concentration of vancomycin mimicking infection (stress 
condition) were compared and found to be similar at 16 h (Figure S1). The viability of bacteria 
after 16 h in both media was evaluated by flow cytometry and colony-forming units (CFU) 
enumeration and showed similar viability which was above 99.6% (Table 1, Figure S2).  
Then, EVs were isolated from S. aureus grown for 16 h under normal or stressed conditions. 
EVs were obtained from bacteria grown under both conditions. However, the number of 
particles, as well as protein concentration, was increased when bacteria were stressed (Figure 
S3 A, B). Unfortunately, the yield of sRNA obtained from EVs isolated from unstressed 
bacteria was too low for RNAseq. Therefore, we focused the study on EVs isolated from 
stressed bacteria. The morphology of EVs was evaluated by AFM and TEM. Aligned with other 
studies on MSSA476 (Gurung et al., 2011;Askarian et al., 2018), EVs were spherical in shape, 
though minor fusions were observed (Figure 1A, B, Figure S4). In addition, the size 
distribution of vesicles was measured using NTA which revealed that the sizes ranged from 20 
nm to 200 nm, although the majority of vesicles are between 100-150 nm. The analysis also 





Next, we wanted to evaluate whether RNA is associated with the EVs. The EVs were treated 
with RNase to remove external RNAs, and thereafter stained with RNA specific dye. EVs are 
known to contain lipids (Ghosal et al., 2015), and were therefore stained with a lipid-specific 
dye. The RNA and lipid-stained particles, which we assumed to be aggregated EVs, were then 
analyzed by confocal microscopy. As seen in (Figure 2A, 2B and Figure S5), RNA and lipid 
stain co-localized in the majority of EVs. To confirm the sensitivity of the method, the 
fluorescence intensity (Figure 2C) was determined in co-stained and only lipid stained EVs 
indicated with dotted line in Figure 2B. Finally, we quantified co-localization of RNA and lipid 
particles by counting 8 random microscopic fields. We observed 73% co-localization of RNA 
and lipid stained particles, while approximately 21% percent of lipid stained particles were 
without any RNA stain. A minor population of about 6% RNA stained particles were not 
associated with lipid stained particles (Figure 2D). The later population might represent either 
non-specific aggregations of RNA dye, or a leakage of RNA from broken EVs during sample 
preparation, or the presence of small amounts of extra-vesicle RNA even after RNase treatment.  
Having found that RNA was associated with RNase treated EVs, we isolated small RNA 
which was analyzed further by bioanalyser. A smear of RNA in size range 50-200 bp was seen 
(Figure 3A). The obtained RNA was treated using the rRNA depletion kit, which reduced the 
average concentration of RNA from 77 to 40 ng/µL. Further analysis of the rRNA-depleted 
samples using bioanalyser revealed appearance of four peaks (Figure 3B, black arrows) at 24-
28 seconds, known to be typical peak for less than 200 bp sRNA. Of note, no strong peaks 
appeared for ribosomal RNA (16S and 23S), indicating efficiency of sRNA enrichment by the 
miRNA kit and subsequent depletion of rRNAs. Hence, our data demonstrated that sRNA are 
associated with S. aureus EVs. 
 
tRNAs and sRNAs were enriched in S. aureus derived EVs 
The transcriptome profiling of the sRNA content in EVs was performed using RNA-seq 
analysis. Paired-end sequencing resulted in approximately 458,000 reads of varying length (35-
151 nucleotides), of which 87% were aligned to the reference genome of S. aureus strain 
MSSA476 (GenBank accession no. NC_002953.3) (Table S2- mapping statistics) and were 
well distributed over the reference genome (Figure S6).  
The reads corresponded to sRNAs with size distribution from 20 to 500 nt (Figure S7). Nearly 
3.5% consisted of tRNAs and 0.3% consisted of sRNAs and the rest were protein encoding 
RNAs or fragments of rRNA (Figure S8). A total of 62 RNAs, 276 5′ untranslated regions (5′ 
UTRs) and 276 3′ untranslated regions (3′ UTRs) were identified. Similarly, further aligning of 
the reads against S. aureus MSSA476 plasmid pSAS resulted in detection of five RNAs, seven 
5' UTRs, and 11 3' UTRs (Table S2 - Summary Rockhopper output). Next, operons in the S. 
aureus genome were defined as regions with continuous coverage of whole transcript reads by 
RNA-seq. This resulted in identification of 486 multi gene operons consisting of 2-18 genes 
(for a total of 1415 genes) (Table S2 - operon Rockhopper output).  Phage RNAs, e. g, 
transcripts encoding terminase subunits, tail proteins and portal protein, were detected among 
the protein encoding RNAs (Table S2 - Rockhopper transcript output). Since our focus is on 
sRNAs, we chose to further describe only the tRNA and sRNA content. 
Coverage of tRNA upstream of a regulatory region is shown in Figure S9. The read counts 
of tRNAs in EVs varied from 4-984, with cove scores from 36.67 to 101.60 (Table S2- tRNAs 
in EVs). The most enriched tRNAs includes tRNA for Met, Asp, Leu, Tyr, Ser, Thr, Gly and 
Phe (Table 2).  
The 67 sRNAs predicted by Rockhopper software were manually checked with Artemis and 49 
sRNAs were validated using the Rfam database. The MSSA476-derived EVs carried several 




SsrA showed the highest read counts of 80 and 65 respectively (Table 3, read density of SsrA 
is shown in Figure S10).  
 
Validation of S. aureus SrrA, RsaC and RNAIII RNA associated with EVs 
Among the enriched sRNA were SsrA, RsaC, and RNAIII (Table 3). SsrA and RsaC RNAs are 
involved in antibiotic resistance through their modulation of RNA fate and protein activity 
(Lalaouna et al., 2014), while RNAIII, not only have regulatory function but also encode 26 
amino acid long δ-toxin (Novick et al., 1993; Caldelari et al., 2013). To validate our results 
obtained from transcriptomic analyses, we performed qPCR on RNA obtained from EVs using 
primers targeting SsrA, RsaC and RNAIII. The results presented in boxplot (Figure 4A) are 
based on three biological repeats (Table S3) which confirmed presence of these three 
transcripts associated with EVs. The presence was finally confirmed by PCR of cDNA yielding 
DNA fragments of expected sizes (Figure 4B), and by Sanger sequencing which confirmed the 
identity of ssrA, RsaC and RNAIII (Figure S11). 
 
DISCUSSION 
S. aureus harbors a multitude of virulence factors that are tightly regulated during infection. 
Several studies have shown that exposure to sub-MIC antibiotic concentrations enhances S. 
aureus ability to adapt to physiological changes, survive and persist in human hosts (Kaplan et 
al., 2012;Howden et al., 2013). One of the mechanisms modulating virulence and pathogenicity 
of S. aureus is via the release of EVs (Gurung et al., 2011; Thay et al., 2013; Askarian et al., 
2018; Schlatterer et al., 2018; Andreoni et al., 2019). Virulence factors such as hemolysin, 
loaded as vesicular cargo, are delivered to host cells via fusion of vesicles with the host 
cholesterol-rich membrane. In addition, S. aureus derived EVs also release lipoproteins, which 
play a significant role in modulating TLR2 activation and are involved in pathogenesis. In 
general, various pathophysiological functions ranging from cellular inflammation to host cell 
death could be mediated by S. aureus EVs (Hong et al., 2011; Kim et al., 2012).  
The first report of RNA associated with EVs was published in 1989 in Neisseria 
gonorrhoeae (Dorward et al., 1989). Henceforth, many intensive studies have been conducted 
to characterize RNAs and their functions (Scanlan, 2014; Sjöström et al., 2015; Blenkiron et 
al., 2016; Koeppen et al., 2016; Choi et al., 2018; Malabirade et al., 2018). In Gram-negative 
organisms, EVs harbor not only virulence factors but also sRNAs that enhance the 
pathogenicity, which allow bacteria to persist longer in the host cells (Koeppen et al., 2016). 
To our knowledge, there have not been any studies to characterize sRNA associated with the 
vesicles of S. aureus. Hence, we aimed to perform high-throughput transcriptome sequencing to 
identify sRNAs associated with S. aureus EVs. 
A crude EV pellet was used as the source material to enable isolation of sufficient small 
RNA for sequencing. The crude EV pellet was further concentrated using ultrafiltration 
columns with cutoff of 10kD, which remove lipoprotein aggregates (Ramirez et. al., 2018). 
However, TEM images show the presence of other materials in addition to EVs (Figure 1). The 
crude EVs were RNase treated to remove any RNA that is not associated with EVs, before 
sRNA was isolated for high-throughput RNA sequencing. Adequately replicated RNA 
quantification isolated from EVs and RNase treated EVs confirmed a reduction in RNA from 
RNase treatment (Table S1). Since staining of RNase treated EVs with RNA and lipid dyes 
showed co-localisation of RNA and lipid particles assumed to be EVs (Figure 2, Figure S5), 
and we could isolate sRNA from RNase-treated EV, we concluded that sRNA is associated 
with EVs. RNA seq data revealed that SsrA, RsaC and RNAIII were among the most enriched 




triplicates from from RNase treated EVs and confirmed presence SsrA, RsaC and RNAIII by 
qPCR, conventional PCR and Sanger sequencing of the PCR products (Figure 4, Table S1).  
We also identified phage-like sequences in EVs RNA-seq (Table S2). The presence of these 
might be due to vancomycin-induced activation of one or two of the prophages harbored by S. 
aureus MSSA476 (Holden et al., 2004), which then pelleted with the vesicles. This agrees with 
others, who also obtained phage or phage tail particles in EVs when bacteria were exposed to 
antibiotics (Kharina et al., 2015;Devos et al., 2017;Andreoni et al., 2019). One of the limitations 
of using the crude pellet as the source of EVs for isolation of RNA is that it not only contains 
EVs, but also other nanoscale contaminants (e.g. the filaments and bacteriophage). We assumed 
that the source of RNA, in our study, is predominantly RNase treated EVs, but it is conceivable 
that some sequences are from other nanoscale contaminants pelleted along with the EVs, in a 
form that is protected from RNase, and at a concentration or of a size that is not visible by the 
fluorescence microscopy.  
In bacteria, 16S and 23S rRNA are the most abundant RNAs that accounts for greater than 
90% of the total RNA biotype (Petrova et al., 2017). The abundance of rRNA reduces the 
sequencing depth for other RNA classes, thus an rRNA depletion strategy was implemented to 
ensure sufficient coverage of the transcriptome from bacterial RNA-seq data. Although in our 
study, fragments of mRNA were most abundant, we focused on characterizing sRNA, given 
they play important roles in EV biogenesis and virulence (Diallo and Provost, 2020; Lécrivain 
and Beckmann, 2020).   
The observed EV sizes agreed with other studies from S. aureus (Gurung et al., 2011; 
Askarian et al., 2018; Wang et al., 2018; He et al., 2019). Antibiotics and other stressful 
conditions are considered as trigger factors for EV formation (Maredia et al., 2012; Prados-
Rosales et al., 2014; Andreoni et al., 2019). Moreover, vancomycin was found to increase EV 
production in another Gram-positive bacterium, E. faecium (Kim et al., 2019). In agreement 
with this, we observed a higher yield of EVs when the bacteria were grown in iron limited 
media supplemented with vancomycin compared to typical bacteriologic media (Figure S3). 
Since, we inoculated iron-chelated BHI media with an overnight grown inoculum in 1:100 
dilutions, there is the possibility of transfer of trace amounts of iron from overnight inoculum 
to iron-chelated media. However, it has been shown that S. aureus utilizes a large proportion of 
iron within 6 h of aerobic growth in tryptic soy broth media (Ledala et. al., 2014) and an 
overnight culture would have further depleted in iron contents. Iron utilization by S. aureus in 
BHI might be similar. In addition, the traces of iron transferred during inoculum would have 
been utilized by growing S. aureus, leaving media chelated for iron after a 16 hour incubation 
(Ledala et. al., 2010 and Ledala et. al, 2014). It will, however, be interesting in the future to 
explore other culture media, such as RPMI 1640, which may better reflect infection conditions 
(Dauros-Singorenko et al., 2017).  
Although there are multiple studies in Gram-positive bacteria showing altered sRNA 
expression due to antibiotic treatment (Felden and Cattoir, 2018;Gao et al., 2020), few studies 
have evaluated RNA content associated with EVs upon antibiotics exposure. Exposure to 
antimicrobials such as ciprofloxacin, tetracycline and melittin treatment of Acholeplasma 
laidlawii resulted in very variable numbers of sequence reads of predominantly 14-60 nt RNAs 
associated with EVs. In addition, tRNA fragments (mainly tRNA-Leu, tRNA-Arg, tRNA-Asn, 
and tRNA-Met) were predominant which is in line with our study (Chernov et al., 2018). There 
are also few reports in eukaryotic exosomes and protozoal EVs confirming that exosome RNA 
levels altered by cellular stress (Bayer-Santos et al., 2014).  
In general, RNAs are unstable and prone to degradation by RNase present in the extracellular 
milieu. However, recent reports indicate that RNAs encapsulated in EVs are protected from 
degradation by the exogenous RNase (Weber et al., 2010;Dauros-Singorenko et al., 2018), 




RNase treatment of EVs would also facilitated degradation of eventual contaminating RNA that 
might passively have been released from the 0.4% dead cells in the culture used for vesicle 
isolation. Nevertheless, some of the RNA-protein complex sticking to the EVs might still have 
been protected from RNase treatment (Ramirez et al., 2018).  
Transcriptome analysis of the EVs revealed the presence of tRNAs and sRNAs (Table 2, 3 
and Table S2). Based on the read counts, the tRNA fragments were found to be most abundant. 
Abundant reads of tRNA fragments have previously been found in EVs released by bacteria 
(Ghosal et al., 2015;Koeppen et al., 2016), fungi (Paracoccidiodes brasiliensis, Histoplasma 
capsulatum) (Da Silva et al., 2015; Alves et al., 2019) and protists (Trypanosoma cruzi, 
Leishmania species) (Garcia-Silva et al., 2014; Lambertz et al., 2015). Interestingly, EVs of 
Pseudomonas aeruginosa also contained  tRNA-Met fragments which entered the host cell and 
inhibited IL-8 secretion, which are considered as a chemoattractant  of neutrophils (Koeppen et 
al., 2016).  
There has been discussed whether RNAs associated with EVs are “intact”, fragmented or 
specifically processed products. EVs have been found to be associated with various fragments 
derived from mRNAs, rRNA and tRNA (Mateescu et al., 2017), which is in agreement with 
our study. Due to the small size of vesicles (20-200 nm), we might speculate that inside EVs, 
mostly smaller fragmented RNAs should be enriched. However, we cannot exclude the 
possibility of  having full length RNA, given Buck and colleagues reported full length YRNAs 
exclusively inside Nematode-derived EVs (Buck et al., 2014). In our case, we see fragment 
lengths of 35-150 nt. 
It has been reported that sRNA present in vibrio and other Gram-negative bacteria play a 
role in vesicle biogenesis (Song et al., 2008;Choi et al., 2017a). MicA from E. coli induce EV 
biogenesis. Likewise, Song and collaborators also identified VrrA, a homolog of E. coli MicA 
in Vibrio cholera that controls EV formation and contributes to bacterial fitness in certain 
stressful environments (Song et al., 2008). Besides sRNAs, Sle1, an autolysin, has been shown 
to facilitate vesicle biogenesis (Wang et al., 2018).  
The presence of EV associated sRNA (SsrA, RsaC, and RNAIII) was confirmed by RNA-
seq, qPCR, RT-PCR and sequencing of obtained replicons. Among these, SsrA is involved in 
defective mRNAs decay, rescue of stalled ribosomes, support of phage growth, and modulation 
of the activity of DNA binding proteins (Karzai et al., 2000; Janssen and Hayes, 2012). Earlier 
reports have shown an increase of SsrA RNA in Streptococcus pyogenes and Helicobacter 
pylori in the presence of antibiotics (Steiner and Malke, 2001; Thibonnier et al., 2008). In our 
study, the high coverage of SsrA RNA associated with S. aureus EVs might be due to the use 
of vancomycin stress prior to vesicle isolation. 6S RNA plays an important role in cell survival 
and persistence during the stationary phase (Wassarman and Storz, 2000; Trotochaud and 
Wassarman, 2004) and was also found associated with the EVs. Interestingly, RNAIII (Table 
3), which has major roles in virulence and pathogenicity (Boisset et al., 2007; Toledo-Arana et 
al., 2007), was also associated with EVs of S. aureus. The validation of RNAIII associated with 
EVs of S. aureus opens further study on the possibility of sRNA-mediated interspecies 
communication, as RNAIII has already been proved to be involved in the regulation of quorum 
sensing communication systems to coordinate the expression of virulence factors (Diallo and 
Provost, 2020; Lécrivain and Beckmann, 2020). Indeed, EVs could be used as communication 
vehicles only if they could transfer associated RNA into host cells and have a functional effect. 
Another possibility is that bacteria utilize EVs to eliminate unwanted RNAs, including  sRNA 
and tRNA fragments (Groot and Lee, 2020). 
Importantly, the role of EVs influence S. aureus virulence over the course of systemic 
infection (Askarian et al., 2018). Recently, RNAs (circulatory/and or EV-associated) were 
considered as virulence factors due to their role in the infection process via multifaceted 




RNA into the host cells. It has been shown that bacterial RNA can be delivered to human cytosol 
(Vanaja et al., 2014) and the phagosomal compartment (Cervantes et al., 2013) and EV 
associated RNA has been localized in the human cell nucleus of human bladder carcinoma cells 
(Blenkiron et al., 2016). The  sRNAs associated with EVs found in this study has been shown 
to be involved in quorum sensing (Novick and Geisinger, 2008), oxidative stress (Lalaouna et 
al., 2019), antibiotic resistance and metabolism (Lalaouna et al., 2014). All these processes are 
important for virulence and modulation of bacterial pathogenicity. EVs have some striking 
similarities with exosomes that are secreted from most mammalian cell types. Exosomes are 
involved in transport of mRNAs and miRNAs from donor to recipient cells to modulate gene 
expression (Zhang et al., 2015;Lu et al., 2019). They have similar size (around 50-200 nm in 
diameter) and carry payloads of proteins, lipids, and genetic materials such as the bacterial 
membrane vesicles. Both types can deliver functional molecules to distant extracellular 
compartments and tissues. 
Recently, it was described that eukaryotic sRNA profiles of serum exosomes derived from 
individuals with tuberculosis can facilitate the development of potential molecular targets for 
detection/diagnosis of latent and active tuberculosis (Lvu et al., 2019). In addition to eukaryotic 
sRNA in exosomes, circulating sRNA (ASdes) from Mycobacterium tuberculosis was found in 
patients suffering from active tuberculosis, implicating their role as diagnostic biomarkers ((Fu 
et al., 2018). This makes us hypothesize that some of the sRNA we have validated in EVs 
(RNAIII, SsrA) have a potential to be used as biomarkers for bloodstream infections (Bordeau 
et al., 2016), joint infections (osteomyelitis) (Deng et al., 2020), tissues infections (e.g. chronic 
biofilm infections) and/or bacterial persistence (Romilly et al., 2014; Schoenfelder et al., 2019). 
Identifying sRNAs as biomarkers should not be limited to pathogenic strains but also to nasal 
and other commensal strains.  
A previous study compared RNA contents of group A streptococcal cells versus their EVs, 
and found that some RNA species were differentially abundant (Resch et al., 2016). For future 
studies, it would be interesting to do similar studies in S. aureus, and also to compare whether 
media or antibiotics influence the EV cargo. Further investigation is also needed to address 
whether RNAs found inside the vesicles are entrapped during vesicle biogenesis or if there are 
some sorting of RNA into the vesicles  
In conclusion, to our knowledge, this is the first study describing sRNA associated with S. 
aureus extracellular vesicles. Various tRNAs and sRNAs associated fragments have been 
identified with several biological or regulatory functions were associated with the EVs. This 
study opens further questions concerning sorting mechanisms by which RNA can be packed 
inside EVs and their roles in host-microbe as well as microbe-microbe interactions. Targeting 
those sRNA may open avenues towards a novel anti-virulence strategy to treat intractable 
bacterial infections.  
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Staphylococcus aureus is an opportunistic pathogen that can cause infections ranging from 
minor superficial skin infections to severe life-threatening infections such as endocarditis, 
bacteremia and sepsis. S. aureus releases extracellular vesicles and several groups have 
characterized their protein cargo. However, whether S. aureus extracellular vesicles can carry 
RNAs, including regulatory RNA, remained elusive. In this study, we imaged RNA in RNase-
treated extracellular vesicles, suggesting association of RNA with vesicles that is protected 
against extra-vesicular environment. RNA was isolated and transcriptomic and qPCR analysis 
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Flow cytometry data 
  Plate count (CFU) 
Bacterial count  
(bacteria/mL) 
Live bacteria (%) Dead bacteria (%) 
S. aureus grown under 
normal condition 1.8×10
10
 99.9  0.1 3×10
10
  
S. aureus grown under 
stress condition  8.8×10
9
























Table 2. The most enriched MSSA476 EV-associated tRNAs based on read counts 











Bases of selection 
tRNA 1937102..1937175 tRNA Met 
(CAT) 
75.92 984 62.16 CGCGGGATGGAGCAGTTCGGTAGCTCGTCGGGCTCATAACCCGAAG
GTCGGTGGTTCAAATCCGCCTCCCGCAA 
tRNA 1937017..1937092 tRNA Asp 
(GTC) 
83.32 859 61.84 GGTCTCGTAGTGTAGCGGTTAACACGCCTGCCTGTCACGCAGGAGAT
CGCGGGTTCGATTCCCGTCGAGACCGCCA 
tRNA 533919..534007 tRNA Leu 
(TAA) 
75.33 607 61.80 GCCGGGGTGGCGGAACTGGCAGACGCACAGGACTTAAAATCCTGCG
GTGAGAGATCACCGTACCGGTTCGATTCCGGTCCTCGGCACCA 
tRNA 1937971..1938059 tRNA Leu 
(TAA) 
76.44 590 61.80 GCCGGGGTGGCGGAACTGGCAGACGCACAGGACTTAAAATCCTGCG
GTGAGTGATCACCGTACCGGTTCGATTCCGGTCCTCGGCACCA 
tRNA 1936757..1936837 tRNA Tyr 
(GTA) 
69.29 525 61.73 GGAGGGGTAGCGAAGTGGCTAAACGCGGCGGACTGTAAATCCGCTC
CTTCGGGTTCGGCAGTTCGAATCTGCCCCCCTCCA 
tRNA 1937190..1937282 tRNA Ser 
(TGA) 
74.09 829 61.29 GGAGGAATACCCAAGTCCGGCTGAAGGGATCGGTCTTGAAAACCGA
CAGGGCCTTAACGGGCCGCGGGGGTTCGAATCCCTCTTCCTCCGCCA 
tRNA 1937407..1937496 tRNA Ser 
(TGA) 
61.04 657 60.00 GGAGGAATACCCAAGTCCGGCTGAAGGGATCGGTCTTGAAAACCGA
CAGGGGCTTAACGGCTCGCGGGGGTTCGAATCCCTCTTCCTCCG 
tRNA 1936843..1936918 tRNA Thr 
(TGT) 
92.93 560 55.26 GCCGGCCTAGCTCAATTGGTAGAGCAACTGACTTGTAATCAGTAGGT
TGGGGGTTCAAGTCCTCTGGCCGGCACCA 
tRNA 533837..533911 tRNA Gly 
(GCC) 
86.82 518 54.67 GCAGAAGTAGTTCAGCGGTAGAATACAACCTTGCCAAGGTTGGGGT
CGCGGGTTCGAATCCCGTCTTCTGCTCCA 
tRNA 1936926..1936998 tRNA Phe 
(GAA) 





Table 3. The most enriched MSSA476EV- associated small RNAs ranked based on read countsa 
Element RFAM 
accession 














6S RNA RF00013 protein-
binding small 
RNA 
Involved in antibiotic 
resistance (Lalaouna et al., 
2014) 
1685656..1685846 197 R 80 97.5 42.41 
SsrA RNA RF00023 protein-
binding small 
RNA 
Rescues stalled ribosomes 
during translation of defective 
mRNAs and biosynthesis of 
pigment (Liu et al., 
2010;Guillet et al., 2013) 
837496..837857 362 F 65 162.6 43.92 
RsaC RF0188 trans-encoded 
antisense RNA 
Oxidative stress and metal-
dependent nutritional immunity 
(Lalaouna et al., 2019) 
6736626..674066 441 R 33 555.6 35.37 
T-box RF00230 regulatory 
elements 
Involved in amino acid 
































4.5S RNA RF00169 trans-encoded 
antisense RNA 
Processing of tRNAs 
(Szafranska et al., 2014) 





Controls expression of de novo 
riboflavin 





Involved in amino acid 
(methionine) metabolism 
2372869..2372964 96 R 21 78.2 47.92 
fstAT RF01797 trans-encoded 
antisense RNA 
Type I toxin-antitoxin system 
that interfere with bacterial 
membrane (Schuster and 
Bertram, 2016) 
1873399..1873493 95 R 19 90.2 42.11 
rli28 RF01492 trans-encoded 
antisense RNA 
Role in virulence (Romby and 
Charpentier, 2010) 




L19_leader RF00556 regulatory 
element 
NA 1254259..1254301 43 F 18 50.0 41.86 
yjdF RF01764 regulatory 
element 
Regulate gene expression upon 
binding with heterocyclic 
aromatic compounds (Li et al., 
2016). 
423980..424080 101 F 17 92.9 38.61 
rli28 RF01492 trans-encoded 
antisense RNA 
Role in virulence (Romby and 
Charpentier, 2010) 





Involved in biosynthesis and 
transport of thiamine (Sudarsan 
et al., 2005) 





Involved in amino acid 
metabolism 
1791148..1791366 203 R 15 80.52 31.53 
RNAIII RF00503 trans-encoded 
antisense RNA 
Involved in virulence 
(hemolysins) (Boisset et al., 
2007) 
2086458..2086973 516 R 14 472.2 28.68 
RsaJ RF01822 trans-encoded 
antisense RNA 





Regulate expression of lysine 
biosynthesis and transport 
genes (Blount et al., 2007) 
1732415..1732590 176 F 12 104.6 31.82 
fstAT RF01797 trans-encoded 
antisense RNA 
Type-I toxin-antitoxin systems 
(Blenkiron et al., 2016) 
2483979..2484075 97 F 12 78.12 40.21 
L10_Leader RF00557 regulatory 
element 
NA 566720..566866 127 F 10 86.8 31.21 
See Supplementary Table S2 for the full list of sRNAs  







Table S1. Description of sample preparation and downstream applications from three independent EVs sample preparation. RNA concentration 
was measured by Qubit (RNA HS Kit) in crude EVs, EVs treated with RNase and RNA isolated from RNase-treated EVs 
 
 No. of overnight cultures 
combined for isolation of  
crude EVs 
RNA concentration (ng/µL) Downstream 








RNA concentration in 
Biological Replicate (I) 
5 NA NA 77 40 RNA seq, AFM, 
confocal microscopy, 
TEM 
RNA concentration in 










RNA concentration in 








NA qPCR, PCR and Sanger 
seq 
 





Table S3. Average Ct values of EV associated RNA from three different biological replicates with one-two technical replicates, as detected by 
real-time PCR 
 
Gene Biological replicate (I) Biological replicate (II) Biological replicate (III) 
 Ct values 
 Technical replicate (I)          Technical replicate (II) Technical replicate (I) Technical replicate (I)             Technical replicate (II) 
ssrA 27.89±0.34 33.92±0.83 35.52±0.07 38.79±0.3 35.88±0.21 
rsaC 23.68±0.09 25.04±0.31 24.19±0.12 26.12±0.2 26.4±0.13 
RNAIII 30.81±0.18 34.54±1.47 24.77±0.24 23.95±0.2 24.3±0.23 







Figure 1. S. aureus MSSA 476 grown under infection mimicking condition produces spherical 
EVs of various sizes. (A) Low and (B) high magnification TEM images of crude EVs isolated 
from bacteria grown in iron-depleted BHI supplemented with subinhibitory concentration of 
vancomycin (black arrow indicates vesicles) (C) NTA showing size distribution of EVs (mean 
in nm ± SD) isolated from S. aureus MSSA476.  
Figure 2. Confocal microscopy of (A) enlarged extracellular vesicle particles/aggregates and 
(B) multiple EV particles/aggregates from the field of view. The vesicles were stained with 
lipid specific dye, PKH2 (red) and RNA-specific dye, SYTO RNASelect (green). Scale bar, 5 
μm. (C) Line graph showing fluorescence intensity profile of the dotted line across the 
extracellular vesicles in panel (B). Arrowhead indicates absence of SYTO RNASelect 
fluorescence in the PKH2 stained extracellular vesicle. (D) Quantification of RNA and lipid 
positive particles. Data points from two different experiments and 8 fields of view (180 μm). 
 
Figure 3. Analysis of the sRNA isolated from S. aureus EVs. (A) Virtual gel like image from 
bioanalyser. L: Ladder and lane 2 shows the RNA of the EVs. (B) Electropherogram displaying 
sRNA. The first peak in the electropherogram represent lower marker that is used as an 
alignment to RNA ladder. Other four small peaks appearing at the interval of migration time 24 
to 28 sec represent sRNA.  
 
Figure 4. Real Time PCR validation analysis. Boxplot representation of Ct values for SsrA, 
RsaC and RNAIII isolated from S. aureus EVs. Boxes represent interquartile range, central line 
is median, Whiskers are upper and lower adjacent values and Dots represent number of data 
points. B) Agarose gel electrophoresis of the RT-PCR products obtained from RNA isolated 
from RNase treated EVs. The expected amplicon sizes for SsrA, RsaC and RNAIII are 204, 
204 and 202 bp, respectively. The left lane shows molecular weight markers. 
 
Figure S1. Growth curves of S. aureus grown under BHI (normal condition) and iron depleted 
BHI media with subinhibitory concentration of vancomycin (stressed condition). 
 
Figure S2. Flow cytometry analysis of S. aureus grown in A) BHI (normal condition)B) iron 
depleted BHI media with subinhibitory concentration of vancomycin (stressed condition) for 
16 h. Side scatter is represented on X-axis and AF488 on Y- axis. Gates P1, P3 and P6 were set 
for beads, live cells and dead cells, respectively. 
 
Figure S3: Measurement of EVs yield obtained from bacteria grown in BHI (normal condition) 
and iron-depleted BHI with subinhibitory concentration of vancomycin (stressed condition). A) 
EV number quantified by NTA B) Protein concentration in EVs. The mean ± SD is shown. 
Results represent three independent experiments. *P < 0.05, unpaired t-test.  
 
Figure S4. AFM image of MVs isolated from bacteria grown in iron-depleted BHI 
supplemented with subinhibitory concentration of vancomycin (White arrow indicates 
vesicles).  
 
Figure S5. Confocal microscopy on intact RNase treated EV particles/aggregates stained with 
(A) lipid specific dye, DiD (red), and (B) RNA-specific dye, SYTO RNAselect (green). (C) 
The image shows the overlay observed under the microscope. The overall percentage of co-
localisation in one microscopic field was found to be 78.3% which is in line with the results 
 
 
using another lipid specific dye in Figure 2. The white rectangular box and lower panel 
highlights the magnified region in the inset. The scale bar is drawn to 7.5 μm. 
 
Figure S6. Transcriptome landscape of S. aureus EVs. RNA sequencing reads were mapped to 
reference genome (NC_002953) using Rockhopper v 2.0.3. The mapped RNAs, UTRs and, 
multi-gene operons were visualized in the IGV genome browser. The first red track corresponds 
to RNA transcripts. The blue track corresponds to UTRs of protein coding genes. The pink track 
corresponds to multi-gene operons. The final purple track at the bottom of the image 
corresponds to protein coding genes and RNA genes annotated in RefSeq.  
 
Figure S7. A) Schematic representation of sRNAs identification. B)  Size length distribution 
of sRNAs associated with EVs of S. aureus.   
 
Figure S8. Distribution of EV RNAs showing percent of reads mapped to each RNA biotype 
in S aureus chromosomes and plasmid respectively.  
 
Figure S9. Coverage of tRNA downstream of the PerR regulatory region visualized by Artemis 
genome browser. The pink highlighted region represents the coverage plot. The X-axis 
represent the position in the genome and the Y-axis represent the numbers of reads mapped 
(coverage) at that location. 
 
Figure S10. Artemis genome viewer windows showing read density profiles of SsrA (tmRNA). 
The pink highlighted region represents the coverage plot. X-axis represent the position in the 
genome and the Y-axis represent the numbers of reads mapped (coverage) at the specific 
location. 
 
Figure S11. Sanger’s sequencing alignment of SsrA, RsaC and RNAIII RNAs. Sequences were 
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M3.3_Reverse Primer_Reverse Co -----GGGGTT---TGGGGCTCACGACCATACTTATTATTAAGGGAATGTTTTACAGTTATTTTTTCAATCTATTTTTGGGGATGTTATTAATTATGAAA
110 120 130 140 150 160 170 180 190 200
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
RNAIII AAAATTTTATTTATCAAATAATGATAAATCGATGTTGTTTACGATAGCTTACATGCTAGAAATAATTATCTGTAATGATAATTAAGAAAAATACATAGCA
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TABLE S2, Sheet 1:  Mapping statistics of the RNA-sequencing results 
  MVs 
Read number 457861 
Bowtie aligned read number 358758 
Reads with multiple alignments (%) 4 












TABLE S2, Sheet 2: Staphylococcus aureus subsp. aureus MSSA476 (Summary 
Rockhopper outout) 
Total reads:             463516   
Successfully aligned reads: 390362 84 % 
Staphylococcus aureus subsp. aureus MSSA476 
chromosome 
Aligning (sense) to protein-coding genes: 47 % 
  Aligning (antisense) to protein-coding genes: 45 % 
  Aligning (sense) to ribosomal RNAs: 2 % 
  Aligning (antisense) to ribosomal RNAs: 2 % 
  Aligning (sense) to transfer RNAs: 0 % 
  Aligning (antisense) to transfer RNAs: 0 % 
  Aligning (sense) to miscellaneous RNAs: 0 % 
  Aligning (antisense) to miscellaneous RNAs: 0 % 
  Aligning to unannotated regions:         4 % 
Successfully aligned reads: 1922 0 % 
Staphylococcus aureus subsp. aureus MSSA476 
plasmid pSAS 
Aligning (sense) to protein-coding genes: 31 % 
  Aligning (antisense) to protein-coding genes: 29 % 
  Aligning (sense) to ribosomal RNAs: 0 % 
  Aligning (antisense) to ribosomal RNAs: 0 % 
  Aligning (sense) to transfer RNAs: 0 % 
  Aligning (antisense) to transfer RNAs: 0 % 
  Aligning (sense) to miscellaneous RNAs: 0 % 
  Aligning (antisense) to miscellaneous RNAs: 0 % 
  Aligning to unannotated regions:         41 % 
      
Analyzing transcripts     
Staphylococcus aureus subsp. aureus MSSA476 
chromosome 
    
Computing transcript boundaries     
  Number of 5'UTRs:                        276 
  Number of 3'UTRs: 276 
  Number of predicted RNAs: 62 
  Number of predicted RNAs (not antisense): 7 
  Number of predicted RNAs (antisense): 55 
      
Computing likely operons     
  Number of gene-pairs predicted to be part of the 
same operon: 
934 
  Number of predicted multi-gene operons: 481 
Staphylococcus aureus subsp. aureus MSSA476 
plasmid pSAS 
    
Computing transcript boundaries     
  Number of 5'UTRs: 7 
  Number of 3'UTRs: 11 
  Number of predicted RNAs: 5 
  Number of predicted RNAs (not antisense): 1 
  Number of predicted RNAs (antisense): 4 
Computing likely operons     
  Number of gene-pairs predicted to be part of the 
same operon: 
5 





TABLE S2, Sheet 3:  Staphylococcus aureus subsp. aureus MSSA476 (Operon 
Rockhopper outout)  
Start Stop Strand 
Number of 
Genes Genes 
3670 9668 + 4 SAS0003, recF, SAS0005, SAS0006 
14724 15745 + 2 SAS0010, SAS0011 
17321 22164 + 4 SAS0013, SAS0014, rplI, SAS0016 
24924 29586 + 4 SAS0018, SAS0019, SAS0020, SAS0021 
34546 40678 - 3 SAS0025, SAS0026, SAS0027 
40866 41931 - 3 SAS0028, SAS0029, SAS0030 
42831 45827 - 2 ccrB, ccrA1 
46015 48080 - 2 SAS0034, SAS0035 
49912 51482 + 2 SAS0037, SAS0038 
62876 63897 - 2 SAS0054, SAS0055 
64028 67672 + 3 SAS0056, SAS0057, SAS0058 
70254 72024 - 2 SAS0062, SAS0063 
82989 85773 + 4 SAS0074, SAS0075, SAS0076, SAS0077 
88413 90981 + 2 SAS0079, SAS0080 
101255 104253 - 3 SAS0087, SAS0088, SAS0089 
104484 115701 + 9 
SAS0090, SAS0091, SAS0092, SAS0093, SAS0094, SAS0095, SAS0096, 
SAS0097, SAS0098 
118313 119939 + 2 SAS0102, SAS0103 
120149 123954 + 3 SAS0104, SAS0105, SAS0106 
127096 129162 + 2 SAS0110, SAS0111 
129243 131111 + 2 SAS0112, SAS0113 
131242 133629 - 3 SAS0114, SAS0115, SAS0116 
144318 158530 + 14 
SAS0124, SAS0125, SAS0126, SAS0127, SAS0128, SAS0129, SAS0130, 
SAS0131, SAS0132, SAS0133, SAS0134, SAS0135, SAS0136, SAS0137 
161133 161849 - 2 SAS0140, SAS0141 
166897 170427 + 4 SAS0147, SAS0148, SAS0149, SAS0150 
174285 182117 + 2 SAS0154, SAS0155 
183194 187481 - 4 SAS0157, argJ, argC, SAS0160 
194532 198827 + 4 SAS0165, murQ, SAS0167, SAS0168 
203176 205783 + 3 SAS0172, SAS0173, SAS0174 
205990 207967 + 2 SAS0175, SAS0176 
208026 209366 + 3 SAS0177, SAS0178, SAS0179 
211796 218108 + 4 SAS0182, SAS0183, SAS0184, SAS0185 
221180 225673 + 4 SAS0189, SAS0190, SAS0191, SAS0192 
225744 227888 + 2 SAS0193, SAS0194 
231737 235009 - 3 SAS0198, SAS0199, SAS0200 
235597 240723 + 4 SAS0201, SAS0202, SAS0203, SAS0204 
243925 247400 - 2 SAS0207, SAS0208 
248910 252003 - 2 SAS0210, SAS0211 
256101 257445 - 2 SAS0215, SAS0216 
261182 262323 + 2 SAS0219, SAS0219a 
262433 265303 + 3 SAS0220, SAS0221, SAS0222 
265530 269077 + 4 SAS0223, SAS0224, SAS0225, SAS0226 
269605 273055 + 3 ispD, SAS0228, SAS0229 
275526 280724 + 4 ispD, SAS0233, SAS0234, SAS0235 
281786 284283 + 2 SAS0237, SAS0238 
284396 285533 + 2 SAS0239, SAS0240 
286494 288737 + 2 SAS0242, SAS0243 
290242 292484 - 3 SAS0245, SAS0246, SAS0247 
298545 301301 - 3 SAS0253, SAS0254, SAS0255 
304740 318351 + 11 
SAS0259, SAS0260, SAS0261, SAS0262, SAS0263, SAS0264, SAS0265, 
SAS0266, SAS0267, SAS0268, SAS0269 
 
 
Start Stop Strand 
Number of 
Genes Genes 
320202 324267 + 8 
SAS0272, SAS0273, SAS0274, SAS0275, SAS0276, SAS0277, SAS0278, 
SAS0279 
330158 331897 + 2 SAS0285, SAS0286 
333479 336726 + 3 SAS0288, SAS0289, SAS0290 
336832 339285 - 2 SAS0291, SAS0292 
348766 352868 + 5 SAS0300, SAS0301, SAS0302, SAS0303, SAS0304 
354302 358352 - 4 ulaA, SAS0307, SAS0308, SAS0309 
362745 365326 + 3 SAS0314, SAS0315, SAS0316 
367498 371271 + 3 SAS0319, SAS0320, SAS0321 
371363 372296 - 2 SAS0322, SAS0323 
373033 375442 + 4 SAS0325, SAS0326, SAS0327, SAS0328 
379563 385858 - 4 SAS0332, SAS0333, SAS0334, SAS0335 
387524 389747 + 3 SAS0337, SAS0338, SAS0339 
390268 391088 + 2 rpsF, SAS0342 
400727 402835 - 2 SAS0357, SAS0358 
409524 414440 + 4 SAS0364, SAS0365, SAS0366, guaA 
416684 417577 - 2 SAS0370, SAS0371 
423051 423741 - 2 SAS0377, SAS0378 
426094 427418 - 3 SAS0381a, SAS0382, SAS0383 
438971 441779 + 2 SAS0394, SAS0395 
442185 444401 + 2 SAS0396, SAS0397 
446012 447605 + 2 SAS0400, SAS0401 
448633 451416 + 4 SAS0403, SAS0404, SAS0405, SAS0406 
454880 459082 + 2 SAS0410, SAS0411 
460289 461734 + 2 SAS0414, SAS0415 
463744 465784 + 2 SAS0417, SAS0418 
466081 468648 + 3 SAS0419, SAS0420, SAS0421 
470578 471457 + 2 SAS0424, SAS0425 
471626 473523 - 2 SAS0426, SAS0427 
474704 480684 + 2 SAS0429, gltD 
483006 485399 + 2 SAS0432, SAS0433 
488422 489342 + 2 SAS0436, recR 
496066 498379 + 3 SAS0438, tmk, SAS0440 
498593 500687 + 3 SAS0441, SAS0442, SAS0443 
500961 502768 + 3 SAS0444, SAS0445, SAS0446 
503053 505830 + 2 SAS0447, SAS0448 
505997 507437 + 2 SAS0449, ksgA 
508110 510193 + 3 ipk, SAS0453, SAS0454 
514458 521915 + 6 SAS0459, SAS0460, SAS0461, SAS0462, SAS0463, SAS0464 
522601 524440 + 2 SAS0466, SAS0467 
529227 530846 + 3 SAS0471, SAS0472, SAS0473 
546794 548245 + 2 SAS0476, SAS0477 
549823 554336 + 4 SAS0479, SAS0480, SAS0481, SAS0482 
554820 557282 + 2 SAS0483, SAS0484 
559716 563422 + 5 SAS0486, cysS, SAS0488, SAS0489, SAS0490 
564386 565129 + 2 secE, SAS0494 
590563 591835 - 2 SAS0514, SAS0515 
592519 593975 + 2 SAS0517, SAS0518 
609049 610978 - 3 SAS0524, SAS0525, SAS0526 
612092 613274 + 2 SAS0528, SAS0529 
616187 619609 + 5 SAS0532, SAS0533, SAS0534, SAS0535, SAS0536 
621498 622535 + 2 SAS0539, SAS0540 
624782 626011 - 2 SAS0543, SAS0544 
627480 629305 + 2 eutD, SAS0548 
629892 632889 + 3 SAS0549, SAS0550, SAS0551 
633459 635208 - 2 SAS0553, SAS0554 
635833 637872 + 2 SAS0555, SAS0556 
643511 644833 + 2 SAS0565, SAS0566 
647818 649629 + 2 SAS0570, SAS0571 
651952 654038 + 2 SAS0574, argS 
657356 658859 + 2 SAS0579, SAS0580 
664032 664476 - 2 SAS0586, SAS0587 
 
 
Start Stop Strand 
Number of 
Genes Genes 
664635 671049 + 8 
SAS0588, SAS0589, SAS0590, SAS0591, SAS0592, SAS0593, SAS0594, 
SAS0595 
674592 677091 - 3 SAS0597, SAS0598, SAS0599 
681802 683963 + 2 SAS0605, SAS0606 
691210 694060 + 3 SAS0612, SAS0613, SAS0614 
695304 696243 + 2 SAS0616, SAS0617 
701159 703805 + 3 SAS0623, SAS0624, SAS0625 
703949 706589 + 2 SAS0626, SAS0627 
707314 708954 + 2 SAS0628, SAS0629 
714886 716075 + 2 SAS0634, SAS0635 
718393 720098 + 2 SAS0638, SAS0639 
723073 724785 - 3 SAS0645, SAS0646, SAS0647 
726051 729352 + 2 SAS0649, SAS0650 
731178 732408 + 2 SAS0653, SAS0654 
735858 736759 - 2 SAS0657, SAS0658 
740392 744034 + 3 SAS0663, SAS0664, SAS0665 
749341 751530 - 3 SAS0670, SAS0671, SAS0672 
753276 755082 - 3 SAS0675, SAS0676, SAS0677 
755433 757769 + 3 SAS0678, SAS0679, SAS0680 
758129 759827 + 2 SAS0682, SAS0683 
762518 766188 + 2 SAS0685, SAS0686 
766410 768894 + 2 SAS0687, SAS0688 
774742 776128 - 2 SAS0693, SAS0694 
776929 779395 + 2 nrdI, SAS0696 
781192 783864 + 3 SAS0698, SAS0699, SAS0700 
785328 786583 - 2 SAS0702, murB 
790431 792944 - 3 SAS0708, SAS0709, SAS0710 
797770 799519 + 2 SAS0715, SAS0716 
805944 806827 + 2 SAS0721, SAS0722 
807090 811935 + 2 SAS0723, uvrA 
812542 816259 + 4 SAS0725, SAS0726, SAS0727, SAS0728 
818026 819929 + 2 SAS0730, SAS0731 
828845 831126 + 2 tpiA, SAS0741 
833773 837405 + 3 SAS0745, SAS0746, smpB 
851300 851777 - 2 SAS0761, SAS0762 
860286 860961 + 2 SAS0776, SAS0777 
861211 863763 + 3 SAS0779, SAS0780, SAS0781 
868004 869699 + 2 SAS0786, SAS0787 
872256 874377 + 2 SAS0790, SAS0791 
874553 877587 + 3 SAS0792, SAS0793, SAS0794 
879544 881749 + 3 SAS0798, SAS0799, SAS0800 
882161 886423 + 5 SAS0801, SAS0802, SAS0803, SAS0804, SAS0805 
888792 889400 + 2 SAS0809, SAS0810 
893079 894788 + 2 SAS0813, SAS0814 
896247 902011 - 7 SAS0816, SAS0817, SAS0818, SAS0819, SAS0820, SAS0821, SAS0822 
909875 912449 - 2 SAS0830, SAS0831 
914456 916151 + 3 SAS0833, SAS0834, SAS0835 
916311 923441 + 2 SAS0836, SAS0837 
934225 937605 + 4 SAS0847, SAS0848, SAS0849, SAS0850 
939087 941284 + 2 SAS0853, SAS0854 
941953 947652 + 5 SAS0856, SAS0857, SAS0858, SAS0859, SAS0860 
949630 953447 + 4 SAS0862, SAS0863, SAS0864, SAS0865 
959681 960875 - 2 SAS0871, SAS0872 
961758 967694 + 6 SAS0874, SAS0875, ppnK, SAS0877, SAS0878, SAS0879 
973651 975994 - 2 SAS0885, SAS0886 
976427 979714 + 3 SAS0887, SAS0888, prfC 
983262 984941 - 4 SAS0894, SAS0895, SAS0896, SAS0897 
985836 986512 + 3 SAS0901, SAS0902, SAS0903 
986905 989287 + 4 SAS0905, SAS0906, SAS0907, SAS0908 
989347 995400 + 14 
SAS0909, SAS0910, SAS0911, SAS0912, SAS0913, SAS0914, SAS0915, 
SAS0916, SAS0917, SAS0918, SAS0919, SAS0920, SAS0921, SAS0922 
998944 1001041 + 3 SAS0927, SAS0928, SAS0929 
 
 
Start Stop Strand 
Number of 
Genes Genes 
1001648 1006809 + 5 SAS0931, SAS0932, SAS0933, SAS0934, SAS0935 
1006878 1008970 + 5 SAS0936, SAS0937, SAS0938, SAS0939, SAS0940 
1009967 1022983 + 9 
SAS0943, SAS0944, SAS0945, SAS0946, SAS0947, SAS0948, SAS0949, 
SAS0950, SAS0951 
1023464 1025231 + 2 SAS0953, SAS0954 
1025807 1029491 + 2 SAS0955, SAS0956 
1033891 1034684 + 2 SAS0961, SAS0962 
1037934 1038892 + 2 SAS0967, SAS0968 
1039611 1041385 + 2 SAS0970, SAS0971 
1045611 1050245 + 4 SAS0978, SAS0979, SAS0980, SAS0981 
1050483 1052031 - 2 SAS0982, SAS0983 
1065266 1069236 - 4 SAS0993, SAS0994, SAS0995, SAS0996 
1071969 1083203 + 11 
SAS1000, SAS1001, SAS1002, SAS1003, SAS1004, SAS1005, SAS1006, 
SAS1007, SAS1008, purH, SAS1010 
1083468 1086257 - 3 SAS1011, SAS1012, SAS1013 
1090769 1092756 + 2 SAS1018, SAS1019 
1093424 1095801 + 2 SAS1021, SAS1022 
1096945 1098860 - 2 SAS1024, SAS1025 
1101055 1103148 + 2 SAS1028, SAS1029 
1103239 1105941 + 2 SAS1030, SAS1031 
1106528 1110852 + 5 SAS1033, SAS1034, SAS1035, SAS1036, SAS1037 
1118297 1118948 - 2 SAS1045, SAS1046 
1126401 1127798 + 2 SAS1051, SAS1052 
1128125 1129612 + 2 SAS1053, SAS1054 
1131556 1132582 + 2 SAS1058, coaD 
1138275 1141887 + 4 SAS1065, SAS1066, SAS1067, SAS1068 
1141949 1143169 + 3 SAS1069, SAS1070, SAS1070a 
1144530 1147990 + 2 pheS, pheT 
1149533 1150321 + 2 SAS1075, SAS1076 
1150394 1154464 + 2 SAS1077, SAS1078 
1158046 1160627 + 2 sdhA, sdhB 
1160863 1162758 + 3 SAS1084, SAS1085, SAS1086 
1170680 1171007 + 2 SAS1097a, SAS1098 
1174258 1176214 + 2 SAS1102, SAS1103 
1184723 1188735 + 4 SAS1112, mraW, SAS1114, SAS1115 
1189027 1192678 + 3 mraY, murD, SAS1118 
1192784 1195401 + 2 SAS1119, SAS1120 
1195661 1198006 + 4 SAS1121, SAS1122, SAS1123, SAS1124 
1198089 1199536 + 2 SAS1125, SAS1126 
1204450 1205858 + 2 lspA, SAS1131 
1207003 1214779 + 5 SAS1133, pyrB, pyrC, SAS1136, carB 
1214886 1216434 + 3 SAS1138, pyrE, SAS1140 
1219507 1220348 + 2 gmk, rpoZ 
1220564 1224171 + 2 SAS1145, SAS1146 
1226292 1232850 + 6 SAS1149, SAS1150, SAS1151, SAS1152, SAS1153, SAS1154 
1233078 1235246 + 3 SAS1155, SAS1156, SAS1157 
1236258 1238293 + 2 SAS1159, SAS1160 
1240761 1243955 + 4 SAS1162, SAS1163, SAS1164, SAS1165 
1245552 1252080 + 4 SAS1168, SAS1169, SAS1170, SAS1171 
1252978 1254218 + 2 rimM, trmD 
1258147 1259782 + 2 rbgA, rnhB 
1259891 1261987 + 2 sucC, SAS1180 
1262214 1264604 + 2 SAS1181, SAS1182 
1269778 1271216 + 2 SAS1186, SAS1187 
1271282 1273483 + 2 hslU, SAS1189 
1275792 1277087 + 2 pyrH, frr 
 
 
Start Stop Strand 
Number of 
Genes Genes 
1277460 1279019 + 2 SAS1194, SAS1195 
1279231 1282240 + 2 SAS1196, SAS1197 
1287104 1291508 + 5 SAS1199, nusA, SAS1201, SAS1202, infB 
1292414 1294317 + 2 SAS1205, SAS1206 
1299331 1305704 + 5 SAS1210, SAS1211, SAS1212, SAS1213, SAS1214 
1305809 1307659 + 3 SAS1215, SAS1216, SAS1217 
1313781 1316408 + 2 SAS1223, SAS1224 
1316929 1319357 + 3 SAS1226, SAS1227, SAS1228 
1319660 1324848 + 3 SAS1229, mutL, SAS1231 
1329747 1331862 + 3 SAS1235, miaA, SAS1237 
1332672 1335167 + 2 SAS1239, SAS1240 
1335411 1337138 + 2 SAS1241, SAS1242 
1343195 1343599 + 2 SAS1251, SAS1252 
1348288 1351590 + 4 SAS1259, SAS1260, SAS1261, SAS1262 
1356093 1359356 + 3 SAS1268, SAS1269, SAS1270 
1372505 1376659 + 2 SAS1285, SAS1286 
1384872 1389271 + 2 SAS1294, SAS1295 
1392379 1393675 + 2 SAS1298, SAS1299 
1403108 1409425 + 7 SAS1307, SAS1308, trpD, trpC, SAS1311, SAS1312, trpA 
1409747 1412287 + 2 SAS1314, SAS1315 
1414916 1418179 - 4 SAS1320, SAS1321, SAS1322, SAS1323 
1420985 1422484 - 2 SAS1326, SAS1327 
1422531 1424376 - 2 SAS1328, SAS1329 
1431312 1434655 + 4 SAS1335, dapA, SAS1337, SAS1338 
1434798 1438294 + 3 SAS1339, SAS1340, SAS1341 
1439974 1442059 + 3 SAS1345, SAS1346, SAS1347 
1444640 1447331 - 2 SAS1351, SAS1352 
1447512 1448553 - 2 SAS1353, SAS1354 
1449133 1453213 - 2 SAS1355, sucA 
1453497 1455508 - 2 SAS1357, SAS1358 
1456295 1458517 - 3 SAS1359, murG, SAS1361 
1461387 1463074 - 4 SAS1364, SAS1365, SAS1366, SAS1367 
1463160 1464493 - 2 SAS1368, SAS1369 
1466073 1468146 - 4 SAS1371, SAS1372, SAS1373, SAS1374 
1468391 1469261 + 2 SAS1375, SAS1375a 
1498906 1501299 - 2 SAS1380, SAS1381 
1502988 1507326 - 2 SAS1383, SAS1384 
1511752 1513016 - 3 SAS1388, SAS1389, SAS1390 
1513555 1516361 + 2 recU, SAS1393 
1516925 1518606 - 3 SAS1394, SAS1395, SAS1396 
1520548 1526572 - 4 SAS1398, SAS1399, SAS1400, SAS1401 
1528219 1534200 - 6 SAS1404, SAS1405, SAS1406, SAS1407, aroB, SAS1409 
1535539 1537800 - 3 SAS1411, ubiE, SAS1413 
1538674 1540999 - 2 gpsA, engA 
1547914 1550236 - 2 SAS1422, SAS1423 
1554595 1557677 - 2 SAS1429, SAS1430 
1557922 1560397 - 2 SAS1431, SAS1432 
1560512 1562532 - 3 SAS1433, SAS1434, SAS1435 
1566422 1567444 - 2 SAS1441, SAS1442 
1572396 1575080 - 2 SAS1447, SAS1448 
1579040 1580471 - 2 SAS1452, SAS1453 
 
 
Start Stop Strand 
Number of 
Genes Genes 
1580822 1585521 - 4 SAS1454, SAS1455, SAS1456, SAS1457 
1585672 1587819 - 2 SAS1458, SAS1459 
1588251 1591076 - 4 SAS1460, SAS1461, xseA, nusB 
1591136 1593332 - 3 SAS1464, SAS1465, SAS1466 
1593806 1595450 - 2 SAS1467, SAS1468 
1595555 1596368 + 2 SAS1469, SAS1470 
1598171 1602093 - 3 SAS1473, SAS1474, gcvT 
1603009 1606475 - 6 SAS1477, SAS1478, SAS1479, SAS1480, SAS1481, SAS1482 
1606527 1610657 - 6 SAS1483, SAS1484, SAS1485, SAS1486, SAS1487, SAS1488 
1614199 1615459 - 2 SAS1492, SAS1493 
1616412 1618658 - 2 SAS1495, SAS1496 
1618772 1620552 - 2 SAS1497, SAS1498 
1627220 1631071 - 6 SAS1504, era, SAS1506, SAS1507, SAS1508, SAS1509 
1631375 1633804 - 3 SAS1510, SAS1511, SAS1512 
1634493 1638681 - 4 SAS1514, SAS1515, prmA, SAS1517 
1640718 1642353 - 2 SAS1519, SAS1520 
1647640 1650307 - 2 SAS1525, SAS1526 
1651125 1656792 - 9 
SAS1528, SAS1529, SAS1530, SAS1531, SAS1532, SAS1533, SAS1534, 
SAS1535, SAS1536 
1660543 1666096 - 6 SAS1540, SAS1541, SAS1542, SAS1543, SAS1544, SAS1545 
1666422 1670393 - 5 greA, SAS1547, SAS1548, SAS1549, SAS1550 
1670678 1671693 - 3 SAS1551, SAS1552, SAS1553 
1674729 1677876 - 2 SAS1555, SAS1556 
1678457 1680718 - 2 mnmA, SAS1558 
1682280 1682648 - 2 SAS1560, SAS1561 
1685924 1688968 - 2 aspS, hisS 
1689429 1692975 - 3 SAS1568, SAS1569, SAS1570 
1693382 1696195 - 2 SAS1571, SAS1572 
1698952 1704832 - 7 SAS1574, tgt, queA, ruvB, ruvA, SAS1579, obgE 
1705317 1706247 - 3 rpmA, SAS1582, rplU 
1706609 1707981 - 2 SAS1584, SAS1585 
1709672 1711062 - 2 radC, SAS1590 
1711332 1715246 - 2 SAS1591, valS 
1716432 1717628 - 2 SAS1594, SAS1595 
1719035 1721628 - 3 SAS1597, SAS1598, hemC 
1721670 1723853 - 2 SAS1600, hemA 
1727691 1729247 - 2 SAS1605, SAS1606 
1729792 1730548 - 2 rpmI, infC 
1735045 1737836 - 3 SAS1612, SAS1613, nrdR 
1739242 1743399 - 3 coaE, SAS1617, SAS1618 
1745679 1748044 - 2 SAS1620, SAS1621 
1752929 1755676 - 2 SAS1625, pfkA 
1755945 1757746 - 2 SAS1627, SAS1628 
1759620 1763779 - 2 SAS1630, SAS1631 
1774460 1776822 - 2 SAS1642, SAS1643 
1781934 1784685 + 2 SAS1649, SAS1650 
1799578 1801404 + 2 SAS1660, SAS1661 
1806507 1813171 - 4 murC, SAS1667, SAS1668, SAS1669 
1816558 1818008 - 2 trmB, SAS1675 
1818559 1820820 - 2 SAS1676, SAS1677 
1821513 1824305 - 3 SAS1678, SAS1679, SAS1680 
 
 
Start Stop Strand 
Number of 
Genes Genes 
1832983 1835736 - 2 SAS1683, leuS 
1837318 1838831 + 2 SAS1686, SAS1687 
1842110 1845461 - 4 ribH, SAS1692, SAS1693, SAS1694 
1847967 1849573 + 2 SAS1696, SAS1697 
1855492 1856285 + 2 SAS1706, SAS1707 
1862281 1863511 - 2 SAS1713, SAS1714 
1863825 1866309 - 2 SAS1716, SAS1717 
1871836 1872406 - 2 SAS1725, SAS1726 
1879882 1882630 - 2 SAS1731, SAS1732 
1888168 1896483 - 7 SAS1739, SAS1740, SAS1741, SAS1742, SAS1743, SAS1744, SAS1745 
1897813 1899733 - 2 hlgB, hlgA 
1900630 1901886 + 2 SAS1750, SAS1751 
1905219 1907566 - 2 SAS1753, hemH 
1909551 1911507 - 2 SAS1757, SAS1758 
1912205 1912754 + 2 SAS1760, SAS1760a 
1915148 1920208 - 3 SAS1763, SAS1764, SAS1765 
1923626 1925383 - 2 SAS1769, SAS1770 
1928923 1929345 + 2 SAS1774, SAS1775 
1929410 1930186 - 2 SAS1776, SAS1777 
1930345 1931947 - 2 SAS1778, SAS1779 
1932098 1934270 - 2 SAS1780, SAS1781 
1944993 1946401 - 2 SAS1784, SAS1785 
1954651 1958138 - 4 SAS1792, SAS1793, SAS1794, recX 
1962608 1964082 - 2 SAS1801, SAS1802 
1964214 1964960 + 2 SAS1803, SAS1804 
1966561 1969322 - 4 SAS1806, SAS1807, SAS1808, SAS1809 
1972943 1974989 - 2 SAS1813, SAS1814 
1981852 1985053 - 3 gatB, gatA, gatC 
1987047 1993147 - 4 SAS1826, SAS1827, SAS1828, SAS1829 
1995886 1997409 + 2 SAS1832, SAS1833 
1997701 1998457 - 2 SAS1834, SAS1835 
1998728 2001011 - 2 nadE, SAS1837 
2001195 2003085 + 2 SAS1838, SAS1839 
2013965 2015361 - 2 SAS1850, SAS1851 
2016695 2020333 - 5 SAS1854, SAS1855, SAS1856, SAS1857, SAS1858 
2025851 2026362 + 2 SAS1863a, SAS1864 
2029184 2030205 - 2 SAS1869, SAS1870 
2032611 2042693 - 4 SAS1875, SAS1876, SAS1877, SAS1878 
2043442 2047254 - 7 SAS1881, SAS1882, SAS1883, SAS1884, SAS1885, SAS1886, SAS1887 
2047342 2051553 - 5 SAS1888, SAS1889, SAS1890, SAS1891, SAS1892 
2051682 2052494 - 2 SAS1893, SAS1894 
2052609 2054260 - 5 SAS1895, SAS1896, SAS1897, SAS1898, SAS1899 
2054601 2057118 - 5 SAS1901, SAS1902, SAS1903, SAS1904, SAS1905 
2057331 2060737 - 4 SAS1906, SAS1907, SAS1908, SAS1909 
2060830 2061308 - 2 SAS1910, SAS1911 
2062014 2062382 - 2 SAS1912a, SAS1913 
2063763 2064265 - 2 SAS1917, SAS1918 
2065390 2066870 + 2 SAS1920, SAS1921 
2069110 2071200 - 2 SAS1924, SAS1925 
2078674 2079476 - 2 SAS1932, SAS1933 
2087174 2089933 + 4 SAS1941, SAS1942, SAS1943, SAS1944 
 
 
Start Stop Strand 
Number of 
Genes Genes 
2090302 2092742 - 2 SAS1945, SAS1946 
2102039 2104631 - 4 SAS1954, SAS1955, SAS1956, SAS1957 
2105109 2108594 + 2 SAS1958, SAS1959 
2108985 2115837 + 6 SAS1961, SAS1962, SAS1963, SAS1964, leuD, SAS1966 
2122456 2125054 - 2 SAS1967, SAS1968 
2125487 2127039 - 3 SAS1969, SAS1970, SAS1971 
2128508 2129037 - 2 SAS1973, SAS1974 
2130336 2133232 - 4 acpS, SAS1977, SAS1978, SAS1979 
2133441 2137743 - 3 SAS1980, SAS1981, SAS1982 
2138015 2141367 + 2 SAS1983, SAS1984 
2143773 2146216 - 2 SAS1986, ddl 
2148243 2148757 - 2 SAS1990, SAS1991 
2148923 2151082 + 2 SAS1992, SAS1993 
2152654 2155584 - 4 thiE, SAS1996, SAS1997, SAS1998 
2158279 2160018 - 2 fabZ, SAS2003 
2160924 2166269 - 6 atpC, SAS2006, SAS2007, SAS2008, SAS2009, SAS2010 
2166721 2167823 - 2 SAS2012, SAS2013 
2167990 2171587 - 4 SAS2014, upp, glyA, SAS2017 
2171694 2173156 - 2 SAS2018, SAS2019 
2173240 2175739 - 3 SAS2020, prfA, SAS2022 
2189418 2191795 - 2 SAS2035, SAS2036 
2192728 2194393 - 2 SAS2038, SAS2039 
2200041 2201240 - 2 SAS2045, SAS2046 
2202493 2203795 + 2 SAS2048, SAS2049 
2211611 2216868 + 4 SAS2057, SAS2058, SAS2059, SAS2060 
2224979 2228104 - 3 glmM, SAS2064, SAS2065 
2240465 2242354 - 2 SAS2071, SAS2072 
2245088 2248079 - 3 SAS2076, SAS2077, SAS2078 
2248471 2252485 - 3 SAS2079, SAS2080, SAS2081 
2255295 2256083 - 2 SAS2084, SAS2085 
2261788 2268157 - 7 SAS2090, SAS2091, SAS2092, SAS2093, SAS2094, SAS2095, SAS2096 
2276958 2279363 - 2 SAS2105, SAS2106 
2280339 2281188 - 2 rpsI, rplM 
2281428 2284698 - 4 truA, SAS2111, cbiO, cbiO 
2285236 2286565 - 2 rplQ, SAS2115 
2286640 2287804 - 4 SAS2116, rpsM, rpmJ, infA 
2287997 2296295 - 18 
adk, secY, rplO, rpmD, rpsE, rplR, rplF, rpsH, rpsN, rplE, rplX, rplN, rpsQ, 
SAS2133, rplP, rpsC, rplV, rpsS 
2296362 2299151 - 5 rplB, rplW, rplD, rplC, rpsJ 
2314265 2315909 + 2 SAS2155, SAS2156 
2316939 2321027 - 6 SAS2158, mobA, SAS2160, SAS2161, SAS2162, SAS2163 
2321586 2323127 - 2 SAS2165, SAS2166 
2323297 2325370 - 3 SAS2167, SAS2168, SAS2169 
2333148 2338196 + 7 ureA, ureB, ureC, ureE, SAS2182, SAS2183, SAS2184 
2339550 2342275 - 2 SAS2187, SAS2188 
2351356 2352405 - 2 SAS2198, SAS2199 
2352615 2356042 - 2 SAS2200, SAS2201 
2364723 2365261 + 2 SAS2210, SAS2211 
2365357 2366194 - 2 SAS2212, SAS2213 
2376462 2379361 - 2 SAS2223, SAS2224 
2385197 2386572 - 2 SAS2230, SAS2231 
 
 
Start Stop Strand 
Number of 
Genes Genes 
2386790 2388914 - 2 SAS2232, SAS2233 
2392365 2394392 - 2 SAS2237, SAS2238 
2394489 2395396 + 2 SAS2239, SAS2240 
2397516 2400107 - 2 SAS2243, SAS2244 
2405957 2407677 - 2 SAS2250, SAS2251 
2407813 2409853 + 2 SAS2252, SAS2253 
2410016 2410911 + 2 SAS2254, SAS2255 
2420982 2422453 - 2 SAS2263, SAS2264 
2440294 2448976 - 7 SAS2282, SAS2283, SAS2284, SAS2285, SAS2286, SAS2287, SAS2288 
2449284 2452975 - 3 SAS2289, SAS2290, SAS2291 
2458576 2459093 - 2 SAS2298, SAS2299 
2459366 2460346 - 2 SAS2300, SAS2301 
2461948 2464155 - 3 SAS2303, SAS2304, SAS2305 
2472070 2473996 + 2 SAS2311, SAS2312 
2474048 2479353 - 6 SAS2313, SAS2314, SAS2315, SAS2316, SAS2317, SAS2318 
2479806 2483348 - 2 SAS2319, SAS2320 
2502112 2505623 - 4 SAS2337, SAS2338, SAS2339, SAS2340 
2512013 2513444 - 2 SAS2345, SAS2346 
2515124 2515647 - 2 SAS2348, SAS2349 
2519513 2525684 - 6 SAS2353, SAS2354, SAS2355, SAS2356, SAS2357, SAS2358 
2525824 2528771 - 3 SAS2359, SAS2360, SAS2361 
2533848 2535141 - 3 SAS2366, SAS2367, SAS2368 
2541264 2544519 - 2 SAS2376, SAS2377 
2547569 2548976 - 2 SAS2381, SAS2382 
2565005 2567262 - 2 SAS2391, SAS2392 
2575508 2576975 + 2 SAS2399, SAS2400 
2580839 2582422 - 2 SAS2403, SAS2404 
2587844 2589216 + 2 SAS2412, SAS2413 
2591598 2594237 - 3 SAS2416, SAS2417, SAS2418 
2602604 2603681 - 2 SAS2426, SAS2427 
2612090 2614506 - 3 SAS2435, SAS2436, SAS2437 
2624315 2626490 - 2 SAS2445, SAS2446 
2626917 2632453 - 5 SAS2447, SAS2448, SAS2449, SAS2450, SAS2451 
2641488 2643022 - 3 SAS2461, SAS2462, SAS2463 
2643154 2644408 + 2 SAS2464, SAS2465 
2644506 2646354 + 2 SAS2466, SAS2467 
2647488 2649928 - 2 SAS2469, SAS2470 
2650223 2651168 - 3 SAS2471, SAS2472, SAS2473 
2659104 2661151 - 3 SAS2482, panC, panB 
2682280 2684663 - 2 SAS2502, SAS2503 
2691619 2694371 - 2 SAS2508, SAS2509 
2694479 2696268 - 3 SAS2510, SAS2511, SAS2512 
2703620 2706014 - 2 SAS2518, SAS2519 
2706099 2708377 - 2 SAS2520, SAS2521 
2714927 2717831 + 2 SAS2527, SAS2528 
2726137 2736664 - 7 SAS2533, SAS2534, SAS2535, SAS2536, SAS2537, SAS2538, secY 
2745171 2746404 + 2 SAS2542, SAS2543 
2747692 2748671 - 2 SAS2546, SAS2547 
2748906 2751041 - 3 SAS2548, SAS2549, SAS2550 
2752614 2756029 + 4 SAS2552, SAS2553, SAS2554, SAS2555 
 
 
Start Stop Strand 
Number of 
Genes Genes 
2759610 2766535 - 9 SAS2557, SAS2558, SAS2559, hisH, hisB, SAS2562, SAS2563, hisG, hisZ 
2768625 2771167 - 2 SAS2568, SAS2569 
2771220 2772651 - 2 SAS2570, SAS2571 
2788329 2790957 + 2 SAS2585, SAS2586 










Strand Name Synonym Product Expression  
1878   + dnaA SAS0001 chromosomal replication initiation 
protein 
67 
3289   + - SAS0002 DNA polymerase III subunit beta 88 
3915   + - SAS0003 hypothetical protein 30 
5024   + recF SAS0004 recombination protein F 22 
6968 7004 + - SAS0005 - 111 
9668 9808 + - SAS0006 DNA gyrase subunit A 128 
9755 9677 - - SAS0007 hypothetical protein 306 
12407   + hutH SAS0008 histidine ammonia-lyase 77 
  12725 + - SASs001 - 3 
14072   + - SAS0009 seryl-tRNA synthetase 76 
15419   + - SAS0010 hypothetical protein 127 
15745   + - SAS0011 hypothetical protein 37 
  16047 + - SASs002 - 48 
17076 17076 + - SAS0012 hydrolase 124 
18307   + - SAS0013 hypothetical protein 65 
20289   + - SAS0014 hypothetical protein 116 
20732 20763 + rplI SAS0015 50S ribosomal protein L9 172 
22164 22164 + - SAS0016 replicative DNA helicase 184 
23726 23726 + - SAS0017 adenylosuccinate synthetase 158 
  24230 + - SASt001 Glu tRNA 708 
  24310 + - SASt002 Asp tRNA 1206 
  24308 - - Predicted 
RNA 
antisense: SASt002 801 
25631   + - SAS0018 response regulator protein 79 
27470   + - SAS0019 sensor kinase 139 
28797   + - SAS0020 hypothetical protein 248 
29586   + - SAS0021 hypothetical protein 98 
30775   + - SAS0022 metallo-beta-lactamase superfamily 
protein 
79 
33321 33449 + - SAS0023 5'-nucleotidase 163 
  31389 - - Predicted 
RNA 
antisense: SAS0023 650 
34168   + - SAS0024 rRNA large subunit methyltransferase 95 
34546   - - SAS0025 type I restriction enzyme protein 76 
37588   - - SAS0026 type I restriction enzyme specificity 
protein 
10 
38891   - - SAS0027 type I restriction enzyme methylase 80 
40866   - - SAS0028 hypothetical protein 78 
41101 41098 - - SAS0029 hypothetical protein 132 
41620   - - SAS0030 hypothetical protein 98 
42024   - - SAS0031 hypothetical protein 93 
42831   - ccrB SAS0032 site-specific recombinase 78 
44478   - ccrA1 SAS0033 site-specific recombinase 94 
46015   - - SAS0034 hypothetical protein 97 
47784   - - SAS0035 hypothetical protein 94 
48253   - - SAS0036 hypothetical protein 20 
50616   + - SAS0037 hypothetical protein 9 
51482   + - SAS0038 hypothetical protein 23 
52234   + - SAS0040 hypothetical protein 0 
53458   + - SAS0043 fusidic acid resistance protein 49 
54773   + - SAS0044 hypothetical protein 8 
55452   - - SAS0046 hypothetical protein 32 
56889   + - SAS0047 hypothetical protein 6 
58476   + - SAS0048 hypothetical protein 48 
60956   + seh SAS0051 enterotoxin H 38 







Strand Name Synonym Product Expression  
62876   - - SAS0054 hypothetical protein 41 
63631   - - SAS0055 hypothetical protein 17 
65095   + - SAS0056 hypothetical protein 83 
66460   + - SAS0057 metallo-beta-lactamase superfamily 
protein 
60 
67672   + - SAS0058 oxidoreductase 59 
68339   - - SAS0059 hypothetical protein 43 
69837   + - SAS0060 hypothetical protein 16 
70182   + - SAS0061 hypothetical protein 10 
70254   - - SAS0062 hypothetical protein 55 
71467   - - SAS0063 hypothetical protein 48 
72991   + - SAS0064 LysR family regulatory protein 35 
73346   - - SAS0065 hypothetical protein 32 
74713   + - SAS0066 LysR family regulatory protein 17 
75749   + - SAS0067 hypothetical protein 14 
79168   + - SAS0068 hypothetical protein 61 
79707   + - SAS0069 hypothetical protein 52 
81888   + - SAS0072 lipoprotein 14 
82710   + - SAS0073 lipoprotein 7 
83753 83753 + - SAS0074 lipoprotein 134 
85132   + - SAS0075 hypothetical protein 60 
85458   + - SAS0076 hypothetical protein 67 
85773   + - SAS0077 hypothetical protein 44 
88262   + - SAS0078 regulatory protein 95 
89591 89591 + - SAS0079 peptidase 105 
90981 90981 + - SAS0080 transporter protein 199 
91468   - - SAS0081 Na+/Pi-cotransporter protein 96 
93453   - - SAS0082 myosin-cross-reactive antigen 94 
96052   + - SAS0083 hypothetical protein 58 
97906   + - SAS0084 L-lactate permease 1 70 
98235   - - SAS0085 immunoglobulin G binding protein A 
precursor 
74 
100134   - - SAS0086 regulatory protein 54 
101255 101222 - - SAS0087 siderophore transport system permease 117 
102250   - - SAS0088 siderophore transport system permease 178 
103261   - - SAS0089 lipoprotein 52 
105464   + - SAS0090 pyridoxal-phosphate dependent protein 161 
106471 106471 + - SAS0091 ornithine cyclodeaminase 130 
108246   + - SAS0092 siderophore biosynthesis protein 158 
109495   + - SAS0093 transport protein 487 
  108493 - - predicted 
RNA 
antisense: SAS0093 676 
111221   + - SAS0094 siderophore biosynthesis protein 92 
112980   + - SAS0095 siderophore biosynthesis protein 229 
113731   + - SAS0096 aldolase 406 
114933 114933 + - SAS0097 pyridoxal-dependent decarboxylase 161 
115701 115707 + - SAS0098 hypothetical protein 346 







Strand Name Synonym Product Expression  
116980   + - SAS0100 hypothetical protein 45 
117968 118155 + - SAS0101 acetoin reductase 103 
118017 117905 - - SAS0101a hypothetical protein 216 
119284   + - SAS0102 NAD dependent epimerase/dehydratase 
family protein 
64 
119939   + - SAS0103 sugar transferase 91 
121315   + - SAS0104 galactosyl transferase 76 
122534   + - SAS0105 hypothetical protein 88 
123954   + - SAS0106 polysaccharide biosynthesis protein 61 
124821 124856 + - SAS0107 superoxide dismutase 113 
125914 126168 + - SAS0108 surface anchored protein 112 
126105   - - SAS0109 GntR family transcriptional regulator 50 
127803   + - SAS0110 purine nucleoside phosphorylase 83 
129162   + - SAS0111 transport system protein 63 
129905   + - SAS0112 deoxyribose-phosphate aldolase 74 
131111 131625 + - SAS0113 phosphopentomutase 170 
131242 130934 - - SAS0114 binding-protein-dependent transport 
systems membrane component 
197 
132054   - - SAS0115 binding-protein-dependent transport 
system membrane component 
131 
132856 132856 - - SAS0116 ABC transporter ATP binding protein 199 
133843   - - SAS0117 lipoprotein 23 
136572 136572 + - SAS0118 hypothetical protein 189 
138158   + - SAS0119 nucleotidase 80 
143980 144317 + - SAS0123 bifunctional acetaldehyde-CoA/alcohol 
dehydrogenase 
141 
144986 145001 + - SAS0124 capsular polysaccharide synthesis 
enzyme 
146 
145688 145688 + - SAS0125 capsular polysaccharide synthesis 
enzyme 
117 
146455   + - SAS0126 capsular polysaccharide synthesis 
enzyme 
54 
148298   + - SAS0127 capsular polysaccharide synthesis 
enzyme 
117 
149316   + - SAS0128 capsular polysaccharide synthesis 
enzyme 
25 
150438 150441 + - SAS0129 capsular polysaccharide synthesis 
enzyme 
208 
151566   + - SAS0130 capsular polysaccharide synthesis 
enzyme 
82 
152648   + - SAS0131 capsular polysaccharide synthesis 
enzyme 
24 
154035   + - SAS0132 capsular polysaccharide synthesis 
enzyme 
54 
154589   + - SAS0133 capsular polysaccharide synthesis 
enzyme 
22 
155836   + - SAS0134 capsular polysaccharide synthesis 
enzyme 
18 









Strand Name Synonym Product Expression  
157643   + - SAS0136 capsular polysaccharide synthesis 
enzyme 
62 
158530 158530 + - SAS0137 capsular polysaccharide synthesis 
enzyme 
165 
159846 159846 + - SAS0138 capsular polysaccharide synthesis 
enzyme 
202 
161068   + - SAS0139 capsular polysaccharide synthesis 
enzyme 
37 
161133 161104 - - SAS0140 heme-degrading monooxygenase IsdI 104 
161466   - - SAS0141 hypothetical protein 21 
163763 163763 + - SAS0142 aldehyde dehydrogenase 197 
165368   + - SAS0143 cation efflux system protein 60 
165702 165702 + - SAS0144 hypothetical protein 159 
165662 165444 - - SAS0145 hypothetical protein 124 
166555   + - SAS0146 hypothetical protein 0 
167637 167637 + - SAS0147 ABC transporter ATP-binding protein 179 
168625   + - SAS0148 lipoprotein 194 
169383   + - SAS0149 transport system permease 59 
170427   + - SAS0150 hypothetical protein 52 
171003   + - SAS0151 hypothetical protein 50 
172202   + - SAS0152 formate dehydrogenase 55 
173838   + - SAS0153 transporter protein 24 
181460 181460 + - SAS0154 non-ribosomal peptide synthetase 196 
182117 182395 + - SAS0155 4'-phosphopantetheinyl transferase 112 
182445   - - SAS0156 hypothetical protein 26 
183194   - - SAS0157 amino acid kinase 59 




185227 185227 - argC SAS0159 N-acetyl-gamma-glutamyl-phosphate 
reductase 
111 
186297 186297 - - SAS0160 ornithine aminotransferase 164 
187734 187667 - - SAS0161 branched-chain amino acid transport 
system carrier protein 
105 
189365   - - SAS0162 isochorismatase 82 
189989 189923 - - SAS0163 thiamine pyrophosphate enzyme 137 
191902 191630 - - SAS0164 glucose-specific PTS transporter protein, 
IIABC component 
249 
  193224 + - predicted 
RNA 
antisense: SAS0164 753 
195587   + - SAS0165 hypothetical protein 183 
196483 196483 + murQ SAS0166 N-acetylmuramic acid 6-phosphate 
etherase 
246 
197949   + - SAS0167 sucrose-specific PTS transporter protein 189 
198827 198827 + - SAS0168 transcriptional regulator 234 
199021 197806 - - SAS0169 hypothetical protein 149 
202304   + - SAS0170 type I restriction enzyme 74 







Strand Name Synonym Product Expression  
203931   + - SAS0172 hypothetical protein 11 
204608   + - SAS0173 ABC transporter ATP-binding protein 16 
205783   + - SAS0174 permease 31 
206211   + - SAS0175 hypothetical protein 18 
207967   + - SAS0176 hypothetical protein 68 
208469   + - SAS0177 hypothetical protein 28 
209203   + - SAS0178 ATP-binding transport protein 75 
209366   + - SAS0179 hypothetical protein 46 
209413   - - SAS0180 hypothetical protein 1 
210076 210076 - - SAS0181 ABC transporter ATP-binding protein 237 
213103 213108 + - SAS0182 transport system permease 115 
214272   + - SAS0183 transport system permease 93 
216064   + - SAS0184 RGD-containing lipoprotein 67 
218108 218288 + - SAS0185 gamma-glutamyltranspeptidase 231 
218421   - - SAS0186 hypothetical protein 86 
219384   - acpD SAS0187 azoreductase 48 
220797   + - SAS0188 peptidase 65 
222277   + - SAS0189 ABC transporter ATP-binding protein 58 
223561   + - SAS0190 extracellular sugar-binding lipoprotein 36 
224832 224832 + - SAS0191 sugar transport system permease 145 
225673 225673 + - SAS0192 sugar transport system permease 159 
226823 226834 + - SAS0193 oxidoreductase 194 
227888   + - SAS0194 oxidoreductase 97 
228911 229081 + - SAS0195 hypothetical protein 113 
229272   - - SAS0196 hypothetical protein 25 
231378 232551 + uhpT SAS0197 sugar phosphate antiporter 114 
231737   - - SAS0198 response regulator 70 
232488   - - SAS0199 sensor kinase 39 
234041   - - SAS0200 lipoprotein 196 
237846 237868 + - SAS0201 formate acetyltransferase 167 
238624   + - SAS0202 pyruvate formate-lyase activating 
enzyme 
98 
238922 238959 + - SAS0203 hypothetical protein 166 
240723   + - SAS0204 hypothetical protein 61 
240887   - - SAS0205 hypothetical protein 102 
243322   + - SAS0206 staphylocoagulase precursor 76 
243925 243925 - - SAS0207 thiolase 249 
245139 245139 - - SAS0208 fatty oxidation complex protein 145 
247587 247587 - - SAS0209 acyl-CoA dehydrogenase 148 
248910 248799 - - SAS0210 acyl-CoA synthetase 153 
250441 250441 - - SAS0211 acetyl-CoA transferase 242 
253601   + - SAS0212 hypothetical protein 81 
253915   - - SAS0213 extracellular solute-binding lipoprotein 72 







Strand Name Synonym Product Expression  
256101   - - SAS0215 hypothetical protein 30 
256300   - - SAS0216 flavohemoprotein 89 
258971 258971 + - SAS0217 L-lactate dehydrogenase 182 
259291 259291 - - SAS0218 PTS transport system, IIBC component 184 
262117 262117 + - SAS0219 inosine-uridine preferring nucleoside 
hydrolase 
311 
262323   + - SAS0219a hypothetical protein 90 
264550   + - SAS0220 PTS regulator 86 
265002 265024 + - SAS0221 PTS transport system, IIA component 274 
265303 265303 + - SAS0222 PTS transport system, IIB component 127 
266789 266789 + - SAS0223 PTS transport system, IIC component 154 
267862   + - SAS0224 zinc-binding dehydrogenase 69 
268010   + - SAS0225 hypothetical protein 62 
269077 269077 + - SAS0226 zinc-binding dehydrogenase 220 
270321   + ispD SAS0227 2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase 
69 
271339   + - SAS0228 zinc-binding dehydrogenase 34 
273055   + - SAS0229 hypothetical protein 22 
273367 273307 - - SAS0230 hypothetical protein 104 
273828   + - SAS0230a hypothetical protein 49 
275250 275525 + - SAS0231 teichoic acid biosynthesis protein 145 
276242   + ispD SAS0232 2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase 
47 
277260   + - SAS0233 zinc-binding dehydrogenase 65 
278970   + - SAS0234 hypothetical protein 50 
280724   + - SAS0235 glycosyl transferase family protein 58 
281542   + - SAS0236 cell wall biosynthesis protein ScdA 11 
283540   + - SAS0237 autolysin sensor kinase 80 
284283 284335 + - SAS0238 two-component response regulator 109 
284839   + - SAS0239 murein hydrolase regulator LrgA 122 
285533 285639 + - SAS0240 antiholin-like protein LrgB 136 
285641   - - SAS0241 GntR family transcriptional regulator 79 
287285 287300 + - SAS0242 PTS transport system protein 183 
288737 288761 + - SAS0243 6-phospho-beta-glucosidase 211 
289230   - - SAS0244 hypothetical protein 93 
290242 290092 - - SAS0245 ribokinase 124 
291184   - - SAS0246 D-ribose pyranase 35 
291603 291603 - - SAS0247 sugar transport protein 114 
292716 292586 - - SAS0248 LacI family regulatory protein 150 
294045   + - SAS0248a hypothetical protein 0 
294487   + - SAS0249 hypothetical protein 9 
294615 294615 - - SAS0250 transport protein 148 
297217   + - SAS0251 choloylglycine hydrolase 83 
298493 298894 + - SAS0252 peptidoglycan hydrolase 113 







Strand Name Synonym Product Expression  
299218 299218 - - SAS0254 hypothetical protein 108 
300135   - - SAS0255 hypothetical protein 65 
301369   - - SAS0256 hypothetical protein 23 
303223   - - SAS0257 hypothetical protein 100 
304657   + - SAS0258 hypothetical protein 78 
307769   + - SAS0259 hypothetical protein 50 
308227   + - SAS0260 hypothetical protein 18 
308441   + - SAS0261 hypothetical protein 0 
309788   + - SAS0262 hypothetical protein 21 
314249 314249 + - SAS0263 hypothetical protein 126 
314671   + - SAS0264 hypothetical protein 3 
315001   + - SAS0265 hypothetical protein 43 
315675   + - SAS0266 hypothetical protein 1 
315992   + - SAS0267 hypothetical protein 95 
317846   + - SAS0268 hypothetical protein 101 
318351   + - SAS0269 hypothetical protein 3 
319245   + - SAS0270 hypothetical protein 41 
320003   + - SAS0271 hypothetical protein 10 
320702   + - SAS0272 hypothetical protein 59 
321213   + - SAS0273 hypothetical protein 18 
321724   + - SAS0274 hypothetical protein 27 
322235   + - SAS0275 hypothetical protein 41 
322746   + - SAS0276 hypothetical protein 26 
323257   + - SAS0277 hypothetical protein 3 
323768   + - SAS0278 hypothetical protein 7 
324267   + - SAS0279 hypothetical protein 0 
325266   + - SAS0280 hypothetical protein 9 
325814   + - SAS0281 hypothetical protein 3 
326064   - - SAS0282 formate/nitrite transporter 12 
327127   - - SAS0283 amino acid transport system 49 
329908   + - SAS0284 hypothetical protein 40 
331207   + - SAS0285 hypothetical protein 22 
331897   + - SAS0286 ABC transporter ATP-binding protein 0 
333136 333287 + - SAS0287 hypothetical protein 136 
334597   + - SAS0288 PfkB family carbohydrate kinase 80 
335495 335495 + - SAS0289 hypothetical protein 214 
336726 336831 + - SAS0290 nucleoside permease 167 
336832 336330 - - SAS0291 sodium:solute symporter family protein 125 
338404   - - SAS0292 N-acetylneuraminate lyase 60 
340303   + - SAS0293 ROK family protein 77 
340580 340438 - - SAS0294 hypothetical protein 193 
342189 342568 + - SAS0295 N-acetylmannosamine-6-phosphate 2-
epimerase 
110 







Strand Name Synonym Product Expression  
346123   + - SAS0297 lipase precursor 92 
346365 345024 - - SAS0298 hypothetical protein 110 
347265 347265 - - SAS0299 NADH:flavin oxidoreductase / NADH 
oxidase family protein 
208 
349767 349800 + - SAS0300 luciferase family protein 178 
350133   + - SAS0301 glycine cleavage H-protein 236 
350934   + - SAS0302 hypothetical protein 143 
351868   + - SAS0303 hypothetical protein 184 
352868   + - SAS0304 lipoate-protein ligase A 63 
354209 357757 + - SAS0305 reductase 116 
354302 354302 - ulaA SAS0306 PTS system ascorbate-specific 
transporter subunit IIC 
313 
355663 355653 - - SAS0307 PTS transport system protein 184 
355949 355949 - - SAS0308 PTS transport system IIA component 152 
356397 356393 - - SAS0309 PTS regulator 179 
358983 358983 + - SAS0310 MarR family transcriptional regulator 140 
360445   + - SAS0311 hypothetical protein 69 
360992   + - SAS0312 hypothetical protein 27 
361075 361075 - - SAS0313 glycerol-3-phosphate transporter 117 
363671   + - SAS0314 dioxygenase 58 
364746 364759 + - SAS0315 luciferase-like monooxygenase 126 
365326   + - SAS0316 NADH-dependent FMN reductase 85 
365386   - - SAS0317 hypothetical protein 68 
367231   + - SAS0318 acetyltransferase 29 
368352   + - SAS0319 lipoprotein 44 
369578   + - SAS0320 Sec-independent exported protein 69 
371271   + - SAS0321 hypothetical protein 60 
371363   - - SAS0322 Sec-independent protein translocase 30 
372081   - - SAS0323 Sec-independent protein translocase 51 
372404   - - SAS0324 hypothetical protein 5 
373236   + - SAS0325 DNA-binding protein 161 
373946 373946 + - SAS0326 hypothetical protein 147 
374813   + - SAS0327 ABC transporter ATP-binding protein 49 
375442   + - SAS0328 hypothetical protein 73 
375832   - - SAS0329 hypothetical protein 81 
378685 378744 + - SAS0330 acetyl-CoA acetyltransferase 291 
378768 378709 - - SAS0331 hypothetical protein 154 
379563 379563 - - SAS0332 5-methyltetrahydropteroyltriglutamate/ 
homocysteine S-methyltransferase 
178 




383598   - - SAS0334 Cys/Met metabolism PLP-dependent 
enzyme 
128 









Strand Name Synonym Product Expression  
  386022 - - SASs003 - 131 
387367   + - SAS0336 DNA-binding protein 32 
388405   + - SAS0337 hypothetical protein 15 
388638   + - SAS0338 hypothetical protein 58 
389747   + - SAS0339 GTP-dependent nucleic acid-binding 
protein EngD 
95 
389833   - - SAS0340 hypothetical protein 23 
390564 390583 + rpsF SAS0341 30S ribosomal protein S6 181 
391088 391088 + - SAS0342 single-strand DNA-binding protein 105 
391382 391444 + rpsR SAS0343 30S ribosomal protein S18 128 
391648   - - SAS0344 hypothetical protein 51 
394156 394176 + - SAS0347 hypothetical protein 109 
394926   + - SAS0348 hypothetical protein 5 
395646   + - SAS0349 hypothetical protein 44 
395784   - - SAS0350 hypothetical protein 67 
396592   + - SAS0351 hypothetical protein 22 
396631   - - SAS0352 hypothetical protein 0 
397599   + - SAS0353 phosphoglycerate mutase family protein 30 
397665   - - SAS0354 hypothetical protein 69 
398234   + - SAS0354a hypothetical protein 0 
398303   - - SAS0355 hypothetical protein 41 
399002   - - SAS0356 hypothetical protein 7 
400727   - - SAS0357 alkyl hydroperoxide reductase 100 
402266   - - SAS0358 alkyl hydroperoxide reductase 93 
404082 405395 + - SAS0359 nitroreductase family protein 107 
404163 404163 - - SAS0360 sodium:dicarboxylate symporter protein 302 
405734   + - SAS0360a hypothetical protein 0 
406725 406725 - - SAS0361 hypothetical protein 217 
407799   - - SAS0362 hypothetical protein 58 
408604   - - SAS0363 hypothetical protein 44 
  409294 + - SASs004 - 0 
410102   + - SAS0364 xanthine phosphoribosyltransferase 70 
411370   + - SAS0365 xanthine permease 58 
412874 412874 + - SAS0366 inosine-5'-monophosphate 
dehydrogenase 
148 
414440 414498 + guaA SAS0367 GMP synthase 137 
416058   + - SAS0368 hypothetical protein 35 
416687   + - SAS0369 hypothetical protein 17 
416684   - - SAS0370 hypothetical protein 89 
417098   - - SAS0371 hypothetical protein 21 
417703   - - SAS0372 hypothetical protein 54 
418835   + - SAS0373 hypothetical protein 19 
421766   + - SAS0375 hypothetical protein 27 
422304   - - SAS0376 hypothetical protein 24 







Strand Name Synonym Product Expression  
423580   - - SAS0378 hypothetical protein 28 
424502   + - SAS0379 hypothetical protein 6 
425031   + - SAS0380 hypothetical protein 0 
425920   + - SAS0381 hypothetical protein 15 
426094   - - SAS0381a hypothetical protein 25 
426195   - - SAS0382 hypothetical protein 28 
426573   - - SAS0383 hypothetical protein 100 
428570   + - SAS0384 superantigen-like protein 30 
429551   + - SAS0385 superantigen-like protein 46 
430912   + - SAS0386 superantigen-like protein 16 
432224   + - SAS0387 superantigen-like protein 84 
433292   + - SAS0388 superantigen-like protein 5 75 
434436   + - SAS0389 superantigen-like protein 0 
435553   + - SAS0390 superantigen-like protein 7 11 
436590   + - SAS0391 superantigen-like protein 15 
437667   + - SAS0392 superantigen-like protein 8 
438709   + - SAS0393 superantigen-like protein 28 
438918   + - SAS0393a hypothetical protein 83 
440527   + - SAS0394 restriction enzyme modification protein 134 
441779   + - SAS0395 restriction and modification system 
specificity protein 
62 
442877   + - SAS0396 superantigen-like protein 21 
444401   + - SAS0397 hypothetical protein 36 
444508   - - SAS0398 hypothetical protein 0 
445964   + - SAS0399 lipoprotein 7 
446782   + - SAS0400 hypothetical protein 4 
447605   + - SAS0401 lipoprotein 37 
448454   + - SAS0402 lipoprotein 30 
449448   + - SAS0403 lipoprotein 12 
450763   + - SAS0404 hypothetical protein 30 
451083   + - SAS0405 hypothetical protein 0 
451416   + - SAS0406 hypothetical protein 7 
451700   - - SAS0407 hypothetical protein 18 
453294   + - SAS0408 cobalamin synthesis protein 74 
453691   + - SAS0409 hypothetical protein 62 
456364   + - SAS0410 NADH dehydrogenase subunit 5 72 
459082 459243 + - SAS0411 hypothetical protein 293 
  458954 - - predicted 
RNA 
antisense: SAS0411 644 
459606 459694 + - SAS0412 hypothetical protein 521 
459835   - - SAS0413 hypothetical protein 9 
460963 460963 + - SAS0414 hypothetical protein 187 
461734   + - SAS0415 hypothetical protein 65 







Strand Name Synonym Product Expression  
463527   + - SAS0416 sodium:neurotransmitter symporter 
family protein 
73 
464649   + - SAS0417 pyridoxal-phosphate dependent protein 113 
465784   + - SAS0418 Cys/Met metabolism PLP-dependent 
enzyme 
95 
467106   + - SAS0419 ABC transporter ATP-binding protein 57 
467769   + - SAS0420 transport system membrane protein 92 
468648   + - SAS0421 lipoprotein 85 
469984   + - SAS0422 hypothetical protein 42 
470169   - - SAS0423 hypothetical protein 0 
470982   + - SAS0424 MutT domain-containing protein 69 
471457 471590 + - SAS0425 acetyltransferase 132 
471626   - - SAS0426 hypothetical protein 90 
472405   - - SAS0427 hypothetical protein 141 
473638 473638 - - SAS0428 LysR family regulatory protein 130 
479203 479220 + - SAS0429 glutamate synthase 147 
480684 480684 + gltD SAS0430 glutamate synthase 131 
  481045 + - SASt003 Ser tRNA 57 
482942 482987 + - SAS0431 sugar-specific PTS transport system, 
IIBC component 
224 
484646   + - SAS0432 glycosyl hydrolase 78 
485399   + - SAS0433 GntR family transcriptional regulator 64 
  485680 + - SASs005 - 163 
486566   + - SAS0434 acetyltransferase (GNAT) family protein 90 
488332   + - SAS0435 DNA polymerase III, tau subunit 62 
488739   + - SAS0436 hypothetical protein 19 
489342   + recR SAS0437 recombination protein RecR 50 
  491750 + - SASr001 16S ribosomal RNA 1791 
  490527 - - predicted 
RNA 
antisense: SASr001 1869 
  494975 + - SASr002 23S ribosomal RNA 1040 
  493495 - - predicted 
RNA 
antisense: SASr002 840 
  493972 - - predicted 
RNA 
antisense: SASr003 SASr002 1992 
  495162 + - SASr003 5S ribosomal RNA 148 
497403   + - SAS0438 Orn/Lys/Arg decarboxylase family 
protein 
78 
498022   + tmk SAS0439 thymidylate kinase 26 
498379   + - SAS0440 hypothetical protein 72 
499519   + - SAS0441 DNA polymerase III subunit delta' 89 
500323   + - SAS0442 hypothetical protein 33 
500687 500705 + - SAS0443 DNA replication intiation control protein 
YabA 
124 
501686   + - SAS0444 hypothetical protein 16 







Strand Name Synonym Product Expression  
502768 503052 + - SAS0446 tetrapyrrole (corrin/porphyrin) methylase 
family protein 
126 
505026   + - SAS0447 methionyl-tRNA synthetase 89 
505830 505891 + - SAS0448 TatD related DNase 129 
506533   + - SAS0449 hypothetical protein 90 
507437   + ksgA SAS0450 dimethyladenosine transferase 53 
507800   + - SAS0451 hypothetical protein 7 
508958   + ipk SAS0452 4-diphosphocytidyl-2-C-methyl-D-
erythritol kinase 
77 
509796   + - SAS0453 pur operon repressor 42 
510193   + - SAS0454 regulatory protein 74 
510567   + - SAS0455 regulatory protein SpoVG 31 





513375   + - SAS0457 ribose-phosphate pyrophosphokinase 58 
514178   + - SAS0458 50S ribosomal protein L25 100 
515030   + - SAS0459 peptidyl-tRNA hydrolase 137 
518536   + - SAS0460 transcription-repair coupling factor 95 
520052   + - SAS0461 polysaccharide biosynthesis protein 173 
521245   + - SAS0462 tetrapyrrole (corrin/porphyrin) methylase 127 
521505 521522 + - SAS0463 S4 domain-containing protein 125 
521915   + - SAS0464 cell division protein 102 
522421   + - SAS0465 hypothetical protein 32 
523896   + - SAS0466 hypothetical protein 37 
524440   + - SAS0467 hypoxanthine phosphoribosyltransferase 2 
526790 526805 + - SAS0468 cell division protein 119 
527900   + hslO SAS0469 Hsp33-like chaperonin 80 
529011   + - SAS0470 O-acetylserine (thiol)-lyase 57 
530030   + - SAS0471 dihydropteroate synthase 81 
530373   + - SAS0472 dihydroneopterin aldolase 16 




532872 532904 + lysS SAS0474 lysyl-tRNA synthetase 103 
  533544 + - SASr004 5S ribosomal RNA 130 
  533632 + - SASt004 Val tRNA 170 
  533724 + - SASt005 Thr tRNA 461 
  533803 + - SASt006 Lys tRNA 716 
  533911 + - SASt007 Gly tRNA 1950 
  533882 - - predicted 
RNA 
antisense: SASt011 SASt010 SASt009 
SASt008 SASt007 
1689 
  534007 + - SASt008 Leu tRNA 2723 
  534089 + - SASt009 Arg tRNA 2604 







Strand Name Synonym Product Expression  
  534282 + - SASt011 Ala tRNA 588 
  535958 + - SASr005 16S ribosomal RNA 1812 
  534703 - - predicted 
RNA 
antisense: SASt012 SASr005 1872 
  536126 + - SASt012 Ile tRNA 173 
  539216 + - SASr006 23S ribosomal RNA 1022 
  537687 - - predicted 
RNA 
antisense: SASr006 737 
  538199 - - predicted 
RNA 
antisense: SASr007 SASr006 2166 
  539403 + - SASr007 5S ribosomal RNA 290 
  541169 + - SASr008 16S ribosomal RNA 1788 
  539964 - - predicted 
RNA 
antisense: SASr008 1961 
  544410 + - SASr009 23S ribosomal RNA 1026 
  542871 - - predicted 
RNA 
antisense: SASr009 842 
  543436 - - predicted 
RNA 
antisense: SASr010 SASr009 2155 
  544597 + - SASr010 5S ribosomal RNA 104 
545308   - - SAS0475 GntR family transcriptional regulator 20 
547681 547681 + - SAS0476 pyridoxal biosynthesis lyase PdxS 192 
548245   + - SAS0477 glutamine amidotransferase subunit 
PdxT 
64 
548451   - - SAS0478 nucleoside permease 10 
550284   + - SAS0479 DNA-binding protein 12 
550869   + - SAS0480 hypothetical protein 132 
551866 551866 + - SAS0481 ATP:guanido phosphotransferase 107 
554336   + - SAS0482 stress response-related Clp ATPase 59 
556184 556208 + - SAS0483 DNA repair protein RadA 157 
557282   + - SAS0484 hypothetical protein 33 
559293 559338 + gltX SAS0485 glutamyl-tRNA synthetase 150 
560363   + - SAS0486 serine acetyltransferase 30 
561747   + cysS SAS0487 cysteinyl-tRNA synthetase 107 
562144   + - SAS0488 hypothetical protein 33 
562898   + - SAS0489 SpoU rRNA methylase family protein 20 
563422   + - SAS0490 hypothetical protein 42 
564072   + - SAS0491 hypothetical protein 46 
564330   + rpmG SAS0492 50S ribosomal protein L33 60 
564568   + secE SAS0493 preprotein translocase subunit SecE 19 
565129   + - SAS0494 transcription antitermination protein 102 
565732 565785 + rplK SAS0495 50S ribosomal protein L11 128 
566632   + rplA SAS0496 50S ribosomal protein L1 98 
567404   + rplJ SAS0497 50S ribosomal protein L10 98 
567815   + rplL SAS0498 50S ribosomal protein L7/L12 65 







Strand Name Synonym Product Expression  
572364 572364 + rpoB SAS0500 DNA-directed RNA polymerase subunit 
beta 
218 
576124 576124 + - SAS0501 DNA-directed RNA polymerase subunit 
beta' 
128 
576515   + - SAS0502 ribosomal protein L7Ae-like 47 
577026   + rpsL SAS0503 30S ribosomal protein S12 92 
577562   + - SAS0504 30S ribosomal protein S7 76 
579766 579766 + - SAS0505 elongation factor G 201 
581167 581353 + tuf SAS0506 elongation factor Tu 283 
581449 581449 - - SAS0507 peptidase 182 
583982   + - SAS0508 2-amino-3-ketobutyrate CoA ligase 15 
585127   + - SAS0509 chaperone protein HchA 80 
586923   + - SAS0510 ribulokinase 31 
588102   + - SAS0511 hypothetical protein 45 
589513   + - SAS0512 branched-chain amino acid 
aminotransferase 
47 
590447   + - SAS0513 haloacid dehalogenase 67 
590563   - - SAS0514 deoxyadenosine kinase 41 
591218   - - SAS0515 deoxyadenosine kinase 66 
592372   + - SAS0516 deaminase 45 
593388   + - SAS0517 haloacid dehalogenase 24 
593975   + - SAS0518 hypothetical protein 29 
597279   + - SAS0519 surface anchored protein 58 
601743   + - SAS0520 surface anchored protein 69 
605562   + - SAS0521 bone sialoprotein-binding protein 101 
607153   + - SAS0522 glycosyl transferase family protein 58 
607277   - - SAS0523 glycosyl transferase family protein 40 
609049 608974 - - SAS0524 GTP cyclohydrolase 143 
609940   - - SAS0525 hypothetical protein 61 
610619 610619 - - SAS0526 hypothetical protein 129 
612015   + - SAS0527 glucosamine-6-phosphate isomerase 59 
612724   + - SAS0528 hexulose-6-phosphate synthase 86 
613274   + - SAS0529 6-phospho 3-hexuloisomerase 67 
614034   + - SAS0530 haloacid dehalogenase 45 
615936   + - SAS0531 proline/betaine transporter 100 
616480   + - SAS0532 hypothetical protein 50 
617856   + - SAS0533 AMP-binding protein 30 
618997   + - SAS0534 ketoacyl-CoA thiolase 104 
619337   + - SAS0535 hypothetical protein 52 
619609   + - SAS0536 hypothetical protein 82 
619810   - - SAS0537 hypothetical protein 24 
620484   - - SAS0538 phosphomethylpyrimidine kinase 74 
622154   + - SAS0539 uracil-DNA glycosylase 39 
622535   + - SAS0540 hypothetical protein 100 







Strand Name Synonym Product Expression  
624641   + - SAS0542 amino acid permease 83 
624782   - - SAS0543 hypothetical protein 43 
625247   - - SAS0544 hypothetical protein 66 
626519   + - SAS0545 hypothetical protein 44 
626560   - - SAS0546 heme peroxidase 52 
628466 628466 + eutD SAS0547 phosphotransacetylase 217 
629305 629351 + - SAS0548 lipoate-protein ligase A 105 
630812   + - SAS0549 mevalonate kinase 94 
631800 631800 + - SAS0550 mevalonate diphosphate decarboxylase 143 
632889   + - SAS0551 phosphomevalonate kinase 69 
633407   + - SAS0552 hypothetical protein 59 
633459 633459 - - SAS0553 pyridine nucleotide-disulfide 
oxidoreductase 
112 
634768   - - SAS0554 hypothetical protein 264 
637242 637242 + - SAS0555 hypothetical protein 105 
637872   + - SAS0556 hypothetical protein 66 
638640   + - SAS0557 hypothetical protein 29 
639345   + - SAS0558 hypothetical protein 0 
640049   + - SAS0559 hypothetical protein 9 
641638   + - SAS0562 hypothetical protein 2 
642314   + - SAS0563 hypothetical protein 9 
643396 643451 + - SAS0564 hypothetical protein 144 
644161   + - SAS0565 hypothetical protein 25 
644833   + - SAS0566 hypothetical protein 45 
645694   + - SAS0567 hypothetical protein 26 
646902   + - SAS0568 aldo/keto reductase 86 
647649 647649 + - SAS0569 hypothetical protein 117 
648294 648333 + - SAS0570 acetyltransferase 115 
649629   + - SAS0571 phosphohydrolase 56 
650178   + - SAS0572 hypothetical protein 47 
651687 651738 + - SAS0573 alcohol dehydrogenase 136 
651871   + - SAS0573a hypothetical protein 7 
652380   + - SAS0574 hypothetical protein 0 
654038   + argS SAS0575 arginyl-tRNA synthetase 85 
655064   + - SAS0576 DNA repair protein 24 
656202   + - SAS0577 transport system lipoprotein 9 
657301   + - SAS0578 FecCD transport family protein 36 
658075   + - SAS0579 haloacid dehalogenase 89 
658859 658859 + - SAS0580 hydrolase 126 
659501   + - SAS0581 hypothetical protein 20 
660379   + - SAS0582 hypothetical protein 18 
661336   + - SAS0583 esterase 49 







Strand Name Synonym Product Expression  
662908   - - SAS0585 hypothetical protein 30 
664032   - - SAS0586 hypothetical protein 0 
664273   - - SAS0587 hypothetical protein 9 
665195   + - SAS0588 phage integrase family protein 16 
667616   + - SAS0589 monovalent cation/H+ antiporter subunit 
A 
82 
668028   + - SAS0590 monovalent cation/H+ antiporter subunit 
B 
81 
668369   + - SAS0591 monovalent cation/H+ antiporter subunit 
C 
85 
669855   + - SAS0592 monovalent cation/H+ antiporter subunit 
D 
82 
670338   + - SAS0593 monovalent cation/H+ antiporter subunit 
E 
44 
670637   + - SAS0594 monovalent cation/H+ antiporter subunit 
F 
57 
671049   + - SAS0595 monovalent cation/H+ antiporter subunit 
G 
2 
673431   + - SAS0596 sodium/hydrogen exchanger family 
protein 
46 
674592   - - SAS0597 ABC transporter extracellular binding 
protein 
90 
675518   - - SAS0598 ABC transporter permease 67 
676348   - - SAS0599 ABC transporter ATP-binding protein 114 
677857   + - SAS0600 metalloregulator 16 
677937   - - SAS0601 hypothetical protein 28 
679689 679828 + - SAS0602 teichoic acid biosynthesis protein 106 
679750   - - SAS0603 teichoic acids export protein ATP-
binding subunit 
96 
681703   + - SAS0604 teichoic acid ABC transporter permease 98 
682905   + - SAS0605 teichoic acid biosynthesis protein 28 
683963   + - SAS0606 glycosyl transferase family protein 56 
684424   + - SAS0607 glycerol-3-phosphate 
cytidylyltransferase 
53 
684541   - - SAS0608 penicillin-binding protein 4 60 
687984   + - SAS0609 ABC transporter ATP-binding protein 77 
689570   + - SAS0610 Na+ dependent nucleoside transporter 101 
690928   + - SAS0611 hypothetical protein 52 
692007   + - SAS0612 ferrichrome ABC transporter ATP-
binding protein 
75 
693047   + - SAS0613 ferrichrome transport permease 79 
694060   + - SAS0614 ferrichrome transport permease 93 
695262 695262 + - SAS0615 dihydroxyacetone kinase subunit DhaK 107 
695888   + - SAS0616 dihydroxyacetone kinase 38 
696243   + - SAS0617 PTS system mannnose-specific 
transporter subunit IIA 
66 
696856   + - SAS0618 hypothetical protein 12 







Strand Name Synonym Product Expression  
699574   + - SAS0620 esterase 46 
700331   + - SAS0621 hypothetical protein 52 
700540   - - SAS0622 hypothetical protein 58 
702082   + - SAS0623 hypothetical protein 63 
702772   + - SAS0624 response regulator protein 75 
703805   + - SAS0625 sensor histidine kinase 20 
704710   + - SAS0626 ABC transporter 43 
706589   + - SAS0627 ABC transporter permease 21 
707931   + - SAS0628 hypothetical protein 22 
708954   + - SAS0629 phosphate transport protein 84 
709542 709542 - - SAS0630 hypothetical protein 115 
  709939 + - predicted 
RNA 
antisense: SAS0630 641 
711344   + - SAS0631 hypothetical protein 37 
714191   + - SAS0632 AraC family transcriptional regulator 38 
714696   + - SAS0633 hypothetical protein 11 
715602   + - SAS0634 hypothetical protein 145 
716075   + - SAS0635 hypothetical protein 40 
717072   + - SAS0636 hypothetical protein 21 
718054   + - SAS0637 LysR family regulatory protein 6 
719613   + - SAS0638 sugar efflux transporter 75 
720098   + - SAS0639 hypothetical protein 29 
720197   - - SAS0640 hypothetical protein 24 
721456   + - SAS0641 acetyltransferase 20 
721918 722055 + - SAS0642 hypothetical protein 124 
722355 722367 + - SAS0643 hypothetical protein 128 
722977   + - SAS0644 acetyltransferase 50 
723073   - - SAS0645 hypothetical protein 87 
723641   - - SAS0646 hypothetical protein 69 
724102   - - SAS0647 hypothetical protein 70 
724957   - uppP SAS0648 undecaprenyl pyrophosphate 
phosphatase 
25 
727682   + - SAS0649 ABC transporter ATP-binding protein 47 
729352   + - SAS0650 ABC transporter ATP-binding protein 56 
729479   - - SAS0651 MarR family transcriptional regulator 31 
731075   + - SAS0652 cobalamin synthesis protein 92 
732086   + - SAS0653 aldo/keto reductase 75 
732408   + - SAS0654 hypothetical protein 23 
734244 734244 + - SAS0655 sodium:sulfate symporter protein 152 
735703   + - SAS0656 DNA photolyase 95 
735858   - - SAS0657 hypothetical protein 87 
736139   - - SAS0658 hypothetical protein 24 
736942   - - SAS0659 hypothetical protein 27 







Strand Name Synonym Product Expression  
739484 739656 + - SAS0661 hypothetical protein 104 
740139   + - SAS0662 hypothetical protein 1 
741153   + - SAS0663 DeoR ramily regulatory protein 27 
742070   + - SAS0664 phosphofructokinase 59 
744034 744160 + - SAS0665 PTS transport system, fructose-specific 
IIABC component 
174 
745523   + - SAS0666 N-acetylglucosamine-6-phosphate 
deacetylase 
54 
747093   + - SAS0667 hypothetical protein 55 
748154   + - SAS0668 aldo/keto reductase 23 
749269   + - SAS0669 glucosyl transferase 31 
749341   - - SAS0670 histidine kinase 73 
750396   - - SAS0671 response regulator protein 41 
751057   - - SAS0672 hypothetical protein 71 
751873   - - SAS0673 hypothetical protein 45 
752593 752466 - - SAS0674 hypothetical protein 132 
753276   - - SAS0675 radical activating enzyme 95 
753993   - - SAS0676 6-pyruvoyl tetrahydrobiopterin synthase 36 
754414   - - SAS0677 hypothetical protein 25 
756026   + - SAS0678 glutamine amidotransferase class-I 
protein 
58 
757161   + - SAS0679 para-aminobenzoate synthase component 87 
757769   + - SAS0680 para-aminobenzoate synthetase 
component 
0 
758041   + - SAS0681 hypothetical protein 25 
758839   + - SAS0682 hypothetical protein 125 
759827   + - SAS0683 hypothetical protein 52 
762241   + - SAS0684 sulfatase 39 
764395   + - SAS0685 ABC transporter ATP-binding protein 40 
766188   + - SAS0686 ATP-dependent DNA helicase 27 
767387   + - SAS0687 ABC transporter ATP-binding protein 75 
768894   + - SAS0688 ABC transporter permease 74 
770192 770253 + - SAS0689 histidinol-phosphate aminotransferase 148 
771029 771029 + - SAS0690 hypothetical protein 184 
771710   - - SAS0691 diacylglycerol kinase 39 
772896   - - SAS0692 proton-dependent oligopeptide transport 
protein 
69 
774742   - - SAS0693 7-cyano-7-deazaguanine reductase 29 
775262   - - SAS0694 hypothetical protein 44 
777327   + nrdI SAS0695 ribonucleotide reductase stimulatory 
protein 
22 
779395   + - SAS0696 ribonucleotide-diphosphate reductase 
subunit alpha 
57 
780484 780884 + nrdF SAS0697 ribonucleotide-diphosphate reductase 
subunit beta 
142 







Strand Name Synonym Product Expression  
783106   + - SAS0699 FecCD transport family protein 8 
783864   + - SAS0700 ABC transporter ATP-binding protein 30 
785011   + - SAS0701 lipoprotein 20 
785328   - - SAS0702 hypothetical protein 24 
785660   - murB SAS0703 UDP-N-acetylenolpyruvoylglucosamine 
reductase 
87 
786710 786584 - - SAS0704 hypothetical protein 116 
788226   + - SAS0705 hypothetical protein 15 
788700   + - SAS0706 hypothetical protein 0 
790249   + - SAS0707 glycerate kinase 40 
790431 790423 - - SAS0708 peptidase T 116 
791671   - - SAS0709 hypothetical protein 51 
792183   - - SAS0710 hypothetical protein 77 
793140   - - SAS0711 hypothetical protein 55 
795583   + - SAS0712 glycosyl transferase 52 
795755   - - SAS0713 hypothetical protein 50 
797406   + - SAS0714 hypothetical protein 49 
798852   + - SAS0715 helicase 44 
799519   + - SAS0716 hypothetical protein 37 
800152   + - SAS0717 S30EA family ribosomal protein 21 
803097 803114 + secA SAS0718 preprotein translocase subunit SecA 144 
804522 804522 + prfB SAS0719 peptide chain release factor 2 255 
805770   + - SAS0720 hypothetical protein 92 
806594   + - SAS0721 phosphohydrolase 15 
806827   + - SAS0722 hypothetical protein 10 
809081   + - SAS0723 excinuclease ABC subunit B 69 
811935   + uvrA SAS0724 excinuclease ABC subunit A 90 
813474   + - SAS0725 HPr kinase/phosphorylase 21 
814319   + - SAS0726 prolipoprotein diacylglyceryl transferase 17 
814812   + - SAS0727 acetyltransferase 28 
816259   + - SAS0728 hypothetical protein 65 
817261   + - SAS0729 thioredoxin reductase 57 
818937   + - SAS0730 hypothetical protein 56 
819929   + - SAS0731 hypothetical protein 45 
820984   + - SAS0732 hypothetical protein 50 
  821299 - - SASt013 Arg tRNA 0 
822144 822275 + clpP SAS0733 ATP-dependent Clp protease proteolytic 
subunit 
140 
822387   - - SAS0734 hypothetical protein 71 
824621   + - SAS0736 hypothetical protein 54 
826331 826359 + - SAS0737 glycolytic operon regulator 164 
827394 827394 + - SAS0738 glyceraldehyde 3-phosphate 
dehydrogenase 1 
183 







Strand Name Synonym Product Expression  
829606   + tpiA SAS0740 triosephosphate isomerase 79 
831126 831126 + - SAS0741 phosphoglyceromutase 158 
832560 832898 + eno SAS0742 phosphopyruvate hydratase 116 
833357   + - SAS0743 hypothetical protein 35 
833657   + secG SAS0744 preprotein translocase subunit SecG 56 
834513   + - SAS0745 carboxylesterase 64 
836919 836919 + - SAS0746 ribonuclease R 188 
837405 837405 + smpB SAS0747 SsrA-binding protein 250 
  837854 + tmRNA SASs006 - 167 
838270 838270 - - SAS0749 hypothetical protein 123 
840117   + - SAS0750 hypothetical protein 0 
840786   + - SAS0751 acetyltransferase 48 
843835 843835 + - SAS0752 clumping factor 138 
845582   + - SAS0753 hypothetical protein 15 
846955   + - SAS0754 hypothetical protein 48 
847811   + - SAS0755 hypothetical protein 39 
848838   + - SAS0756 thermonuclease precursor 54 
849395   + - SAS0757 cold shock protein 0 
849891 849698 - - SAS0758 hypothetical protein 110 
850171   - - SAS0759 hypothetical protein 19 
850543   - - SAS0760 hypothetical protein 60 
851300   - - SAS0761 hypothetical protein 45 
851517   - - SAS0762 hypothetical protein 11 
852320   + - SAS0763 hypothetical protein 0 
852317   - - SAS0764 hypothetical protein 7 
853358   + - SAS0765 phosphoglycerate mutase family protein 59 
853407   - - SAS0766 LysE type translocator protein 40 
854179   - - SAS0767 hypothetical protein 37 
855072   - - SAS0768 OsmC-like protein 34 
856358   + - SAS0769 3-dehydroquinate dehydratase 32 
856980   + - SAS0770 nitroreductase family protein 12 
857130   - - SAS0771 thioredoxin 11 
857950   + - SAS0772 hypothetical protein 3 
858488   + - SAS0773 glycine cleavage system protein H 93 
859545   + - SAS0774 hypothetical protein 50 
859569   - - SAS0775 hypothetical protein 68 
860672   + - SAS0776 hypothetical protein 29 
860961   + - SAS0777 hypothetical protein 26 
  861122 + - SASs007 - 0 
862236   + - SAS0779 ABC transporter ATP-binding protein 20 
862924   + - SAS0780 ABC transporter permease 61 
863763   + - SAS0781 lipoprotein 14 







Strand Name Synonym Product Expression  
864544   - - SAS0783 hypothetical protein 46 
866484   + - SAS0784 ABC transporter ATP-binding protein 42 
867889 867912 + - SAS0785 hypothetical protein 124 
869245   + - SAS0786 selenocysteine lyase 249 
869699   + - SAS0787 NifU-like protein 42 
871247 871247 + - SAS0788 hypothetical protein 115 
871571 871571 + - SAS0788a hypothetical protein 137 
871577   - - SAS0789 hypothetical protein 50 
873296 873302 + - SAS0790 hypothetical protein 113 
874377   + - SAS0791 dioxygenase 65 
875401   + - SAS0792 hypothetical protein 75 
876241 876241 + - SAS0793 hypothetical protein 181 
877587   + - SAS0794 5'-nucleotidase 68 
878588   + - SAS0795 lipoyl synthase 43 
879101 879459 + - SAS0796 hypothetical protein 127 
879180 879118 - - SAS0797 hypothetical protein 110 
879978   + - SAS0798 hypothetical protein 77 
880757   + - SAS0799 haloacid dehalogenase 86 
881749   + - SAS0800 D-isomer specific 2-hydroxyacid 
dehydrogenase 
86 
882313   + - SAS0801 hypothetical protein 15 
883786   + - SAS0802 D-alanine--poly(phosphoribitol) ligase 
subunit 1 
66 
884997   + - SAS0803 activated D-alanine transport protein 47 
885251   + - SAS0804 D-alanine--poly(phosphoribitol) ligase 
subunit 2 
6 
886423   + - SAS0805 lipoteichoic acid biosynthesis protein 26 
886686   - - SAS0806 hypothetical protein 90 
887352 887904 + - SAS0807 hypothetical protein 137 
887411   - - SAS0808 pyridine nucleotide-disulfide 
oxidoreductase 
83 
889028   + - SAS0809 hypothetical protein 82 
889400 889631 + - SAS0810 hypothetical protein 130 
891062   + - SAS0811 pyridine nucleotide-disulfide 
oxidoreductase 
88 
892668   + - SAS0812 cytosol aminopeptidase 95 
894395   + - SAS0813 transporter protein 58 
894788 894808 + - SAS0814 hypothetical protein 137 
894844   - - SAS0815 hypothetical protein 71 
896247   - - SAS0816 monovalent cation/H+ antiporter subunit 
G 
53 
896581   - - SAS0817 monovalent cation/H+ antiporter subunit 
F 
18 
896874   - - SAS0818 monovalent cation/H+ antiporter subunit 
E 
83 









Strand Name Synonym Product Expression  
898844   - - SAS0820 monovalent cation/H+ antiporter subunit 
C 
169 
899185   - - SAS0821 monovalent cation/H+ antiporter subunit 
B 
145 
899606   - - SAS0822 monovalent cation/H+ antiporter subunit 
A 
98 
902142   - - SAS0823 hypothetical protein 9 
903182   + - SAS0824 cyclophilin type peptidyl-prolyl cis-trans 
isomerase 
24 
903974   + - SAS0825 S1 RNA-binding domain-containing 
protein 
64 
905463 905731 + - SAS0826 NADH:flavin oxidoreductase / NADH 
oxidase family protein 
104 
906961   + rocD SAS0827 ornithine--oxo-acid transaminase 37 
908314 908343 + - SAS0828 NAD-specific glutamate dehydrogenase 169 
908704   - - SAS0829 glycerophosphoryl diester 
phosphodiesterase 
64 
909875   - - SAS0830 argininosuccinate lyase 98 
911244   - - SAS0831 argininosuccinate synthase 79 
914131 914131 + pgi SAS0832 glucose-6-phosphate isomerase 126 
915031   + - SAS0833 hypothetical protein 47 
915560   + - SAS0834 signal peptidase Ia 20 
916151   + - SAS0835 signal peptidase Ib 15 
919787   + - SAS0836 hypothetical protein 61 
923441   + - SAS0837 hypothetical protein 41 
924509   + - SAS0838 fumarylacetoacetate (FAA) hydrolase 
family protein 
46 
925227   + - SAS0839 hypothetical protein 88 
925399   - - SAS0840 coenzyme A disulfide reductase 75 
926767   - - SAS0841 haloacid dehalogenase 48 
928013   + - SAS0842 hypothetical protein 1 
928010   - - SAS0843 hypothetical protein 25 
930375   + - SAS0844 hypothetical protein 59 
933187   + - SAS0845 ATPase of an ATP-dependent protease 75 
933246   - - SAS0846 LysR family regulatory protein 20 
935370   + - SAS0847 hypothetical protein 42 
935995   + - SAS0848 hypothetical protein 76 
937106   + - SAS0849 hypothetical protein 36 
937605   + - SAS0850 hypothetical protein 52 
938350   + - SAS0851 hypothetical protein 12 
938607   - - SAS0852 hypothetical protein 44 
940028   + - SAS0853 3-oxoacyl-ACP synthase 48 
941284 941284 + - SAS0854 3-oxoacyl-ACP synthase 186 
941339   - - SAS0855 hypothetical protein 93 
942879   + - SAS0856 oligopeptide transport system permease 91 







Strand Name Synonym Product Expression  
945047   + - SAS0858 oligopeptide transport ATP-binding 
protein 
160 
945978 945996 + - SAS0859 oligopeptide transport ATP-binding 
protein 
136 
947652   + - SAS0860 transport system extracellular binding 
lipoprotein 
74 
949579   + - SAS0861 transport system extracellular binding 
lipoprotein 
40 
950616   + - SAS0862 oligopeptide transport ATP-binding 
protein 
28 
951599   + - SAS0863 oligopeptide transport ATP-binding 
protein 
29 
952554   + - SAS0864 oligopeptide transport system permease 18 
953447   + - SAS0865 oligopeptide transport system permease 20 
953489   - - SAS0866 tryptophanyl-tRNA synthetase 66 
955168   + spxA SAS0867 transcriptional regulator Spx 5 
956258   + - SAS0868 adaptor protein 37 
957365   + - SAS0869 hypothetical protein 24 
959221   + - SAS0870 oligopeptidase 55 
959681   - - SAS0871 hypothetical protein 13 
960510   - - SAS0872 hypothetical protein 23 
960979   - - SAS0873 hypothetical protein 17 
962105   + - SAS0874 hypothetical protein 5 
962757   + - SAS0875 GTP pyrophosphokinase 20 
963583   + ppnK SAS0876 inorganic polyphosphate/ATP-NAD 
kinase 
85 
964434   + - SAS0877 RNA pseudouridylate synthase 15 
965840   + - SAS0878 divalent cation transport protein 66 
967694   + - SAS0879 cation transport protein 67 
968742   + - SAS0880 enoyl-(acyl carrier protein) reductase 25 
968937   - - SAS0881 hypothetical protein 49 
971932   + - SAS0882 sodium:alanine symporter family protein 61 
972835   + - SAS0883 hypothetical protein 27 
973538   + - SAS0884 hypothetical protein 29 
973651   - - SAS0885 hypothetical protein 73 
974819   - - SAS0886 diacylglycerol glucosyltransferase 141 
977911   + - SAS0887 UDP-N-acetylmuramoylalanyl-D-
glutamate--L-lysine ligase 
87 
978152   + - SAS0888 hypothetical protein 57 
979714   + prfC SAS0889 peptide chain release factor 3 75 
980819   + - SAS0890 hypothetical protein 62 
981108   - - SAS0891 phage integrase 36 
983063   + - SAS0892 hypothetical protein 59 
983050   - - SAS0893 hypothetical protein 7 
983262   - - SAS0894 hypothetical protein 35 







Strand Name Synonym Product Expression  
984138   - - SAS0896 hypothetical protein 75 
984612   - - SAS0897 phage regulatory protein 33 
985293 985337 + - SAS0898 phage regulatory protein 135 
985553   + - SAS0899 hypothetical protein 0 
985550   - - SAS0900 hypothetical protein 45 
986051   + - SAS0901 hypothetical protein 71 
986339   + - SAS0902 DNA-binding protein 13 
986512   + - SAS0903 hypothetical protein 41 
987165   + - SAS0905 hypothetical protein 64 
987541   + - SAS0906 hypothetical protein 17 
988704 988729 + - SAS0907 hypothetical protein 193 
989287   + - SAS0908 hypothetical protein 103 
991308 991311 + - SAS0909 DNA polymerase 163 
991506   + - SAS0910 hypothetical protein 0 
991907   + - SAS0911 DNA-binding protein 123 
992161 992166 + - SAS0912 hypothetical protein 208 
992409 992409 + - SAS0913 hypothetical protein 149 
992629 992629 + - SAS0914 hypothetical protein 103 
993036   + - SAS0915 hypothetical protein 128 
993380   + - SAS0916 hypothetical protein 30 
993685   + - SAS0917 hypothetical protein 29 
993926   + - SAS0918 hypothetical protein 142 
994455 994491 + - SAS0919 hypothetical protein 119 
994665   + - SAS0920 hypothetical protein 82 
994876   + - SAS0921 hypothetical protein 32 
995400   + - SAS0922 hypothetical protein 59 
995600   + - SAS0923 hypothetical protein 60 
995868   + - SAS0924 exported phage protein 60 
995895   - - SAS0925 hypothetical protein 66 
998603 998943 + - SAS0926 hypothetical protein 136 
999234   + - SAS0927 hypothetical protein 68 
1000591 1000591 + - SAS0928 hypothetical protein 155 
1001041 1001138 + - SAS0929 phage regulatory protein 142 
1001522   + - SAS0930 hypothetical protein 72 
1001953   + - SAS0931 terminase small subunit 81658 
1003634 1003634 + - SAS0932 terminase large subunit 236552 
1004877   + - SAS0933 portal protein 131150 
1005634 1005634 + - SAS0934 phage protease 70278 
1006809 1006809 + - SAS0935 hypothetical protein 68090 
1007156 1007156 + - SAS0936 hypothetical protein 37280 
1007500 1007526 + - SAS0937 hypothetical protein 17258 
1007898   + - SAS0938 hypothetical protein 23265 







Strand Name Synonym Product Expression  
1008970 1009031 + - SAS0940 major tail protein 19122 
1009517 1009517 + - SAS0941 major tail protein 12542 
1009925 1009966 + - SAS0942 hypothetical protein 6985 
1010125 1010138 + - SAS0943 hypothetical protein 7629 
1016339   + - SAS0944 hypothetical protein 3438 
1017163 1017163 + - SAS0945 hypothetical protein 189 
1018755   + - SAS0946 hypothetical protein 165 
1019045 1019045 + - SAS0947 hypothetical protein 156 
1020971   + - SAS0948 hypothetical protein 142 
1022437   + - SAS0949 hypothetical protein 78 
1022826   + - SAS0950 hypothetical protein 37 
1022983   + - SAS0951 hypothetical protein 101 
1023328 1023463 + - SAS0952 hypothetical protein 120 
1023766   + - SAS0953 holin 85 
1025231   + - SAS0954 amidase 15 
1028116   + - SAS0955 protease 25 
1029491   + - SAS0956 sodium transport protein 100 
1031141   + - SAS0957 5'-nucleotidase 36 
  1031321 - - SASt014 Ser tRNA 46 
  1031412 - - SASt015 Asn tRNA 369 
  1031480 + - predicted 
RNA 
antisense: SASt015 787 
1031628 1031487 - - SAS0958 regulatory protein 147 
1032625   + - SAS0959 hypothetical protein 61 
1032706   - - SAS0960 lipoate-protein ligase A 61 
1034067   + - SAS0961 hypothetical protein 0 
1034684   + - SAS0962 hypothetical protein 82 
1035002   + - SAS0963 hypothetical protein 11 
1035924   + - SAS0964 hypothetical protein 7 
1038254   + - SAS0967 hypothetical protein 14 
1038892   + - SAS0968 ABC transporter ATP-binding protein 25 
1038980   - - SAS0969 hypothetical protein 30 
1039898   + - SAS0970 hypothetical protein 1 
1041385   + - SAS0971 glycosyl transferase family protein 19 
1041474   - - SAS0972 hypothetical protein 38 
1043277   + - SAS0973 transport system extracellular binding 
lipoprotein 
60 
1043323   - - SAS0974 hypothetical protein 0 
1043518   - - SAS0975 hypothetical protein 30 
1044449   + - SAS0976 hypothetical protein 10 
1044500   - - SAS0977 1,4-dihydroxy-2-naphthoate 
octaprenyltransferase 
66 
1046981   + - SAS0978 chorismate binding protein 41 









Strand Name Synonym Product Expression  
1049431   + - SAS0980 hydrolase 47 
1050245   + - SAS0981 naphthoate synthase 48 
1050483   - - SAS0982 hypothetical protein 52 
1050850   - - SAS0983 cysteine protease precursor 46 
1052113   - - SAS0984 glutamyl endopeptidase precursor 52 
1053642 1053642 - - SAS0985 aminotransferase 119 
1054992   - - SAS0986 hypothetical protein 98 
1056574   + - SAS0987 MarR family transcriptional regulator 48 
1056781   - - SAS0988 bifunctional autolysin precursor 93 
1060761   - - SAS0989 acetyltransferase (GNAT) family protein 86 
1061350   - - SAS0990 hypothetical protein 34 
1061868   - - SAS0991 hypothetical protein 38 
1064729   + - SAS0992 autolysis and methicillin resistant-related 
protein 
32 
1065266   - - SAS0993 quinol oxidase polypeptide IV 72 
1065553   - - SAS0994 quinol oxidase polypeptide III 91 
1066148   - - SAS0995 quinol oxidase polypeptide I 218 
1068136   - - SAS0996 quinol oxidase polypeptide II precursor 227 
1069808   - - SAS0997 hypothetical protein 74 





1072451   + - SAS1000 phosphoribosylaminoimidazole 
carboxylase catalytic subunit 
9 
1073562   + - SAS1001 phosphoribosylaminoimidazole 
carboxylase ATPase subunit 
27 
1074270   + - SAS1002 phosphoribosylaminoimidazole-
succinocarboxamide synthase 
83 
1074533   + - SAS1003 hypothetical protein 48 
1075206   + - SAS1004 phosphoribosylformylglycinamidine 
synthase I 
52 
1077388   + - SAS1005 phosphoribosylformylglycinamidine 
synthase II 
50 
1078851   + - SAS1006 amidophosphoribosyltransferase 115 
1079872   + - SAS1007 phosphoribosylaminoimidazole 
synthetase 
61 
1080441   + - SAS1008 phosphoribosylglycinamide 
formyltransferase 
45 





1083203 1083302 + - SAS1010 phosphoribosylamine--glycine ligase 126 
1083468   - - SAS1011 cobalt transport protein 77 
1084267   - - SAS1012 ABC transporter ATP-binding protein 49 
1085682   - - SAS1013 hypothetical protein 66 
  1086334 - - SASs008 - 46 







Strand Name Synonym Product Expression  
1088422   + - SAS1015 hypothetical protein 32 
1090019   + - SAS1016 hypothetical protein 17 
1090615   + - SAS1017 hypothetical protein 38 
1091035   + - SAS1018 phosphocarrier protein HPr 0 
1092756 1092820 + - SAS1019 phosphoenolpyruvate-protein 
phosphotransferase 
112 
1092993   - - SAS1020 glutaredoxin 80 
1094785   + - SAS1021 cytochrome ubiquinol oxidase 67 
1095801   + - SAS1022 hypothetical protein 23 
1096596   + - SAS1023 potassium transport protein 34 
1096945   - - SAS1024 hypothetical protein 59 
1098642   - - SAS1025 hypothetical protein 9 
1099342   - def SAS1026 peptide deformylase 34 
1100884   + - SAS1027 hypothetical protein 33 
1102167 1102167 + - SAS1028 pyruvate dehydrogenase E1 component 
subunit alpha 
118 
1103148 1103238 + - SAS1029 pyruvate dehydrogenase E1 component 
subunit beta 
249 
1104531 1104531 + - SAS1030 branched-chain alpha-keto acid 
dehydrogenase E2 
178 
1105941 1105941 + - SAS1031 dihydrolipoamide dehydrogenase 202 
1106384   + - SAS1032 hypothetical protein 49 
1107067   + - SAS1033 DNA-binding protein 3 
1108174   + - SAS1034 ABC transporter ATP binding protein 50 
1108964   + - SAS1035 ABC transporter permease 0 
1109779   + - SAS1036 ABC transporter permease 24 
1110852   + - SAS1037 ABC transporter extracellular binding 
protein 
14 
1111945   + - SAS1038 hypothetical protein 41 
1112647   + - SAS1039 hypothetical protein 26 
1112729   - - SAS1040 manganese transport protein MntH 101 
1114265   - - SAS1041 hypothetical protein 44 
1115863   + - SAS1042 inositol monophosphatase 9 
1116017   - - SAS1043 hypothetical protein 20 
1118157   + - SAS1044 BipA family GTPase 85 
1118297   - - SAS1045 hypothetical protein 54 
1118466   - - SAS1046 hypothetical protein 47 
1119364   + - SAS1047 hypothetical protein 0 
1120904   + - SAS1048 cell division protein 37 
1124910   + - SAS1049 pyruvate carboxylase 87 
1125050   - - SAS1050 heme A synthase 71 
1127312   + - SAS1051 protoheme IX farnesyltransferase 32 
1127798   + - SAS1052 hypothetical protein 37 
1129162   + - SAS1053 hypothetical protein 49 







Strand Name Synonym Product Expression  
1129675 1129675 - - SAS1055 hypothetical protein 198 
1131094   + - SAS1056 hypothetical protein 6 
1131097   - - SAS1057 hypothetical protein 3 
1132098   + - SAS1058 methylase 38 
1132582   + coaD SAS1059 phosphopantetheine adenylyltransferase 42 
1132644   - - SAS1060 hypothetical protein 30 
1134467   + - SAS1061 hypothetical protein 29 
1134720   + rpmF SAS1062 50S ribosomal protein L32 90 
1134874   - - SAS1063 iron-regulated heme-iron binding protein 58 
1137014   - - SAS1064 iron-regulated heme-iron binding protein 102 
1138958   + - SAS1065 surface anchored protein 15 
1140034   + - SAS1066 hypothetical protein 5 
1140909   + - SAS1067 transport system extracellular binding 
lipoprotein 
43 
1141887   + - SAS1068 iron/heme permease 78 
1142683   + - SAS1069 sortase 20 
1143025   + - SAS1070 heme-degrading monooxygenase IsdG 0 
1143169   + - SAS1070a hypothetical protein 0 
1144149 1144246 + - SAS1071 SpoU rRNA methylase family protein 107 
  1144470 + - SASs009 - 108 
1145588   + pheS SAS1072 phenylalanyl-tRNA synthetase subunit 
alpha 
75 
1147990 1147990 + pheT SAS1073 phenylalanyl-tRNA synthetase subunit 
beta 
114 
1148225 1148047 - - SAS1074 ribonuclease HIII 111 
1149799   + - SAS1075 hypothetical protein 24 
1150321   + - SAS1076 hypothetical protein 3 
1152106   + - SAS1077 hypothetical protein 51 
1154464   + - SAS1078 recombination and DNA strand 
exchange inhibitor protein 
74 
1154951   + - SAS1079 thioredoxin 0 
1157056   + uvrC SAS1080 excinuclease ABC subunit C 18 
1157994   + - SAS1081 succinate dehydrogenase cytochrome 
b558 
22 
1159812   + sdhA SAS1082 succinate dehydrogenase flavoprotein 
subunit 
98 
1160627   + sdhB SAS1083 succinate dehydrogenase iron-sulfur 
subunit 
69 
1161663 1161674 + - SAS1084 glutamate racemase 111 
1162262   + - SAS1085 nucleoside-triphosphatase 56 
1162758   + - SAS1086 hypothetical protein 39 
1163053   + - SAS1087 hypothetical protein 4 
1163564   + - SAS1088 hypothetical protein 21 
1163934   - - SAS1089 formyl peptide receptor-like 1 inhibitory 
protein 
5 
1165509   + - SAS1090 hypothetical protein 55 







Strand Name Synonym Product Expression  
1166769   + - SAS1092 hypothetical protein 41 
1167409   + - SAS1093 hypothetical protein 40 
1167534   - - SAS1094 hypothetical protein 11 
1167926   - - SAS1095 hypothetical protein 48 
1168338   - - SAS1096 hypothetical protein 60 
1169048   - - SAS1097 alpha-hemolysin precursor 85 
1170826   + - SAS1097a hypothetical protein 30 
1171007   + - SAS1098 hypothetical protein 5 
1171451   - - SAS1099 superantigen-like protein 44 
1172275   - - SAS1100 superantigen-like protein 32 
1173095   - - SAS1101 superantigen-like protein 74 
1175259   + - SAS1102 ornithine carbamoyltransferase 62 
1176214   + - SAS1103 carbamate kinase 67 
1177942 1178062 + - SAS1104 hypothetical protein 132 
1178476   + - SAS1105 hypothetical protein 6 
1178782   - - SAS1106 hypothetical protein 9 
1180166   + - SAS1107 DNA-binding protein 0 
  1180641 - - SASt016 Arg tRNA 52 
1181212   + - SAS1107a anti protein 4 
1181403   + - SAS1108 anti protein 23 
1182222   + - SAS1109 haloacid dehalogenase 29 
1182331   - - SAS1110 hypothetical protein 0 
1184579   + - SAS1111 hypothetical protein 48 
1185154 1185154 + - SAS1112 cell division protein MraZ 152 
1186105   + mraW SAS1113 S-adenosyl-methyltransferase MraW 73 
1186520   + - SAS1114 cell division protein 73 
1188735   + - SAS1115 penicillin-binding protein 1 42 
1189992   + mraY SAS1116 phospho-N-acetylmuramoyl-
pentapeptide-transferase 
20 
1191343   + murD SAS1117 UDP-N-acetylmuramoyl-L-alanyl-D-
glutamate synthetase 
30 
1192678   + - SAS1118 cell division protein 39 
1194196   + - SAS1119 cell division protein 94 
1195401   + - SAS1120 cell division protein FtsZ 59 
1196452   + - SAS1121 hypothetical protein 31 
1197144   + - SAS1122 hypothetical protein 53 
1197704 1197704 + - SAS1123 hypothetical protein 105 
1198006   + - SAS1124 hypothetical protein 30 
1198895   + - SAS1125 hypothetical protein 16 
1199536   + - SAS1126 hypothetical protein 16 
  1199743 + - SASs010 - 80 
1202510 1202556 + ileS SAS1127 isoleucyl-tRNA synthetase 109 
1203597   + - SAS1128 glyoxalase/bleomycin resistance 
protein/dioxygenase superfamily protein 
23 







Strand Name Synonym Product Expression  
1205858   + - SAS1131 RNA pseudouridylate synthase 23 




1208310   + - SAS1133 uracil permease 96 
1209219   + pyrB SAS1134 aspartate carbamoyltransferase 100 
1210511   + pyrC SAS1135 dihydroorotase 86 
1211613   + - SAS1136 carbamoyl phosphate synthase small 
subunit 
201 
1214779   + carB SAS1137 carbamoyl phosphate synthase large 
subunit 
100 
1215581   + - SAS1138 orotidine 5'-phosphate decarboxylase 63 
1216192   + pyrE SAS1139 orotate phosphoribosyltransferase 72 
1216434 1216496 + - SAS1140 hypothetical protein 179 
1217272   + - SAS1141 hypothetical protein 9 
1217535   - - SAS1142 hypothetical protein 88 
1220130   + gmk SAS1143 guanylate kinase 14 
1220348   + rpoZ SAS1144 DNA-directed RNA polymerase subunit 
omega 
0 
1221763   + - SAS1145 flavoprotein 61 
1224171 1224229 + - SAS1146 primosomal protein n' 156 
1225627   + - SAS1147 lipoprotein 0 
1225790   - - SAS1148 hypothetical protein 16 
1226780   + - SAS1149 peptide deformylase 37 
1227708   + - SAS1150 methionyl-tRNA formyltransferase 70 
1229012   + - SAS1151 hypothetical protein 70 
1230109 1230109 + - SAS1152 ribosomal RNA large subunit 
methyltransferase N 
112 
1230859   + - SAS1153 protein phosphatase 30 
1232850   + - SAS1154 serine/threonine-protein kinase 67 
1233953   + - SAS1155 hypothetical protein 41 
1234598   + - SAS1156 ribulose-phosphate 3-epimerase 64 
1235246   + - SAS1157 hypothetical protein 17 
1235627   - rpmB SAS1158 50S ribosomal protein L28 9 
1236632   + - SAS1159 hypothetical protein 8 
1238293   + - SAS1160 hypothetical protein 46 
1240543   + - SAS1161 ATP-dependent DNA helicase RecG 69 
1241318   + - SAS1162 fatty acid biosynthesis transcriptional 
regulator 
49 
1242309   + - SAS1163 glycerol-3-phosphate acyltransferase 
PlsX 
110 
1243228   + - SAS1164 malonyl CoA-acyl carrier protein 
transacylase 
44 
1243955   + - SAS1165 3-oxoacyl-ACP reductase 77 
1244558   + acpP SAS1166 acyl carrier protein 24 







Strand Name Synonym Product Expression  
1249118   + - SAS1168 chromosome partition protein 53 
1250368   + - SAS1169 cell division protein 73 
1250687 1250687 + - SAS1170 DNA-binding protein 157 
1252080 1252133 + - SAS1171 signal recognition particle protein 110 
1252790 1252797 + rpsP SAS1172 30S ribosomal protein S16 152 
1253481   + rimM SAS1173 16S rRNA-processing protein RimM 6 
1254218   + trmD SAS1174 tRNA (guanine-N(1)-)-methyltransferase 23 
1254671 1254671 + rplS SAS1175 50S ribosomal protein L19 150 
1255140   - - SAS1176 hypothetical protein 45 
1259031   + rbgA SAS1177 ribosomal biogenesis GTPase 0 
1259782 1259782 + rnhB SAS1178 ribonuclease HII 108 
1261057   + sucC SAS1179 succinyl-CoA synthetase subunit beta 63 
1261987 1262007 + - SAS1180 succinyl-CoA synthetase subunit alpha 174 
1263332   + - SAS1181 cell wall hydrolase 62 
1264604   + - SAS1182 FemAB family protein 40 
1265649   + - SAS1183 SMF family protein 24 
1267898   + - SAS1184 DNA topoisomerase I 70 
1269361   + - SAS1185 tRNA (uracil-5-)-methyltransferase Gid 17 
1270674   + - SAS1186 integrase/recombinase 52 
1271216 1271237 + - SAS1187 ATP-dependent protease peptidase 
subunit 
210 
1272685   + hslU SAS1188 ATP-dependent protease ATP-binding 
subunit HslU 
56 
1273483   + - SAS1189 transcriptional repressor CodY 36 
1274592   + rpsB SAS1190 30S ribosomal protein S2 71 
1275655 1275680 + tsf SAS1191 elongation factor Ts 166 
1276514 1276532 + pyrH SAS1192 uridylate kinase 185 
1277087 1277395 + frr SAS1193 ribosome recycling factor 112 
1278230   + - SAS1194 undecaprenyl pyrophosphate synthase 28 
1279019   + - SAS1195 phosphatidate cytidylyltransferase 62 
1280517   + - SAS1196 hypothetical protein 78 
1282240   + - SAS1197 prolyl-tRNA synthetase 38 
1286814   + polC SAS1198 DNA polymerase III PolC 91 
1287571   + - SAS1199 hypothetical protein 14 
1288767   + nusA SAS1200 transcription elongation factor NusA 80 
1289072   + - SAS1201 hypothetical protein 102 
1289386   + - SAS1202 ribosomal protein 13 
1291508 1291567 + infB SAS1203 translation initiation factor IF-2 127 
1292244 1292244 + rbfA SAS1204 ribosome-binding factor A 154 
1293331   + - SAS1205 tRNA pseudouridine synthase B 3 
1294317   + - SAS1206 riboflavin biosynthesis protein 18 
1294701   + rpsO SAS1207 30S ribosomal protein S15 54 
1297165   + - SAS1208 polynucleotide phosphorylase 96 







Strand Name Synonym Product Expression  
1301700   + - SAS1210 DNA translocase (FtsK/SpoIIIE family 
protein) 
38 
1302418   + - SAS1211 hypothetical protein 56 
1303714   + - SAS1212 hypothetical protein 43 
1305000   + - SAS1213 protease 52 
1305704 1305704 + - SAS1214 short chain dehydrogenase 121 
1306636   + - SAS1215 hypothetical protein 4 
1307047   + - SAS1216 DNA-binding protein 0 
1307659   + - SAS1217 CDP-diacylglycerol--glycerol-3-
phosphate 3-phosphatidyltransferase 
60 
1309037   + - SAS1218 hypothetical protein 25 
1310245   + recA SAS1219 recombinase A 81 
1312158 1312309 + - SAS1220 phosphodiesterase 108 
1312455   - - SAS1221 hypothetical protein 30 
1313641 1313723 + - SAS1222 hypothetical protein 104 
1315541   + - SAS1223 pyruvate flavodoxin/ferredoxin 
oxidoreductase 
86 
1316408   + - SAS1224 2-oxoglutarate ferredoxin 
oxidoreductase subunit beta 
75 
1316795   + - SAS1225 hypothetical protein 12 
1318473   + - SAS1226 (dimethylallyl)adenosine tRNA 
methylthiotransferase 
67 
1318839   + - SAS1227 hypothetical protein 51 
1319357   + - SAS1228 hypothetical protein 49 
1322278   + - SAS1229 DNA mismatch repair protein MutS 50 
1324300   + mutL SAS1230 DNA mismatch repair protein 21 
1324848   + - SAS1231 glycerol uptake operon antiterminator 
regulatory protein 
25 
1324885   - - SAS1231a hypothetical protein 0 
1326141 1326141 + - SAS1232 glycerol uptake facilitator protein 118 
1327766   + glpK SAS1233 glycerol kinase 65 
1329597   + - SAS1234 aerobic glycerol-3-phosphate 
dehydrogenase 
68 
1330661   + - SAS1235 hydrolase 50 
1331614   + miaA SAS1236 tRNA delta(2)-
isopentenylpyrophosphate transferase 
52 
1331862   + - SAS1237 hypothetical protein 4 
1332084   - - SAS1238 glutathione peroxidase 37 
1333910   + - SAS1239 hypothetical protein 41 
1335167   + - SAS1240 hypothetical protein 68 
1335779 1335797 + - SAS1241 glutamine synthetase 114 
1337138   + - SAS1242 glutamine synthetase 102 
1337838   + - SAS1243 hypothetical protein 25 
1338745   + - SAS1244 hypothetical protein 13 
1339248   + - SAS1245 hypothetical protein 54 







Strand Name Synonym Product Expression  
1341666   + - SAS1247 hypothetical protein 0 
1342575   + - SAS1249 hypothetical protein 32 
1343075   + - SAS1250 hypothetical protein 24 
1343464 1343476 + - SAS1251 hypothetical protein 170 
1343599   + - SAS1252 hypothetical protein 59 
1344522   + - SAS1254 hypothetical protein 0 
1344918   + - SAS1255 hypothetical protein 90 
1345083   - - SAS1256 hypothetical protein 21 
1346575   + - SAS1257 hypothetical protein 2 
1348113   + - SAS1258 cardiolipin synthase 40 
1349196   + - SAS1259 ABC transporter ATP-binding protein 13 
1349896   + - SAS1260 hypothetical protein 35 
1350991   + - SAS1261 sensor kinase 43 
1351590   + - SAS1262 response regulator 12 
1351703   - - SAS1263 hypothetical protein 3 
1352563   + - SAS1264 thermonuclease 0 
1352706   - - SAS1265 hypothetical protein 30 
1354466   + - SAS1266 hypothetical protein 48 
1354520   - - SAS1267 aspartate kinase 33 
1357373   + - SAS1268 homoserine dehydrogenase 53 
1358440   + - SAS1269 threonine synthase 63 
1359356 1359413 + - SAS1270 homoserine kinase 104 
1360217 1360217 + - SAS1271 haloacid dehalogenase 109 
1360510   - - SAS1272 hypothetical protein 36 
1361042   - - SAS1273 amino acid permease 24 
1364217   + - SAS1274 catalase 91 
1364457   + rpmG SAS1275 50S ribosomal protein L33 18 
1365180   + rpsN SAS1276 30S ribosomal protein S14 4 
1366314   + - SAS1277 guanosine 5'-monophosphate 
oxidoreductase 
42 
1367352   + - SAS1278 hypothetical protein 15 
1367732   - - SAS1279 LexA repressor 22 
1368731   + - SAS1280 hypothetical protein 0 
1369106   + - SAS1281 hypothetical protein 7 
1371215   + - SAS1282 transketolase 80 
1371735   + - SAS1283 hypothetical protein 22 
1372381 1372431 + - SAS1284 hypothetical protein 125 
1373626   + - SAS1285 exonuclease 46 
1376659   + - SAS1286 exonuclease 12 
1376730   - mscL SAS1287 large-conductance mechanosensitive 
channel 
0 
1378942   + - SAS1288 glycine betaine transporter 1 101 
1382539   + - SAS1289 aconitate hydratase 83 







Strand Name Synonym Product Expression  
1383393   - - SAS1292 hypothetical protein 23 
1384064   - - SAS1293 hypothetical protein 35 
1386869   + - SAS1294 DNA topoisomerase IV subunit B 85 
1389271   + - SAS1295 DNA topoisomerase IV subunit A 63 
1390981   + - SAS1296 sodium:alanine symporter family protein 83 
1392332   + - SAS1297 transcription antiterminator 30 
1392474   + - SAS1298 hypothetical protein 42 
1393675   + - SAS1299 hypothetical protein 100 
1396678   + - SAS1300 hypothetical protein 28 
1396881   - - SAS1301 methionine sulfoxide reductase A 17 
1398510   + - SAS1302 hypothetical protein 17 
1398598   - - SAS1303 4-oxalocrotonate tautomerase 95 
1400193   + - SAS1304 ImpB/MucB/SamB family protein 41 
1400329   - - SAS1305 prephenate dehydrogenase 61 
1402616   + - SAS1306 peptidase 65 
  1402880 + - SASs011 - 7 
  1403094 + - SASs012 - 0 
1404514   + - SAS1307 anthranilate synthase component I 31 
1405077 1405077 + - SAS1308 anthranilate synthase component II 133 
1406081   + trpD SAS1309 anthranilate phosphoribosyltransferase 80 
1406865   + trpC SAS1310 indole-3-glycerol phosphate synthase 13 
1407497   + - SAS1311 N-(5'-phosphoribosyl)anthranilate 
isomerase 
81 
1408704   + - SAS1312 tryptophan synthase subunit beta 139 
1409425   + trpA SAS1313 tryptophan synthase subunit alpha 55 
1411009   + - SAS1314 factor essential for expression of 
methicillin resistance 
20 
1412287   + - SAS1315 methicillin resistance expression factor 81 
1413232   + - SAS1316 hypothetical protein 62 
1414319   - - SAS1319 hypothetical protein 50 
1414916   - - SAS1320 oligopeptide transporter ATPase 31 
1415610   - - SAS1321 oligopeptide transporter ATPase 4 
1416370   - - SAS1322 oligopeptide transport system permease 45 
1417193   - - SAS1323 oligopeptide transport system permease 38 
1418483   - - SAS1324 hypothetical protein 30 
1420846   + - SAS1325 peptidase 68 
1420985   - - SAS1326 phosphate transport system protein 51 
1421633   - - SAS1327 phosphate transporter ATP-binding 
protein 
29 
1422531   - - SAS1328 ABC transporter permease 32 
1423450 1423450 - - SAS1329 ABC transporter permease 112 
1424567   - - SAS1330 phosphate-binding lipoprotein 21 
1426526   - - SAS1332 hypothetical protein 15 
1429176   + - SAS1333 ABC transporter ATP-binding protein 11 
  1429961 + - SASs013 - 0 







Strand Name Synonym Product Expression  
1432301 1432301 + - SAS1335 aspartate semialdehyde dehydrogenase 208 
1433190   + dapA SAS1336 dihydrodipicolinate synthase 84 
1433909   + - SAS1337 dihydrodipicolinate reductase 80 
1434655 1434674 + - SAS1338 tetrahydrodipicolinate acetyltransferase 103 
1435949 1435949 + - SAS1339 peptidase 122 
1437039   + - SAS1340 alanine racemase 90 
1438294   + - SAS1341 diaminopimelate decarboxylase 51 
1438534   - - SAS1342 hypothetical protein 58 
1439132   - - SAS1343 cold shock protein 10 
1439503   - - SAS1344 hypothetical protein 65 
1440243   + - SAS1345 acylphosphatase 79 
1440891   + - SAS1346 hypothetical protein 39 
1442059   + - SAS1347 hypothetical protein 69 
1443072   - - SAS1350 branched-chain amino acid transporter 
protein 
8 
1444640   - - SAS1351 hypothetical protein 37 
1446540   - - SAS1352 hypothetical protein 24 
1447512   - - SAS1353 hypothetical protein 40 
1447744   - - SAS1354 hypothetical protein 43 
1449133   - - SAS1355 dihydrolipoamide succinyltransferase 25 
1450415   - sucA SAS1356 2-oxoglutarate dehydrogenase E1 89 
1453497   - - SAS1357 sensor kinase 10 
1454849   - - SAS1358 response regulator protein 35 
1455979   - - SAS1358a hypothetical protein 11 
1456295   - - SAS1359 hypothetical protein 83 




1458008   - - SAS1361 acetyltransferase 13 
1459705   - - SAS1363 protease 17 
1461387   - - SAS1364 hypothetical protein 0 
1461608   - - SAS1365 PTS system glucose-specific transporter 
subunit IIA 
50 
1462120   - - SAS1366 methionine sulfoxide reductase B 96 
1462541   - - SAS1367 methionine sulfoxide reductase A 64 
1463160   - - SAS1368 hypothetical protein 90 
1464014   - - SAS1369 dihydrofolate reductase 87 
1464693 1464494 - thyA SAS1370 thymidylate synthase 122 
1466073   - - SAS1371 hypothetical protein 70 
1466526   - - SAS1372 hypothetical protein 89 
1467689   - - SAS1373 hypothetical protein 78 
1467952   - - SAS1374 hypothetical protein 88 
1469095   + - SAS1375 hypothetical protein 13 
1469261   + - SAS1375a hypothetical protein 34 







Strand Name Synonym Product Expression  
  1480047 - - predicted 
RNA 
- 634 
  1479687 + - predicted 
RNA 
- 634 
  1479775 + - predicted 
RNA 
- 650 
1497358   - - SAS1379 transporter protein 99 
1498906   - - SAS1380 amino acid permease 83 
1500259   - - SAS1381 threonine dehydratase 77 
1501394   - - SAS1382 alanine dehydrogenase 23 
1502988   - - SAS1383 5'-3' exonuclease 36 
1503886   - - SAS1384 hypothetical protein 81 
1508969   + - SAS1385 hypothetical protein 43 
1509540   - - SAS1386 hypothetical protein 83 
1509956   - - SAS1387 hypothetical protein 82 
  1511315 - rnpB SASs014 - 20 
1511752   - - SAS1388 hypothetical protein 49 
1512110   - - SAS1389 hypothetical protein 44 
1512666   - - SAS1390 hypothetical protein 8 
1513070   - - SAS1391 hypothetical protein 0 
1514181   + recU SAS1392 Holliday junction-specific endonuclease 29 
1516361 1516361 + - SAS1393 penicillin-binding protein 2 109 
1516925   - - SAS1394 hypothetical protein 23 
1517271   - - SAS1395 endonuclease 26 
1517920   - - SAS1396 hypothetical protein 34 
1518934   - asnC SAS1397 asparaginyl-tRNA synthetase 69 
1520548   - - SAS1398 hypothetical protein 48 
1523265   - - SAS1399 BirA bifunctional protein [includes: 
biotin operon repressor; biotin--[acetyl-
CoA-carboxylase] synthetase 
29 
1524223   - - SAS1400 tRNA CCA-pyrophosphorylase 25 
1525430   - - SAS1401 glycosyl transferase family protein 36 
1526814   - - SAS1402 hypothetical protein 16 
1527467   - - SAS1403 hypothetical protein 83 
1528219   - - SAS1404 hypothetical protein 73 
1528796   - - SAS1405 hypothetical protein 0 
1529385   - - SAS1406 hypothetical protein 37 
1530636 1530636 - - SAS1407 3-phosphoshikimate 1-
carboxyvinyltransferase 
162 
1531944 1531944 - aroB SAS1408 3-dehydroquinate synthase 110 
1533034   - - SAS1409 chorismate synthase 88 
1534588   - - SAS1409a hypothetical protein 75 
1534998   - ndk SAS1410 nucleoside diphosphate kinase 60 
1535539   - - SAS1411 heptaprenyl diphosphate synthase 
component II 
43 









Strand Name Synonym Product Expression  
1537228   - - SAS1413 hypothetical protein 92 
1538231   - - SAS1414 DNA-binding protein HU 22 
1538674   - gpsA SAS1415 NAD(P)H-dependent glycerol-3-
phosphate dehydrogenase 
4 
1539689   - engA SAS1416 GTP-binding protein EngA 43 
1541221   - rpsA SAS1417 30S ribosomal protein S1 37 
1543094   - cmk SAS1418 cytidylate kinase 49 
1544798   + - SAS1419 L-asparaginase 100 
1544913 1544745 - - SAS1420 pyridine nucleotide-disulfide 
oxidoreductase 
151 
1546301 1546301 - - SAS1421 cell surface elastin binding protein 117 
1547914   - - SAS1422 DEAD/DEAH box helicase 33 
1549283   - - SAS1423 hypothetical protein 33 
1550592   + - SAS1424 ferredoxin 82 
1550698   - - SAS1425 hypothetical protein 32 
  1551305 - - SASs015 - 35 
1551653   - - SAS1426 lipoprotein 40 
1552624   - - SAS1427 lipoprotein 27 
1553599   - - SAS1428 lipoprotein 37 
1554595   - - SAS1429 hypothetical protein 24 
1556769   - - SAS1430 lipoprotein 18 
1557922   - - SAS1431 sensor kinase 51 
1559654   - - SAS1432 response regulator protein 33 
1560512   - - SAS1433 ribosomal large subunit pseudouridine 
synthase B 
25 
1561242   - - SAS1434 hypothetical protein 22 
1561777   - - SAS1435 hypothetical protein 97 
1563106   + - SAS1436 hypothetical protein 42 
1563184   - - SAS1437 integrase/recombinase 102 
1564120   - - SAS1438 iron uptake regulatory protein 90 
1564674   - - SAS1439 ADP-ribose pyrophosphatase 52 
1566206   + - SAS1440 aldo/keto reductase 12 
1566422   - - SAS1441 hypothetical protein 6 
1566686   - - SAS1442 short chain dehydrogenase 55 
1568398   + - SAS1443 pyrroline-5-carboxylate reductase 59 
1568501 1568481 - - SAS1444 hypothetical protein 105 
1571218   + - SAS1445 glucose-6-phosphate 1-dehydrogenase 89 
1572314   + - SAS1446 AraC family transcriptional regulator 48 
1572396   - - SAS1447 alpha-D-1,4-glucosidase 92 
1574061   - - SAS1448 maltose operon transcriptional repressor 31 
1575274   - - SAS1449 glyoxalase/bleomycin resistance 
protein/dioxygenase superfamily protein 
0 
1575864   - - SAS1450 6-phosphogluconate dehydrogenase 43 
1577338 1577271 - - SAS1451 peptidase 110 
1579040   - - SAS1452 hypothetical protein 0 







Strand Name Synonym Product Expression  
1580822   - - SAS1454 lipoamide acyltransferase component of 
branched-chain alpha-keto acid 
dehydrogenase complex 
56 
1582109 1582109 - - SAS1455 2-oxoisovalerate dehydrogenase subunit 
beta 
191 
1583092   - - SAS1456 2-oxoisovalerate dehydrogenase subunit 
alpha 
174 
1584100 1584100 - - SAS1457 dihydrolipoamide dehydrogenase 143 
1585672   - - SAS1458 DNA repair protein 34 
1587367   - - SAS1459 arginine repressor ArgR 3 
1588251   - - SAS1460 geranyltranstransferase 29 
1589110   - - SAS1461 exodeoxyribonuclease VII small subunit 15 
1589333   - xseA SAS1462 exodeoxyribonuclease VII large subunit 39 
1590687   - nusB SAS1463 transcription antitermination protein 
NusB 
40 
1591136   - - SAS1464 hypothetical protein 0 
1591513   - - SAS1465 acetyl-CoA carboxylase biotin 
carboxylase subunit 
82 
1592868   - - SAS1466 biotin carboxyl carrier protein of acetyl-
CoA carboxylase 
204 
1593806   - - SAS1467 elongation factor P 6 
1594389   - - SAS1468 peptidase 61 
1596136   + - SAS1469 hypothetical protein 11 
1596368   + - SAS1470 hypothetical protein 0 
1596432   - - SAS1471 lipoate-protein ligase A 73 
1597806   + - SAS1472 hypothetical protein 0 
1598171   - - SAS1473 glycine dehydrogenase subunit 2 48 
1599636   - - SAS1474 glycine dehydrogenase subunit 1 104 
1601002   - gcvT SAS1475 glycine cleavage system 
aminomethyltransferase T 
59 
1602252   - - SAS1476 shikimate kinase 20 
1603009   - - SAS1477 hypothetical protein 7 
1603424   - - SAS1478 hypothetical protein 7 
1603710   - - SAS1479 hypothetical protein 22 
1604134   - - SAS1480 hypothetical protein 33 
1604459   - - SAS1481 hypothetical protein 9 
1605501   - - SAS1482 hypothetical protein 28 
1606527   - - SAS1483 metallo-beta-lactamase superfamily 
protein 
1 
1607147   - - SAS1484 hypothetical protein 6 
1607476   - - SAS1485 glucokinase 6 
1608459   - - SAS1486 hypothetical protein 9 
1608643   - - SAS1487 hypothetical protein 51 
1610118   - - SAS1488 5-formyltetrahydrofolate cyclo-ligase 7 







Strand Name Synonym Product Expression  
1611128   - - SAS1490 penicillin-binding protein 3 72 
1613324   - - SAS1491 superoxide dismutase 38 
1614199   - - SAS1492 zinc-specific metalloregulatory protein 17 
1614596   - - SAS1493 ABC transporter permease 28 
1615501 1615460 - - SAS1494 ABC transporter ATP-binding protein 137 
1616412   - - SAS1495 endonuclease IV 26 
1617312   - - SAS1496 helicase 40 
1618772   - - SAS1497 hypothetical protein 18 
1619875   - - SAS1498 hypothetical protein 31 
1620683 1620647 - - SAS1499 RNA polymerase sigma factor RpoD 116 
1622013   - - SAS1500 DNA primase 20 
1623891   - - SAS1501 hypothetical protein 58 
1627069   + - SAS1503 glycyl-tRNA synthetase 88 
1627220   - - SAS1504 recombination protein O 88 
1627994   - era SAS1505 GTP-binding protein Era 15 
1628894   - - SAS1506 cytidine deaminase 35 
1629309 1629307 - - SAS1507 diacylglycerol kinase 137 
1629656   - - SAS1508 hypothetical protein 63 
1630124   - - SAS1509 PhoH-like protein 54 
1631375   - - SAS1510 hypothetical protein 30 
1632090   - - SAS1511 hypothetical protein 99 
1633097 1633097 - - SAS1512 hypothetical protein 178 
1634024 1633844 - rpsU SAS1513 30S ribosomal protein S21 180 
1634493   - - SAS1514 hypothetical protein 79 
1635846 1635840 - - SAS1515 16S ribosomal RNA methyltransferase 
RsmE 
146 
1636600   - prmA SAS1516 50S ribosomal protein L11 
methyltransferase 
65 
1637542   - - SAS1517 molecular chaperone DnaJ 84 
1638817   - dnaK SAS1518 molecular chaperone DnaK 52 
1640718   - - SAS1519 heat shock protein GrpE 34 
1641376   - - SAS1520 heat-inducible transcription repressor 59 
1642454   - - SAS1521 coproporphyrinogen III oxidase 22 
1644144   - - SAS1522 GTP-binding protein LepA 70 
1646564   + rpsT SAS1523 30S ribosomal protein S20 38 
1646609   - holA SAS1524 DNA polymerase III subunit delta 48 
1647640   - - SAS1525 hypothetical protein 19 
1649846   - - SAS1526 deaminase 75 
1650399   - - SAS1527 hypothetical protein 36 
1651125   - - SAS1528 hypothetical protein 67 







Strand Name Synonym Product Expression  
1652198   - - SAS1530 hypothetical protein 38 
1652772   - - SAS1531 hypothetical protein 68 
1653344   - - SAS1532 hypothetical protein 4 
1653638   - - SAS1533 shikimate 5-dehydrogenase 36 
1654458   - - SAS1534 GTP-binding protein YqeH 51 
1655559   - - SAS1535 hypothetical protein 29 
1656106   - - SAS1536 5'-methylthioadenosine/S-
adenosylhomocysteine nucleosidase 
42 
1657375   + - SAS1537 hypothetical protein 73 
1657577   - - SAS1538 enterotoxin 14 
1659036   - - SAS1539 hypothetical protein 17 
1660543   - - SAS1540 hypothetical protein 46 
1661784 1661784 - - SAS1541 LamB/YcsF family protein 151 
1662536   - - SAS1542 biotin carboxylase 99 
1663911   - - SAS1543 biotin carboxyl carrier protein of acetyl-
CoA carboxylase 
42 
1664362 1664362 - - SAS1544 hypothetical protein 131 
1665362   - - SAS1545 hypothetical protein 93 
1666422   - greA SAS1546 transcription elongation factor GreA 64 
1666926   - - SAS1547 uridine kinase 20 
1667549   - - SAS1548 peptidase 84 
1668829   - - SAS1549 peptidase 46 
1669755   - - SAS1550 O-methyltransferase 47 
1670678   - - SAS1551 hypothetical protein 2 
1671001   - - SAS1552 Holliday junction resolvase-like protein 29 
1671433   - - SAS1553 hypothetical protein 25 
1671756 1671756 - alaS SAS1554 alanyl-tRNA synthetase 169 
  1674489 - - SASs016 - 165 
1674729   - - SAS1555 hypothetical protein 81 
1677208   - - SAS1556 hypothetical protein 41 
1678457   - mnmA SAS1557 tRNA-specific 2-thiouridylase MnmA 75 
1679576   - - SAS1558 cysteine desulfurase 59 
1682043 1682191 + - SAS1559 oxygenase 130 
1682280 1681982 - - SAS1560 hypothetical protein 104 
1682466   - - SAS1561 hypothetical protein 38 
1682748   - - SAS1562 hypothetical protein 20 
1684529   + - SAS1563 recombination factor protein RarA 101 
1684690   - - SAS1564 hypothetical protein 29 
1685677   - - SAS1565 hypothetical protein 26 
1685924 1685779 - aspS SAS1566 aspartyl-tRNA synthetase 135 
1687706   - hisS SAS1567 histidyl-tRNA synthetase 75 
1689429   - - SAS1568 N-acetylmuramoyl-L-alanine amidase 31 
1690301   - - SAS1569 D-tyrosyl-tRNA(Tyr) deacylase 22 







Strand Name Synonym Product Expression  
1693382   - - SAS1571 adenine phosphoribosyltransferase 9 
1693922   - - SAS1572 single-stranded-DNA-specific 
exonuclease 
102 
1696398   - - SAS1573 bifunctional preprotein translocase 
subunit SecD/SecF 
65 
1698952   - - SAS1574 hypothetical protein 53 
1699231   - tgt SAS1575 queuine tRNA-ribosyltransferase 62 
1700393   - queA SAS1576 S-adenosylmethionine--tRNA 
ribosyltransferase-isomerase 
88 
1701420 1701419 - ruvB SAS1577 Holliday junction DNA helicase RuvB 112 
1702456   - ruvA SAS1578 Holliday junction DNA helicase RuvA 27 
1703072   - - SAS1579 hypothetical protein 52 
1703540   - obgE SAS1580 GTPase ObgE 64 
1705317   - rpmA SAS1581 50S ribosomal protein L27 20 
1705613   - - SAS1582 hypothetical protein 49 
1705939   - rplU SAS1583 50S ribosomal protein L21 48 
1706609   - - SAS1584 hypothetical protein 15 
1707139   - - SAS1585 rod shape-determining protein MreC 35 
1708180   - - SAS1585a hypothetical protein 76 
1708373   - - SAS1586 hypothetical protein 29 
1709203   + - SAS1587 hypothetical protein 16 
1709320   - - SAS1588 hypothetical protein 0 
1709672   - radC SAS1589 DNA repair protein RadC 52 
1710355   - - SAS1590 type III leader peptidase family protein 2 
1711332   - - SAS1591 folylpolyglutamate synthase 36 
1712616   - valS SAS1592 valyl-tRNA synthetase 39 
1716209   + - SAS1593 DNA-3-methyladenine glycosylase I 63 
1716432   - - SAS1594 hypothetical protein 70 
1717539   - - SAS1595 hypothetical protein 3 
1717701 1717701 - - SAS1596 glutamate-1-semialdehyde 
aminotransferase 
144 
1719035 1718988 - - SAS1597 delta-aminolevulinic acid dehydratase 105 
1720012   - - SAS1598 uroporphyrinogen III synthase 75 
1720702   - hemC SAS1599 porphobilinogen deaminase 94 
1721670   - - SAS1600 hypothetical protein 28 
1722507   - hemA SAS1601 glutamyl-tRNA reductase 49 
1724070   - engB SAS1602 ribosome biogenesis GTP-binding 
protein YsxC 
28 
1724814   - clpX SAS1603 ATP-dependent protease ATP-binding 
subunit ClpX 
38 
1726227 1726227 - tig SAS1604 trigger factor 120 
1727691   - - SAS1605 hypothetical protein 54 
1728639   - - SAS1606 hypothetical protein 34 
1729389   - rplT SAS1607 50S ribosomal protein L20 66 
1729792 1729746 - rpmI SAS1608 50S ribosomal protein L35 121 







Strand Name Synonym Product Expression  
1730777   - - SAS1610 lysine-specific permease 55 
  1732415 - - SASs017 - 118 
1732696 1732696 - thrS SAS1611 threonyl-tRNA synthetase 169 
  1734764 - - SASs018 - 7 
1735045   - - SAS1612 primosomal protein DnaI 83 
1735965   - - SAS1613 chromosome replication 
initiation/membrane attachment protein 
95 
1737366   - nrdR SAS1614 transcriptional regulator NrdR 34 
1738047   - - SAS1615 glyceraldehyde 3-phosphate 
dehydrogenase 2 
47 
1739242   - coaE SAS1616 dephospho-CoA kinase 28 
1739881   - - SAS1617 formamidopyrimidine-DNA glycosylase 58 
1740769   - - SAS1618 DNA polymerase I 68 
1743693   - - SAS1619 hypothetical protein 5 
1745679   - - SAS1620 alkaline phosphatase synthesis sensor 
protein 
55 
1747340   - - SAS1621 alkaline phosphatase synthesis 
transcriptional regulatory protein 
67 
1748434   - - SAS1622 isocitrate dehydrogenase 53 
1749751   - - SAS1623 citrate synthase 80 
1752581   + - SAS1624 D-serine/D-alanine/glycine transporter 55 
1752929 1752108 - - SAS1625 pyruvate kinase 126 
1754708   - pfkA SAS1626 6-phosphofructokinase 76 
1755945   - - SAS1627 acetyl-CoA carboxylase 
carboxyltransferase subunit alpha 
66 
1756889   - - SAS1628 acetyl-CoA carboxylase subunit beta 59 
1757941   - - SAS1629 NAD-dependent malic enzyme 72 
1759620   - - SAS1630 DNA polymerase III subunit alpha 47 
1762838   - - SAS1631 hypothetical protein 96 
1764233   - - SAS1632 DNA-binding protein 51 
1766149   + - SAS1633 universal stress protein 89 
1766454   - - SAS1634 metal-dependent hydrolase 81 
1768373   + - SAS1635 metallopeptidase 60 
1768689 1768547 - - SAS1636 alanine dehydrogenase 108 
1770448   + - SAS1637 universal stress protein 0 
1770694 1770694 - - SAS1638 acetate kinase 125 
1771984   - - SAS1639 hypothetical protein 21 
1773054   - tpx SAS1640 thiol peroxidase 16 
1773646   - - SAS1641 hypothetical protein 48 
1774460 1774417 - - SAS1642 thiamine biosynthesis protein ThiI 142 
1775683   - - SAS1643 aminotransferase class-V protein 40 
1777194 1777194 - - SAS1644 septation ring formation regulator EzrA 116 
1779489   + - SAS1645 hypothetical protein 51 
1780335   + rpsD SAS1646 30S ribosomal protein S4 42 
1780551   - - SAS1647 hypothetical protein 60 







Strand Name Synonym Product Expression  
1783094   + - SAS1649 soluble hydrogenase subunit 50 
1784685 1784886 + - SAS1650 D-3-phosphoglycerate dehydrogenase 116 
1784835   - - SAS1651 hypothetical protein 33 
1786072   - - SAS1652 PTS system IIBC component 84 
1787666   - - SAS1653 acyltransferase 67 
1789729   + - SAS1654 protease 75 
1789823   - - SAS1655 tyrosyl-tRNA synthetase 75 
  1791148 - - SASs019 - 66 
1792372   + - SAS1656 transglycosylase 52 
1792575   - - SAS1657 haptoglobin-binding surface anchored 
protein 
49 
1795350   + - SAS1657a hypothetical protein 30 
1795596   - - SAS1658 formate--tetrahydrofolate ligase 77 
1797703 1797703 - - SAS1659 acetyl-CoA synthetase 123 
1800210   + - SAS1660 acetoin utilization protein 73 
1801404   + - SAS1661 histone deacetylase family protein 44 
1801502 1801502 - - SAS1662 catabolite control protein A 131 




1804822   - - SAS1664 hypothetical protein 44 
1805942   - - SAS1665 hypothetical protein 40 
1806507   - murC SAS1666 UDP-N-acetylmuramate--L-alanine 
ligase 
38 
1807844 1807824 - - SAS1667 FtsK/SpoIIIE family protein 112 
1811689   - - SAS1668 hypothetical protein 38 
1812314   - - SAS1669 hypothetical protein 0 
1813271   - - SAS1670 thioredoxin 17 
1813647   - - SAS1671 aminopeptidase 50 
1815121   + - SAS1672 hypothetical protein 31 
1815246   - - SAS1673 metallo-beta-lactamase superfamily 
protein 
89 
1816558   - trmB SAS1674 tRNA (guanine-N(7)-)-methyltransferase 26 
1817217   - - SAS1675 hypothetical protein 12 
1818559   - - SAS1676 D-alanine aminotransferase 24 
1819411   - - SAS1677 dipeptidase PepV 43 
1821513   - - SAS1678 hypothetical protein 19 
1821952   - - SAS1679 RNA pseudouridine synthase 0 
1822644   - - SAS1680 polysaccharide biosynthesis protein 31 
1825980   + - SAS1681 hypothetical protein 95 
1826097 1826051 - - SAS1682 surface anchored protein 202 
  1832245 + - predicted 
RNA 
antisense: SAS1682 974 
1832983   - - SAS1683 hypothetical protein 87 







Strand Name Synonym Product Expression  
1836027   - - SAS1685 hypothetical protein 40 
1838271   + - SAS1686 hypothetical protein 115 
1838831   + - SAS1687 hypothetical protein 14 
1838951   - - SAS1688 repressor of toxins 27 
1839926   - - SAS1689 hypothetical protein 16 
1841988   + - SAS1690 proline dehydrogenase 55 
1842110   - ribH SAS1691 6,7-dimethyl-8-ribityllumazine synthase 24 
1842587   - - SAS1692 riboflavin biosynthesis protein 38 
1843779   - - SAS1693 riboflavin synthase subunit alpha 40 
1844418   - - SAS1694 bifunctional riboflavin biosynthesis 
protein 
84 
  1845588 - - SASs020 - 239 
1845942   - - SAS1695 hypothetical protein 48 
1848281   + - SAS1696 arsenical resistance operon repressor 2 39 
1849573   + - SAS1697 arsenical pump membrane protein 2 63 
1849660   - - SAS1698 hypothetical protein 16 
1850790   - - SAS1699 hypothetical protein 17 
1851683   + - SAS1700 DNA-binding protein 0 
1852239   + - SAS1701 hypothetical protein 55 
1852226   - - SAS1702 hypothetical protein 78 
1854039   - - SAS1704 translaldolase 56 
1855314   + - SAS1705 hypothetical protein 0 
1855935   + - SAS1706 camphor resistance protein CrcB 56 
1856285   + - SAS1707 CrcB-like protein 51 
1856656   + - SAS1708 hypothetical protein 38 
1856668   - - SAS1709 aldo/keto reductase 61 
1857713   - - SAS1710 hypothetical protein 35 
1858746   - - SAS1711 S-adenosylmethionine synthetase 59 
  1860045 - - SASs021 - 72 
1861903   + - SAS1712 phosphoenolpyruvate carboxykinase 98 
1862203 1862326 + - SAS1712a hypothetical protein 278 
1862281 1862044 - - SAS1713 hypothetical protein 156 
1863032   - - SAS1714 hypothetical protein 121 
1863828 1864979 + - SAS1715 hypothetical protein 112 
1863825 1863795 - - SAS1716 hypothetical protein 229 
1864831 1864831 - - SAS1717 AMP-binding protein 138 
1866468   - - SAS1718 lipoprotein 28 
1867876   + - SAS1719 hypothetical protein 38 
1868952   + - SAS1720 hypothetical protein 69 
1869652   + - SAS1721 lipoprotein 86 
1870034   + - SAS1722 hypothetical protein 43 
1870707   + - SAS1723 hypothetical protein 22 
1870995   - - SAS1724 hypothetical protein 0 







Strand Name Synonym Product Expression  
1872023   - - SAS1726 hypothetical protein 7 
1879882   - - SAS1731 restriction modification DNA specificity 
protein 
40 
1881074   - - SAS1732 type I restriction enzyme modification 
protein 
155 
1882993 1882926 - - SAS1733 serine protease 115 
1883833   - - SAS1734 serine protease 90 
1884610   - - SAS1735 serine protease 67 
1885457   - - SAS1736 serine protease 68 
1886600   - - SAS1737 hypothetical protein 56 
1887694   + - SAS1738 hypothetical protein 41 
1888168   - - SAS1739 lantibiotic ABC transporter protein 0 
1888863   - - SAS1740 lantibiotic ABC transporter protein 15 
1889621   - - SAS1741 lantibiotic transport ATP-binding protein 65 
1890336   - - SAS1742 lantibiotic leader peptide processing 
serine protease 
80 
1891719   - - SAS1743 lantibiotic modifying enzyme 41 
1892253   - - SAS1744 lantibiotic biosynthesis protein 27 
1893490   - - SAS1745 lantibiotic biosynthesis protein 42 
1896548   - - SAS1746 lantibiotic protein 16 
  1896904 - - predicted 
RNA 
- 905 
  1896958 + - predicted 
RNA 
- 695 
1897428   - - SAS1747a lantibiotic protein 0 
1897813   - hlgB SAS1748 gamma-hemolysin component B 
precursor 
31 
1898798   - hlgA SAS1749 gamma-hemolysin component A 
precursor 
64 
1901085   + - SAS1750 hypothetical protein 25 
1901886   + - SAS1751 hypothetical protein 16 
  1903131 - - SASt017 Ser tRNA 219 
  1903761 + - predicted 
RNA 
antisense: SASt023 SASt022 SASt021 
SASt020 SASt019 SASt018 
1135 
  1903274 - - SASt018 Glu tRNA 352 
  1903347 - - SASt019 Asn tRNA 576 
  1903436 - - SASt020 Gly tRNA 915 
  1903525 - - SASt021 His tRNA 935 
  1903614 - - SASt022 Phe tRNA 964 
  1903703 - - SASt023 Asp tRNA 1151 
  1903800 - - SASt024 Met tRNA 1042 
1904343 1903874 - - SAS1752 hypothetical protein 136 
1905219   - - SAS1753 protoporphyrinogen oxidase 64 
1906643   - hemH SAS1754 ferrochelatase 82 
1907624   - hemE SAS1755 uroporphyrinogen decarboxylase 63 







Strand Name Synonym Product Expression  
1909551   - - SAS1757 transporter protein 56 
1910767   - - SAS1758 ABC transporter ATP-binding protein 181 
1912063   + - SAS1759 HIT-family protein 41 
1912570   + - SAS1760 hypothetical protein 24 
1912754   + - SAS1760a hypothetical protein 0 
1913860   + - SAS1761 hypothetical protein 5 
1915027   + - SAS1762 peptidyl-prolyl cis-isomerase 7 
1915148 1915094 - - SAS1763 3'-5' exoribonuclease 121 
1916086   - - SAS1764 hypothetical protein 61 
1919012   - - SAS1765 DNA repair exonuclease 77 
1921090   - - SAS1766 hypothetical protein 23 
1921503   - - SAS1767 hypothetical protein 12 
1922806   - - SAS1768 DNA-binding protein 35 
1923626   - - SAS1769 response regulator 35 
1924271   - - SAS1770 histidine kinase 53 
1926367   + - SAS1771 RNA pseudouridylate synthase 54 
1926828   - fumC SAS1772 fumarate hydratase 39 
1928409   - - SAS1773 hypothetical protein 87 
1929075   + - SAS1774 hypothetical protein 44 
1929345   + - SAS1775 hypothetical protein 67 
1929410 1929225 - - SAS1776 hypothetical protein 125 
1929587   - - SAS1777 hypothetical protein 13 
1930345   - - SAS1778 SpoU rRNA methylase family protein 90 
1930820   - - SAS1779 (Fe-S)-binding protein 97 
1932098   - - SAS1780 glutamine transport ATP-binding protein 90 
1932813   - - SAS1781 extracellular glutamine-binding protein 28 
1934528   - - SAS1782 hypothetical protein 7 
  1936137 - - SASt025 Leu tRNA 41 
  1938446 + - predicted 
RNA 
antisense: SASt031 SASt030 SASt050 
SASt028 SASt027 SASt049 SASt026 
SASt048 SASt047 SASt046 SASt045 
SASt044 SASt043 SASt029 SASt042 
SASt041 SASt040 SASt039 SASt038 
SASt037 SASt036 SASt035 SASt034 
SASt033 SASt032 
3011 
  1936262 - - SASt026 Xaa tRNA 241 
  1936349 - - SASt027 Gly tRNA 490 
  1936431 - - SASt028 Cys tRNA 647 
  1936510 - - SASt029 Gln tRNA 645 
  1936593 - - SASt030 His tRNA 967 
  1936668 - - SASt031 Trp tRNA 1894 
  1936757 - - SASt032 Tyr tRNA 2911 
  1936843 - - SASt033 Thr tRNA 3180 
  1936926 - - SASt034 Phe tRNA 3398 







Strand Name Synonym Product Expression  
  1937102 - - SASt036 Met tRNA 3531 
  1937190 - - SASt037 Ser tRNA 4674 
  1937321 - - SASt038 Asp tRNA 4801 
  1937407 - - SASt039 Ser tRNA 4584 
  1937506 - - SASt040 Met tRNA 4577 
  1937605 - - SASt041 Met tRNA 3947 
  1937703 - - SASt042 Ala tRNA 3200 
  1937796 - - SASt043 Pro tRNA 2361 
  1937879 - - SASt044 Arg tRNA 2189 
  1937971 - - SASt045 Leu tRNA 2005 
  1938070 - - SASt046 Gly tRNA 2216 
  1938148 - - SASt047 Leu tRNA 2981 
  1938233 - - SASt048 Lys tRNA 3107 
  1938314 - - SASt049 Thr tRNA 2899 
  1938406 - - SASt050 Val tRNA 2507 
  1938493 - - SASr011 5S ribosomal RNA 1962 
  1938680 - - SASr012 23S ribosomal RNA 1093 
  1939936 + - predicted 
RNA 
antisense: SASr012 2314 
  1940469 + - predicted 
RNA 
antisense: SASr012 1067 
  1941894 - - SASt051 Ala tRNA 0 
  1941988 - - SASt052 Ile tRNA 70 
  1942154 - - SASr013 16S ribosomal RNA 1602 
  1943577 + - predicted 
RNA 
antisense: SASr013 2100 
1944450   - - SAS1783 peroxide operon regulator 28 
1944993   - - SAS1784 hypothetical protein 11 
1945949   - - SAS1785 AhpC/TSA family protein 39 
1947774 1947774 + - SAS1786 glutamate-1-semialdehyde 
aminotransferase 
109 
1949161   + - SAS1787 hypothetical protein 43 
1949353   - - SAS1788 ABC transporter ATP-binding protein 67 
1951380   - - SAS1789 hypothetical protein 38 
1952224   - - SAS1790 HhH-GPD superfamily base excision 
DNA repair protein 
19 
1954390   + - SAS1791 hypothetical protein 70 
1954651   - - SAS1792 hypothetical protein 10 
1955496   - - SAS1793 hypothetical protein 22 
1957028   - - SAS1794 hypothetical protein 8 
1957320   - recX SAS1795 recombination regulator RecX 15 
1958399   - - SAS1796 glycosyltransferase 29 
1959547   - - SAS1797 ThiJ/PfpI family protein 36 
1960193   - - SAS1798 hypothetical protein 31 







Strand Name Synonym Product Expression  
1961989   - - SAS1800 hypothetical protein 52 
1962608 1962608 - - SAS1801 aminopeptidase 140 
1963867   - - SAS1802 hypothetical protein 32 
1964678   + - SAS1803 low molecular weight phosphotyrosine 
protein phosphatase 
70 
1964960   + - SAS1804 hypothetical protein 28 
1966449   + - SAS1805 hypothetical protein 52 
1966561   - - SAS1806 response regulator 59 
1967180   - - SAS1807 histidine kinase sensor 68 
1968220   - - SAS1808 hypothetical protein 37 
1968936   - - SAS1809 hypothetical protein 28 
1969539   - - SAS1810 methionine aminopeptidase 26 
1971814   + - SAS1811 hypothetical protein 91 
1972112   - - SAS1811a hypothetical protein 50 
1972304   - - SAS1812 hypothetical protein 50 
1972943   - - SAS1813 hypothetical protein 29 
1973676   - - SAS1814 Mur ligase family protein 65 
1975781   + - SAS1815 ferritin 44 
1976725   + - SAS1816 exonuclease 52 
1976792   - - SAS1817 DNA polymerase IV 41 
1978109   - - SAS1818 hypothetical protein 73 
1978809   - - SAS1819 RNA methyltransferase 22 
1980251   - - SAS1820 lipid kinase 69 
1981852 1981852 - gatB SAS1822 aspartyl/glutamyl-tRNA 
amidotransferase subunit B 
113 
1983292   - gatA SAS1823 aspartyl/glutamyl-tRNA 
amidotransferase subunit A 
91 
1984751   - gatC SAS1824 aspartyl/glutamyl-tRNA 
amidotransferase subunit C 
2 
1986958   + - SAS1825 high affinity proline permease 77 
1987047   - - SAS1826 lipoprotein 76 
1988259   - - SAS1827 DNA ligase 79 
1990266   - - SAS1828 ATP-dependent DNA helicase 77 
1992455   - - SAS1829 geranylgeranylglyceryl phosphate 
synthase 
18 
1993319   - - SAS1830 hypothetical protein 41 
1993730   - - SAS1831 adenylosuccinate lyase 74 
1997052   + - SAS1832 staphopain protease 24 
1997409   + - SAS1833 hypothetical protein 10 
1997701   - - SAS1834 hypothetical protein 44 
1997855   - - SAS1835 hypothetical protein 82 
1998728   - nadE SAS1836 NAD synthetase 50 
1999542   - - SAS1837 nicotinate phosphoribosyltransferase 54 
2002271   + - SAS1838 oxygenase 29 







Strand Name Synonym Product Expression  
2003275   - - SAS1840 sodium:sulfate symporter 101 
2005042   - - SAS1841 hypothetical protein 60 
2007071   + - SAS1842 isochorismatase family protein 45 
2008053   + - SAS1843 manganese-dependent inorganic 
pyrophosphatase 
50 
2009852 2009852 + - SAS1844 aldehyde dehydrogenase 240 
2009972   - - SAS1845 hypothetical protein 68 
2011671   + - SAS1846 hypothetical protein 18 
2012244   - - SAS1848 hypothetical protein 21 
2013908   + - SAS1849 hypothetical protein 72 
2013965   - - SAS1850 hypothetical protein 26 
2014804   - - SAS1851 hypothetical protein 12 
2015421   - - SAS1852 hypothetical protein 0 
2016629 2016633 + - SAS1853 hypothetical protein 168 
2016695   - - SAS1854 hypothetical protein 16 
2017435   - - SAS1855 ABC transporter ATP-binding protein 31 
2018304   - - SAS1856 hypothetical protein 36 
2018985   - - SAS1857 ABC transporter ATP-binding protein 6 
2019878   - - SAS1858 GntR family transcriptional regulator 14 
2020517   - - SAS1859 hypothetical protein 45 
2020936 2020905 - - SAS1859.1 hypothetical protein 413 
2022520   + - SAS1860 hypothetical protein 51 
2026030   + - SAS1863a hypothetical protein 13 
2026362   + - SAS1864 hypothetical protein 5 
2026601   + - SAS1865 hypothetical protein 0 
2026654   - - SAS1866 hypothetical protein 42 
2028502 2028502 - - SAS1868 staphylokinase precursor 117 
2029184   - - SAS1869 autolysin 61 
2029951 2029940 - - SAS1870 holin 141 
2030417 2030206 - - SAS1871 hypothetical protein 106 
2030702   - - SAS1872 enterotoxin type A precursor 68 
2031848 2031476 - - SAS1873 hypothetical protein 109 
2032278 2032232 - - SAS1874 hypothetical protein 177 
2032611   - - SAS1875 hypothetical protein 103 
2032756   - - SAS1876 hypothetical protein 128 
  2033666 + - predicted 
RNA 
antisense: SAS1876 635 
  2033881 + - predicted 
RNA 
antisense: SAS1876 734 
2036554 2036539 - - SAS1877 hypothetical protein 127 
2038044   - - SAS1878 hypothetical protein 250 
  2038523 + - predicted 
RNA 
antisense: SAS1878 634 
  2041190 + - predicted 
RNA 







Strand Name Synonym Product Expression  
2042749 2042749 - - SAS1879 hypothetical protein 374 
2042931 2042931 - - SAS1880 hypothetical protein 207 
2043442 2043378 - - SAS1881 hypothetical protein 288 
2044396   - - SAS1882 hypothetical protein 166 
2044773   - - SAS1883 hypothetical protein 166 
2045150   - - SAS1884 hypothetical protein 243 
2045472   - - SAS1885 hypothetical protein 263 
2045813 2045805 - - SAS1886 hypothetical protein 334 
2046007 2046007 - - SAS1887 capsid protein 200 
2047342 2047342 - - SAS1888 prohead protease 241 
  2048033 + - predicted 
RNA 
antisense: SAS1888 SAS1889 870 
2047919   - - SAS1889 portal protein 375 
2049175 2049175 - - SAS1890 hypothetical protein 413 
  2049495 + - predicted 
RNA 
antisense: SAS1891 724 
2049389 2049389 - - SAS1891 terminase-large subunit 1026 
  2051480 + - predicted 
RNA 
antisense: SAS1891 SAS1892 1513 
2051086 2051084 - - SAS1892 hypothetical protein 2837 
2051682 2051682 - - SAS1893 hypothetical protein 909 
2052042 2052036 - - SAS1894 hypothetical protein 177 
2052609   - - SAS1895 hypothetical protein 67 
2053102   - - SAS1896 hypothetical protein 31 
2053302   - - SAS1897 hypothetical protein 48 
2053959   - - SAS1898 hypothetical protein 61 
2054111   - - SAS1899 hypothetical protein 30 
2054601 2054599 - - SAS1901 hypothetical protein 263 
2055014 2055006 - - SAS1902 hypothetical protein 218 
2055239 2055239 - - SAS1903 phage regulatory protein 211 
2056162 2056162 - - SAS1904 single-strand DNA-binding protein 153 
2056633   - - SAS1905 hypothetical protein 170 
2057331 2057331 - - SAS1906 hypothetical protein 182 
2058253   - - SAS1907 hypothetical protein 81 
2060205   - - SAS1908 hypothetical protein 52 
2060477   - - SAS1909 hypothetical protein 41 
2060830   - - SAS1910 hypothetical protein 16 
2060988   - - SAS1911 hypothetical protein 56 
2061999   + - SAS1912 hypothetical protein 80 
2062014   - - SAS1912a hypothetical protein 56 
2062185   - - SAS1913 hypothetical protein 49 
2063739   + - SAS1916 hypothetical protein 33 
2063763   - - SAS1917 hypothetical protein 95 







Strand Name Synonym Product Expression  
2065194 2065389 + - SAS1919 repressor 134 
2066118   + - SAS1920 enterotoxin 73 
2066870   + - SAS1921 enterotoxin 15 
2067991   + - SAS1922 integrase 93 
2069110   - - SAS1924 leukocidin F subunit 26 
2070148   - - SAS1925 leukocidin S subunit 58 
2072859   + - SAS1926 succinyl-diaminopimelate desuccinylase 60 
2073231   - - SAS1927 hypothetical protein 58 
2074138   - - SAS1928 ferrichrome-binding protein precursor 30 
2076517   + - SAS1929 sodium transport protein 41 
2077371   - - SAS1930 GNAT family acetyltransferase 12 
2077920   - - SAS1931 hypothetical protein 11 
2078674   - - SAS1932 terminase small subunit 25 
2079261   - - SAS1933 hypothetical protein 5 
2080175 2080073 - groEL SAS1935 molecular chaperone GroEL 187 
2081867   - groES SAS1936 co-chaperonin GroES 41 
2083069   + - SAS1937 hypothetical protein 62 
2083094 2083094 - - SAS1938 membrane anchored protein 201 
2085059   + - SAS1939 hypothetical protein 65 
2086205   + - SAS1940 carbon-nitrogen hydrolase 55 
  2086458 - - SASs022 - 37 
2086804   - - SAS1940a delta-hemolysin 60 
2087737   + - SAS1941 autoinducer processing protein 28 
2087881   + - SAS1942 autoinducer peptide 30 
2089198   + - SAS1943 autoinducer sensor protein 73 
2089933   + - SAS1944 autoinducer sensor protein response 
regulator protein 
25 
2090302   - - SAS1945 fructokinase 34 
2091258   - - SAS1946 sucrose-6-phosphate hydrolase 38 
2092891   - - SAS1947 sucrose operon repressor 70 
2094024   - - SAS1948 ammonium transporter family protein 68 
2095482   - - SAS1949 hypothetical protein 102 
2095766   - - SAS1950 hypothetical protein 94 
2097149   - - SAS1951 redox-sensing transcriptional repressor 
Rex 
40 
2099965   + - SAS1952 ABC transporter ATP-binding protein 37 
2101937   + - SAS1953 hypothetical protein 68 
2102039   - - SAS1954 DNA-binding/iron metalloprotein/AP 
endonuclease 
54 
2103057   - - SAS1955 acetyltransferase 51 
2103494   - - SAS1956 hypothetical protein 97 
2104137   - - SAS1957 hypothetical protein 40 
2106797 2106797 + - SAS1958 dihydroxy-acid dehydratase 217 







Strand Name Synonym Product Expression  
2109989 2109989 + - SAS1961 ketol-acid reductoisomerase 152 
2111548 2111550 + - SAS1962 2-isopropylmalate synthase 164 
2112597 2112610 + - SAS1963 3-isopropylmalate dehydrogenase 168 
2113981   + - SAS1964 isopropylmalate isomerase large subunit 86 
2114554   + leuD SAS1965 isopropylmalate isomerase small subunit 46 
2115837   + - SAS1966 threonine dehydratase 73 
  2116304 - - SASr014 5S ribosomal RNA 177 
  2116491 - - SASr015 23S ribosomal RNA 1019 
  2117678 + - predicted 
RNA 
antisense: SASr015 2574 
  2117898 + - predicted 
RNA 
antisense: SASr015 668 
  2118260 + - predicted 
RNA 
antisense: SASr015 921 
  2119960 - - SASr016 16S ribosomal RNA 1710 
  2121480 + - predicted 
RNA 
antisense: SASr016 2267 
  2121632 - - SASt053 Gly tRNA 805 
  2121724 - - SASt054 Leu tRNA 689 
2122456 2122456 - - SAS1967 hypothetical protein 120 
2122904   - - SAS1968 RNA binding protein 91 
2125487   - - SAS1969 RNA polymerase sigma factor SigB 54 
2126232   - - SAS1970 serine-protein kinase RsbW 5 
2126713 2126712 - - SAS1971 anti-sigma B factor antagonist 169 
2127158   - - SAS1972 sigma factor sigB regulation protein 53 
2128508   - - SAS1973 hypothetical protein 49 
2128867   - - SAS1974 hypothetical protein 90 
2129122 2129050 - - SAS1975 alanine racemase 153 
2130336   - acpS SAS1976 4'-phosphopantetheinyl transferase 11 
2130699   - - SAS1977 hypothetical protein 38 
2131177   - - SAS1978 hypothetical protein 91 
2132753   - - SAS1979 hypothetical protein 2 
2133441   - - SAS1980 potassium-transporting ATPase subunit 
C 
29 
2134021   - - SAS1981 potassium-transporting ATPase subunit 
B 
87 
2136067   - - SAS1982 potassium-transporting ATPase subunit 
A 
80 
2140672   + - SAS1983 sensor kinase 89 
2141367   + - SAS1984 response regulator protein 70 
2141736   - - SAS1985 helicase 54 




2145146   - ddl SAS1987 D-alanyl-alanine synthetase A 49 
2147715 2147768 + - SAS1988 hypothetical protein 115 







Strand Name Synonym Product Expression  
2148243   - - SAS1990 hypothetical protein 0 
2148464   - - SAS1991 hypothetical protein 41 
2150407   + - SAS1992 cardiolipin synthetase 55 
2151082 2151955 + - SAS1993 hypothetical protein 113 
2151696 2151058 - - SAS1994 hypothetical protein 125 
2152654   - thiE SAS1995 thiamine-phosphate pyrophosphorylase 101 
2153288   - - SAS1996 hydroxyethylthiazole kinase 91 
2154072   - - SAS1997 phosphomethylpyrimidine kinase 170 
2154895   - - SAS1998 transcriptional activator 147 
  2155664 - - SASs023 - 68 
2156092   + - SAS1998b hypothetical protein 5 
2156108 2156108 - - SAS1999 hypothetical protein 217 
2157192   - - SAS2000 ssDNA-binding protein 10 
2158221   + - SAS2001 hypothetical protein 24 
2158279 2158279 - fabZ SAS2002 (3R)-hydroxymyristoyl-ACP 
dehydratase 
118 
2158753   - - SAS2003 UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 
71 
2160129   - - SAS2004 hypothetical protein 24 
2160924   - atpC SAS2005 ATP synthase F0F1 subunit epsilon 62 
2161348   - - SAS2006 ATP synthase F0F1 subunit beta 93 
2162782 2162779 - - SAS2007 ATP synthase F0F1 subunit gamma 117 
2163679   - - SAS2008 ATP synthase F0F1 subunit alpha 93 
2165209   - - SAS2009 ATP synthase F0F1 subunit delta 46 
2165748   - - SAS2010 ATP synthase F0F1 subunit B 28 
2166466   - - SAS2011 F0F1 ATP synthase subunit C 59 
2166721   - - SAS2012 ATP synthase F0F1 subunit A 97 
2167470 2167450 - - SAS2013 ATP synthase I 123 
2167990   - - SAS2014 UDP-GlcNAc 2-epimerase 78 
2169141   - upp SAS2015 uracil phosphoribosyltransferase 74 
2169798   - glyA SAS2016 serine hydroxymethyltransferase 62 
2171063   - - SAS2017 hypothetical protein 37 
2171694   - - SAS2018 low molecular weight protein-tyrosine-
phosphatase 
92 
2172110   - - SAS2019 hypothetical protein 88 
2173240   - - SAS2020 hypothetical protein 49 
2174063   - prfA SAS2021 peptide chain release factor 1 90 
2175140   - - SAS2022 thymidine kinase 231 
2176086   - rpmE2 SAS2023 50S ribosomal protein L31 40 
2176458   - rho SAS2024 transcription termination factor Rho 46 
2178021   - - SAS2025 aldehyde dehydrogenase 36 
2179686   - - SAS2026 hypothetical protein 71 
2180110 2180107 - - SAS2027 UDP-N-acetylglucosamine 1-
carboxyvinyltransferase 
116 







Strand Name Synonym Product Expression  
2183434   + - SAS2029 hypothetical protein 46 
2183543   - pyrG SAS2030 CTP synthetase 41 
2185489   - - SAS2031 DNA-directed RNA polymerase subunit 
delta 
78 
2186131   - - SAS2032 acetyltransferase 69 
2188218 2188218 + - SAS2033 pantothenate kinase 117 
2188348 2188049 - - SAS2034 hypothetical protein 142 
2189418   - - SAS2035 hypothetical protein 28 
2190611   - - SAS2036 peptidase 53 
2192576   + - SAS2037 S-ribosylhomocysteinase 52 
2192728 2192686 - - SAS2038 hypothetical protein 176 
2193092 2193079 - - SAS2039 pyrimidine-nucleoside phosphorylase 118 
2194674   - - SAS2040 deoxyribose-phosphate aldolase 67 
2196361 2196445 + deoD SAS2041 purine nucleoside phosphorylase 113 
2196482   - - SAS2042 non-heme iron-containing ferritin 4 
2197125   - - SAS2043 hypothetical protein 6 
2197996   - - SAS2044 hypothetical protein 31 
2200041   - - SAS2045 hypothetical protein 38 
2200302   - - SAS2046 mannose-6-phosphate isomerase 38 
2201676   - - SAS2047 hypothetical protein 9 
2202813   + - SAS2048 zinc and cobalt transport repressor 
protein 
69 
2203795 2203888 + - SAS2049 zinc resistance protein 137 
2205152   + - SAS2050 hypothetical protein 23 
2207056   + - SAS2052a hypothetical protein 0 
2207186   - - SAS2053 haloacid dehalogenase 74 
2208111   - - SAS2054 ABC transporter ATP-binding protein 35 
2209125   - - SAS2055 glucosamine--fructose-6-phosphate 
aminotransferase 
75 
  2211132 - - SASs024 - 0 
2211553   + - SAS2056 hypothetical protein 0 
2213149 2213149 + - SAS2057 PTS system mannitol-specific 
transporter subunit IIBC 
182 
2215316   + - SAS2058 transcriptional antiterminator 99 
2215762   + - SAS2059 PTS system mannitol-specific 
transporter subunit IIA 
86 
2216868   + - SAS2060 mannitol-1-phosphate 5-dehydrogenase 63 
  2217774 + - predicted 
RNA 
- 685 
2224979 2223844 - glmM SAS2063 phosphoglucosamine mutase 348 
  2224800 + - predicted 
RNA 
- 6549 
2226361   - - SAS2064 hypothetical protein 25 
2227295   - - SAS2065 hypothetical protein 39 
2228293   - - SAS2066 arginase 50 







Strand Name Synonym Product Expression  
  2229415 - - SASt056 Gln tRNA 47 
  2229499 - - SASt057 Tyr tRNA 191 
  2229891 + - predicted 
RNA 
antisense: SASt059 SASt058 SASt057 
SASt060 SASr017 
994 
  2229612 - - SASt058 Val tRNA 420 
  2229695 - - SASt059 Glu tRNA 651 
  2229768 - - SASt060 Asn tRNA 939 
  2229853 - - SASr017 5S ribosomal RNA 1219 
  2230040 - - SASr018 23S ribosomal RNA 1084 
  2231284 + - predicted 
RNA 
antisense: SASr018 2411 
  2231404 + - predicted 
RNA 
antisense: SASr018 684 
  2231819 + - predicted 
RNA 
antisense: SASr018 1169 
  2233386 - - SASr019 16S ribosomal RNA 1635 
  2234839 + - predicted 
RNA 
antisense: SASr019 1848 
2235396 2234940 - - SAS2067 hypothetical protein 110 
2236608   - - SAS2068 transport protein 80 
2238373   - - SAS2069 hypothetical protein 46 
2238945   - - SAS2070 transport protein 32 
2240465   - - SAS2071 hypothetical protein 2 
2241167   - - SAS2072 UTP-glucose-1-phosphate 
uridylyltransferase 
44 
2242398   - - SAS2073 hypothetical protein 26 
2243350   + - SAS2074 hypothetical protein 60 
2243482   - - SAS2075 hypothetical protein 40 
2245088   - - SAS2076 FecCD transport family protein 62 
2246053   - - SAS2077 FecCD transport family protein 59 
2247096   - - SAS2078 transport system binding lipoprotein 44 
2248471   - - SAS2079 hypothetical protein 44 
2249548   - - SAS2080 hypothetical protein 67 
2251292   - - SAS2081 hypothetical protein 29 
2254563   + - SAS2082 hypothetical protein 40 
2254723   - - SAS2083 alkaline shock protein 23 51 
2255295   - - SAS2084 hypothetical protein 32 
2255547   - - SAS2085 hypothetical protein 35 
2256258 2256258 - - SAS2086 glycine betaine transporter 2 104 
2258128   - - SAS2087 zinc-binding dehydrogenase 47 
2259369 2259136 - - SAS2088 zinc-binding dehydrogenase 145 
2260653   - - SAS2089 hypothetical protein 25 
2261788 2261535 - - SAS2090 6-phospho-beta-galactosidase 120 
2263218 2263218 - - SAS2091 PTS system lactose-specific transporter 
subunit IIBC 
152 









Strand Name Synonym Product Expression  
2265269   - - SAS2093 tagatose 1,6-diphosphate aldolase 92 
2266253 2266250 - - SAS2094 tagatose-6-phosphate kinase 142 
2267198   - - SAS2095 galactose-6-phosphate isomerase subunit 
LacB 
93 
2267729   - - SAS2096 galactose-6-phosphate isomerase subunit 
LacA 
82 
2268525   - - SAS2097 lactose phosphotransferase system 
repressor 
16 
2270262 2270262 + - SAS2098 NAD-dependent deacetylase 178 
2270460   + - SAS2099 hypothetical protein 83 
2270553   - - SAS2100 hypothetical protein 57 
2271423 2271327 - - SAS2100a hypothetical protein 150 
2271767   - - SAS2101 aldo/keto reductase 51 
2272685   - - SAS2102 MerR family transcriptional regulator 38 
2275957   + - SAS2103 hyaluronate lyase precursor 2 51 
2276571   + - SAS2104 hypothetical protein 41 
2276958   - - SAS2105 hypothetical protein 35 
2277699   - - SAS2106 acetolactate synthase 43 
2279736   + - SAS2107 hypothetical protein 0 
2279810   - - SAS2107a hypothetical protein 0 
2280339 2280339 - rpsI SAS2108 30S ribosomal protein S9 112 
2280751   - rplM SAS2109 50S ribosomal protein L13 100 
2281428   - truA SAS2110 tRNA pseudouridine synthase A 74 
2282236   - - SAS2111 cobalt transport protein 84 
2283032   - cbiO SAS2112 cobalt transporter ATP-binding subunit 93 
2283889   - cbiO SAS2113 cobalt transporter ATP-binding subunit 159 
2285236   - rplQ SAS2114 50S ribosomal protein L17 42 
2285621 2285605 - - SAS2115 DNA-directed RNA polymerase subunit 
alpha 
163 
2286640 2286640 - - SAS2116 30S ribosomal protein S11 202 
2287053 2287049 - rpsM SAS2117 30S ribosomal protein S13 209 
2287441   - rpmJ SAS2118 50S ribosomal protein L36 90 
2287586 2287555 - infA SAS2119 translation initiation factor IF-1 161 
2287997 2287805 - adk SAS2120 adenylate kinase 115 
2288661 2288661 - secY SAS2121 preprotein translocase subunit SecY 151 
2289953   - rplO SAS2122 50S ribosomal protein L15 44 
2290410 2290410 - rpmD SAS2123 50S ribosomal protein L30 261 
2290606 2290590 - rpsE SAS2124 30S ribosomal protein S5 346 
2291127   - rplR SAS2125 50S ribosomal protein L18 96 
2291517 2291517 - rplF SAS2126 50S ribosomal protein L6 117 
2292078   - rpsH SAS2127 30S ribosomal protein S8 21 
2292508 2292495 - rpsN SAS2128 30S ribosomal protein S14 130 
2292716   - rplE SAS2129 50S ribosomal protein L5 56 







Strand Name Synonym Product Expression  
2293635   - rplN SAS2131 50S ribosomal protein L14 91 
2294035   - rpsQ SAS2132 30S ribosomal protein S17 20 
2294322   - - SAS2133 50S ribosomal protein L29 22 
2294521   - rplP SAS2134 50S ribosomal protein L16 101 
2294958 2294956 - rpsC SAS2135 30S ribosomal protein S3 170 
2295635 2295635 - rplV SAS2136 50S ribosomal protein L22 114 
2296017   - rpsS SAS2137 30S ribosomal protein S19 36 
2296362 2296362 - rplB SAS2138 50S ribosomal protein L2 151 
  2296703 + - predicted 
RNA 
antisense: rplB 634 
2297228 2297196 - rplW SAS2139 50S ribosomal protein L23 311 
2297503   - rplD SAS2140 50S ribosomal protein L4 179 
2298153   - rplC SAS2141 50S ribosomal protein L3 70 
2298843   - rpsJ SAS2142 30S ribosomal protein S10 102 
2299897   + - SAS2143 hypothetical protein 22 
2300088   - - SAS2144 xanthine/uracil permeases family protein 67 
2301535   - - SAS2145 DNA topoisomerase III 47 
2304744   + - SAS2146 acetyltransferase (GNAT) family protein 29 
2305788   + - SAS2147 glucose uptake protein 95 
2306207   - - SAS2148 hypothetical protein 46 
2307412   + - SAS2149 hypothetical protein 3 
2307974   + - SAS2150 hypothetical protein 67 
2308158   - - SAS2151 AcrB/AcrD/AcrF family protein 69 
2311442   - - SAS2152 peptidoglycan pentaglycine interpeptide 
biosynthesis protein 
30 
2313347   + - SAS2153 hypothetical protein 6 
2313339   - - SAS2154 hypothetical protein 35 
2314705   + - SAS2155 MarR family transcriptional regulator 25 
2315909   + - SAS2156 transporter protein 62 
2316011   - - SAS2157 hypothetical protein 98 
2316939 2316939 - - SAS2158 molybdenum cofactor biosynthesis 
protein A 
197 
2317981   - mobA SAS2159 molybdopterin-guanine dinucleotide 
biosynthesis protein MobA 
41 
2318587   - - SAS2160 molybdopterin-synthase small subunit 47 
2318826   - - SAS2161 molybdopterin-synthase large subunit 58 
2319286   - - SAS2162 molybdopterin-guanine dinucleotide 
biosynthesis protein B 
101 
2319768   - - SAS2163 molybdenum cofactor biosynthesis 
protein 
160 
2321584 2321621 + moaC SAS2164 molybdenum cofactor biosynthesis 
protein MoaC 
195 
2321586 2321586 - - SAS2165 molybdenum cofactor biosynthesis 
protein B 
128 
2322123 2322093 - - SAS2166 molybdopterin synthase sulfurylase 138 
2323297   - - SAS2167 molybdenum transport ATP-binding 
protein 
93 







Strand Name Synonym Product Expression  
2324588   - - SAS2169 molybdate-binding lipoprotein precursor 88 
2326457   + - SAS2170 formate dehydrogenase accessory 
protein 
51 
2326629   - - SAS2171 acetyltransferase (GNAT) family protein 42 
2327476   - - SAS2172 BioY family protein 41 
2328151   - - SAS2173 inosine-uridine preferring nucleoside 
hydrolase 
102 
2329490   - - SAS2174 ferrichrome-binding lipoprotein 
precursor 
35 
2330612   - - SAS2175 hypothetical protein 73 
2331813 2331767 - - SAS2176 hypothetical protein 109 
2331983 2331983 - - SAS2177 hypothetical protein 141 
2333450   + ureA SAS2178 urease subunit gamma 47 
2333874   + ureB SAS2179 urease subunit beta 67 
2335586 2335586 + ureC SAS2180 urease subunit alpha 185 
2336051   + ureE SAS2181 urease accessory protein UreE 95 
2336733   + - SAS2182 urease accessory protein UreF 24 
2337360   + - SAS2183 urease accessory protein UreG 96 
2338196   + - SAS2184 urease accessory protein UreD 58 
2338385   - - SAS2185 accessory regulator A 38 
2339160   - - SAS2186 hypothetical protein 66 
2339550   - - SAS2187 hypothetical protein 22 
2340320   - - SAS2188 transcriptional regulator 23 
2343694 2343783 + - SAS2189 hypothetical protein 239 
2343711 2343468 - - SAS2190 hypothetical protein 353 
2344127 2344127 - - SAS2191 Na+/H+ antiporter 136 
2345622   - - SAS2192 dehydrogenase 40 
2347374   + - SAS2193 hypothetical protein 38 
2348111 2348206 + - SAS2194 hypothetical protein 211 
2348416 2348416 + - SAS2195 hypothetical protein 161 
2349426   + - SAS2196 glycerate dehydrogenase 81 
2349507   - - SAS2197 hypothetical protein 23 
2351356 2351305 - - SAS2198 N-acetylmuramoyl-L-alanine amidase 252 
2352154   - - SAS2199 hypothetical protein 90 
2352615   - - SAS2200 hypothetical protein 23 
2353088   - - SAS2201 bifunctional protein GlmU 167 
  2355696 + - predicted 
RNA 
antisense: SAS2201 661 
2356644   - - SAS2202 hypothetical protein 87 
2357724   - - SAS2203 inositol monophosphatase 20 
2359598   + - SAS2204 DeoR family regulatory protein 40 
2360245   - - SAS2206 hypothetical protein 38 
2361360   + - SAS2207 hypothetical protein 26 
2362677   + - SAS2208 transcriptional regulator 17 







Strand Name Synonym Product Expression  
2365079   + - SAS2210 hypothetical protein 24 
2365261   + - SAS2211 hypothetical protein 65 
2365357 2364444 - - SAS2212 hypothetical protein 115 
2365559   - - SAS2213 haloacid dehalogenase 40 
2366269   - - SAS2214 sodium/bile acid symporter family 
protein 
93 
2367984   + - SAS2215 hypothetical protein 39 
2368050   - - SAS2216 PTS system, arbutin-like IIBC 
component 
57 
2370748   + - SAS2217 transcriptional regulator 36 
2370806 2370794 - - SAS2218 hypothetical protein 154 
2371479 2371479 - - SAS2219 transporter 130 
  2372869 - - SASs025 - 78 
2373017 2372965 - - SAS2220 hypothetical protein 128 
2374073   - - SAS2221 short chain dehydrogenase 54 
2375065   - - SAS2222 peptidase 83 
2376462 2376187 - - SAS2223 imidazolonepropionase 197 
2377700   - - SAS2224 urocanate hydratase 216 
2380405 2380524 + - SAS2225 LysR family regulatory protein 108 
2380898   - - SAS2226 formimidoylglutamase 95 
2383382 2383382 + - SAS2227 hypothetical protein 112 
2383448   - - SAS2228 ribose-5-phosphate isomerase A 36 
2384961   + - SAS2229 hypothetical protein 55 
2385197 2385197 - - SAS2230 aldose 1-epimerase 117 
2386246   - - SAS2231 hypothetical protein 96 
2386790   - - SAS2232 hypothetical protein 83 
2388015   - - SAS2233 ABC transporter ATP-binding protein 78 
2389145   - - SAS2234 hypothetical protein 44 
2389879   + - SAS2234a hypothetical protein 0 
2390076   + - SAS2234b hypothetical protein 92 
2390772 2390913 + - SAS2235 3-methylpurine glycosylase 117 
2392317   + - SAS2236 permease 48 
2392365 2392365 - - SAS2237 isopentenyl pyrophosphate isomerase 219 
2393445   - - SAS2238 CorA-like Mg2+ transporter protein 88 
2394980   + - SAS2239 hypothetical protein 16 
2395396   + - SAS2240 hypothetical protein 78 
2395504   - - SAS2241 hypothetical protein 50 
2397270   + - SAS2242 hypothetical protein 41 
2397516   - - SAS2243 transporter 52 
2399460   - - SAS2244 hypothetical protein 27 
2400779   + - SAS2245 TetR family regulatory protein 37 
2401009   - - SAS2246 teicoplanin resistance associated 
membrane protein 
96 









Strand Name Synonym Product Expression  
2404108   - - SAS2248 MarR family transcriptional regulator 39 
2405726   + - SAS2249 hypothetical protein 66 
2405957   - - SAS2250 ABC transporter ATP-binding protein 63 
2406622   - - SAS2251 permease 69 
2408487   + - SAS2252 response regulator protein 62 
2409853   + - SAS2253 sensor kinase 81 
2410459   + - SAS2254 hypothetical protein 42 
2410911   + - SAS2255 hypothetical protein 14 
2410977 2410977 - - SAS2256 malate:quinone oxidoreductase 111 
2412836   - - SAS2257 L-lactate permease 2 34 
2416424   + - SAS2258 hypothetical protein 42 
2416578   - - SAS2259 hypothetical protein 29 
2417506   - - SAS2260 acetyltransferase (GNAT) family protein 13 
2419216   + - SAS2261 zinc-binding dehydrogenase 77 
2420706   + - SAS2262 hypothetical protein 16 
2420982   - - SAS2263 acetyltransferase (GNAT) family protein 75 
2421419   - - SAS2264 pyridine nucleotide-disulfide 
oxidoreductase family protein 
68 
2422685   - - SAS2265 hypothetical protein 19 
2423323   - - SAS2266 hypothetical protein 88 
2425384   + - SAS2267 TetR family regulatory protein 18 
2426374   + - SAS2268 CorA-like Mg2+ transporter protein 10 
2426459   - - SAS2269 PTS system, sucrose-specific IIBC 
component 
34 
2428467   + - SAS2270 hypothetical protein 56 
2432060   + - SAS2271 AraC family transcriptional regulator 23 
2432553   + - SAS2272 hypothetical protein 83 
2433174   + - SAS2273 hypothetical protein 48 
2433445   - - SAS2274 proton/sodium-glutamate symport 
protein 
61 
2434904   - - SAS2275 hypothetical protein 22 
2436113   + - SAS2276 MarR family transcriptional regulator 20 
2436757   + - SAS2277 small heat shock protein 19 
2436864 2436864 - - SAS2278 nitrite transport protein 181 
2438223   + - SAS2278a hypothetical protein 11 
2440036   + - SAS2281 MerR family transcriptional regulator 92 
2440294   - - SAS2282 response regulator 32 
2440970 2440970 - - SAS2283 histidine kinase 109 
2442028   - - SAS2284 hypothetical protein 80 
2442500   - - SAS2285 nitrate reductase gamma chain 77 
2443170   - - SAS2286 respiratory nitrate reductase delta chain 148 
2443738   - - SAS2287 nitrate reductase subunit beta 52 
2445287   - - SAS2288 nitrate reductase subunit alpha 214 









Strand Name Synonym Product Expression  
2450252   - - SAS2290 assimilatory nitrite reductase small 
subunit 
137 
2450570 2450567 - - SAS2291 nitrite reductase large subunit 140 
2453041   - - SAS2292 hypothetical protein 54 
2454001   - - SAS2293 acetyltransferase (GNAT) family protein 80 
2454772   - - SAS2294 nitrite transporter 62 
2455813 2455729 - - SAS2295 hypothetical protein 109 
2456079   - - SAS2296 hypothetical protein 34 
2456732   - - SAS2297 solute binding lipoprotein 20 
2458576   - - SAS2298 hypothetical protein 0 
2458842   - - SAS2299 hypothetical protein 27 
2459366   - - SAS2300 lipoprotein 68 
2459984   - - SAS2301 lipoprotein 98 
2461851   + - SAS2302 FemAB family protein 53 
2461948 2461866 - - SAS2303 ABC transporter ATP-binding protein 170 
2462676   - - SAS2304 transport system membrane protein 84 
2463376   - - SAS2305 extracellular solute-binding lipoprotein 45 
2464276   - - SAS2306 transport system protein 99 
2466147   - gpmA SAS2307 phosphoglyceromutase 31 
2467160 2467160 - - SAS2308 cation efflux family protein 118 
2470037   + - SAS2309 IgG-binding protein 37 
2471502   + - SAS2310 gamma-hemolysin component A 
precursor 
82 
2473017   + - SAS2311 gamma-hemolysin component C 
precursor 
30 
2473996   + - SAS2312 gamma-hemolysin component C 
precursor 
34 
2474048   - - SAS2313 hypothetical protein 69 
2474526   - - SAS2314 6-carboxyhexanoate--CoA ligase 4 
2475229   - - SAS2315 8-amino-7-oxononanoate synthase 20 
2476322   - - SAS2316 biotin synthase 52 
2477331   - - SAS2317 adenosylmethionine-8-amino-7-
oxononanoate aminotransferase 
34 
2478667   - - SAS2318 dethiobiotin synthetase 101 
2479806   - - SAS2319 ABC transporter ATP-binding protein 51 
2481564   - - SAS2320 ABC transporter ATP-binding protein 40 
2483877   - - SAS2320a hypothetical protein 60 
2484269   + - SAS2322 hypothetical protein 80 
2484252   - - SAS2323 hypothetical protein 26 
2486038 2486097 + - SAS2324 glycerate kinase 183 
2486757 2486830 + - SAS2325 hypothetical protein 123 
2488150   + - SAS2326 transporter protein 66 
2488273   - - SAS2327 hypothetical protein 82 
2489515 2489752 + - SAS2328 hypothetical protein 107 







Strand Name Synonym Product Expression  
2492079   + - SAS2330 amino acid permease 84 
2494295   + - SAS2331 sodium/hydrogen exchanger family 
protein 
49 
2494435 2494435 - - SAS2332 hypothetical protein 111 
2497992 2497992 + - SAS2333 hypothetical protein 105 
2498084   - - SAS2334 hypothetical protein 58 
2499257   - - SAS2335 2-dehydropantoate 2-reductase 21 
2500418 2500418 - - SAS2336 transport protein 129 
2502112   - - SAS2337 glycine betaine/carnitine/choline 
transport system permease 
98 
2502807   - - SAS2338 glycine betaine/carnitine/choline-binding 
lipoprotein precursor 
25 
2503765   - - SAS2339 glycine betaine/carnitine/choline 
transport system permease 
97 
2504397   - - SAS2340 glycine betaine/carnitine/choline 
transport ATP-binding protein 
180 
2506293   - - SAS2341 hypothetical protein 99 
2508709   + - SAS2342 amino acid permease 71 
2510368   + - SAS2343 carboxylesterase 95 
2510430   - - SAS2344 transport protein 76 
2512013   - - SAS2345 hypothetical protein 77 
2512782   - - SAS2346 ABC transporter ATP-binding protein 39 
2513692   - - SAS2347 hypothetical protein 103 
2515124   - - SAS2348 hypothetical protein 49 
2515390   - - SAS2349 hypothetical protein 82 
2516461   + - SAS2350 lipoprotein 51 
2516629 2516629 - - SAS2351 hypothetical protein 158 
2519151   + - SAS2352 hypothetical protein 29 
2519300   - - SAS2352a hypothetical protein 66 
2519513 2519459 - - SAS2353 transporter 117 
2520718 2520718 - - SAS2354 oligopeptide transporter ATPase 116 
2521460   - - SAS2355 oligopeptide transporter ATPase 120 
2522272   - - SAS2356 oligopeptide transporter membrane 
permease 
229 
2523138   - - SAS2357 oligopeptide transporter membrane 
permease 
99 
2524086   - - SAS2358 oligopeptide transporter substrate 
binding protein 
95 
2525824 2525824 - - SAS2359 hypothetical protein 200 
2527121   - - SAS2360 hypothetical protein 56 
2527950 2527947 - - SAS2361 hypothetical protein 131 
2529646   - - SAS2362 hypothetical protein 85 
2530271   - - SAS2363 short chain dehydrogenase 61 
2532862   + - SAS2364 transporter 102 
2532974   - - SAS2365 hypothetical protein 58 







Strand Name Synonym Product Expression  
2534285   - - SAS2367 hypothetical protein 0 
2534731   - - SAS2368 hypothetical protein 3 
2535409   - - SAS2369 hypothetical protein 11 
2536082 2536082 - - SAS2370 short chain dehydrogenase 104 
2537347   + - SAS2371 hypothetical protein 2 
2537607 2537607 - - SAS2372 hypothetical protein 150 
2538338   - - SAS2373 hypothetical protein 9 
2539267   - - SAS2374 hypothetical protein 22 
2540200   - - SAS2375 lipoprotein 3 
2541264   - - SAS2376 helicase 26 
2544127   - - SAS2377 NUDIX hydrolase 6 
2546459   + - SAS2378 phosphomannomutase 85 
2547009   + - SAS2379 hypothetical protein 94 
2547461   + - SAS2380 hypothetical protein 28 
2547569   - - SAS2381 hypothetical protein 16 
2547783   - - SAS2382 hypothetical protein 51 
2549359 2549359 - - SAS2383 cell wall-anchored protein 286 
  2550831 + - predicted 
RNA 
antisense: SAS2383 758 
  2551788 + - predicted 
RNA 
antisense: SAS2383 622 
2553779   - - SAS2384 accessory regulator 85 
2555202   + - SAS2385 accessory regulator 73 
2555414   - - SAS2386 UTP--glucose-1-phosphate 
uridylyltransferase 
66 
2556460 2556346 - fnbB SAS2387 fibronectin-binding protein precursor 494 
  2557283 + - predicted 
RNA 
antisense: fnbB 1551 
  2560952 + - predicted 
RNA 
antisense: SAS2388 2723 
2560014 2560014 - - SAS2388 fibronectin-binding protein precursor 878 
2563196   - - SAS2389 hypothetical protein 74 
2563530 2563530 - - SAS2390 gluconate permease 171 
2565005 2564949 - - SAS2391 gluconokinase 106 
2566582 2566559 - - SAS2392 gluconate operon transcriptional 
repressor 
143 
2567416 2567263 - - SAS2393 MerR family transcriptional regulator 174 
2568345   - - SAS2394 hypothetical protein 44 
2569268   - - SAS2395 hypothetical protein 24 
2569823   - - SAS2396 hypothetical protein 45 
2572158   - - SAS2396a hypothetical protein 20 
2572555 2572555 - - SAS2397 transporter protein 109 
2574990 2575342 + - SAS2398 DedA family protein 107 
2576203   + - SAS2399 ABC transporter ATP-binding protein 26 
2576975   + - SAS2400 hypothetical protein 38 







Strand Name Synonym Product Expression  
2580734 2581161 + - SAS2402 hypothetical protein 108 
2580839   - - SAS2403 phospholipase/carboxylesterase 65 
2581463   - - SAS2404 dioxygenase 16 
2582499   - - SAS2405 MarR family transcriptional regulator 51 
2583443   + - SAS2406 acetyltransferase (GNAT) family protein 94 
2584543   - - SAS2409 nitroreductase family protein 48 
2586476   + - SAS2410 D-lactate dehydrogenase 94 
2586723   - - SAS2411 haloacid dehalogenase 24 
2588479   + - SAS2412 ABC transporter ATP-binding protein 0 
2589216   + - SAS2413 hypothetical protein 52 
2589378   - - SAS2414 sortase 71 
2590683   + - SAS2415 acetyltransferase (GNAT) family protein 28 
2591249   - - SAS2415a hypothetical protein 85 
2591598 2591549 - - SAS2416 L-serine dehydratase subunit alpha 564 
  2592264 + - predicted 
RNA 
antisense: SAS2416 935 
2592511   - - SAS2417 L-serine dehydratase subunit beta 92 
2593194 2593192 - - SAS2418 hypothetical protein 132 
2594990   + - SAS2419 hypothetical protein 45 
2596108 2596108 + - SAS2420 hypothetical protein 105 
2596189 2596079 - - SAS2421 hypothetical protein 167 
2597290   - - SAS2422 hypothetical protein 101 
2597676   - - SAS2423 hypothetical protein 70 
2598451 2598350 - - SAS2424 PTS system, glucose-specific IIABC 
component 
152 
2600818 2600518 - - SAS2425 pyruvate oxidase 109 
2602604   - - SAS2426 hypothetical protein 40 
2603286   - - SAS2427 hypothetical protein 45 
2603894   - - SAS2428 LysR family regulatory protein 67 
2605157   + - SAS2429 hypothetical protein 51 
2605978   + - SAS2430 hypothetical protein 42 
2606116 2606094 - - SAS2431 3-hydroxy-3-methylglutaryl-CoA 
reductase 
139 
2608816 2608816 + - SAS2432 3-hydroxy-3-methylglutaryl-CoA 
synthase 
160 
2608986 2608986 - - SAS2433 6-O-methylguanine DNA 
methyltransferase 
262 
2612021 2612268 + - SAS2434 ATP-dependent protease ATP-binding 
subunit ClpL 
103 
2612090   - - SAS2435 hypothetical protein 25 
2612273   - - SAS2436 ferrous iron transport protein B 77 
2614279   - - SAS2437 hypothetical protein 30 
2614722   - - SAS2438 transport protein 68 
2617904   + - SAS2439 TetR family regulatory protein 26 









Strand Name Synonym Product Expression  
2619993 2619993 - - SAS2441 acetyltransferase 160 
2621022 2621065 + - SAS2442 hypothetical protein 107 
2623670 2623682 + - SAS2443 copper importing ATPase A 297 
2624225 2624557 + - SAS2444 heavy-metal-associated protein 477 
2624315 2624248 - - SAS2445 D-lactate dehydrogenase 233 
2625336 2625325 - - SAS2446 aminotransferase 209 
2626917   - - SAS2447 squalene synthase 43 
2628437   - - SAS2448 squalene desaturase 75 
2629337   - - SAS2449 glycosyl transferase 100 
2630470   - - SAS2450 phytoene dehydrogenase related protein 50 
2631956   - - SAS2451 hypothetical protein 66 
2632619   - - SAS2452 secretory antigen precursor 90 
2633747   - - SAS2453 hypothetical protein 47 
2636070   - - SAS2454 acetyltransferase (GNAT) family protein 9 
2636834 2636834 - - SAS2455 immunodominant antigen A 146 
2638143 2638143 - - SAS2456 hypothetical protein 224 
2639547   + - SAS2457 hypothetical protein 21 
2640177 2640311 + - SAS2458 TetR family regulatory protein 110 
2640875 2641064 + - SAS2459 hypothetical protein 117 
2641325   + - SAS2460 hypothetical protein 43 
2641488   - - SAS2461 glyoxalase 61 
2641882   - - SAS2462 hypothetical protein 59 
2642723   - - SAS2463 hypothetical protein 71 
2643711   + - SAS2464 TetR family regulatory protein 47 
2644408   + - SAS2465 short chain dehydrogenase 48 
2645516   + - SAS2466 hypothetical protein 59 
2646354   + - SAS2467 hydrolase 93 
2646501   - - SAS2468 cobalamin synthesis protein/P47K 
family protein 
96 
2647488   - - SAS2469 hypothetical protein 91 
2648822   - - SAS2470 hypothetical protein 112 
2650223   - - SAS2471 hypothetical protein 80 
2650507   - - SAS2472 hypothetical protein 119 
2650890   - - SAS2473 hypothetical protein 18 
2651507 2651507 - - SAS2474 hypothetical protein 151 
2653655   + - SAS2475 dihydroorotate dehydrogenase 2 55 
2654085 2654085 + - SAS2476 hypothetical protein 167 
2654271   - - SAS2477 hypothetical protein 68 
2655796   + - SAS2478 hypothetical protein 34 
2655877   - - SAS2479 DNA-binding protein 48 
2658289 2658304 + - SAS2480 hypothetical protein 172 
2659104   - - SAS2482 aspartate alpha-decarboxylase 43 







Strand Name Synonym Product Expression  
2660333   - panB SAS2484 3-methyl-2-oxobutanoate 
hydroxymethyltransferase 
156 
2662084 2662175 + - SAS2485 2-dehydropantoate 2-reductase 170 
2662170 2661800 - - SAS2486 alpha-acetolactate decarboxylase 133 
2663152   - - SAS2487 L-lactate dehydrogenase 2 62 
2666246 2666246 + - SAS2488 amino acid permease family protein 250 
2666326 2666292 - - SAS2489 4-aminobutyrate aminotransferase 115 
2668337   + - SAS2490 hypothetical protein 55 
2669350   + - SAS2491 fructose-1,6-bisphosphate aldolase 61 
2669544 2669544 - - SAS2492 malate:quinone oxidoreductase 162 
2671665 2672385 + - SAS2493 hypothetical protein 137 
2671725 2671725 - - SAS2494 AMP-binding protein 232 
2673517   - - SAS2495 hypothetical protein 68 
2674240   - - SAS2496 hypothetical protein 0 
2674730 2674730 - - SAS2497 choline dehydrogenase 141 
2676700 2676440 - - SAS2498 betaine aldehyde dehydrogenase 107 
2679006   + - SAS2499 hypothetical protein 78 
2679194 2678864 - - SAS2500 metallo-beta-lactamase superfamily 
protein 
122 
2680139   - - SAS2501 choline transporter 70 
2682280   - - SAS2502 anaerobic ribonucleotide reductase 
activating protein 
11 
2682813   - - SAS2503 anaerobic ribonucleoside triphosphate 
reductase 
117 
2684909   - - SAS2504 transporter protein 73 
2686755   - - SAS2505 precorrin-2 dehydrogenase 15 
2687423 2687361 - - SAS2506 sulfite reductase [NADPH] flavoprotein 
alpha-component 
145 
2689698   - - SAS2507 glutathione peroxidase 0 
2691619   - - SAS2508 hypothetical protein 51 
2693616   - - SAS2509 ABC transporter ATP-binding protein 40 
2694479   - - SAS2510 sensor kinase 65 
2695377   - - SAS2511 response regulator protein 40 
2696068   - - SAS2512 hypothetical protein 58 
2697890   + - SAS2513 alkaline phosphatase III precursor 43 
2697950   - - SAS2513a hypothetical protein 76 
2698173   - - SAS2514 regulatory protein 77 
2698873 2698859 - - SAS2515 esterase 135 
2699750 2699750 - - SAS2516 fibrinogen and keratin-10 binding 
surface anchored protein 
2397 
  2701150 + - predicted 
RNA 
antisense: SAS2516 7270 
2702817   - - SAS2517 regulatory protein 44 
2703620 2703620 - - SAS2518 carbamate kinase 144 
2704578 2704578 - - SAS2519 arginine/ornithine antiporter 139 
2706099   - - SAS2520 ornithine carbamoyltransferase 88 







Strand Name Synonym Product Expression  
2708724   - - SAS2522 arginine repressor ArgR 27 
2709540   - - SAS2523 zinc metalloproteinase aureolysin 48 
2711493   - - SAS2524 immunodominant antigen B 0 
2712736   + - SAS2525 hypothetical protein 72 
2714850   + - SAS2526 transcriptional regulator 50 
2716879 2716892 + - SAS2527 PTS transport system, IIABC component 233 
  2716234 - - predicted 
RNA 
antisense: SAS2527 699 
2717831 2717832 + - SAS2528 mannose-6-phosphate isomerase 117 
2717943 2717699 - - SAS2529 hypothetical protein 109 
2722994   + - SAS2530 N-acetylmuramoyl-L-alanine amidase 91 
2723259   - - SAS2531 isochorismatase family protein 47 
2723988   - - SAS2532 surface anchored protein 101 
2726137 2726137 - - SAS2533 hypothetical protein 172 
2727488   - - SAS2534 hypothetical protein 128 
2729014   - - SAS2535 preprotein translocase subunit SecA 44 
2731394   - - SAS2536 hypothetical protein 253 
2732331   - - SAS2537 hypothetical protein 108 
2733889   - - SAS2538 hypothetical protein 195 
2735453 2735443 - secY SAS2539 preprotein translocase subunit SecY 116 
2736794 2736794 - - SAS2540 cell wall-anchored protein 358 
  2738345 + - predicted 
RNA 
antisense: SAS2540 799 
  2738744 + - predicted 
RNA 
antisense: SAS2540 659 
  2739008 + - predicted 
RNA 
antisense: SAS2540 783 
  2739600 + - predicted 
RNA 
antisense: SAS2540 800 
  2739983 + - predicted 
RNA 
antisense: SAS2540 953 
  2740487 + - predicted 
RNA 
antisense: SAS2540 788 
  2740558 + - predicted 
RNA 
antisense: SAS2540 655 
2744166   - - SAS2541 hypothetical protein 44 
2746115   + - SAS2542 lipoprotein 80 
2746404   + - SAS2543 hypothetical protein 79 
2746917   + - SAS2544 hypothetical protein 22 
2747002 2746988 - - SAS2545 hypothetical protein 149 
2747692   - - SAS2546 methionine sulfoxide reductase A 33 
2748171   - - SAS2547 acetyltransferase (GNAT) family protein 65 
2748906   - - SAS2548 capsule synthesis protein 29 
2749670   - - SAS2549 capsule synthesis protein 54 
2750379   - - SAS2550 capsule synthesis protein 44 
2751890   - - SAS2551 ica operon transcriptional regulator 28 







Strand Name Synonym Product Expression  
2754121   + - SAS2553 intercellular adhesion protein D 69 
2754990   + - SAS2554 intercellular adhesion protein B 40 
2756029   + - SAS2555 intercellular adhesion protein C 9 
2756475   - - SAS2556 lipase precursor 97 
2759610 2759362 - - SAS2557 bifunctional phosphoribosyl-AMP 
cyclohydrolase/phosphoribosyl-ATP 
117 
2760239   - - SAS2558 imidazole glycerol phosphate synthase 
subunit HisF 
143 
2760994   - - SAS2559 1-(5-phosphoribosyl)-5-[(5-
phosphoribosylamino)methylideneamino
] imidazole-4-carboxamide isomerase 
139 
2761691   - hisH SAS2560 imidazole glycerol phosphate synthase 
subunit HisH 
174 
2762266   - hisB SAS2561 imidazoleglycerol-phosphate 
dehydratase 
299 
2762813   - - SAS2562 aminotransferase 97 
2763842   - - SAS2563 histidinol dehydrogenase 83 
2765085   - hisG SAS2564 ATP phosphoribosyltransferase 47 
2765717 2765717 - hisZ SAS2565 ATP phosphoribosyltransferase 112 
2766839   - - SAS2566 hypothetical protein 64 
2768081   - - SAS2567 hypothetical protein 42 
2768625   - - SAS2568 ABC transporter permease 34 
2769455   - - SAS2569 ABC transporter ATP-binding protein 41 
2771220   - - SAS2570 hypothetical protein 23 
2771803   - - SAS2571 hypothetical protein 45 
2773546   + - SAS2572 hypothetical protein 88 
2773657   - - SAS2573 hypothetical protein 22 
2774026   - - SAS2574 hypothetical protein 52 
2776197   + - SAS2575 hypothetical protein 90 
2776987 2777009 + - SAS2576 pyrrolidone-carboxylate peptidase 131 
2777555   + - SAS2577 hypothetical protein 37 
2777716   - - SAS2578 collagen adhesin precursor 78 
2783063   + - SAS2579 sodium:sulfate symporter family protein 40 
2783476   - - SAS2580 hypothetical protein 19 
2785181   + - SAS2581 hypothetical protein 70 
2786363 2786416 + - SAS2582 nickel transport protein 225 
2787400   + - SAS2583 N-acetyltransferase 72 
2787534   - - SAS2584 hypothetical protein 59 
2789087   + - SAS2585 ABC transporter ATP-binding protein 158 
2790957   + - SAS2586 ABC transporter permease 45 
2791241   + - SAS2586a hypothetical protein 26 
2791834   + - SAS2587 cold shock protein 19 
2791952   - - SAS2588 hypothetical protein 44 
2792781   - - SAS2589 hypothetical protein 78 
2793244   - - SAS2590 hypothetical protein 70 
2793914   - - SAS2591 DNA-binding protein 30 







Strand Name Synonym Product Expression  
2795515   - - SAS2593 tRNA uridine 5-
carboxymethylaminomethyl 
modification protein GidA 
107 
2797459   - trmE SAS2594 tRNA modification GTPase TrmE 45 
2798977   - rnpA SAS2595 ribonuclease P 44 





TABLE S2, Sheet 5: "tRNA in EVs isolated from isolated from MSSA476 






Bases of selection 
tRNA 1941988 1942064 tRNA Ile ( GAT) 101.60 42  59.74 gggcctatagctcagctggttagagcgcacgcctgataagcgtgaggtcggtggttcgagtccacttaggcccacca 
tRNA 1938233 1938308 tRNA Lys (TTT) 98.23 379 47.37 gagccattagctcagttggtagagcatctgacttttaatcagagggtcagaggttcgaatcctctatggctcacca 
tRNA 2229612 2229687 tRNA Val (TAC) 95.74 213 56.58 ggagaattagctcagctgggagagcatctgccttacaagcagagggtcggcggttcgaacccgtcattctccacca 
tRNA 1936843 1936918 tRNA Thr (TGT) 92.93 560 55.26 gccggcctagctcaattggtagagcaactgacttgtaatcagtaggttgggggttcaagtcctctggccggcacca 
tRNA 2229336 2229411 tRNA Lys (TTT) 90.55 45 46.05 gagccattagctcagttggtagagcatctgacttttaatcagagggtcagaggttcgaatcctctatggctcacta 
tRNA 533731 533803  tRNA Lys (TTT) 89.08 150 47.95 gagccattagctcagctggtagagcatctgacttttaatcagagggtcagaggttcgaatcctctatggctca 
tRNA 1937703 1937778 tRNA Ala  (TGC) 89.05 244 64.47 gggggcttagctcagctgggagagcgcctgctttgcacgcaggaggtcagcggttcgatcccgctagtctccacca 
tRNA 1937506 1937579 tRNA Met (CAT) 88.12 463 54.05 ggacctttagctcagttggttagagctaacggctcataaccgttcggtcgcaggttcgagtcctgcaaggtcca 
tRNA 1937796 1937869 tRNA Pro  (TGG) 86.85 346 56.76 cgggaagtagctcagcttggtagagcacttggtttgggaccaaggggtcgcaggttcgaatcctgtcttcccga 
tRNA 1938070 1938144 tRNA Gly (GCC) 86.82 586  54.67 gcagaagtagttcagcggtagaatacaaccttgccaaggttggggtcgcgggttcgaatcccgtcttctgctcca 
tRNA 1903347 1903421 tRNA Asn ( GTT) 85.44 216 54.67 tccacagtagctcagtggtagagctatcggctgttaaccgatcggtcgtaggttcgagtcctacctgtggagcca 
tRNA 1937017 1937092 tRNA Asp (GTC) 83.32 859 61.84 ggtctcgtagtgtagcggttaacacgcctgcctgtcacgcaggagatcgcgggttcgattcccgtcgagaccgcca 
tRNA 1937605 1937681 tRNA Met (CAT) 82.22 284 63.64 ggcggtgtagctcagctggctagagcgtacggttcatacccgtgaggtcgggggttcgatcccctccaccgccacta 
tRNA 1180641 1180714 tRNA Arg  (TCT) 81.85 8 59.46 gtcctggtagctcagctggatagagcaatggccttctaagccatcggtcgggggttcgaatccctcccaggacg 
tRNA 1936431 1936504 tRNA Cys  (GCA) 79.57 400 55.41 ggcggcatagccaagtggtaaggcagaggtctgcaaaacctttatcaccggttcaaatccggttgccgcctcca 
tRNA 1937971 1938059 tRNA Leu  (TAA) 76.44 590 61.80 gccggggtggcggaactggcagacgcacaggacttaaaatcctgcggtgagtgatcaccgtaccggttcgattccggtcctcggcacca 
tRNA 1936926 1936998 tRNA Phe  (GAA) 76.42 635  50.68 ggttcagtagctcagttggtagagcaatggattgaagctccatgtgtcggcagttcgactctgtcctgaacca 
tRNA 1937102 1937175 tRNA Met (CAT) 75.92 984 62.16 cgcgggatggagcagttcggtagctcgtcgggctcataacccgaaggtcggtggttcaaatccgcctcccgcaa 
tRNA 1903436 1903509 tRNA Gly  (TCC) 75.68 220 52.70 gcgggtgtagtttaatggcaaaacctcagccttccaagctgatgttgtgggttcgattcccatcacccgctcca 
tRNA 533919 534007 tRNA Leu (TAA) 75.33 607 61.80 gccggggtggcggaactggcagacgcacaggacttaaaatcctgcggtgagagatcaccgtaccggttcgattccggtcctcggcacca 
tRNA 24238 24310 tRNA Asp(GTC) 75.02 217 61.64 ggtctcgtagtgtagcggttaacacgcctgcctgtcacgcaggagatcgcgggttcgattcccgtcgagaccg 
tRNA 1937190 1937282 tRNA Ser (TGA) 74.09 829 61.29 ggaggaatacccaagtccggctgaagggatcggtcttgaaaaccgacagggccttaacgggccgcgggggttcgaatccctcttcctccgcca 
tRNA 1903525 1903600 tRNA His (GTG) 72.71 229 56.58 gcggttgtggtgaagtggttaacacatcggattgtggttccgacattcgagggttcgatccccttcagccgcccca 
tRNA 1936510 1936581 tRNA Gln ( TTG) 70.48 449 55.56 tgggctatagccaagcggtaaggcaacggactttgactccgtcactcgttggttcgaatccagctagcccag 
tRNA 1938148 1938229 tRNA Leu  (TAG) 70.09 473 62.20 gcgggtgtggcggaattggcagacgcactagacttaggatctagcgccttacggcgtgggggttcgactcccttcacccgca 
 
 






Bases of selection 
tRNA 1936668 1936741 tRNA Trp (CCA) 69.76 422 51.35 aggggcatagttcaacggtagaatagaggtctccaaaacctttggtgtgggttcgattcctactgcccctgcca 
tRNA 1936757 1936837 tRNA Tyr (GTA) 69.29 525 61.73 ggaggggtagcgaagtggctaaacgcggcggactgtaaatccgctccttcgggttcggcagttcgaatctgcccccctcca 
tRNA 1937879 1937952 tRNA Arg (ACG) 69.23 445 55.41 gcgcccgtagctcaattggatagagcgtttgactacggatcaagaggttatgggttcgactcctatcgggcgcg 
tRNA 2229695 2229766 tRNA Glu (TTC) 68.58 259  59.72 ggctccttggtcaagcggttaagacaccgccctttcacggcggtaacacgggttcgagtcccgtaggagtca 
tRNA 1936593 1936665 tRNA His (GTG) 68.08 446 57.53 gcggctgtggtgaagtggttaacacatcggattgtggttccgacattcgagggttcgatccccttcagccgcc 
tRNA 1031321 1031409 tRNA Ser (GCT) 63.03 131 60.67 ggaaacgtactcaagttggctgaagaggcgcccctgctaagggtgtaggtcgcgaaagcggcgcgagggttcgaatccctccgtttccg 
tRNA 1937407 1937496 tRNA Ser  (TGA) 61.04 657 60.00 ggaggaatacccaagtccggctgaagggatcggtcttgaaaaccgacaggggcttaacggctcgcgggggttcgaatccctcttcctccg 
tRNA 1936137 1936220 tRNA Leu (CAA) 59.46 89 63.10 gccggtgtggcggaattggcagacgcgcgggactcaaaatcccgttccacttgtggagtgtcggttcgaccccgaccaccggta 
tRNA 2121724 2121809 tRNA Leu (GAG) 57.05 29 62.79 gcggtcgtggcggaatggcagacgcgctaggttgagggcctagtgggagaaatcccgtggaggttcaagtcctctcggccgcatca 
tRNA 1903131 1903219 tRNA Ser (GGA) 51.22 97 58.43 ggaaggttgtccgagctggccgaaggagcacgcctggaaagtgtgtaggcgtcacaagcgtctcaagggttcgaatcccttaccttccg 
tRNA 821299 821370 tRNA Arg (CCG) 45.36 4 44.44 ctccttgtggtgtaatggataacacgtaagattccggttcttaagataggggttcaattcccttcaaggagg 
tRNA 1936349 1936423 tRNA Gly (TCC) 41.66 280 49.33 gcgggagtagttcaacttttagaacacgttccttcccggaacgaggtataggtgcaaatcctatcttccgctcca 
tRNA 1936262 1936333 tRNA pseudo anticodon 
(TCC) 





Table S2, Sheet 6: Small RNA in MVs isolated from MSSA476 
sRNA Id RFAM 
Accession 
Type Description Genomic 
coordinates 










ssas1686.1 RF00013 protein-binding small RNA 6s RNA 1685656..1685846 197 R 80 97.5 42.41 
ssas838.1 RF00023 protein-binding small RNA SsrA (tmRNA) 837496..837857 362 F 65 162.6 43.92 
ssas474.1 RF0188 trans-encoded antisense RNA RsaC  673626..674066 441 R 33 555.6 35.37 
ssas1675.1 RF00230 regulatory element T-box 1674489..1674687 178 R 32 90.55 34.27 
ssas386.6 RF00230 Regulatory element T-box 386022..386281 200 F 24 96.6 31.52 
ssas486.1 RF00169 Trans-encoded antisense RNA small cytoplasmic 
RNA(4.5sRNA, ffs) 
485461..485730 270 F 24 69.1 48.52 
ssas1552.1 RF00050 regulatory element FMN riboswitch 1551305..1551439 135 R 23 121.7 46.67 
ssas387.1 RF00230 Regulatory element T-box 386093..386293 201 R 22 114.2 39.80 
ssas2373.1 RF00162 regulatory element SAM riboswitch 2372869..2372964 96 R 21 78.2 47.92 
ssas1874.1  RF01797 trans-encoded antisense RNA fstAT 1873399..1873493 95 R 19 90.2 42.11 
ssas2206.1  RF01492 trans-encoded antisense RNA rli28 2205592..2205772 181 R 19 123.8 34.25 
ssas1255.1 RF00556 regulatory element L19_leader 1254259..1254301 43 F 18 50.0 41.86 
ssas424.1 RF01764 Regulatory element yjdF 423980..424080 101 F 17 92.9 38.61 
ssas2031.1 RF01492 trans-encoded antisense RNA rli28 2030445..2030623 179 R 17 85.6 37.43 
ssas1200.1 RF00230 regulatory element T-box 1199542..1199714 173 F 16 80.94 34.10 
ssas2156.1  RF00059 regulatory element TPP riboswitch 2155664..2155766 103 F 16 70.9 40.78 
ssas1792.1 RF00230 regulatory element T-box leader  1791148..1791366 203 R 15 80.52 31.53 
ssas2087.1  RF00503 trans-encoded antisense RNA RNAIII 2086458..2086973 516 R 14 472.2 28.68 
ssas13.1 RF00230 Regulatory element T-box 12486..12696 211 F 13 93.3 33.65 
ssas2480.1 RF01822 trans-encoded antisense RNA RsaJ 2479454..2479740 287 F 13 332.1 30.66 
ssas1733.1 RF00168 regulatory element Lysine riboswitch 1732415..1732590 176 F 12 104.6 31.82 
ssas2484.1 RF01797 trans-encoded antisense RNA fstAT 2483979..2484075 97 F 12 78.12 40.21 
ssas567.1 RF00557 Regulatory element L10_Leader 566720..566866 127 F 10 86.8 31.21 
ssas756.1 RF00552 Regulatory element PreQ1-I Riboswitch 755252..755298 47 R 9 38.61 36.17 
ssas1716.2 RF00230 regulatory element T-box 1715403..1715591 189 R 9 70.41 33.86 
ssas2028.1 RF01828 trans-encoded antisense RNA SprD  2027163..2027304 142 R 9 161.8 37.32 
ssas560.1 RF00230 Regulatory element T-box 559398..559623 226 F 8 68.35 35.40 
ssas16.1 RF00162 Regulatory element SAM riboswitch 159449..16047 99 F 7 74.3 44.42 
ssas1861.1 RF00162 regulatory element SAM riboswitch 1860045..1860156 112 F 7 67.3 43.75 
ssas2580.1  RF01797 trans-encoded antisense RNA fstAT 2579344..2579434 91 R 7 71.47 46.15 
 
 
sRNA Id RFAM 
Accession 
Type Description Genomic 
coordinates 










sssas980.1 RF00080 regulatory element yybP-ykoY leader 979834..979962 129 F 6 56.9 35.66 
ssas1145.1 RF00230 regulatory element T-box 1144228..1144441 214 F 6 75.8 31.31 
ssas1035.1 RF01492 trans-encoded antisense RNA rli28 1034785..1034968 184 F 5 66.9 34.24 
ssas1512.1 RF00010 regulatory element RNaseP_bact_b 1511315..1511662 380 R 5 273.3 39.47 
ssas1716.1  RF00230 regulatory element T-box 1715293..1715324 32 R 5 24.87 43.75 
ssas1731.1  RF00558 regulatory element L20_leader 1730577..1730702 126 R 5 82.9 44.44 
ssas1087.1  RF00059 regulatory element TPP riboswitch 1086334..1086434 101 R 4 71.0 43.56 
ssas1846.1 RF00050 regulatory element FMN riboswitch 1845588..1845723 136 R 4 116.8 43.38 
ssas410.1 RF00167 Regulatory element Purine riboswitch 409191..409293 103 F 3 77.7 29.13 
ssas627.1 RF0186 trans-encoded antisense RNA RsaA 626252..626390 139 F 2 112.3 33.81 
ssas824.1 RF01821 Trans-encoded antisense RNA RsaH 823438..823561 124 F 2 128.0 38.71 
ssas862.1 RF00162 Regulatory element SAM riboswitch 861019.. 861122 104 F 2 82.8 44.23 
ssas960.2 RF01858 trans-encoded antisense RNA RsaF 959384..959502 119 F 2 140.3 26.05 
ssas1403.1 RF00230 Regulatory element T-box 1402686..1402880 177 F 2 70.61 36.16 
ssas1430.1  RF00168 regulatory element Lysine riboswitch 1429786..1429961 176 F 2 95.8 34.09 
ssas1603.1 RF00504 regulatory element Glycine riboswitch 1602168..1602265 98 R 2 68.14 38.78 
ssas2282.1  RF00555 regulatory element L13_leader 2281316..2281385 70 R 2 53.7 37.14 
ssas2359.1 RF01775 trans-encoded antisense RNA RsaOG  2358615..2358758 144 R 2 174.6 36.11 
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